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Gait impairment is a primary symptom of cervical spondylotic myelopathy (CSM), yet it is poorly 
understood due to a lack of quantitative data on kinematics, kinetics, and electromyography 
(EMG) of muscle activity during gait. Furthermore, the effect of surgical decompression of the 
spinal cord on gait impairment is not well established. The aims of this study were to analyse 
and describe the gait patterns of people with CSM compared to age- and gender-matched 
healthy controls (HCs), and to determine the effect of surgery on gait impairment. A secondary 
objective was to measure changes in CSM severity, functional mobility, health-related quality of 
life (HRQOL) and spasticity following surgery. The thesis was divided into three studies: a 
reliability study of three-dimensional gait analysis (3DGA) and EMG parameters in the CSM 
population, a cross-sectional study to compare gait in CSM with HCs, and an experimental 
study to evaluate changes in gait following surgery. 
A test-retest reliability study of 12 participants with CSM determined that most temporal-spatial, 
kinematic and kinetic parameters showed sufficient repeatability for use in clinical and research 
practice. EMG parameters were more variable. A range of measures of the timing and 
amplitude of muscle activation and its response to lengthening were chosen based on the 
results of the reliability study. 
The cross-sectional study involving CSM participants (N = 16) and age- and gender-matched 
HCs (N = 16), found that CSM participants had a significantly slower comfortable gait speed, 
with reductions in multiple peak kinematic and kinetic parameters in the sagittal plane. At 
matched speed, differences persisted in several parameters pertaining to propulsion and 
momentum generation, and this was confirmed by principal components analysis. EMG analysis 
showed prolonged duration of activation of rectus femoris, biceps femoris and tibialis anterior, 
and excessive co-activation between rectus and biceps femoris, in the CSM cohort. Analysis of 
the 3DGA and EMG data indicated that paresis was a significant underlying factor to the CSM 
gait. Spasticity and proprioception appeared to have less effect. 
Thirteen participants underwent decompressive surgery and participated in the experimental 
study. At last post-operative follow-up, there were significant improvements in CSM severity, 
functional mobility and HRQOL. No changes were detected in temporal-spatial or kinematic gait 
parameters, however kinetic parameters showed an improvement in the absorption and 
generation of power at the knee and ankle at key points in the gait cycle. EMG analysis showed 
compensatory responses in muscle activation patterns of tibialis anterior, and an increase in 
lengthening velocity threshold, indicating reduced spasticity, of the rectus femoris. The results 
confirmed that surgery had achieved its aim in preventing further deterioration of function. 
Kinetic and EMG changes indicated that the locomotor system showed potential for 
improvement following surgery, a novel finding given that recovery of function is not generally 
expected. It was recommended that this potential should be explored through rehabilitation 
strategies aimed at maximising the locomotor system’s ability to recover following spinal cord 
injury through neuroplasticity and compensatory mechanisms. 
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The purpose of this thesis was to identify and describe the changes in gait in people with 
cervical spondylotic myelopathy, and to determine the impact of decompressive surgery 
to the spinal cord on gait impairment.  
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Cervical spondylotic myelopathy (CSM) is a degenerative disorder of the cervical spine 
characterised by narrowing of the cervical spinal canal and compression of the spinal 
cord (Montgomery and Brower, 1992). It is the most common cause of spinal cord 
dysfunction in individuals over the age of 55 (Fehlings and Skaf, 1998). The clinical 
presentation may include symptoms such as clumsy hands (Olindo et al., 2008), 
hyperreflexia, paraesthesia in one or both upper limbs, neck pain and gait disturbance 
(Nurick, 1972). The diagnosis relies heavily on clinical examination with support from 
radiological findings (Cook et al., 2009).  
Gait impairment is one of the primary symptoms of CSM. The condition often manifests 
initially through subtle changes in gait and balance, progressing to weakness, stiffness 
and sensory loss and the feeling of an awkward, clumsy gait pattern (Rao, 2002). Some 
patients may present with spastic paraparesis or tetraparesis (Dvorak et al., 2003). There 
is little evidence to date in the literature to describe the gait patterns of people with CSM. 
Many published studies are limited to temporal-spatial and kinematic analysis (Kuhtz-
Buschbeck et al., 1999, Maezawa et al., 2001, Kim et al., 2010, Lee et al., 2011), without 
analysis of kinetics or electromyography (EMG). The rehabilitation of people with CSM is 
limited by this lack of evidence, as without a clear description of the problem, therapists 
cannot design rehabilitation interventions to address it.  
CSM can be managed conservatively, through the use of traction (Yoshimatsu et al., 
2001) or soft cervical collars (Phillips, 1973, LaRocca, 1988), or surgically, by 
decompression of the spinal cord (Furlan et al., 2011). The aim of surgery in most cases 
is to arrest the progression of neurological signs and symptoms by stabilising the 
degenerative cervical levels. Improvement in function is not generally expected (Rao et 
al., 2006). Due to its uncertain natural history, the possibility of rapid irreversible loss of 
function, and unsatisfactory outcomes with conservative management, surgery has 
emerged as the gold standard of treatment (Jankowitz and Gerszten, 2006). However, 
prediction of outcome following surgery is limited by the lack of robust evidence from 
published research. Many studies have been criticised for methodological flaws such as 
inadequate randomisation, retrospective designs, and small sample sizes (Jankowitz and 
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Gerszten, 2006). In particular, many of the scales commonly used to assess outcome 
following surgery are ordinal in nature, and may be insensitive to change. One category 
can cover a range of severity and non-quantitative measures may be prone to bias (Singh 
and Crockard, 1999). There is a need for more sensitive, quantitative and reliable 
measures to ensure that outcomes for people with CSM are accurately measured, and to 
provide greater certainty in clinical decision-making (Jankowitz and Gerszten, 2006).    
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It was evident that several gaps existed in the literature on CSM. Firstly, the lack of 
quantitative data on gait impairment in this condition was a significant barrier for 
rehabilitation professionals and patients alike. A disorder cannot be effectively treated if it 
is not fully understood. It has been stated that a detailed analysis of gait, such as that 
provided by three-dimensional analysis of joint motion, moments and powers, coupled 
with electromyographic analysis of muscle activity, can significantly enhance the 
understanding of a deficit (Patrick, 2003). Such analysis forms the mainstay of the 
assessment and classification of gait in cerebral palsy (CP) (Gough and Shortland, 2008). 
The use of three-dimensional gait analysis (3DGA) and EMG to compare gait in people 
with CSM to healthy matched controls has potential to address the gaps in knowledge on 
gait in CSM, and to direct rehabilitation protocols towards the key deficits. 
The second major gap in the literature concerned the lack of quantitative, sensitive data 
on outcomes following decompressive surgery to the spinal cord. In determining the best 
approach to management, the surgeon and patient must weigh up the risks of intra-
operative complications against the possibility of further irreversible neurological 
deterioration if the cord is not decompressed. Previous studies have been hampered by 
the use of ordinal scales as outlined above (Jankowitz and Gerszten, 2006). The 
introduction of a standardised timed walk test has provided more quantitative data in the 
evaluation of CSM (Singh and Crockard, 1999) however gait speed alone provides no 
indication of the quality of a gait pattern. There may be changes in gait following surgery 
that are not apparent from an ordinal scale or a timed walk test. Analysis of gait using 
3DGA and EMG would allow greater precision and sensitivity in the evaluation of post-
operative outcomes, and could reveal changes in the quality of gait that were not 
previously documented.  
DFJ& C+/:.+:/%&'(&+?%&+?%,0,&
The thesis is divided into ten chapters, including the current chapter. The literature review 
is contained in Chapters 2, 3 and 4. The aims and objectives of the thesis are outlined in 
detail at the end of Chapter 4. To achieve these aims and objectives, the project is 
divided into three distinct but related studies: 1) a reliability study of the primary outcome 
measure, 3DGA and EMG analysis of gait, 2) a cross-sectional study to compare gait in 
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people with CSM to age- and gender-matched healthy controls, and 3) an experimental 
study to evaluate gait impairment in people with CSM before and after surgical 
decompression of the spinal cord. Chapter 5 discusses the development of methodology 
common to the three studies, and Chapter 6 describes the implementation of this 
methodology. The results of the three studies are detailed and discussed in Chapters 7, 8 
and 9, respectively. The concluding chapter, Chapter 10, draws together the findings of 
the three studies and discusses their implications for patients, surgeons and 
physiotherapists in the understanding of CSM and its management. Figure 1.1 illustrates 
the structure of the thesis. 
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This chapter will examine the pathophysiology and aetiological mechanisms underlying 
the development of CSM. The clinical presentation and diagnosis of the disorder will be 
discussed. Finally, current understanding of the natural history of CSM, and its response 
to surgical and conservative management, will be considered. The aim of this chapter is 
to outline the aspects of pathophysiology, prognosis and current management of CSM 
that led to the development of the hypotheses, aims and objectives of this thesis. 
GFDFD& !%/80*'$'7>&
Many of the terms used in this chapter describe a pathophysiological process involving 
some related but distinct entities. To ensure clarity, the terminology used will be as 
follows. 
• Cervical spondylosis: Progressive, degenerative changes within the cervical 
spine. 
• Cervical myelopathy: Compression of the spinal cord in the cervical canal due to 
any cause. 
• Myelopathy: Compression of the spinal cord at any spinal level or levels. 
• Cervical spondylotic myelopathy (CSM): Compression of the spinal cord in the 
cervical canal due to narrowing of the spinal canal as a result of cervical 
spondylosis. 
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Cervical spondylosis is a common progressive disorder of the ageing cervical spine and 
has been reported to affect up to 95% of people over the age of 65 (Garfin, 2000). It is 
characterised by degenerative changes affecting the intervertebral discs, vertebrae, facet 
joints, and ligamentous structures around the cervical spinal canal (Tracy and Bartleson, 
2010). The most common symptoms of cervical spondylosis are neck pain and 
radiculopathy (Shedid and Benzel, 2007). In a small number of cases, spondylosis can 
progress to the point where it affects the function of the spinal cord due to narrowing of 
the central spinal canal, resulting in the condition known as CSM (Asgari, 1996).  
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The exact prevalence of CSM is unknown (Dvorak et al., 2003). In many cases, the 
symptoms are incorrectly attributed to age or other neurological conditions (Rao, 2002). 
Research has generally been confined to a select population of patients who have a 
definite diagnosis and well-established disease, resulting in a lack of data on the true 
epidemiology of CSM. Given its degenerative aetiology, it is almost certain that the true 
incidence is significantly higher than the number of people who present to the health 
service with symptoms and signs. 
GFGFG& 3%+0'$'7>&
Risk factors for the development of CSM have not been fully established, but are believed 
to include a combination of genetic and environmental factors. CSM is also associated 
with other medical conditions. 
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Racial factors have been implicated in the genetic aspects of CSM aetiology. Asian 
populations in particular have a higher incidence of CSM than other races. This has been 
attributed to an increased prevalence of defects in the nucleotide pyrophosphatase gene, 
which is associated with ossification of the posterior longitudinal ligament (Nakamura et 
al., 1999).  
CSM is also more prevalent in Down syndrome. In this population, it tends to present at a 
young age with progressive deterioration in gait and weakness of all four limbs (Bosma et 
al., 1999). Down syndrome is associated with ligamentous laxity. This could be a risk 
factor for spondyloarthrosis of the cervical spine, in addition to its association with 
instability of the atlanto-axial joint (Tyrrell et al., 1998).  
Gender has also been considered a genetic risk factor. Salvi et al (2006) reported that 
males are more frequently affected by CSM than females, with a ratio of 2.4 to 1. A 
radiographic analysis of the canal to vertebral body ratio of the cervical spine in young 
healthy adults found a smaller ratio in males, and this could explain the higher prevalence 
of CSM in men (Hukuda and Kojima, 2002). 
2)2)2)2! 647#&.48'4,59!/5-,.&1!
Environmental factors implicated in CSM include repeated occupational trauma, such as 
the carrying of heavy axial loads (Baron and Young, 2007) and the repeated cervical 
extension strains sustained in occupations with a high prevalence of overhead activities, 
such as fruit farming (Takamiya et al., 2006). These factors might also account for the 
prevalence of the disorder among males, who may be more likely than females to engage 
in occupations involving load carrying or other cervical stresses.  
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Smoking has been associated with disc degeneration, and some authors have 
considered it a risk factor for the development of spondylosis (Hadley and Reddy, 1997). 
However, there is no conclusive evidence of a greater prevalence of CSM among 
smokers compared to non-smokers. 
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CSM has been linked to co-existing medical conditions. One of the most common 
associated conditions is rheumatoid arthritis (RA), where progressive joint destruction can 
affect the cervical spine, leading to cord compression (Ranawat et al., 1979, Iizuka et al., 
2009). Acquired immunodeficiency syndrome (AIDS) has been suggested as a possible 
factor in vascular CSM, however histological studies of spinal cord pathology in 90 AIDS 
patients did not support the hypothesis that AIDS was directly involved in the 
pathogenesis of CSM (Shepherd et al., 1999).  
Many other causes of cervical myelopathy have been described in the literature, however 
some of these presentations do not have a clear spondylotic aetiology. The potential 
adverse effects of spinal manipulation were described in a case series involving 18 
patients, nine of which had symptoms of spinal cord injury (SCI) (Oppenheim et al., 
2005). Two cases of delayed radiation myelopathy following radiotherapy treatment for 
cancer have been documented (Koehler et al., 1996). A case study described the course 
of cervical myelopathy due to acute disc protrusion during maternal labour (Tsai et al., 
2006). A complete picture of the risk factors for these rare causes of myelopathy has not 
been established, but risk factors may have included diabetes and hypertension in the 
radiation group (Koehler et al., 1996). Three of 18 patients with complications following 
manipulation had pre-existing spinal pathology such as syringomyelia and atlanto-axial 
instability (Oppenheim et al., 2005). Some of these presentations may have been more 
consistent with acute traumatic SCI than CSM, though it is difficult to separate traumatic 
cord injury from degenerative cord compression on retrospective analysis. In this review, 
focus will be maintained on CSM as a degenerative process, though it is acknowledged 
that the symptoms and signs of this degenerative process may be accelerated by acute 
trauma (Matsunaga et al., 2002, Bednarik et al., 2011).   
GFGFI& 2"+?'=?>,0'$'70."$&=/'.%,,%,&&
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Stookey (1928) published the first reports of spinal cord compression due to degenerative 
changes, describing compression of the cord by cartilaginous nodules of degenerated 
disc material. A landmark paper later attributed the clinical signs of neurological 
deterioration to cervical spondylosis (Brain et al., 1952). This section will now consider 
the pathophysiology of cervical spondylosis, and will then discuss its progression to CSM. 
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The understanding of the pathophysiology of cervical spondylosis has evolved over time. 
It is now generally accepted that spondylosis results from degenerative processes that 
alter the mechanics of the spinal column in bearing axial load (Baptiste and Fehlings, 
2006). White and Panjabi (1988) divided the factors involved in the pathogenesis into 
static and dynamic factors. The static factors relate to primary degenerative processes, 
precipitated by non-inflammatory disc degeneration in the ageing cervical spine. The 
process of disc degeneration is complex. It involves alterations of normal physiology as 
well as the process of ageing (Shedid and Benzel, 2007).  The chemical composition of 
the disc deteriorates with age (Rao, 2002). This leads to a gradual loss of water within the 
discs, causing fragmentation and collapse of the inner nucleus pulposus (Baron and 
Young, 2007). The discs lose their effectiveness in bearing and transferring load, and 
begin to split medially (Baptiste and Fehlings, 2006). The load on the uncovertebral 
processes increases, causing them to become flattened (Kumaresan et al., 2001). 
Greater stress is then placed on the articular cartilage of the vertebrae and their end 
plates, leading to the formation of osteophytic spurs at the margins of the end plates to 
increase the weight-bearing surface of the vertebrae (Baptiste and Fehlings, 2006). The 
ligamentum flavum also thickens and may buckle posteriorly (Muthukumar, 2005). 
Degeneration or calcification of the posterior longitudinal ligaments may occur (White and 
Panjabi, 1988). The net effect of these changes is a reduction in the sagittal spinal canal 
diameter (Shedid and Benzel, 2007).  
Dynamic pathological factors also contribute to the development of cervical spondylosis. 
With progression of the static changes outlined above, abnormal forces on the spinal cord 
and spinal column are generated during movement (White and Panjabi, 1988). Changes 
in the dynamics of neck flexion and extension cause narrowing of the spinal canal during 
movement, increasing the strain and shear forces on the spinal cord (Baptiste and 
Fehlings, 2006). This further contributes to osteophytosis. Mihara et al. (2000) found that 
elderly patients with CSM had increased segmental mobility at C3/4, the level at which 
their myelopathy developed, than at C4/5 and caudal segments. This provided evidence 
for the role of dynamic factors in the pathophysiology of CSM. Dynamic factors explain 
why occupational activities such as the carrying of heavy loads contribute to the 
development of CSM. Further abnormal forces will be generated during these activities, 
compounding the development of osteophytosis.  
2)2):):! C'7'9.A8'4,!./!8B'9.A5,0B!51!5!&'1%9,!./!-'&7#-59!1A.4<B9.1#1!
In the majority of people, spondylotic changes have no adverse effects on the spinal cord. 
Individuals who become symptomatic with cervical spondylosis will usually present with 
symptoms of axial neck pain or radiculopathy, rather than with spinal cord signs (Shedid 
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and Benzel, 2007). The exact degree of canal stenosis that leads to the development of 
symptoms and signs of cord compression is not fully known.  
Attempts to correlate the size of the cervical spinal canal with neurological signs have 
shown variable results (Rao and Fehlings, 1999). On plain radiographs, clinical signs of 
cord compression have been associated with sagittal anterior-posterior (AP) canal 
diameters of varying sizes including less than 13 millimetres (mm) (Arnold, 1955), 11 mm 
during extremes of flexion and extension (Penning, 1962), 9 mm (Fukui et al., 1990), and 
17 mm (Edwards and LaRocca, 1985). The sensitivities and specificities of these cut-off 
points varied from below 50% in some studies to over 80% in others (Rao and Fehlings, 
1999).  
Computed tomography (CT) myelography has been used to measure the cross-sectional 
area of the spinal cord. One study found that the onset of long tract neurological signs 
was associated with a 30% reduction in the cross sectional area of the spinal canal 
(Penning et al., 1986), a finding reported to have more than 80% sensitivity and 80% 
specificity for clinical cord compression (Rao and Fehlings, 1999). A 60% encroachment 
into the spinal canal from an ossified posterior longitudinal ligament has been linked with 
the development of cord symptoms and signs (Matsunaga et al., 2004). In a further study 
using CT myelography, Hukuda et al. (1996) found that, when compared to controls, 
CSM was associated with a larger vertebral body size as well as a narrowed spinal canal. 
The authors suggested that a high vertebral body to spinal canal size ratio, known as the 
Torg ratio, could be indicative of a greater degree of osteophyte formation and disc 
protrusion. A review paper found few studies that provided objective, quantifiable, and 
reliable radiographic measurements of cervical spinal canal compromise or cord 
compression (Rao and Fehlings, 1999).  
Magnetic resonance imaging (MRI) may provide a greater degree of accuracy. The use of 
T1- and T2-weighted images to evaluate mid-sagittal AP cervical canal diameter found 
that a reduction in diameter of 25% or more showed 76% sensitivity and 98% specificity 
for clinical cord compression (Fehlings et al., 1999). However, this study was conducted 
in acute cervical SCI, and the findings may not generalise to a degenerative aetiology 
such as CSM. Further studies are needed to establish a more accurate measurement of 
canal stenosis at which neurological deterioration can be predicted.  
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From a mechanical point of view, a narrowed spinal canal is thought to cause 
compression of the spinal cord, leading to local tissue ischaemia and injury to the neural 
cells (Baptiste and Fehlings, 2006). The spinal cord can also be damaged dynamically by 
tensile stretch during extremes of flexion and extension, as demonstrated by Shi and 
Pryor (2002). The cord initially responds well to stretch, but then becomes progressively 
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stiffer as the fibres straighten out and begin to bear tensile load. The effects of tensile 
stretch are limited initially to temporary ionic imbalances across the nerve cell membrane, 
but this can progress to more permanent conduction loss as the membranes suffer more 
profound anatomical damage (Shi and Pryor, 2002). As a result, damage to the spinal 
cord occurs from both a narrowed spinal canal diameter and the resulting pathological 
changes in spinal cord biomechanics. 
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Mechanical factors alone, however, do not adequately explain the spectrum of clinical 
findings in CSM. While a narrowed spinal canal may be an essential prerequisite for the 
development of myelopathy, the degree of canal stenosis does not always correlate with 
the neurological deficit, and indeed many patients with a spinal canal diameter of less 
than 13 mm have a normal neurological examination (Hayashi et al., 1987). Nurick (1972) 
first put forward this consideration, stating: “CSM is associated with a narrow canal, 
although a narrow canal does not always lead to CSM”. Other processes are therefore 
implicated in the pathophysiology.  
There is considerable evidence that vascular ischaemia may be an important factor. 
Cadaveric studies have shown that compression of the spinal cord anteriorly will reduce 
the perfusion through the transverse arterioles arising from the anterior sulcal arteries, 
while posterior compression will compromise perfusion through the intramedullary 
branches of the central gray matter (Baptiste and Fehlings, 2006). Furthermore, 
angiographic studies have shown a reduction in perfusion to the spinal cord in animal 
models of myelopathy (Hukuda and Wilson, 1972). Shedid and Benzel (2007) stated that 
although the degeneration of cervical spinal elements is the primary pathological lesion in 
cervical spondylosis, it is the secondary vascular sequelae that lead to myelopathy.  
Ischaemic or traumatic injury to the central nervous system (CNS) can result in 
programmed cell death, namely apoptosis. Studies in traumatic brain injury (TBI) and SCI 
have found that oligodendrocytes are particularly vulnerable to the effects of ischaemia. 
Post-mortem studies of both human and animal spinal cord compression have found 
evidence of oligodendroglial death alongside intact but demyelinated axons (Bunge et al., 
1993). Oligodendrocytes are critical to the CNS in the promotion of neurological 
development and the formation and maintenance of myelin sheaths. Their apoptosis may 
explain the demyelination associated with chronic myelopathy (Pfeiffer et al., 1993). Kim 
et al. (2003) also suggested that early apoptosis of oligodendrocytes may contribute to 
the profound and irreversible neurological deficits found in chronic CSM. 
The effects of mechanical compression and ischaemic cell death do not manifest 
uniformly throughout the spinal cord. Histological analyses of the cord in affected people 
have found that the central grey matter and medial portions of the white matter are the 
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most severely affected areas, showing evidence of gliosis, cystic cavitation and 
demyelination (Fehlings and Skaf, 1998). By contrast, the anterior columns are usually 
less severely damaged. Wallerian degeneration tends to affect the posterior columns 
cephalad to the site of compression, and the corticospinal tracts below the site of 
compression. The progression of these pathological changes depends on the extent of 
cord compression. The lateral corticospinal tracts are the most vulnerable, while severe 
compression can lead to anterior horn cell loss or localised infarction of grey matter 
(Fehlings and Skaf, 1998). The extent and distribution of these changes within the cord 
may in part account for variations in the clinical presentation of CSM. The clinical features 
of CSM will now be considered. 
GFI& )$0*0."$&=/%,%*+"+0'*&
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CSM presents with variable combinations of symptoms and signs depending on the 
relative involvement of corticospinal tracts, posterior columns and spinothalamic tracts. 
Most people with CSM will present with involvement of more than one of these structures 
(Takayama et al., 2005a). Early symptoms include subtle changes in gait and balance 
(Emery, 2001). This can progress to weakness, stiffness, or sensory loss in the lower 
limbs, often in an asymmetrical distribution (Baron and Young, 2007). Patients may 
complain of increasing difficulty with balance and an “awkward” gait, though they 
frequently attribute these symptoms to old age or arthritis (Rao, 2002). In the upper limbs, 
a feeling of “numb, clumsy” hands may be described, manifesting as a loss of dexterity, 
worsening of handwriting, or difficulty with fine motor tasks such as fastening zippers and 
buttons (Rao, 2002). Pain can also be a feature. Stabbing pain in a non-dermatomal 
pattern has been reported (Young, 2000). Pain may spread in a cape-like distribution 
across the shoulders (Rao, 2002). A positive Lhermitte’s phenomenon may be present 
with cervical flexion (Salvi et al., 2006). 
Clinical signs feature a mix of upper and lower motor neuron findings, as the exiting nerve 
root may also be compressed at the spondylotic level, causing lower motor neuron signs 
at this level and upper motor neuron signs below this level (Connell and Wiesel, 1992). 
Physical examination may reveal limitation in the range of motion (ROM) of the cervical 
spine, particularly of lateral flexion and rotation to the side of greatest degenerative 
changes (Salvi et al., 2006). Muscle weakness and wasting can be evident on 
assessment of power. This is often bilateral and affects multiple muscle groups, rather 
than one cervical root (Salvi et al., 2006). Some people will present with spastic 
paraparesis or tetraparesis (Montgomery and Brower, 1992, Dvorak et al., 2003). 
Findings on sensory examination depend on the area of the cord that is involved, and the 
extent of compression of the nerve root at the exit foramen of the affected level (Rao, 
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2002). Bilateral loss of sensation to vibration and joint position sense in the lower limbs 
has been described as a characteristic pattern in CSM (Brain et al., 1952, Dvorak et al., 
2003). Clinical signs that pinpoint upper motor neurone pathology include hyperreflexia, 
an extensor plantar response, ankle clonus, a positive Hoffman’s sign, and an inverted 
supinator response (Cook et al., 2007). The term “myelopathy hand” has been used to 
describe a pattern of dysfunction of the intrinsic hand muscles associated with CSM, 
which is characterised by positive finger escape and grip-and-release tests (Ono et al., 
1987, Ebara et al., 1988). A summary of these signs is provided in Table 2.1. 
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Clinical Sign Description Positive Finding 
for CSM 
Reference 
Inverted 
supinator sign 
 
Brachioradialis reflex elicited 
in the normal way 
Reactive flexion 
of the ipsilateral 
fingers 
(Kiely et al., 
2010) 
Grip and release 
test 
Hand outstretched. Patient 
grips and releases with the 
fingers as rapidly as possible, 
and the number of complete 
cycles in 10 seconds is 
counted 
Less than 20 
complete cycles 
in 10 seconds 
(Ono et al., 
1987) 
Finger escape 
sign 
Hand held outstretched with 
palms down, fingers extended 
and adducted for 30-60 
seconds 
Ring and little 
fingers drift into 
abduction and 
flexion 
(Ono et al., 
1987) 
Hoffman’s sign Proximal interphalangeal joint 
of the middle finger is 
stabilised, distal phalanx then 
“flicked” into a flexed position  
Adduction of the 
thumb and flexion 
of the fingers 
(Sung and 
Wang, 2001) 
Suprapatellar 
quadriceps test 
Sitting with feet unsupported, 
suprapatellar tendon tapped 
quickly with reflex hammer 
Hyperreflexive 
knee extension 
(Cook et al., 
2009) 
GFIFG& )$0*0."$&60"7*',0,&
There is no definitive diagnostic test for CSM. Accurate identification of the pathology 
presents a clinical challenge. The vague nature of the early symptoms of myelopathy, 
particularly with respect to lower limb weakness and gait abnormality, often leads to a 
delay in diagnosis (Salvi et al., 2006). In clinical practice, neurological signs are often 
used to identify possible myelopathy, and MRI evidence is then sought to confirm the 
diagnosis (Cook et al., 2009, Harrop et al., 2010). 
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The neurological signs commonly used to diagnose CSM include Hoffman’s sign, the 
Babinski sign, clonus, the hand withdrawal reflex, deep tendon reflexes, the suprapatellar 
quadriceps test, and the inverted supinator sign (Cook et al., 2009). No single test has 
shown sufficiently high sensitivity, nor sufficiently low negative likelihood ratio for effective 
screening of patients with suspected myelopathy (Cook et al., 2009). In fact, many tests 
used in isolation show inconsistent results. One study found that the inverted supinator 
sign demonstrated moderate sensitivity (61%) and high specificity (75%) in tests of 
diagnostic accuracy for myelopathy (Cook et al., 2009). However, the same sign was 
present in 27.6% of healthy individuals, of whom 10% also had a positive Hoffman’s sign 
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but no other signs of myelopathy (Kiely et al., 2010). This indicated a high likelihood of 
false positives. Similarly, two further studies (Houten and Noce, 2008, Chikuda et al., 
2010) found that Hoffman’s sign was more sensitive than the Babinski sign in myelopathy 
with mild neurological deficit. Another study found that the Babinski sign was the most 
accurate finding to confirm the presence of myelopathy on MRI, with a positive likelihood 
ratio of 4.0 (Cook et al., 2009). Combinations of tests did not increase the negative 
likelihood ratios compared with tests used in isolation (Cook et al., 2007). The prevalence 
of positive long tract signs correlated with severity of myelopathy, and therefore these 
signs may be of limited utility in the diagnosis of early or mild CSM (Chikuda et al., 2010). 
A recent systematic review concluded that most clinical tests for CSM demonstrated high 
specificity and low sensitivity, and supported the conclusions of previous studies that the 
tests are of limited utility in screening for myelopathy or in early diagnosis (Cook et al., 
2011).  
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In the absence of a definitive diagnostic test, the clinician must look to MRI to provide 
further clarity. Spinal cord compression can be indicated on MRI by an indentation on the 
spinal cord parenchyma that changes the contour of the perimeter of the cord, or by 
signal intensity (SI) changes within the cord itself (Harrop et al., 2010). SI changes 
manifest as a high SI on T2-weighted images, a low SI on T1-weighted images, or both 
(Uchida et al., 2005). A scale, presented in Table 2.2, was developed by Mehalic et al. 
(1990) to classify these MRI abnormalities into levels of severity.  
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Grade Description 
Grade I 
(N/N) 
Normal intensity on both T1 and T2 weighted images 
Grade II 
(N/Hi) 
No intramedullary signal intensity abnormality on T1 weighted image, with 
high intramedullary signal on T2 weighted image  
Grade III 
(Lo/Hi) 
Low intramedullary signal intensity on T1 weighted image and high 
intramedullary signal intensity on T2 weighted image 
Changes in SI on either T1 or T2 weighted images are usually sufficient to confirm the 
diagnosis of CSM. Increased intramedullary SI on T2 weighted images represents diffuse 
neuronal cell loss, gliosis, oedema, demyelination, and axonal and spongy degeneration 
in the white matter, and is a sign of advanced spinal cord damage (Uchida et al., 2009, 
Chikuda et al., 2010). SI changes on MRI are associated with poorer neurological 
outcomes following surgery for CSM (Morio et al., 2001, Uchida et al., 2005). Therefore, 
although this finding clarifies the diagnosis, it appears that the pathophysiological 
mechanisms underlying SI change are indicative of more severe, perhaps irreversible 
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cord damage, and therefore an earlier diagnosis would be desirable. MRI evidence of 
spinal cord compression by indentation into the cord surface without SI changes is 
associated with a better outcome (Uchida et al., 2005), however it can be present in the 
absence of spinal cord pathology. Spinal cord compression without signal change was 
noted in 16% of cervical spine MRI scans in asymptomatic individuals under the age of 
64 years, and in 26% of scans of those aged 65 years and over (Teresi et al., 1987). It is 
clear therefore that MRI cannot be relied upon in isolation. Findings on imaging must be 
correlated to the patient’s clinical presentation.   
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As outlined above, definitive MRI evidence of cord damage, manifesting as altered signal 
intensity, and the presence of long-tract signs on examination, tend to be associated with 
more severe myelopathic presentations. Early diagnosis in the case of mild or 
inconclusive symptoms and signs can be aided by the use of electrophysiological tests, 
including somatosensory evoked potentials (SEP) and motor evoked potentials (MEP). 
Unlike conventional nerve conduction studies and electromyography, these tests evaluate 
CNS integrity (Dvorak et al., 2003). One prospective study evaluated 199 patients who 
had MRI evidence of cord compression but no signs or symptoms of myelopathy on entry 
to the study. During a two-year follow-up period, 22.6% of these patients developed 
clinical evidence of CSM, and this correlated significantly with abnormal MEP and SEP 
findings (Bedna!ík et al., 1998). A further prospective study examined the correlation 
between transcranial magnetic stimulation and MRI in people with CSM. It found that 
prolonged central motor conduction time correlated strongly with classifications of 
disease severity on MRI (Spearman’s rho, 0.73–0.75), and showed 98% sensitivity and 
98% specificity for spinal cord abnormality (Lo et al., 2004). The evidence for 
electrophysiological tests is based, however, on a relatively small cohort of studies, and 
therefore their use cannot be universally recommended in the management of CSM. 
Future studies may point to a more conclusive role for this technology (Lo, 2008). 
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Several authors have acknowledged that the course of CSM varies greatly among 
individuals. Detailed cohort studies on its natural history are lacking. Much current 
knowledge comes from clinical observation or case series studies, with poor 
standardisation of interventions and variable follow-up. A stepwise progression of 
symptoms was described by authors of early publications, who observed periods of 
quiescent stability followed by intervals of marked neurological deterioration in their 
populations (Clarke and Robinson, 1956, Nurick, 1972). Some studies reported an 
inevitable decline in neurological function, while others showed static symptoms (Matz et 
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al., 2009). A number of studies pointed to poorer prognosis in patients who were older 
(Morio et al., 2001, Harrop et al., 2010), had a longer history of symptoms (Morio et al., 
2001), and more severe symptoms (Matz et al., 2009). MRI indicators of poorer prognosis 
included low SI on T1 weighted MRI (Uchida et al., 2009, Avadhani et al., 2010), high SI 
on T2 weighted MRI (Mehalic et al., 1990, Wada et al., 1999, Chen et al., 2001, Suri et 
al., 2003, Uchida et al., 2009, Harrop et al., 2010), and increased transverse area of the 
spinal cord (Wada et al., 1999, Uchida et al., 2009). There was significant variability in the 
management and follow-up time of the individuals with CSM who participated in these 
studies. For this reason, the timescale for these prognostic indicators remains unknown. 
It is not known whether patients with sub-clinical canal stenosis or very mild symptoms 
will inevitably progress to clinical myelopathy. Some risk factors for such progression 
have been identified in a prospective study. Bednarik et al. (2008) followed a cohort of 
199 patients who had radiological but no clinical evidence of myelopathy. During a follow-
up period ranging from two to 12 years, 22.6% of the cohort developed signs and 
symptoms of myelopathy. Using a univariate Cox proportional hazards model, 
progression to clinical myelopathy was predicted from initial symptoms and signs by 
symptomatic cervical radiculopathy (relative risk (RR) 3.68), abnormal SEP (RR 3.21) 
and MEP (RR 2.91), and high SI on T2 weighted images (RR 1.6). The 25th percentile 
time from sub-clinical to clinical myelopathy was 48.4 months. However, some patients 
were followed up for just 24 months, so the true conversion rate may be higher. 
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There are no definitive guidelines underpinning the medical or surgical management of 
CSM (Dvorak et al., 2003). Two options are available, namely conservative management 
and surgical decompression. There is no consistent approach to conservative 
management in the literature. Protocols involving immobilisation of the cervical spine in a 
collar (LaRocca, 1988) or the application of cervical traction (Yoshimatsu et al., 2001) 
have been described. Similarly, a variety of surgical techniques to decompress the spinal 
cord have emerged, including anterior cervical discectomy, anterior cervical discectomy 
and fusion, anterior cervical corpectomy and fusion, laminectomy, laminoplasty, and 
laminectomy and fusion (Mummaneni et al., 2009). These techniques are often broadly 
divided into two groups, determined by an anterior or posterior surgical approach. 
Most reports have found unsatisfactory results with conservative management. There is 
some evidence that intensive conservative management, including cervical traction for 
three to four hours daily for periods of at least a month, may be effective in patients with 
milder symptoms (Yoshimatsu et al., 2001). However, there are no high quality 
randomised controlled trials (RCTs) comparing surgical and conservative management. A 
Cochrane review in 2010 found just two trials. Both showed inadequate randomisation 
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and had small sample sizes. One included patients with mild symptoms only. The 
reviewers found low quality evidence that patients with mild myelopathy felt subjectively 
better shortly after surgery, but no evidence of a long-term benefit (Nikolaidis et al., 
2010).  
In the absence of definitive evidence for or against surgery or conservative management, 
a number of arguments in favour of surgical intervention have emerged (Jankowitz and 
Gerszten, 2006). Firstly, degenerative changes within the cervical spine are widely 
considered to be irreversible and progressive. It is thought that surgical decompression 
may arrest the progression of further degenerative changes, leading to stabilisation of 
symptoms and prevention of further deterioration (Jankowitz and Gerszten, 2006, Rao et 
al., 2006). However, this argument is based on assumption that untreated individuals will 
inevitably experience progressive neurological deterioration. There is no convincing 
evidence of this in the literature (Fouyas et al., 2002), although it is generally accepted in 
clinical practice that neurological function may deteriorate in a stepwise fashion, with 
periods of stability followed by intervals of rapid deterioration (Nurick, 1972). 
Secondly, it is thought that patients with spinal canal stenosis are at a higher risk of SCI 
after relatively minor trauma (Baron and Young, 2007). A recent study found no evidence 
of this in patients with asymptomatic cord compression (Bednarik et al., 2011). However, 
the patients in that study had been advised to avoid activities with a risk of trauma. It is 
unclear whether the pursuit of normal, unrestricted activities would lead to a greater 
incidence of traumatic events and therefore of neurological deterioration.  
A third factor that mitigates against conservative management is the fact that the existing 
protocols involve multiple hours of continued traction (Yoshimatsu et al., 2001) This could 
be associated with significant risks relating to immobility, as well as the impact of such 
time-consuming and restrictive procedures on quality of life. The lack of evidence leaves 
the choice of surgical or conservative management as a matter of clinical judgement. In 
many cases, given the fact that the evidence suggests possible improvement with 
surgical management and unsatisfactory or unclear outcomes from conservative 
management, early surgical decompression is often recommended.  
The lack of certainty around the management of CSM is further compounded by variable 
quality of evidence on different surgical options. A number of studies have been criticised 
for methodological flaws, including retrospective study designs, small sample sizes, 
tabular interpretation of results without statistical analysis, and poor choice of outcome 
measures (Jankowitz and Gerszten, 2006). There is a risk that surgery may be performed 
unnecessarily on some patients whose symptoms might have stabilised, while in others, 
the fear of complications from surgery, coupled with uncertainty about the benefits of 
decompression, might lead to delays in surgery until irreversible damage has already 
occurred (Singh and Crockard, 1999). There is therefore a need for greater 
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methodological rigour in studies of CSM, including longer follow-up periods and the use 
of robust, sensitive and reliable outcome measures (Jankowitz and Gerszten, 2006).  
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The evidence on the pathophysiology of CSM suggests a primary degenerative process, 
with some genetic and environmental factors that might precede or accelerate the 
development of CSM. Signs and symptoms of the disease are somewhat variable. The 
most common symptoms include gait disturbance, weakness or loss of sensation in the 
lower limbs, and clumsiness or weakness of the upper limbs, particularly the hands. The 
diagnosis is suspected in the presence of positive long tract signs and confirmed by MRI 
evidence of cord compression. Surgical decompression of the spondylotic cervical spine 
is favoured above conservative management as a treatment for CSM, however previous 
studies have lacked methodological rigour. The next chapter will explore gait impairment 
in CSM and its evaluation using three-dimensional gait analysis (3DGA).  
 
19 
)?"=+%/&IE&)://%*+&P*6%/,+"*60*7&'(&A"0+&0*&)%/@0."$&
C='*6>$'+0.&N>%$'="+?>&"*6&18=$0."+0'*,&('/&Q%?"#0$0+"+0'*&
IFD& 1*+/'6:.+0'*&
As outlined in Chapter 2, gait impairment is one of the primary features of CSM. Gait is of 
interest to physiotherapists, doctors and patients alike. It is the focus of many 
rehabilitation goals (Field-Fote, 2000) and demands significant amounts of therapy time 
(Lang et al., 2009). Physiotherapists require a detailed appreciation of the biomechanical 
and neuromuscular mechanisms underlying gait in order to assess and treat it. 
Assessment of gait is important to physicians and surgeons as it provides a clinical 
indication of disease severity. Patients are concerned with the impact of their disease on 
their quality of life, as their mobility will dictate their ability to participate in their chosen 
professions or activities. A greater understanding of gait in CSM could therefore inform 
the interpretation of the course of the disease for patients and clinicians, and provide for 
improved clinical analysis and treatment strategies in rehabilitation. 
Gait analysis is the systematic measurement, description, and assessment of quantities 
that characterise a person's walking pattern (Gage et al., 1995). Methods of gait analysis 
can be divided into four categories, 1) visual observation, either in real time or from a 
video recording, 2) timed walk tests, 3) carpeted recording mats with embedded pressure 
sensors, such as the GaitRite®, for measurement of temporal-spatial parameters (TSPs), 
and 4) 3DGA incorporating motion analysis cameras, force plates and sophisticated 
computer algorithms to determine joint biomechanics, which in some cases also 
incorporates EMG. Visual observation is the most commonly used method in clinical 
practice, but it demonstrates poor inter-rater and test-retest reliability and poor criterion 
validity against the more sophisticated methods (Bilney et al., 2003). A more accurate 
and reliable method is therefore required for research purposes. 
3DGA is widely considered to be the “gold standard” technology for gait analysis (Kirtley, 
2006). It has been recommended in incomplete SCI, where three-dimensional 
measurements of dynamic joint ROM and calculation of joint forces, moments and 
powers can significantly improve the understanding of a gait deficit (Patrick, 2003). It has 
been used to evaluate many neurological disorders, such as stroke (Lamontagne et al., 
2007), traumatic SCI (Heller et al., 1996, Gil-Agudo et al., 2009), Parkinson’s disease 
(Morris et al., 2005, Nieuwboer et al., 2007), TBI (Williams et al., 2009b) and CP 
(Lebiedowska et al., 2004, Gough and Shortland, 2008). In CP, 3DGA is used extensively 
in the evaluation of complex gait abnormalities and in assessing the effect of surgical 
interventions to alleviate deformities in the growing child (DeLuca et al., 1997). In seeking 
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to build a comprehensive picture of gait impairment in CSM, 3DGA is therefore the 
method of choice. 
The aims of this chapter are 1) to review current understanding of gait in CSM, with 
particular reference to studies using 3DGA, 2) to consider the possible neuromuscular 
and biomechanical causes of gait impairment, 3) to examine the implications of this 
knowledge for rehabilitation, and 4) to identify areas in need of further research.  
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A literature search was conducted using the databases Medline, Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), and the Physiotherapy Evidence 
Database (PEDro). The following Medical Subject Heading (MeSH) terms were used in 
the search strategy: cervical myelopathy, cervical spondylotic myelopathy, compressive 
myelopathy, spinal cord compression, cervical spondylosis, spondylosis, gait, gait 
analysis. Studies were included in the literature review if quantitative evaluation of gait in 
people with CSM had been conducted using either 3DGA, carpeted mats such as the 
GaitRite®, or timed walk tests.  
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Six studies that used 3DGA in the evaluation of gait in CSM were found (Kuhtz-
Buschbeck et al., 1999, Maezawa et al., 2001, Suzuki et al., 2002, Moorthy et al., 2005, 
Kim et al., 2010, Lee et al., 2011). Two studies evaluated gait speed using a validated 
timed walking test (Singh and Crockard, 1999, Singh et al., 2009). A case report that 
evaluated changes in gait speed, strength and spasticity in a patient with CSM was also 
identified (Engsberg et al., 2003). Table 3.1 shows the main methodological features of 
the studies using 3DGA. 
 
21 
!"#$%&'()*&+%,-./.$.012"$&3%",45%6&.3&6,4/1%6&46170&'89:&,.&%;"$4",%&0"1,&17&<=+&
Authors Sample Size 3DGA System Healthy Controls Follow-Up Parameters 
Kuhtz-Buschbeck 
et al. (1999) 
12 Qualisys (Savedalen, 
Sweden), over 
treadmill 
N = 14, age matched 12 days and 2 
months post 
surgery 
TSPs, kinematics (key points) 
Maezawa et al. 
(2001) 
24 Anima (Tokyo, Japan), 
over ground 
N = 72, matched for age 
and body weight 
Variable: mean 32.4 
months post 
surgery, range not 
specified 
TSPs, kinematics (key 
points), ground reaction 
forces (peaks) 
Suzuki et al. 
(2002) 
15 Vicon 370 (Oxford, 
UK) 
N = 12, not matched None TSPs, kinematics (visual 
interpretation of curves) 
Moorthy et al. 
(2005) 
6 Not specified Unpublished normative 
data, no age, gender or 
sample size specified 
12 months post 
surgery for 5 
patients, 19 months 
for the 6th patient 
TSPs, kinematics (total 
ROM), ground reaction forces 
(peaks), EMG (visual 
interpretation) 
Kim et al. (2010) 36 Motion Analysis 
(Santa Rosa, 
California, USA) 
None None TSPs, kinematics (peak 
ROM) 
Lee et al. (2011) 38 Motion Analysis 
(Santa Rosa, 
California, USA) 
N = 36, similar age and 
gender 
None TSPs, kinematics (ROM at 
key points) 
3DGA = three dimensional gait analysis, N = number of participants, TSPs = temporal-spatial parameters, ROM = range of motion, EMG = electromyography
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TSPs, the time and distance measurements of gait, have been described as the “vital 
signs” of gait analysis (Kirtley, 2006). Studies in CSM have consistently shown reduced 
gait speed compared to healthy controls (HCs) (Kuhtz-Buschbeck et al., 1999, Maezawa 
et al., 2001, Suzuki et al., 2002, Lee et al., 2011). One study did not find a significant 
difference in gait speed between people with CSM and HCs (Moorthy et al., 2005), 
however the sample size of six participants with CSM may have had insufficient statistical 
power to detect change.   
Gait speed is a product of stride length and cadence (Kirtley, 2006). Three studies found 
evidence of both reduced cadence and reduced stride length in CSM (Maezawa et al., 
2001, Suzuki et al., 2002, Lee et al., 2011). However, cadence did not correlate with 
scores on the Nurick scale or Myelopathy Disability Index, whereas gait speed showed a 
moderate correlation (Singh and Crockard, 1999). Achievement of adequate stride and 
step length depends on the duration of the single support and double support phases in 
stance, which are in turn influenced by a number of factors such as stability, strength and 
proprioception (Whittle, 2002). One study reported a significant reduction in the duration 
of single support in moderate CSM (27.2% gait cycle (GC) duration) and severe CSM 
(22.5% GC duration) compared to HCs (33% GC duration) (Maezawa et al., 2001). 
Another study found an increase in double support duration in CSM patients (12.7–13.1% 
GC duration) compared to HCs (10.3–10.4% GC duration) (Lee et al., 2011). These 
findings could indicate either 1) impaired stability of the ipsilateral limb in single-leg 
stance or 2) ineffective momentum generation into swing by the contralateral limb, or 
both. To date, kinetic and EMG analyses have not evaluated these potential contributing 
factors. 
Dynamic base of support, or step width, has also been measured in gait in CSM. One 
study found significantly greater step width compared to HCs under three conditions, 1) 
normal walking on a 13 metre (m) walkway (step width 7.4 centimetres (cm) in HCs 
compared to 9.9 cm in CSM), 2) blindfolded walking on the walkway (HC 8.9 cm, CSM 
13.7 cm), and 3) treadmill walking (HC 10.9 cm, CSM 15.2 cm) (Kuhtz-Buschbeck et al., 
1999). The finding of increased step width in CSM was supported by a later study, who 
found that more severely-affected patients with CSM employed significantly greater step 
width during overground walking compared to HCs (Maezawa et al., 2001). A further 
study found no difference in step width between CSM and HC groups (Lee et al., 2011). 
Step width may be an indicator of dynamic balance during gait (Whittle, 2002), however 
its significance as a stand-alone measure is unclear. Further investigation of this 
parameter is warranted. 
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The characteristics of the comparison HC group are poorly stated in most studies, and 
this poses a limitation on the interpretation of the results. One study demonstrated 
adequate gender and age matching, and used similar sample sizes in both groups with 
38 in the CSM group and 36 HCs (Lee et al., 2011). Two studies specified that HCs were 
matched to age and anthropometric characteristics, but did not specify gender matching 
(Kuhtz-Buschbeck et al., 1999, Maezawa et al., 2001). In one study, different sample 
sizes were used (72 HCs compared to 24 CSM participants) (Maezawa et al., 2001). This 
may have reduced the variance of the HC group. Another study did not state the size, 
gender, age or other characteristics of their HCs, but stated that it comprised “previously 
unpublished normative data” (Moorthy et al., 2005). In a further study, the HC group was 
significantly younger (mean age 39 years) than the CSM group (mean age of 55 years) 
(Suzuki et al., 2002). Age and gender have been found to influence gait parameters, and 
therefore matching of these factors would be necessary to avoid any confounding effects 
in the interpretation of findings (Roislien et al., 2009).  
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A number of studies have examined kinematics in CSM and found deviations in ROM 
compared to HCs. Each study examined different kinematic key points, leading to 
difficulty in amassing evidence for a particular abnormality. However, certain trends have 
emerged. Altered kinematics of the knee in stance have been noted, such as reduced 
flexion during loading (Kuhtz-Buschbeck et al., 1999, Suzuki et al., 2002) and 
hyperextension in mid stance (Maezawa et al., 2001). A case report described a patient 
with CSM whose initial presentation was of a hyperextension disorder at the knee 
(Moorhead, 1993). Knee flexion in stance is one of Saunders’ determinants of gait 
(Saunders et al., 1953), as it adjusts the effective length of the leg to keep the height of 
the hip constant and allow for efficient forward progression of the body mass (Whittle 
2003). Therefore, any reduction in knee flexion at loading response could have a 
significant impact on gait efficiency. Knee flexion in stance also allows for acceptance of 
body weight through the weight-bearing limb and ensures a smooth transition through 
mid stance (Perry, 1992). A reduction in the eccentric yield on loading could signify an 
inability to allow the quadriceps to undergo controlled lengthening, and could be a feature 
of spasticity as well as of weakness (Kerrigan et al., 2001). 
Reduced knee flexion in swing has been found in two studies comparing CSM to HCs. 
The first study found a reduction of approximately 5° (63.5–63.8° in HCs, 58.2–58.7° in 
CSM) (Lee et al., 2011), and the second, 10° (56.5° in HCs, 45.2–46.5° in CSM) 
(Maezawa et al., 2001). Other studies did not evaluate this parameter. Knee flexion in 
swing could be impaired by a reduced yield in the lengthening quadriceps due to 
spasticity (Sutherland and Davids, 1993) or by lack of momentum generation in pre swing 
(Gage, 1991). It could also be an erroneous finding due to differences in gait speed 
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between the groups, as knee flexion in swing shows a strong correlation with gait speed 
(Lelas et al., 2003). 
Changes in kinematics at the ankle at toe-off have been identified in two studies. One 
study found a reduction in peak ankle plantarflexion in CSM (5–10.5°) compared to HCs 
(15°) (Lee et al., 2011). The other identified a reduction in peak ankle plantarflexion in 
patients with moderate (7.5°) and severe (8°) CSM compared to HCs (12.8°) (Maezawa 
et al., 2001). This may indicate a lack of power generation at the ankle during the pre 
swing phase of gait, however analysis of kinetics would be necessary for a more precise 
interpretation. 
At the hip, no differences in peak flexion or extension, or in total ROM, have been found 
in CSM compared to HCs (Kuhtz-Buschbeck et al., 1999, Maezawa et al., 2001, Lee et 
al., 2011). Kinematics at the pelvis were examined in one study, which found a significant 
reduction in pelvic obliquity in less chronic CSM compared to controls, but also a 
significant increase in the same parameter in those with more chronic disease, namely 
symptoms of at least one year’s duration (Suzuki et al., 2002). The magnitude of this 
change was 1°, and was probably of little clinical significance.   
The information from these studies helped to identify features of the gait pattern 
associated with CSM. However, most studies evaluated only a limited number of 
parameters. A greater insight could be attained through the systematic analysis of a 
number of discrete parameters at specific points in the GC across three planes of motion 
(Hanlon and Anderson, 2006). In addition, the timing of joint motion should be examined, 
as the timing of peak values must be appropriate to the tasks of that phase in the GC 
(Perry, 1992). Therefore, although significant contributions have been gleaned from the 
studies discussed above, a complete kinematic profile of CSM patients, across all planes 
of motion and multiple key points of interest, has not been described. 
A further limitation of previous studies is the presence of potential confounding factors 
that may affect the interpretation of the findings. One study (Kuhtz-Buschbeck et al., 
1999) recorded kinematics during treadmill walking at a standard velocity of 2 kilometres 
per hour (km/h). This speed was significantly slower than the mean self-selected speed of 
the CSM group, 4.28 km/h. Changes in joint ROM may have been imposed by forcing a 
shorter stride length to accommodate the slow speed. The slow speed may also have 
masked the possible influence of spasticity on joint kinematics, which due to its velocity-
dependent nature might be more apparent during faster walking. Furthermore, although 
treadmill walking has been shown to be equivalent to overground walking in healthy 
people (Riley et al., 2007), it is not known whether this is the case for people with 
neurological deficits. The kinematic findings in this study must therefore be considered in 
the context of these potential limitations. 
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In order to achieve an accurate evaluation of gait, participants should walk with a pattern 
that is close to their natural preference (Gormley et al., 1999). One study using the Anima 
system required participants to fold their arms while walking to avoid interference with the 
reflective markers during motion capture (Maezawa et al., 2001). This may have had an 
erroneous influence on the movement of the trunk and pelvis during the GC, and may 
have impacted on lower limb kinematics.  
An important feature of the study of gait is the inter-dependence of many gait variables. 
Gait speed is known to influence lower limb kinematics, with faster speeds associated 
with larger ROM, though the associations vary depending on the joint itself and the timing 
within the GC (Hanlon and Anderson, 2006). In particular peak knee flexion in stance and 
swing show strong positive correlations with gait speed (Lelas et al., 2003). Apart from 
Kuhtz-Buschbeck et al. (1999), who assessed gait over a constant speed of 2 km/h, all 
studies compared the CSM and HC groups at different speeds (Maezawa et al., 2001, 
Suzuki et al., 2002, Moorthy et al., 2005). While it is important that HCs should walk at 
self-selected speed in order to evaluate natural walking performance, there is also a need 
to match the speeds of CSM and HC participants to avoid confounding effects on 
kinematics (Jordan et al., 2007, Roislien et al., 2009, Williams et al., 2009b). Otherwise, it 
cannot be known whether reduced joint excursion is caused by the slower gait speed, or 
co-exists with it as a pathological feature in its own right.  
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The study of kinetics is of particular importance in determining the biomechanical factors 
that produce movement. The forces produced by the body cannot be measured directly, 
but can be inferred from the magnitude and position of the ground reaction vector with 
respect to axes of the lower limb joints during gait. The ground reaction force (GRF) can 
be recorded during stance by a force plate, and quantitative values for joint moments and 
powers can then be determined using inverse dynamics (Kirtley, 2006).  
There is a lack of reported data on the kinetics of gait in CSM. Two studies have 
evaluated changes in the components of the GRF. One study found significantly lower 
anterior-posterior (AP) GRF in the CSM group compared to HCs, but not in vertical or 
medial-lateral GRF (Moorthy et al., 2005). The second study found significant reductions 
in peak vertical and AP GRF in patients with moderate and severe CSM compared to 
HCs (Maezawa et al., 2001). Again, this finding may be confounded by the slower gait 
speed of the CSM group. Kinetic parameters tend to show a linear or quadratic 
relationship with speed (Lelas et al., 2003). Without controlling for speed, it is difficult to 
interpret the changes in GRF in these studies.  
Analysis of joint moments and powers would further enhance the current understanding 
of gait in CSM, as it would allow for the interpretation of the forces that produce the 
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observed temporal-spatial and kinematic output. No studies have examined moments 
and powers in gait in CSM to date. 
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Analysis of the EMG signals generated during gait allows for direct interpretation of the 
biological signals responsible for muscle activation (Frigo and Crenna, 2009). EMG can 
evaluate the contributions of individual muscles to a movement pattern. It is therefore an 
important adjunct to kinetic analysis, which calculates only the net effect of a group of 
muscles acting about a joint and assumes no co-contraction (Kirtley, 2006). EMG signals 
from eight lower limb muscles during gait were reported in a cohort of six people with 
CSM (Moorthy et al., 2005). The signals were interpreted visually. All muscles appeared 
to show prolonged duration of activation and delayed onset in relaxation, suggesting a 
problem with co-activation or spasticity (Moorthy et al., 2005). A more complete analysis 
of EMG, including quantitative measurement of timing and amplitude, is lacking in CSM at 
present. Such parameters are critical in the interpretation of neurological gait disorders 
(Frigo and Crenna, 2009). There is a need for future studies to employ more 
sophisticated analysis methods of EMG signals to determine the effect of muscle 
activation on the observed gait patterns in CSM. 
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A number of studies have performed sub-group analysis using various indicators of 
disease severity to determine its effect on gait in CSM. In one study, a reduction in gait 
speed compared to HCs was found in people with moderate and severe CSM indicated 
by lower Japanese Orthopaedic Association (JOA) scores, but not in those with mild CSM 
(Maezawa et al., 2001). There were no significant differences between the groups 
themselves, though there was a non-significant trend towards progressively slower gait 
speed with worsening severity.  
Differences in kinematics were also found in this study. This data provided some 
evidence of the natural history of gait impairment in CSM. Reduced knee flexion was 
common to all groups. Reduced ankle plantarflexion in stance was present in the 
moderate and severe groups, whereas the severe group exhibited hyperextension of the 
knee in stance. Loss of knee flexion in swing was significant in the mildly affected group 
who had an otherwise normal gait, supporting a similar finding in a previous case study 
(Moorhead, 1993). This suggests that loss of knee flexion may be one of the first signs of 
a developing myelopathic gait, and that hyperextension of the knee in stance may 
indicate more advanced disease. 
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Another factor that may affect the performance of gait in CSM is the chronicity of the 
disease. One study on gait performance in CSM dichotomised its participants into two 
sub-groups, one group with a history of symptoms for more than one year and the other, 
less than one year. The more chronic group had significantly slower gait speed, shorter 
stride length and shorter single stance phase duration than the less chronic group, 
suggesting that gait deteriorates as the disease becomes more prolonged (Suzuki et al., 
2002). Chronicity of CSM has been found in previous studies to be predictive of a less 
favourable outcome (Morio et al., 2001, Suri et al., 2003), and is therefore an important 
factor to consider in gait analysis.  
As outlined in Chapter 2, SI changes on MRI are a known predictor of more severe 
disease and poorer outcome in CSM. Kim et al. (2010) used 3DGA to evaluate gait in 36 
pre-operative patients divided into two groups, those with and without high SI on T2-
weighted MRI. Patients with high SI had significantly slower gait speed, longer step time, 
and increased double support time compared to those without high SI. This study also 
supported the hypothesis that gait performance deteriorates with worsening radiological 
outcomes.  
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Changes in TSPs following surgery have been evaluated in five case series, two of which 
used timed walk tests (Singh and Crockard, 1999, Singh et al., 2009), and three used 
3DGA (Kuhtz-Buschbeck et al., 1999, Maezawa et al., 2001, Moorthy et al., 2005). The 
studies showed a general trend of improvement in gait speed. Singh and Crockard (1999) 
found that gait speed increased from a mean of 0.35 metres per second (m/s) pre-
operatively to 0.47 m/s at two months following surgery in 41 patients. This change had a 
moderate correlation with the Nurick score and Myelopathy Disability Index, and led to 
the validation of a 30m timed walk test as an outcome measure for CSM (Singh and 
Crockard, 1999). Kuhtz-Buschbeck et al. (1999) also found a significant improvement in 
gait speed at two months post surgery, from 1.18 m/s to 1.33 m/s. An improvement of 
similar magnitude, from 0.63 m/s to 0.78 m/s, was found by Maezawa et al. (2001), 
though the follow-up time was not standardised across patients and varied from 12 to 44 
months. A longer-term follow-up using the timed 30m walk test as the primary outcome 
measure showed that an increase in gait speed six months after surgery was maintained 
at one, two and three-year follow up (Singh et al., 2009). None of the studies stated 
whether the patients were receiving rehabilitation intervention at the time, a factor that 
may have influenced the recovery of gait. One study found no significant difference in gait 
speed after surgery, however with a sample size of six, it may have been inadequately 
powered (Moorthy et al., 2005).  
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Post-operative changes in kinematics, kinetics and EMG are somewhat less well defined. 
A non-significant trend of increased knee flexion in stance at two months post surgery 
was reported in one study (Kuhtz-Buschbeck et al., 1999). Another noted a statistically 
significant increase of 5.6° in the total sagittal plane range at the knee at one year follow 
up, but no changes at the hip or ankle (Moorthy et al., 2005). A third study found 
statistically significant post-operative increases of 8° in peak hip flexion, 4° in peak knee 
flexion in swing, 4° in knee extension, and 5° in ankle dorsiflexion in stance (Maezawa et 
al., 2001). However, the follow-up time ranged from 12 to 44 months, and with such a 
variable time frame, there may have been other confounding factors affecting gait in this 
cohort. A standardised follow-up interval would be preferable to clarify changes in gait 
performance over time following surgery. A further point to consider is whether the 
magnitude of change in the improved parameters was clinically significant and exceeded 
measurement error. There are no studies on the repeatability of 3DGA in CSM, and 
therefore the influence of measurement error on these findings is unknown.  
Changes in GRF following surgery have been evaluated in two studies. One study found 
significant increases in peak AP GRF, but not the medial-lateral or vertical components in 
six patients at 12 to 19 months post surgery (Moorthy et al., 2005). A second study found 
that peak vertical GRF decreased significantly at mid stance and increased at terminal 
stance, but that the AP component was unchanged (Maezawa et al., 2001). These 
changes in vertical GRF could be explained by the post-operative increase in gait speed 
in Maezawa’s study (Perry, 1992). Without analysis of joint moments and powers, the 
contribution of these changes in GRF to the biomechanics of the lower limbs during gait 
remains unclear.   
Visual interpretation of EMG signals during gait in a study of six patients noted a general 
reduction in the overall activation times of eight lower limb muscles following surgery at 
12- to 19-month follow up (Moorthy et al., 2005). However, there were no quantitative 
data to support this finding. There is therefore no conclusive evidence for changes in 
EMG parameters, either timing or amplitude, following surgery. 
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There is strong evidence for a reduction in gait speed in CSM, and this is associated with 
increased double support duration and decreased cadence. Kinematic data should be 
interpreted with caution due to inadequate matching of HC comparison groups, 
particularly in relation to gait speed. Evidence suggests a reduction in knee flexion during 
swing in the early stages of the disease, followed by reduced ankle plantarflexion at 
terminal stance and reduced knee flexion during loading response in more severely 
affected people. Comparison with HCs of similar age and gender, walking at matched 
speed, would be necessary to confirm that these findings were not erroneous. Kinetic 
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analysis was confined to GRF in two studies, and was potentially confounded by 
differences in speed. These findings are therefore inconclusive and require further study. 
EMG patterns of the lower limb muscles have been reported subjectively in a small 
sample, and suggest an impairment of the timing and duration of muscle activation. There 
is evidence of a correlation between the severity of gait impairment and MRI findings of 
increased SI. Repeated measures studies using pre- and post-operative gait analysis 
data have shown some improvements in TSPs and kinematics, however the 
interpretation of this data in the context of neurological recovery is limited by the variable 
follow-up time and narrow range of parameters used. Finally, there are no data on the 
association of these changes with quality of life and function, so their impacts on 
functional limitation and participation restriction remain unknown. 
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The aim of gait analysis is to provide a comprehensive understanding of the actions of 
the locomotor system during gait, and to identify key features that may relate to the 
underlying pathophysiology of a disorder. The clinical characteristics of an upper motor 
neurone lesion (UMNL) include spasticity, paresis, and impaired sensory function and 
proprioception, all of which influence locomotor performance in people with injuries to the 
CNS (Dietz, 2002). The influences of paresis, tone and sensory deficits on the gait 
pattern of CSM will now be discussed, with the objective of determining the key features 
of the UMNL that lead to changes in gait. 
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To date, kinetic and EMG analyses have not been sufficient to determine the underlying 
contributions of muscle action to the biomechanical output. There is a suggestion that a 
reduction in flexion of the knee in swing occurs prior to any changes in gait speed in the 
milder stages of the disease, and also a tendency towards knee hyperextension in stance 
as the disease progresses (Maezawa et al., 2001). This could represent a reduction in 
eccentric control in the quadriceps, as this finding has been reported in other conditions 
where eccentric strength is impaired, such as anterior cruciate ligament repairs (Lewek et 
al., 2002). There is insufficient evidence from the studies of kinematics in CSM to 
evaluate whether eccentric control may be a problem at other phases of the GC, such as 
at terminal stance, when controlled lengthening of the hamstrings allows for a gradual 
extension of the knee in preparation for initial contact (Perry, 1992).  
A lack of eccentric control during gait would be consistent with muscle weakness. 
Subjective weakness or objective findings of paresis on examination are part of the 
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clinical picture of CSM as discussed in Chapter 2, Section 2.3. One study used 
dynamometry to evaluate peak torque production capabilities at the knee in 39 patients 
with CSM, who were divided into two comparison groups based on those who could walk 
without an aid (A group, 22 patients) and those who required an aid (AA group, 17 
patients). The AA group showed a significantly greater reduction in isokinetic strength at 
faster velocities in the knee flexors, but not in the extensors, compared to the A group at 
the same faster velocities. There were no significant differences in isokinetic strength 
between the groups at slower velocities. Isometric strength in the flexors was also 
significantly lower in the AA group, while extensors were similar (Sairyo et al., 2001). The 
authors suggested that the reduced isokinetic strength of the knee flexors could be 
explained by spasticity of the stronger knee extensors. Provocation of the stretch reflex in 
the extensors at faster velocities may have overpowered the physiologically weaker 
flexors (Sairyo et al., 2001). The lack of a HC comparison group is a limitation of this 
study, as the reduction in isometric and isokinetic strength at the knee in the two groups 
relative to a healthy population remains unknown. A more recent study evaluated 
strength at the knee extensors and flexors using dynamometry in 26 people with CSM 
and age- and gender-matched HCs, and found significantly lower peak torques in the 
CSM group in both muscle groups (Takayama et al., 2005a). There is therefore some 
evidence for paresis as a source of impairment to producing movement in CSM.  
The relationship between lower limb strength and the three-dimensional characteristics of 
gait has yet to be investigated. Lower limb strength has shown a correlation with 
functional walking ability in incomplete SCI (Kim et al., 2004, Wirz et al., 2006, Scivoletto 
et al., 2008), however a close relationship exists only in moderately impaired patients 
(Dietz, 2002). The correlation between strength and gait performance in CSM has not 
been studied. A retrospective study of outcome following anterior cervical decompression 
in 75 CSM patients found that, although between 79.1% and 88.1% of patients showed 
an improvement in lower limb muscle strength of at least one grade on the Oxford scale 
on clinical examination, only 46.7% experienced improvement in lower limb function 
assessed by the Cooper lower limb subscale (Chiles et al., 1999). The follow-up time in 
this study for these particular outcome measures varied from one to 75 months, so there 
may be some confounding factors related to variable follow-up. Despite this limitation, 
there is some evidence from Chiles’ study that functional mobility may be slower to 
improve than strength, and that other factors may be affecting recovery of function.  
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In a previous study, the finding of a greater reduction in isokinetic torque production as 
movement velocity increased was interpreted as evidence of a spastic movement 
disorder in CSM (Sairyo et al., 2001). Spasticity is part of the clinical picture of CSM, and 
is associated with other positive features of the UMNL, such as hyperreflexia and other 
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long tract signs. It has been defined by one expert group as “a velocity-dependent 
increase in the hyperexcitability of the stretch reflex as one component of the upper motor 
neurone syndrome” (Lance, 1980) and by another expert group as “disordered 
sensorimotor control resulting from an upper motor neuron lesion presenting as 
intermittent or sustained involuntary activation of muscles” (Pandyan et al., 2005). There 
is a clear difference in the scope of these definitions, illustrating the difficulty in defining 
the clinical entity of spasticity. Spasticity is difficult to measure objectively, particularly 
during voluntary movement. Scales such as the Ashworth and Modified Ashworth Scales 
and the Tardieu scale have been criticised in recent years for their lack of validity and 
reliability (Haugh et al., 2006, Fleuren et al., 2010). Research in physiology suggests that 
spasticity measured during passive movement and that produced during active 
movement may be different clinical entities, in that the same neurophysiological pathways 
do not underlie both phenomena (Ada et al., 1998, Dietz, 2003). Further studies are 
needed to characterise the influences of spasticity on locomotion in people with CSM. 
Despite the lack of conclusive evidence from gait analysis studies on the presence of 
spasticity during gait, there is strong anecdotal evidence of a spastic gait pattern 
(Montgomery and Brower, 1992, Salvi et al., 2006, Baron and Young, 2007). There is 
some evidence, albeit inconsistent and confounded by a lack of matching for gait speed, 
of an overall reduction in motion amplitude, particularly at the knee (Kuhtz-Buschbeck et 
al., 1999, Maezawa et al., 2001, Suzuki et al., 2002). An abnormal response to stretch in 
the quadriceps group during lengthening could reduce the amplitude of knee flexion 
during swing (Kerrigan and Sheffler, 1995). There is also limited EMG evidence of 
prolonged duration of activation of the lower limb muscles during gait in CSM (Moorthy et 
al., 2005). This could reflect spasticity, but it could also be due to the effects of weakness 
resulting in an increased need for joint stability from co-contraction (Brunner and 
Romkes, 2008). Other muscles prone to the effects of a velocity-dependent increase in 
the stretch reflex include the hamstrings during terminal swing and the gastrocnemius 
during mid stance (Crenna, 1998, Crenna, 1999, Lamontagne et al., 2001). Studies in CP 
and stroke have found evidence of spasticity of these muscles during lengthening, 
confirming the existence of hyperexcitability in response to stretch during gait (Crenna, 
1999, Lamontagne et al., 2001). However, no such evidence exists in CSM or other form 
of SCI.  
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Proprioception is essential for the maintenance of balance during the single support 
phase of gait. Lack of proprioception can result in prolonged double support, reduced 
single support, and a wider dynamic base of support (Whittle, 2002). Studies of TSPs in 
CSM have noted an increase in step width and a decrease in single support duration 
(Kuhtz-Buschbeck et al., 1999, Maezawa et al., 2001). This may suggest an impairment 
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of balance during the GC, which could be proprioceptive in origin. A study of postural 
control in participants with cervical spondylosis, nine with and eight without myelopathy, 
and a comparison group of 17 HCs, found increased postural sway on a force platform in 
both spondylotic groups compared to controls. Although all participants with spondylosis 
showed an increase in sway, the nine participants with myelopathy were more severely 
affected, and also showed longer latencies to onset in the soleus and tibialis anterior with 
postural perturbation (Nardone et al., 2008). The authors concluded that abnormal 
transmission of proprioceptive input through the spinal cord could account for the 
unsteady gait patterns observed in CSM.  
Proprioception has been evaluated by two further studies, in which joint position sense at 
the knee was measured by the absolute angular error in reproducing a predetermined 
position with an electrogoniometer (Takayama et al., 2005b, Okuda et al., 2006). Fifty-
four participants with CSM in the first study produced consistently higher errors than their 
age-matched healthy counterparts (Takayama et al., 2005b). In the second study, 21 
participants with CSM were classified according to their lower limb JOA score of CSM 
severity. It was found that those with the most severe limitation of lower limb function, 
who were unable to mobilise independently, had significantly higher errors in reproducing 
a predetermined knee position than those patients with normal or mildly unsteady gait 
(Okuda et al., 2006). In a post-operative follow-up, angular errors were found to have 
significantly improved at two-week follow-up in 26 patients who underwent posterior 
surgical decompression (Takayama et al., 2005a). These studies support the clinical 
finding of reduced proprioception in CSM, and suggest that there is potential for recovery 
of this sensory modality following decompressive surgery. Proprioception is, however, 
intrinsically linked to other impairments, particularly spasticity, because the disinhibition of 
short-latency reflexes and loss of functionally important long-latency reflexes, as occurs 
in spasticity, causes a profound alteration of proprioception (Dietz, 2002). The impact of 
improved sensory and proprioceptive function following surgery on locomotor 
performance has yet to be established.  
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Studies using dynamometry and isokinetics have confirmed the presence of paresis in 
the CSM population compared to HCs. The relationship with gait has not been studied. 
Follow-up studies using manual muscle testing have found that improvements in 
functional mobility do not necessarily lead to improvements in strength. Evidence for 
spasticity is limited, as no study has specifically evaluated electromyographic responses 
to stretch, however the existence of spasticity as a clinical entity in CSM is generally 
accepted anecdotally. Impairment of proprioception in a condition affecting the long spinal 
cord tracts would be expected, and there is evidence of impaired joint position sense and 
increased postural sway. Again, the clinical significance of these findings in relation to 
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gait and functional mobility is unclear. Detailed evaluation of the kinematics, kinetics and 
EMG features of gait in CSM could improve the understanding of the relative 
contributions of spasticity, paresis and proprioception to locomotion in this cohort. 
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Patients with gait impairment due to CSM will require a rehabilitation programme to 
improve their gait, functional mobility, and quality of life. The evidence base for 
rehabilitation interventions in neurological disorders is growing, however there are no 
guidelines for rehabilitation in CSM, either immediately post surgery or over the following 
months. Studies in incomplete SCI suggest significant potential for neuroplasticity and 
therefore recovery of function, particularly in individuals where the injury is classified by 
the American Spinal Injury Association (ASIA) scale level D, where some sensory and 
motor function are preserved with at least a grade 3 in half of the key muscles (Field-
Fote, 2000). There are no statistics on the percentage of CSM patients who present with 
the various ASIA grades. Clinical experience suggests that most patients are ambulant 
on presentation, and are therefore representative of a motor incomplete population, most 
likely ASIA C or D. However, in comparison to a population with traumatic incomplete 
SCI, CSM patients have the added confounding factor of a potentially progressive 
degenerative process, so it may be the case that much of their recovery would depend on 
the success of surgery in stabilising the cervical spine and preventing further 
impingement of the spinal cord by an ongoing spondylotic process. They also tend to be 
significantly older than patients with traumatic injury (McKinley et al., 1998), and may 
have a higher incidence of co-morbidities that impact on rehabilitation potential. 
Therefore, rehabilitation findings from a general population of incomplete SCI cannot be 
considered representative of CSM, and this group warrants separate investigation.  
A second literature search was conducted to identify papers on the rehabilitation in CSM, 
using the following MeSH search terms: cervical myelopathy, cervical spondylotic 
myelopathy, compressive myelopathy, spinal cord compression, cervical spondylosis, 
spondylosis, rehabilitation, physiotherapy, physical therapy, exercise, exercise therapy. 
No RCTs of rehabilitation interventions were identified. Four relevant studies were found, 
two case series on outcomes for CSM patients in a rehabilitation centre (Yap et al., 1993, 
McKinley et al., 1998), one case series evaluating the effects of robotic treadmill therapy 
on the autonomic system (Magagnin et al., 2010), and a single case report on the use of 
electrical stimulation to the hip and knee (Pastor, 2010).  
The study by McKinley et al. (1998) reported the findings of 46 individuals who were 
admitted to a rehabilitation unit with neurological injury caused by spinal stenosis. 
Nineteen of these patients had CSM and the remaining 27 had cauda equina syndrome 
secondary to lumbar stenosis. The patients were compared to a group with traumatic SCI 
with the same ASIA classification, but not matched on age and gender. The CSM group 
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were on average 28 years older than the traumatic SCI group. Both groups made 
significant progress from admission to discharge in the self-care, sphincter control, 
mobility / locomotion and communication / psychosocial sub-categories of the Functional 
Independence Measure (FIM). There were no significant differences in the rate of 
improvement between groups, though the traumatic group had a trend towards faster and 
greater improvement. It was concluded that people with CSM have potential to benefit 
from inpatient rehabilitation, despite their older age (McKinley et al., 1998). 
A similar retrospective study by Yap et al. (1993) reported the outcomes of 18 patients 
with CSM who were admitted to a rehabilitation centre a mean of 38 days following 
decompressive cervical surgery. The average length of stay in the rehabilitation centre 
was 60.4 days. Outcomes were assessed using the Profile System of Disability 
Classification, an ordinal scale adapted specifically for the study with sub-categories in 
upper and lower limb strength, bladder and bowl function, independence in self-care, and 
functional mobility. At the time of admission, the functional status of 50% of the patients 
had improved following surgery, 27.8% were unchanged and 22.2% had deteriorated. On 
discharge from the rehabilitation unit, there were significant improvements in upper limb 
and lower limb strength, mobility and activities of daily living (ADL) status compared to 
scores on admission (Yap et al., 1993). As with the McKinley study, no information was 
given on the frequency, intensity or nature of the rehabilitation interventions. The study is 
also somewhat limited by the use of a little-used ordinal scale of functional ability. 
Furthermore, the lack of a control group in both studies prevents the improvement being 
attributed to the intervention. However, it is significant that the patients experienced 
further improvement following inpatient rehabilitation, even though 50% had already 
improved after surgery prior to entering the rehabilitation unit. This suggests that 
rehabilitation may be needed to maximise the potential for recovery following surgery. 
Further studies are necessary to evaluate this hypothesis.  
Few studies have evaluated the effect of specific physiotherapy or rehabilitation 
interventions. One study evaluated the efficacy of body-weight supported treadmill 
training (BWSTT) with a robot-driven gait orthosis, the Lokomat®, in six patients with 
CSM (Magagnin et al., 2010). The patients completed daily 30-minute BWSTT sessions 
on the Lokomat® for six weeks. The patients were at least 12 months post injury (range, 
12–180 months), though it is not clear whether this refers to the time following onset of 
symptoms or time since surgery. The patients improved significantly in the mobility score 
of the FIM and on the Barthel index and had a non-significant improvement in JOA score 
of CSM severity. Scores on the Motricity Index did not change (Magagnin et al., 2010). 
BWSTT is of particular interest in incomplete SCI due to its potential to influence the 
spinal reflex circuitry (Field-Fote, 2000). This study was limited by the small sample size 
and the lack of a control group, however it was interesting that improvements occurred 
despite the chronicity of CSM in this group. Further studies are necessary with larger 
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sample sizes, using a control group and comparing BWSTT to more conventional 
therapies, to ascertain the true value of BWSTT in CSM.   
Finally, a case study described positive benefits to one patient with CSM following the 
use of electrical stimulation to the hip and knee extensors in addition to active ROM 
exercises, functional mobility training and gait training (Pastor, 2010). The patient 
participated in therapy five days a week for six weeks, and had electrical stimulation on 
alternate days. Improvement was demonstrated on manual muscle testing, the FIM and 
the Walking Index for Spinal Cord Injury (WISCI). However, longer-term studies with 
larger sample sizes and control groups are necessary to determine if these improvements 
can be attributed to the interventions described in this case study, and to extrapolate the 
findings to a wider population of people with CSM. 
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This chapter has reviewed the evidence summarised current understanding of the 
presentation and nature of gait impairment in people with CSM. It is clear that there are a 
number of gaps in the literature. In particular, there is a need for evaluation of a more 
comprehensive range of kinematic key points, exploration of kinetic and EMG analysis, 
and comparison to healthy controls matched to age, gender and gait speed.  There are 
significant benefits to be gleaned from the use of 3DGA technology, incorporating EMG, 
in this patient population. These potential benefits will inform the development of the 
methodology for this study, and underpin its aims and objectives.  
The neurophysiological factors responsible for the changes in gait in CSM are poorly 
understood to date. As outlined in Section 3.3, impairments such as paresis, spasticity, 
and loss of proprioception may influence gait to varying extents. A recent review of the 
literature on the physiological evaluation of gait impairment following stroke illustrated the 
extent to which gait analysis can be used to improve the understanding of gait impairment 
in a population with a neurological injury (Lamontagne et al., 2007). The same principles 
could be applied to understanding gait in CSM. 
3DGA technology provides the potential for measurement of outcome following surgery 
using sensitive, robust data. The evaluation of the effect of surgery has been limited in 
previous studies by the use of insensitive ordinal outcome measures, which may be 
subject to recall bias and may not capture small but significant changes in the patient’s 
presentation (Singh and Crockard, 1999, Jankowitz and Gerszten, 2006). The validation 
of a 30-metre timed walk test has improved the range of outcome measures available for 
CSM (Singh et al., 2009), however the quality of a gait pattern cannot be captured by a 
timed walk test alone. 3DGA and EMG would allow for the evaluation of subtle but 
relevant changes in gait, and may facilitate greater accuracy in the evaluation of surgical 
decompression and its effect on gait. 
 
36 
Finally, the review in Section 3.4 above shows that rehabilitation protocols for CSM are 
currently poorly defined. The combined results of the studies indicate that there is 
potential for improvement in the functional status of these patients with rehabilitation. 
However, in the absence of any studies of specific intervention, it is difficult to know what 
elements should be included in these rehabilitation protocols, and how they should be 
carried out. It has been said that the principles of human motor control are best 
determined by studying freely moving subjects during natural motor tasks (Capaday, 
1997). Detailed, comprehensive evaluation of gait in patients with CSM should contribute 
to the development of rehabilitation interventions and protocols by allowing the underlying 
factors contributing to the impairment to be identified.  
The next chapter will consider the potential for development of the role of 3DGA and 
EMG analysis in CSM, leading to the aims and objectives of the thesis. 
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It is clear from the evidence presented in Chapter 3 that 3DGA has improved the 
understanding of some features of gait impairment in CSM. However, there are significant 
gaps in current knowledge. Studies to date have confined their analyses to TSPs and a 
limited number of kinematic variables. Kinematics describe the movement of joints during 
gait and the velocities and accelerations of body segments, but they give no information 
on the underlying causes of that movement. Little is known about the contribution of 
individual muscles to the resulting gait pattern. Changes following decompressive surgery 
are poorly understood, and the physiological impairments underlying gait in CSM have 
not been determined. 
This chapter will explore the potential of 3DGA to improve the scientific understanding of 
gait in CSM by evaluating its impact in other pathologies. This will lead to the 
development of aims and objectives for the current study. The thesis will then progress to 
the consideration of methods to achieve these aims and objectives in Chapter 5. 
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Abnormal gait patterns are the result of the combined effects of a primary impairment, 
such as weakness, pain or sensory loss, and the secondary compensation that ensues to 
preserve ambulation or the efficiency of ambulation (Dietz, 2002). Unlike other conditions 
such as stroke, where the injury is sudden and the initial deficit followed by varying 
degrees of neurological recovery and secondary compensation, the insult to the CNS is 
more gradual in CSM. It is possible that compensation for a developing neurological 
deficit may take place as the deficit itself is progressing, particularly if deterioration is 
slow. CSM varies in its rate of progression and severity of neurological impairment (Baron 
and Young, 2007). The relationships between primary impairment and compensation 
cannot be quantified from existing knowledge on gait in this condition.   
The underlying contributory factors to the slow speed, prolonged double-support duration 
and reduced ROM observed in the CSM gait are currently unknown. These features 
could result from changes in muscle strength, tone, co-activation, the need to 
compensate for unreliable sensory input, fear of falling, or other factors. The cause and 
effect relationships between various aspects of gait impairment are of relevance to the 
interpretation of outcome following surgery, as many people with CSM will be treated with 
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surgical decompression. It would be valuable to know if certain gait parameters might 
indicate recovery of neurological function, if recovery does occur. Effective rehabilitation 
of gait in CSM depends to a large extent on the understanding of the underlying deficits 
and their interactions.  
It was considered beyond the scope of this thesis to consider every possible variable that 
might influence gait in CSM. However, it was clear that there was potential for 3DGA to 
explore some of the uncertainties regarding the nature, time frame and recovery of gait 
impairment. Studies of 3DGA in other pathological conditions were examined with a view 
to developing specific aims and objectives for this study. 
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As outlined above and in Chapter 3, most of the work to date using 3DGA in CSM has 
been confined to the interpretation of TSPs and kinematic variables. Two studies have 
examined GRFs (Maezawa et al., 2001, Moorthy et al., 2005). These studies did not 
conduct analysis of the interaction between GRFs and the body segments producing 
these forces. In other words, joint moments and powers were not calculated. A moment is 
the product of a force applied and its distance from the pivot point or fulcrum (Kirtley, 
2006). In gait, a joint moment represents the body’s internal response to an external load 
(Ounpuu et al., 1996). Moments can be used to infer muscle activity at that joint, provided 
a number of assumptions are satisfied (Kirtley, 2006). Power is then calculated as the 
scalar product of the joint moment and the angular velocity of the moving segment 
(Kirtley, 2006). Power quantifies the net energy absorbed or generated by the working 
muscles (Lin et al., 2000). Moments and powers cannot be measured directly, but instead 
they are calculated from the relationship between kinematics and the ground reaction 
vector using inverse dynamics (Kirtley, 2006).  
Information on moments and powers significantly enhances the understanding of a gait 
deficit. In a study of children with myelomeningocele, kinetic analysis identified the 
strategies that compensated for weakness of the hip abductors, hip extensors, knee 
flexors, ankle dorsiflexors, and ankle plantarflexors. For example, compensation for weak 
or absent hip abductors was achieved by increased lateral trunk sway and greater power 
absorption by the hip flexors and adductors during stance (Gutierrez et al., 2005). 
Analysis of joint moments and powers in children with CP identified the strategies behind 
the gait classifications of jump knee, crouch knee, genu recurvatum and mild impairment. 
Lin et al. (2000), for example, found that crouch gait required increased power absorption 
at the knee in terminal stance by the quadriceps to maintain equilibrium with an 
excessively flexed knee. McNee et al. (2004) supported this finding and suggested that 
intervention to maintain knee extension in CP might reduce the exposure of the knee 
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extensor mechanism to increased loads. In other studies, increased hip power generation 
was identified as a compensatory mechanism for weakness of the ankle plantarflexors in 
terminal stance in people with stroke (Nadeau et al., 1999) and in older people (DeVita 
and Hortobagyi, 2000).  
Patrick (2003) commented that the information about muscle actions provided by joint 
moments and powers has improved the management of spasticity in walking in CP, and 
that incomplete SCI could benefit from a similar approach. The current study will include 
the analysis of moments and powers at the hip, knee and ankle during gait with the aim of 
detecting the kinetic contributions to the observed kinematic movement patterns.   
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Joint moments are the net product of a combination of forces exerted by active and 
passive structures. They do not indicate the relative contribution of each individual 
component force (Lin et al., 2000, Dallmeijer et al., 2011). In a neurological population, 
the production of moments and powers may be altered by abnormal co-activation 
between agonist and antagonist muscles (Lamontagne et al., 2000b), abnormal firing of 
muscles due to spasticity (Dallmeijer et al., 2011), or the influence of contracture (Lin et 
al., 2000, Dallmeijer et al., 2011). This can lead to difficulty in interpreting the causes of a 
change in a joint moment. 
The role of individual muscles in the production of movement can be evaluated using 
EMG. Kinesiological EMG, the application of EMG to movement analysis, allows direct 
analysis of the biological signals responsible for muscle activation during gait (Frigo and 
Crenna, 2009). Previous studies have described the activity of individual muscles in 
terms of the appropriateness of their timing during the GC (Buurke et al., 2005), the 
amplitude of the EMG signal at critical points during gait to indicate intensity of activation 
(Baddar et al., 2002), and their responses to stretch during periods of lengthening 
(Crenna, 1999). Combining this information can facilitate interpretation of the causes of 
an abnormal gait pattern.   
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The timing of muscle activation during gait is critical to ensure that motor output is 
optimised to achieve the tasks of the GC (Lauer and Prosser, 2009). Locomotor output 
depends not only on the force a muscle can produce, but also on the appropriateness of 
the timing of that force (Shiavi et al., 1987). 
Changes in temporal activation patterns can provide insights into the motor control 
patterns used by people with neurological disorders (Solnik et al., 2010). Gait 
disturbances in neurological populations have been associated with poor selective 
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activation of muscle groups, which can manifest as activation of a muscle at an 
inappropriate time during the GC, or abnormal co-activation between agonists and 
antagonists (Frigo and Crenna, 2009). Visual observation of EMG patterns during gait in 
six patients with CSM suggested a prolonged duration of activity of each muscle group 
(Moorthy et al., 2005), however these observations were subjective. Timing of muscle 
activation can be quantified by expressing the time for which a muscle is active as a 
percentage of the total duration of the GC, or by measuring the timing of onset and offset 
of individual bursts of activity within that GC. In people with CP and stroke, prolonged 
duration of activation and excessive co-activation between agonist and antagonist 
muscles have been found in EMG studies of muscle activation (Lamontagne et al., 
2000b, Prosser et al., 2010). 
Studies on the timing of muscle activation have provided insights into recovery of mobility 
and function following stroke. In an uncontrolled case series, 13 people with stroke 
showed significant improvements in functional measures of mobility such as walking 
speed, the Rivermead Mobility Index, the Functional Ambulation Categories and the 
Motricity Index from stroke onset to 24 weeks post stroke. However, no significant 
changes were found in the onset or offset times of eight trunk and lower limb muscles on 
the hemiparetic side. Instead, there were changes in the timing of muscle activation on 
the unaffected side. This suggested that functional improvement was related to 
compensatory, adaptive mechanisms in the unaffected leg, and not to the affected side 
regaining its pre-stroke patterns of muscle activation (Buurke et al., 2008). Timing is just 
one aspect of the EMG signal, so it is possible that improvements occurred in other 
aspects that were not examined. However, the findings suggested that recovery of gait 
following stroke is not dependent on the re-organisation of temporal aspects of muscle 
activation on the hemiparetic side (Buurke et al., 2008). This supports the earlier findings 
of Den Otter et al. (2006), who conducted EMG analysis of gait in people with stroke on a 
treadmill. They found no changes in timing of muscle activation in the stroke group over a 
10-week period, despite improvements in functional mobility. The findings of these 
studies are important in the field of stroke rehabilitation, as they suggest that factors other 
than temporal organisation may be of importance in regaining the neuromuscular control 
of gait. These factors could include changes in EMG amplitude within an altered timing 
pattern (Den Otter et al., 2006) or the development of compensatory mechanisms by the 
non-paretic leg and trunk (Buurke et al., 2008). 
Co-activation between agonist and antagonist muscles is also a feature of the timing of 
muscle activation during gait. Co-activation is a motor control strategy that is often 
employed to increase dynamic joint stiffness where greater stability is required, or to 
improve movement accuracy (Damiano, 1993). A finding of increased co-activation may 
reflect a lack of selective muscle activation due to impaired motor control within the CNS 
(Tedroff et al., 2008). Co-activation is also known to be a compensatory strategy for 
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muscle weakness and pain in people with osteoarthritis (Heiden et al., 2009), and has a 
positive association with increasing age (Hortobagyi et al., 2009). Co-activation can be 
quantified by expressing the time for which both agonist and antagonist are active as the 
percentage of GC, provided that cross talk has been ruled out (Frigo and Crenna, 2009). 
Abnormal co-activation has been shown to contribute to deficits in force production in CP 
(Stackhouse et al., 2005) and to reduce moments acting about a joint at key phases of 
the GC in stroke (Lamontagne et al., 2002). It is therefore an important factor to consider 
in the evaluation of deviations in key gait parameters. 
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CSM has been associated with varying degrees of muscle weakness or paresis, similar to 
other neurological disorders. The amplitude of electrical activity on an EMG trace, 
measured in millivolts (mV), indicates the intensity of a muscle contraction at a given 
point in time. However, there is no direct relationship between EMG and muscular force 
(Heintz and Gutierrez-Farewik, 2007), therefore the interpretation of signal amplitude in 
the context of physiological muscle activity is a complex task. Methods have been 
developed to quantify each muscle’s individual force contribution from EMG data (Bogey 
et al., 2010), but have not been tested in neurological populations.  
The value of EMG amplitude as a stand-alone measure has a number of limitations for 
test-retest and group comparison studies, due to variation in electrode placement and 
inter-subject variation in muscle morphology and soft tissue depth (Campanini et al., 
2007). Amplitude is commonly normalised to the peak value within a GC to facilitate 
comparison between performances on different test days and between individuals 
(Lehman and McGill, 1999). Normalisation in this way has the undesirable effect of 
undermining the absolute magnitude of the signal. Muscles that are activated at very low 
amplitude may be over-represented (Lamontagne et al., 2007). Furthermore, inability to 
contract a muscle due to neuromuscular dysfunction will not necessarily be detected 
(Benoit et al., 2003). Normalisation to a maximum voluntary contraction (MVC) provides 
the advantage of a neurophysiological reference. It would be expected that participants 
with greater levels of paresis would demonstrate levels of activation during gait closer to 
their voluntary maximum, however this may be misleading in individuals with neurological 
impairment who are unable to produce sufficient muscle activation to achieve a normal 
force (Damiano et al., 2000). 
Despite these limitations, the amplitude of the EMG signal can provide information on 
whether a muscle’s level of activation is appropriately scaled to the demands of the motor 
task (Frigo and Crenna, 2009). A number of studies have used timing detection 
algorithms to determine phases of muscle activity. The ratio of a signal’s amplitude within 
a burst to its amplitude outside that burst can indicate an individual’s motor control 
capacities and the ability to scale motor output to the demands of the task (Roetenberg et 
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al., 2003). A study of EMG timing and amplitude during gait in people with stroke found 
that the use of gait aids significantly reduced the median amplitude of vastus lateralis and 
tibialis anterior activity, confirming the hypothesis that less muscular effort was required 
when walking with an aid (Roetenberg et al., 2003). The EMG amplitudes of soleus, 
gastrocnemius and tibialis anterior changed significantly during gait in 34 children with CP 
after multilevel surgical treatment. The amplitudes of these muscles’ EMG signals 
decreased at initial contact and increased in terminal stance, while those of the thigh 
muscles did not change (Patikas et al., 2007). Findings such as these could identify 
aspects of motor control that might be amenable to change with the appropriate 
intervention. 
Measurement of EMG amplitude in gait in people with CSM is a novel undertaking. 
Possible methods will need to be explored to determine the most valid and reliable 
approach for this population. These methods will be further examined in Chapter 5, 
Section 5.4.4.4.   
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Spasticity has been defined as “a motor disorder characterised by a velocity-dependent 
increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from 
hyperexcitability of the stretch reflex as one component of the upper motor neurone 
syndrome” (Lance, 1980), and as “disordered sensori-motor control, resulting from an 
upper motor neurone lesion, presenting as intermittent or sustained involuntary activation 
of muscles” (Pandyan et al., 2005). The presence of abnormally increased tone is one of 
the objective findings in a diagnosis of CSM (Salvi et al., 2006). Gait in CSM is often 
subjectively described as a “spastic” pattern (Suzuki et al., 2002). Spasticity in this 
condition therefore deserves further consideration.  
Studies have found a poor correlation between static measurements of spasticity and its 
manifestations during active movement (Dietz, 2003). A study of spasticity in chronic 
stroke patients found that the stretch reflex in the gastrocnemius muscle was enhanced in 
stroke patients during passive movement, but not during active movement of the 
antagonist under conditions designed to simulate limb loading (Ada et al., 1998). Passive 
muscle stretch stimulates the monosynaptic stretch reflex, however this reflex has very 
little function in the regulation of gait, except in single leg stance (Dietz, 2002). As a 
result, it has been suggested that there are differences in the pathophysiology of the 
clinical signs of spasticity, tested by passive stretch, and the spastic movement disorder 
that hinders the patient under dynamic conditions (Dietz, 2003).  
These findings are significant for CSM because the presence of lower limb spasticity, and 
the spastic gait that may result, is one of a number of UMNL signs in the typical CSM 
presentation (Baron and Young, 2007). Lower limb spasticity is usually assessed using 
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either the Modified Ashworth Scale (Bohannon and Smith, 1987), the Tardieu scale 
(Haugh et al., 2006), or by simple clinical examination (Barnes, 2008). The poor 
correlation between resting and dynamic spasticity implies that these scales may be of 
limited value in the assessment of a condition where gait impairment is a primary 
symptom. In the clinical setting, the presence of a spastic gait in CSM is normally 
evaluated by simple observation (Baron and Young, 2007), yet studies have shown the 
accuracy of observation to be poor compared to 3DGA (Williams et al., 2009a). These 
findings underpin the need for the development of a locomotor-specific measurement of 
spasticity in CSM as an objective means of evaluating this clinical feature.  
A locomotor-specific measure of spasticity (LSMS) was developed for children with CP by 
Crenna (1998) and further used for people with stroke by Lamontagne et al. (2001). This 
measurement was based on the relationship between three variables, 1) the lengthening 
velocity of a muscle, 2) EMG signal amplitude and 3) the timing of onset of EMG activity 
during lengthening. Children with spastic CP initiated muscle activity in the hamstrings at 
a lower lengthening velocity during terminal swing than typically developing children. This 
suggested that the lengthening velocity threshold for triggering EMG activity was reduced 
in the CP cohort, indicating higher velocity-related sensitivity to lengthening, namely 
spasticity (Crenna, 1999). A similar approach was used by Lamontagne et al. (2001), who 
found that the direction of the slope between the EMG amplitude and lengthening velocity 
of gastrocnemius was the reverse of normal in people with stroke. In HCs, the slope was 
negative because EMG amplitude did not increase with increasing lengthening velocity, 
but in people with stroke, EMG amplitude showed a positive relationship with lengthening 
velocity. This indicated a pathological response to muscle lengthening and an increase in 
the gain of the stretch reflex (Lamontagne et al., 2001). These methods are 
advantageous because they are specific to gait analysis, particularly as the correlations 
between spasticity during passive and dynamic movement are known to be poor (Ada et 
al., 1998). They also avoid the use of unnatural stimuli, such as the Hoffmann (H) reflex, 
in examining the excitability of the stretch reflex during gait (Lamontagne et al., 2001). 
Further details on the methods involved in the calculation of the locomotor-specific 
measure of spasticity are provided in Chapter 5, Section 5.4.4.5. 
The LSMS has not previously been evaluated in CSM. It has the potential to enhance the 
understanding of the pathophysiology of this condition. If it were found to be valid and 
reliable, it could serve an adjunct to diagnosis in the future, particularly where clinical 
findings of tone-related changes are unclear on physical examination (Salvi et al., 2006, 
Baron and Young, 2007).  
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Individual TSP, kinematic, kinetic, and EMG parameters are of interest in the evaluation 
of neurological gait impairment. However, a greater understanding of motor control 
strategies for the tasks of gait can be obtained by investigating the relationships between 
individual variables. In a study of people with stroke, Lamontagne et al. (2002) 
considered the interaction between EMG timing, amplitude, kinematic key points and 
peak moments in the evaluation of motor control at the ankle during the pre swing phase 
of gait. Participants who had suffered a stroke were assessed using 3DGA and surface 
EMG at their comfortable walking speed. They were compared to HCs at both 
comfortable walking speed and a slower speed approximating that of the stroke group. 
Decreased peak plantarflexor moments at pre swing were noted in both the paretic and 
non-paretic lower limbs in the stroke group, but the mechanisms of disturbed motor 
control differed between the limbs. The paretic limb showed a reduction in the EMG 
amplitude of medial gastrocnemius and a velocity-sensitive response during lengthening, 
which indicated both reduced muscle recruitment and hyperactive stretch reflexes. The 
non-paretic limb showed normal EMG amplitude but greater levels of antagonist co-
activation. This indicated an adaptation either to secondary disuse or to poor postural 
stability during gait (Lamontagne et al., 2000a, Lamontagne et al., 2002). Regression 
found that more than 50% of the variance of gait speed was explained by the lower peak 
activation of the medial gastrocnemius of the paretic lower limb in stance. This finding 
emphasised calf muscle paresis as one of the primary impairments affecting gait after 
stroke (Lamontagne et al., 2002). However, a limitation of the study was that EMG 
amplitude was not normalised, therefore inter-subject variation in electrode placement 
and soft tissue impedance may have affected the results.  
It is not yet known whether similar patterns could be expected in CSM. Both CSM and 
stroke represent injuries to the adult CNS and as such there may be similarities in the 
overall patterns of gait impairment, but they differ in aetiology, speed of onset and site of 
pathology. The application of methods to analyse the interaction between multiple gait 
variables at key phases of the GC, such as those described in the previous paragraph, 
could improve the understanding of the factors contributing to gait impairment in CSM.  
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Gait data is usually interpreted by examining changes in GC curves and specific key 
points, such as peak ROM or power, or the timing of a key point. However, many 
parameters are correlated and therefore show a strong interdependency. For this reason, 
it can be difficult to interpret the dimensions of gait that individual variables represent. 
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Multivariate statistical analysis methods can uncover more complex relationships 
between interdependent variables (Perez and Nussbaum, 2003). Principal components 
analysis (PCA) is one such method. It has been used to classify gait patterns in children 
with CP (Carriero et al., 2009). In Carriero’s study, lower limb kinematic key points from 
typically developing children and children with CP were evaluated using PCA to identify 
the dominant sources of variability in the data and to generate new independent 
variables, the principal components (PCs). The first PC, accounting for 61% of the 
variability in the data, was a function of gait speed and hip and knee movement in the 
sagittal plane, indicating the relationship between these variables. The second PC was a 
function of cadence, step time and frontal plane kinematics. Its scores were effective in 
differentiating jump knee from crouch knee gait patterns (Carriero et al., 2009). Cluster 
analysis of PC scores facilitated the identification of abnormalities that characterised a 
particular gait pattern, while quantitatively accounting for the interdependence between 
component variables.   
In a similar study, Gaudreault et al. (2011) used PCA to analyse kinematic and kinetic 
gait data from adults with osteoarthritis of the knee. Two distinct sub-groups of gait 
impairment were extracted. When the effect of a physiotherapy intervention was 
evaluated, one of the sub-groups showed changes in kinematic and kinetic key points in 
response to the intervention, whereas the other group did not. Pre- to post-intervention 
comparisons of the group as a whole, without accounting for the PCs, found no 
statistically significant differences in gait parameters. The sub-group who responded had 
higher peak knee moments prior to treatment than the non-responding group, suggesting 
that their gait was less severely affected by osteoarthritis. Gaudreault’s study illustrates 
the contribution of multivariate data reduction techniques when evaluating a complex, 
multi-dimensional outcome such as gait, particularly where heterogeneity of a population 
might result in the masking of positive or negative effects of an intervention for a 
particular sub-group.  
A further example of the application of multivariate analysis to 3DGA is the Gait Deviation 
Index (GDI) (Schwartz and Rozumalski, 2008). The GDI provides a single quantitative 
measure of deviation in the kinematic patterns of children with CP compared to those of 
typically developing children. The numerical index generated from the analysis allows the 
subject’s overall gait pattern to be interpreted in the context of deviation from normal. A 
GDI score of 100 points or greater suggests no gait pathology, while each 10 points 
below 100 represents one standard deviation from the overall profile for a typically 
developing child (Schwartz and Rozumalski, 2008). The reduction of data from numerous 
GC curves and key points into a single index has potential advantages in repeated 
measures design studies, particularly where the overall effect of an intervention on a gait 
pattern is of interest, rather than its effect on an individual joint or variable. The GDI has 
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been extensively validated in the paediatric population (Molloy et al., 2010), but its 
applicability to adults with neurological dysfunction is not well established.  
The application of multivariate analysis to 3DGA data in CSM has a number of potential 
advantages. The classification of a large number of interdependent variables would aid in 
the objective determination of gait patterns in CSM compared to HCs. The reduction of 
multiple correlated variables into a smaller number of PCs has advantages for 
communicating an overall change in a gait pattern, which may be of interest when 
evaluating the effects of an intervention, such as surgery. There is potential benefit in the 
development of strategies for rehabilitation, as shown by Gaudreault et al. (2011), who 
found that classifying participants based on their PCA scores led to the identification of a 
sub-group who responded more positively to an exercise intervention. Studies of 
rehabilitation interventions in CSM would require adequate statistical power for sub-group 
analysis if such an objective were to be achieved. 
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The goal at the outset of this project was to analyse gait impairment in CSM, with a view 
to understanding its mechanisms, impact on function and quality of life, and response to 
surgery. Gait is a complex task with many underlying dimensions. It reflects the local 
force-producing capabilities of individual muscles, the ability of the CNS to modulate force 
production and co-ordinate muscles to achieve stability and progression, and 
responsiveness to changes in environmental conditions and functional goals (Dietz, 
2002).  
This chapter has given an overview of the possibilities of 3DGA and EMG data in 
providing information on the biomechanical and neuromuscular impairments underlying a 
pathological gait pattern. Based on the literature review of gait in CSM provided in 
Chapter 3, and the possibilities for improving the understanding of gait outlined in this 
chapter, the aims and objectives of this thesis were devised as follows. 
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The first aim of the thesis was to examine the repeatability of 3DGA measures in CSM, 
incorporating analysis of test-retest reliability of temporal-spatial, kinematic, kinetic and 
EMG parameters. This was addressed using a reliability study.  
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The second aim was to compare gait patterns of people with CSM to those of healthy, 
age- and gender-matched controls. This aim was achieved using a cross-sectional study 
design, and addressed the following objectives. 
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1. To describe the gait patterns of people with CSM with reference to age- and 
gender-based norms. 
a) To compare TSPs, kinematic key points and kinetic key points. 
b) To identify the principal components of these key points in people with 
CSM and HCs. 
c) To investigate EMG patterns of muscle activation during gait in people 
with CSM compared to HCs.  
d) To evaluate timing of muscle activity of major lower limb muscles during 
gait. 
e) To measure co-activation of agonist and antagonist muscles. 
f) To examine indicators of the intensity of muscle activation. 
g) To evaluate dynamic responses to muscle lengthening as a locomotor-
specific measurement of spasticity. 
2. To identify key areas of impairment in gait in CSM. 
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The third aim was to determine changes in temporal-spatial, kinematic, kinetic, and EMG 
variables in gait in people with CSM who undergo surgery. This aim was addressed using 
a repeated-measures experimental study design, with follow-up assessments at six and 
twelve months following surgery. The experimental study also addressed the following 
secondary objectives:  
1. To determine if changes in gait following surgery can be predicted by other 
variables. 
2. To measure change in functional mobility in people with CSM after surgery. 
3. To determine the impact of surgery on health-related quality of life. 
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The review of the literature on the pathophysiology of CSM, its associated gait 
impairment and the impact of 3DGA and EMG analysis on the understanding of other 
neurological conditions, led to the development of three broad aims for this thesis. The 
achievement of these aims and their associated objectives led to the design of three 
separate methodologies, a reliability study, a cross sectional study, and an experimental 
study. Analysis of gait using 3DGA and EMG was a central component of all three 
studies. In the next chapter, the development of methodology common to all studies will 
be discussed, leading to the outline of general methods for recruitment, gait analysis and 
data processing in Chapter 6.  
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The aims and objectives outlined in Chapter 4, Section 4.4, required the development of 
protocols for the primary outcome measures of 3DGA and EMG, and the selection of 
parameters that would address the research questions. Secondary outcome measures to 
quantify spasticity, functional mobility, quality of life, and severity of myelopathy were also 
required. These allowed for interpretation of gait data within the context of a clinical 
assessment of impairment, functional limitation and participation restriction.  
The thesis includes three studies: 1) a test-retest reliability study of 3DGA and EMG 
analysis in CSM, 2) a cross-sectional study to compare gait in people with CSM to age- 
and gender-matched controls, 3) an experimental study to identify changes in gait 
following decompressive surgery for myelopathy. All studies required the recruitment of 
people with CSM. A consistent method of determining this diagnosis was therefore 
required. 3DGA and EMG assessment of gait was a central component of all studies, 
requiring an evidence-based approach to data collection, extraction of parameters, and 
interpretation of data.  
This chapter will outline the development of the methods common to all studies, namely, 
recruitment of participants with CSM, development of 3DGA and EMG assessment 
procedures, extraction of clinically relevant parameters from this data, and the selection 
of secondary outcome measures for CSM. 
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As discussed in Chapter 2, there are no definitive clinical tests for CSM. The diagnosis is 
based on clinical findings with radiological confirmation of spinal cord compression (Cook 
et al., 2009). In clinical practice, some people fall into an uncertain diagnostic category, 
with signs and symptoms but no radiological evidence (Wong et al., 2008). It was decided 
that the CSM cohort in the current study should be representative of people with definite, 
rather than uncertain, CSM. The diagnostic criteria for CSM participants were the 
presence of at least one symptom consistent with spinal cord compression, at least one 
objective long-tract sign, and radiological evidence of spondylotic cord compression with 
the exclusion of other pathologies. This is in keeping with other studies, for example 
Fehlings et al. (2008). The full list of diagnostic criteria is provided in Chapter 6, Section 
6.3. 
In relation to inclusion and exclusion criteria, there were slight differences in the 
requirements of the studies. Previous operative intervention for CSM was considered a 
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confounding factor in the cross-sectional and experimental studies. Recruitment to these 
studies was therefore limited to people with CSM who had no history of operative 
intervention for this condition. Previous surgery for other clinical presentations in the 
cervical spine, such as discectomy for nerve root compression, was not considered an 
exclusion criterion provided that myelopathy was not an indication for that surgery and it 
did not involve the use of instrumentation. In relation to the reliability study, it was 
considered that previous surgery would not confound the quantification of an error range 
of gait parameters specific to CSM. Therefore, recruitment to the reliability study was 
extended to participants who had undergone surgical intervention, provided they met the 
diagnostic criteria for CSM and were still clinically myelopathic. 
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3DGA is considered the “gold standard” in assessment of gait (Kirtley, 2006), and 
therefore was the method of choice in seeking to build a comprehensive picture of the 
gait impairment associated with CSM. A number of methodological parameters required 
consideration to ensure the accuracy of the collected data.   
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Motion analysis was carried out using a five camera Vicon 250 motion analysis system 
(Vicon Motion Systems Ltd., Oxford, UK). The system depends on the accurate 
attachment of lightweight retro-reflective markers to specific bony landmarks, shown in 
Figure 5.1. These were captured in three-dimensional space at a rate of 50 Hertz (Hz). 
The three-dimensional position of a marker can be calculated once it is visible to two 
cameras at the same point in time. Calculation of motion at the centres of each 
underlying joint was carried out via the Plug-in-Gait ® (PiG) software model provided in 
the Vicon Workstation ® application. Data were then exported to the visualisation 
software Polygon ®, where movement at each joint was presented in three planes 
(sagittal, frontal and transverse) over the duration of a GC. Figure 5.2, Figure 5.3 and 
Figure 5.4 show the location of the retro-reflective markers in the capture volume, the 
determination of joint centres using PiG, and the visualisation of time-normalised joint 
motion in Polygon, respectively. 
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Ground reaction forces (GRFs) across three planes were captured using a ground-
mounted Kistler multi-component force plate (Kistler Instruments Ltd., Winterthur, 
Switzerland). The force plate was integrated with the Vicon software, allowing for 
calculation of joint moments and powers from the kinematic and GRF data by inverse 
dynamics. Force plate data were captured at a rate of 1000 Hz. Figure 5.5 shows a 
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participant striking the force plate during a gait trial. Figure 5.6 shows the real-time 
capture of a ground reaction force by the Vicon system. 
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Ground reaction force shown by the vertical yellow line 
White dots represent location of retro-reflective markers 
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The Modified Helen Hayes model (MHH) (Davis et al., 1991) is the Vicon system’s default 
anthropometric model for the calculation of joint centres and subsequently of joint 
kinematics during movement. The model is based on the placement of 13 retro-reflective 
markers, eight bilaterally on the anterior superior iliac spine (ASIS), lateral aspect of the 
knee joint, lateral malleolus, and head of the second metatarsal, and five wand markers, 
one on the sacrum and four on the lateral aspect of the thigh and lower leg bilaterally, as 
shown in Figure 5.1 above. Markers are also placed on the calcanei to aid in the 
identification of heel strike during gait.  
Identification of joint centres depends heavily on accurate marker placement. Some of the 
bony landmarks are not readily identifiable, particularly those for the thigh marker (Baker 
et al., 1999). A previous study demonstrated the consequences of inaccurate marker 
placement. Deliberate misplacement of the knee and thigh markers caused offsets from 
the sagittal to the frontal plane at the knee joint, leading to inaccurate measurement of hip 
joint rotation and knee moments. Misplacement of the ASIS markers resulted in 
relocation of the hip joint centres and inaccurate calculation of frontal plane motion. The 
study concluded that MHH was particularly sensitive marker placement errors (Kirtley, 
2002). A further concern is the hierarchical nature of MHH, such that any proximal marker 
misalignment will result in the propagation of errors to distal joints (Schache et al., 2006).  
It is clear from these results that, in any study using 3DGA to assess patient outcomes, 
particular attention must be given to minimising the errors associated with marker 
placement. A standard protocol was used in the Movement Laboratory to maximise 
consistency and repeatability of the data collection process, provided in Appendix 5.1. 
Test-retest reliability of anthropometric measurements in the laboratory was 
demonstrated in an earlier study (Meldrum et al., 2005). Marker placement was and 
anthropometric measurements were standardised as far as possible by providing 
guidelines within the protocol.  
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An aspect of marker placement that is particularly error-prone is the definition of the 
femoral frontal plane. This plane is based on an estimate of the functional knee joint 
flexion-extension axis from the thigh co-ordinate system (Baker et al., 1999, Schache et 
al., 2006). The Knee Alignment Device (KAD) (Motion Lab Systems Inc., Baton Rouge, 
LA, USA), shown in Figure 5.7, is a spring-loaded clamp that fits over a subject’s knee 
during static calibration of the marker set. A virtual knee marker can be established at the 
central joint of the KAD during calibration, enabling more accurate measurement of the 
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knee flexion-extension axis (Motion Lab Systems Inc., 1998). Errors in the knee joint axis 
can be quantified by the amount of variability in knee varus–valgus motion and hip 
rotation (Schache et al., 2006).  
Repeatability of knee joint axis determination using the KAD has been compared to two 
alternative methods, one based on the trans-epicondylar axis and an alternative dynamic 
optimisation method (Schache et al., 2006). Repeatability of knee varus–valgus motion 
and hip rotation were measured using the coefficient of multiple determination (CMD), a 
reliability statistic where a value of 1 indicates perfect agreement and 0 indicates no 
agreement (Kadaba et al., 1989). Test-retest repeatability of hip rotation using KAD was 
moderate, with CMD values of 0.69. Absolute variability of knee varus–valgus motion was 
2.66–3.45°. An alternative method, the dynamic optimisation method of Baker et al. 
(1999), showed higher repeatability, with a CMD for hip rotation of 0.78 and knee varus–
valgus variability of 1.96°. Schache’s study did not evaluate the repeatability of these 
parameters using a simple knee marker without the aid of an adjunct such as KAD, and 
therefore the effect of KAD compared to “blind” knee marker placement cannot be 
deduced. The study was also limited by the lack of a gold standard method for 
identification of the knee joint flexion-extension axis during motion, meaning that the true 
validity of the values determined by KAD or other methods are unknown. The KAD 
method was the standard protocol in the RCSI Movement Laboratory. Its repeatability 
values, identified by Schache et al. (2006), were considered acceptable for use in the 
current study.  
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The motion of the skin during gait can result in trajectory noise when markers are 
captured in three-dimensional space. This artefact is normally minimised by the use of a 
digital off-line low-pass filter, such as the Woltring cross-validatory quintic spline routine 
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(Woltring, 1986). The Woltring filter is incorporated into the Vicon system. The user is 
required to specify the mean standard error (MSE) of the filter. Higher MSE values result 
in a greater level of filtering, potentially leading to a distortion of gait parameters in phase 
and magnitude (Molloy et al., 2008).  
A brief experiment was conducted to determine the optimal MSE for our data. Kinematic 
and kinetic data from a single participant were captured and saved to three files. Data 
were then processed with Woltring filters of MSE 27, 20 and 15 mm2. The resulting output 
was compared visually by inspection and quantitatively by measuring the peak values 
obtained in each parameter. Figure 5.8 compares the effect of the three filters on the 
knee power curve over one GC.  
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The higher the MSE value, the greater the diminution of the peak values, illustrated by 
the second power generation peak in Figure 5.8 at about 15% GC duration. The lower 
MSE value of 15 mm2 appeared on visual inspection to diminish motion artefact 
sufficiently, without dampening the peak values. A Woltring filter with MSE 15 mm2 was 
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therefore selected. The same MSE was used to filter trajectories in the Vicon system by a 
number of other studies, for example Beaulieu et al. (2010). 
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EMG is the recording of the electrical signals associated with muscle contraction by 
needle, fine-wire, or surface electrodes (Winter, 1990, Reaz et al., 2006). The EMG 
signal itself is a series of individual spikes of varying amplitude and duration, reflecting 
the underlying action potentials. This characteristic waveform results from the 
depolarisation of the muscle’s transverse tubular system and the sarcoplasmic reticulum, 
and its subsequent repolarisation (Winter, 1990). EMG is not a direct measurement of 
muscular activity, but rather an indirect indicator of muscle function (Perry, 1992). 
The use of EMG in motion analysis dates back to the 1940s (Sutherland, 2001). As part 
of a gait analysis protocol, it is the only available assessment tool that allows direct 
analysis of the biological signals responsible for muscle activation (Frigo and Crenna, 
2009). It can therefore provide information on the relationship between agonist and 
antagonist muscle groups during a motor task, which is not possible using kinetic analysis 
alone as only the net torque can be measured. EMG was considered essential in this 
study, as the aims and objectives required the analysis of individual muscle activity. 
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Surface electromygraphy (SEMG), the acquisition of the EMG signal via surface 
electrodes, has been recommended by the American Academy of Neurology as a 
suitable tool for the kinesiological analysis of movement disorders (Pullman et al., 2000). 
SEMG has a number of advantages over fine-wire EMG for this purpose, including ease 
of application and higher reliability (Winter and Scott, 1991). Surface electrodes are non-
invasive and painless, and therefore more acceptable to participants. By contrast, 
indwelling electrodes can interfere with the natural gait pattern. A study found that 
indwelling electrodes caused a 23.5% reduction in gait speed and a 7.9% decrease in 
cadence in children with CP (Young et al., 1989).   
The main limitation of surface electrodes is their potential to record signals generated by 
neighbouring muscles as well as the muscle under examination, a phenomenon known 
as cross talk (Koh and Grabiner, 1993). A contracting muscle generates an electrical 
signal that is dispersed throughout adjacent tissues by volume conduction, potentially 
making it difficult to distinguish individual muscle activation patterns (DeLuca and Merletti, 
1988). Cross talk has been demonstrated during SEMG examinations of rectus femoris 
(Nene et al., 2004), gastrocnemius (Perry et al., 1981), peroneus longus (Johanson and 
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Radtka, 2006), and hamstrings (Koh and Grabiner, 1992). Levels of cross talk of 11–18% 
MVC from adjacent muscles have been reported in studies of lower extremity muscles 
(Johanson and Radtka, 2006).  
The following factors were considered in the acquisition of SEMG data to ensure that the 
recorded signal paralleled the underlying signal of the contracting muscle as closely as 
possible. 
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The location of the electrode on the examined muscle has a fundamental influence on the 
output of the EMG signal. A general recommendation is that the electrode should be 
placed mid-way between the motor end point and the muscle–tendon junction, and be 
aligned in the direction of muscle fibres insofar as this can be estimated on visual 
inspection (Basmajian and DeLuca, 1985). Recommendations for optimum electrode 
placement were published by the Surface Electromyography for Non-Invasive 
Assessment of Muscles (SENIAM) taskforce (Hermens and Freriks, 1997). These 
guidelines were followed in the placement of electrodes for this study. Further details are 
provided in Appendix 5.1. 
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In general, large, superficial muscles are less prone to cross talk than smaller, deeper 
muscles, and can be recorded by SEMG with greater accuracy (Sutherland, 2001). The 
muscles chosen for analysis in this study were rectus femoris (RF), biceps femoris (BF), 
tibialis anterior (TA), and medial head of gastrocnemius (MG). They form antagonistic 
pairs in the thigh and lower leg and thus the influence of neurological changes in timing 
and co-activation during the GC can be measured. All contribute significantly to the 
performance of gait, particularly in relation to support and progression in the sagittal 
plane (Anderson and Pandy, 2003). 
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A SEMG electrode will record any signal that reaches its detection area. It is essential to 
obtain an EMG signal that contains the maximum amount of information from the 
underlying muscle and the minimum amount of contamination from motion artefact at the 
electrode-skin interface, noise from the electricity mains, and cross talk from surrounding 
muscles (DeLuca, 2002). There are two parameters that influence the fidelity of the 
SEMG signal to the underlying muscle activity: 1) the signal-to-noise ratio (SNR), the ratio 
of the signal from the muscle of interest to unwanted artefact or noise (Rash, 2004), and 
2) the distortion of the relative contribution of the frequency components in the signal 
(DeLuca, 2002). The factors discussed in the following sections, namely electrodes, 
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amplification, bandwidth, and sampling frequency, have been recommended for 
consideration when recording SEMG to ensure a high quality signal. 
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The electrodes used in SEMG examination can be either active or passive. Active 
electrodes were used in this study. These have a built-in pre-amplifier to reduce 
impedance, which reduces movement artefact and improves SNR compared to passive 
electrodes (Rash, 2004).  
Either monopolar or bipolar electrodes can be used. Bipolar electrodes are considered 
advantageous due to their ability to reduce cross talk by employing a differentially 
amplified system, where signals common to both electrodes are rejected as noise (Rash, 
2004). The differential amplifier’s accuracy in subtracting these unwanted signals is 
measured by the Common Mode Rejection Ratio (CMRR). The use of double-
differentiated electrodes was found to be effective in reducing cross talk (van Vugt and 
van Dijk, 2001). The MA-300 system in the RCSI Movement Laboratory used double-
differentiated electrodes with a reported CMRR of at least 100 decibels (dB). A CMRR of 
90dB is generally sufficient to suppress extraneous electrical noises (DeLuca, 2002).  
The input impedance of the differential amplifier should be as large as possible to prevent 
attenuation and distortion of the signal caused by impedance at the junction of the skin 
and the electrode. A value of 1012 Ohms has been recommended (DeLuca, 2002). This 
was the input impedance of the electrodes used for the current study. The skin was 
prepared by shaving and cleaning with an alcohol swab prior to application of the 
electrode, a procedure thought to reduce the resistance of the skin by 200% (Rash, 
2004). 
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Correct amplification ensures that the recorded signal is of sufficient magnitude for 
analysis. The gain of an amplifier is the amount of amplification applied to the signal and 
should be sufficient to have an output signal of 1 Volt (V) (Rash, 2004). In this study, a 
gain range of 2,000 to 13,200 was used to achieve a signal of sufficient amplitude. 
Signals were inspected in real time using Windaq® software (Dataq Instruments Inc, 
Akron, Ohio, USA), both at rest and during a maximum voluntary contraction, to ensure 
optimal detection. 
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The bandwidth is the range of collectable frequencies of the amplifier. The bandwidth 
should be high enough to reject the low frequency movement artefacts and low enough to 
attenuate the signal as little as possible. According to DeLuca (2002), the dominant 
energy of the EMG signal is in the range of 50–150 Hz. There is some variation in the 
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optimal bandwidth recommended by different authors. A high-pass filter of 10–20 Hz and 
a low-pass filter of 500 Hz has been recommended to optimise the recording of the entire 
EMG signal while reducing SNR (Basmajian and DeLuca, 1985, DeLuca, 1997, Hermens 
et al., 1999). The International Society for Electromyography and Kinesiology (ISEK) 
recommended a bandwidth within the range of a 5–10 Hz high-pass filter and a 400–450 
Hz low-pass filter (Merletti, 1997). The minimum high-pass filter of the MA-300 unit is 20 
Hz. The bandwidth was set at 20–500 Hz for this study. This is in agreement with the 
recommendations of DeLuca (1997) when using a differentially amplified system.  
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Sampling is the process of acquiring the values of a signal at equally spaced time 
intervals, designated by the sampling frequency, and recording these values into a 
computer (Pozzo et al., 2004). The optimal sampling frequency for any signal is dictated 
by the Nyquist theorem. Nyquist states that the original signal can be fully reconstructed 
from its samples if the sampling frequency is at least twice that of the highest frequency 
present in the signal itself (Winter, 1990, Pozzo et al., 2004). Failure to sample at a 
sufficiently high frequency results in aliasing errors, namely the generation of false 
frequencies in the sampled data that were not present in the original signal. Over-
sampling, or sampling at a rate higher than twice the signal’s maximum frequency, has 
been employed in previous studies, but is unnecessary in determining standard timing 
and amplitude variables of the signal (Ives and Wigglesworth, 2003). In this study, EMG 
data were sampled at a rate of 1,000 Hz in accordance with the Nyquist specification. 
Over-sampling was not employed. Sampling was conducted using a DATAQ® 
Instruments 32-channel DI-720 Data Acquisition System analogue to digital convertor 
with 12-bit resolution (DATAQ Instruments Inc., Akron, Ohio, USA). 
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To enhance its validity as a measurement tool for research purposes, the EMG signal 
should be subjected to further processing, as its variability between individuals precludes 
interpretation of the raw signal across groups of people (Bogey et al., 1992).  
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After the EMG signal has been recorded and sampled into the computer, a filter can then 
be applied to further clean the data (Rash, 2004). A number of filter types are available 
for digital signal processing, and of these, the Butterworth filter has been recommended 
and is most widely used (Winter, 1990).  
The choice of filtering frequency can affect the integrity of the EMG signal, and a balance 
must be sought between removing unwanted frequencies and losing valuable information 
from the signal. High pass filtering is needed to remove unwanted direct current offset 
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created by the half-cell potential of the electrodes, and to remove motion artefact due to 
movements of the lead wires generated during non-isometric activity in EMG recordings 
(Pozzo et al., 2004). Frequency components below 20 Hz are usually corrupted by 
movement artefact and instability in the signal (Hermens and Freriks, 1997, DeLuca, 
2002). Low pass filtering is used to remove unwanted noise beyond the bandwidth of 
interest that could lead to a degradation of the SNR (Pozzo et al., 2004). Most of the 
power in the muscle signal exists below a frequency of 500 Hz (Soderberg and Knutson, 
2000), and the dominant power exists between 50–150 Hz (DeLuca, 2002). 
Winter (1990) recommended that a residual analysis be conducted of the difference 
between filtered and unfiltered signals to ensure the optimal selection of low- and high-
pass filtering frequencies. A low-pass filter of 400 Hz and high-pass filter of 25 Hz have 
been recommended for use in gait analysis (Merletti et al., 2009). In the current study, 
this filter combination was applied to a number of test signals in a forward and backward 
direction using a routine in MATLAB® (The Mathworks, Natick, MA, USA), detailed in 
Appendix 5.2. The effect of the filter was examined by visually inspecting the trace 
patterns of the original signal and the filtered signal. This verified that the filter appeared 
to smooth out artefact from the raw EMG, while maintaining a signal that was close in 
amplitude to the original signal. The effect of the filter is shown Figure 5.9. 
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The blue trace shows the raw data and the red trace shows the filtered data  
A reduction in the amplitude of some individual spikes of activity is seen, while the overall 
appearance of the trace is preserved 
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The amplitude of the EMG signal can be described in two ways, 1) rectification and linear 
envelope detection or 2) calculation of root-mean-square (RMS). Rectification involves 
transposing the negative signals to the positive side of the line, so that positive and 
negative values do not cancel each other out in subsequent processing (Perry, 1992). 
The rectified signals can then be smoothed over a given time constant, usually 10–25 ms, 
to create a function known as the average rectified value (ARV) or linear envelope 
(Merletti, 1997). RMS involves 1) squaring the individual values of the signal to remove 
the positive and negative fluctuations, 2) obtaining the average of the squared values 
over a series of values, and 3) calculating the square root of this average (Rash, 2004). 
RMS value is preferred to ARV as it is a direct measure of the signal’s power and 
therefore has a clear physical meaning (Soderberg and Knutson, 2000, DeLuca, 2002). 
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The RMS method was therefore chosen for amplitude processing of the SEMG data in 
the current study.  
The time interval over which RMS is calculated is a critical factor in the determination of 
EMG amplitude (Merletti, 1997). A 30-millisecond (ms) time window with 20 ms overlap 
was chosen based on observations of differing window lengths (20 ms, 30 ms, 50 ms). 
The 30 ms window has been reported in previous studies using SEMG data (Mercer et 
al., 2009). It was tested in a set of signals from the current study and appeared to provide 
appropriate smoothing while still retaining the quality of the original signal, as shown in 
Figure 5.10. Over-smoothing the data was undesirable due to the potential to eliminate 
important information on the quality of the contraction (Frigo and Crenna, 2009).  
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RMS was calculated over 30 ms windows with 20 ms overlap and interpolated to 101 data points 
representing gait cycle percentage points from 0 to 100 
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The absolute value of the EMG signal amplitude can be affected by intrinsic participant 
characteristics, such as subcutaneous fat thickness (Lehman and McGill, 1999), as well 
as extrinsic factors such as heat, humidity, and the location of the electrode over the 
muscle (Hogrel, 2005). This leads to difficulty in comparing EMG amplitude between 
different individuals and between test days (Hogrel, 2005). The use of standard protocols 
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for electrode placement, such as the SENIAM guidelines, can minimise variability due to 
procedural factors (Gruet et al., 2010). However, despite standard protocols, test-retest 
reliability studies have shown high absolute variability in EMG amplitude (Campanini et 
al., 2007, Gruet et al., 2010). SEM values for non-normalised RMS of the quadriceps 
muscles in people with knee pathology ranged from 0.08 mV for RF to 0.28 mV for vastus 
lateralis, and indicated high variability relative to the mean in all cases (Callaghan et al., 
2009).  
The problem can be addressed by normalising a muscle’s amplitude at each point in the 
signal to a reference level obtained from the muscle in the same assessment (Winter and 
Scott, 1991). This facilitates physiological interpretation of signal amplitude, and allows 
for comparison between performance on different test days and between individuals 
(Lehman and McGill, 1999). EMG signals can be normalised to either a maximal or sub-
maximal reference. The first method expresses the amplitude of each point in a signal as 
a percentage of the mean or peak amplitude of a maximal test of muscle strength. It is 
referred to as the MVC method (Yang and Winter, 1984). Sub-maximal normalisation 
references include 1) activities that isolate a muscle’s function, such as an anti-gravity 
hold (Dankaerts et al., 2004, Mercer et al., 2009), 2) the peak RMS or AMV amplitude in 
the same activity, known as the Peak Dynamic Method (PDM) (Burden et al., 2003), or 3) 
the mean RMS or ARV amplitude during the same activity, namely the Mean Dynamic 
Method (MDM) (Burden et al., 2003). The most valid method of normalisation has not yet 
been determined (Soderberg and Knutson, 2000).  
The advantage of the MVC method is its provision of a meaningful physiological 
reference (Allison et al., 1998). However, its validity depends largely on the extent to 
which the intensity of the MVC is a true maximum. There are concerns that the output of 
MVC can be up to 20–30% less than the muscle’s actual force generation capability 
(Merletti, 1997). The methods used to obtain MVC vary between studies, with some 
studies using the EMG signal as biofeedback to maximise the effort given by participants 
during the test (Benoit et al., 2003). Meldrum et al. (2003) found higher reliability of MVC 
when a more experienced assessor carried out the tests, which suggested a training 
effect.  
Test-retest reliability of EMG signals from MVC testing has been shown to be high in 
healthy people, with standard error of measurement (SEM) values in the range of 1.1– 
6.4% of the mean (Rainoldi et al., 2001). Its application in neurological populations poses 
some difficulty. People with neurological impairment may not reliably produce MVC due 
to their motor impairment (Perry, 1992). A recent study found that peak moments at the 
ankle joint during gait exceeded the maximal isometric strength of the ankle plantarflexors 
in adolescents with CP (Dallmeijer et al., 2011). The authors suggested that the passive 
component of the muscle-tendon unit of the triceps surae contributed to torque 
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generation during gait (Dallmeijer et al., 2011). The finding could also be explained by 
impaired ability to selectively activate specific muscles in a voluntary isometric test, as 
shown in CP by Tedroff et al. (2006). A further potential disadvantage of the MVC method 
is that the contributions of weaker, less effective muscles during gait could be 
exaggerated because these muscles will appear to contract at a higher percentage of a 
low maximum (Damiano et al., 2006). There are also concerns about the validity of an 
isometric test as a normalisation reference, given that the majority of muscle activity in 
gait is concentric or eccentric (Burden et al., 2003).  
The validity of another commonly used alternative, PDM, has not been tested in a 
neurological population. Its main disadvantage is that the amount of activation cannot be 
related to any physiological measure, therefore inability to contract a muscle due to pain 
inhibition or neuromuscular dysfunction may not be detected (Benoit et al., 2003). 
Variation between individuals may also be diluted using this method (Hsu et al., 2006). 
However, differences between injured and non-injured limbs were found in EMG 
amplitude and timing during gait in participants with anterior cruciate ligament deficiency 
when the PDM normalisation method was used (Benoit et al., 2003). This suggested that 
the PDM method did not entirely dilute variation in muscular output.  
In the current study, the purpose of measuring EMG amplitude was to examine each 
participant’s ability to scale a muscle’s output to the demands of the tasks of gait. 
Normalisation was considered critical to ensure comparison of the same individuals in 
test-retest situations and to compare the participants in their groups as a whole. In the 
absence of any definitive evidence on the validity and reliability of normalisation in a 
neurological population in the study of gait, it was decided to compare both PDM and 
MVC normalisation methods for test-retest reliability. The method with better reliability 
would then be used for further analysis. The results of this reliability study are presented 
in Chapter 7. 
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The EMG signal itself is a series of spikes of varying amplitude and frequency. The 
processing methods described above, namely filtering, amplitude processing and 
amplitude normalisation, ensure that the signals can be compared between repeated 
tests of the same participant and groups of participants. While it is of interest to interpret 
the signals as a whole over the course of the GC, there are key parameters contained 
within the signal that represent the nature of the underlying impairment from a 
physiological point of view (Lamontagne, 2006). This section will address the extraction of 
clinically relevant parameters that were required to fulfil the aims and objectives outlined 
in Chapter 4. 
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Measurement of the timing and duration of muscle activity bursts is of significant clinical 
interest in the evaluation of gait impairment. The EMG signal obtained during gait is a 
continuous sequence of electrical activity, with baseline periods alternating with bursts of 
activity. The presence of a burst of activity implies that the muscle is contracting with 
sufficient intensity to contribute to the kinematic and kinetic features of the GC. Temporal 
analysis of the EMG signal therefore dichotomises the EMG signal into either “activity”, 
characterised by a sustained series of spikes in the signal, or “baseline”, characterised by 
a steady state of relatively unchanging background activity, as illustrated in Figure 5.11. 
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Changes in temporal activation have been associated with a number of clinical conditions 
and can provide insight into the motor control strategies used by patients (Solnik et al., 
2010). As a consequence, accurate distinction of periods of muscle activity from the 
baseline signal is of particular importance in EMG analysis. EMG signals will vary due to 
environmental and technical factors, and as such there is no standard reference 
threshold by which to determine muscle activity from the EMG signal. In general, four 
methods can be considered: 1) visual determination, 2) defined thresholds, such as a 
number of standard deviations (SD) above baseline (Hodges and Bui, 1996) or a 
percentage of maximum contraction (Johanson and Radtka, 2006), 3) computerised 
statistical methods, such as the approximated generalised likelihood ratio (AGLR) 
(Staude and Wolf, 1999, Roetenberg et al., 2003), and 4) amplification of the SNR using 
an off-line equation, such as the Teager-Kaiser Energy Operator (TKEO) (Li et al., 2007), 
to increase detection capability.  
Visual determination by a trained observer is regularly used in day-to-day clinical 
practice, however, for research purposes, limitations arise with the possibility of observer 
bias and the excessive time required to process multiple trials (Solnik et al., 2010). 
Previous studies have used threshold criteria to determine onset and offset of muscle 
activity. Hodges and Bui (1996) defined the onset of activity using thresholds of one, two 
and three SDs above the mean of a 50 ms baseline signal lasting for a minimum of 20, 50 
or 100 ms. A threshold of 15–18% MVC was recommended in another study (Johanson 
and Radtka, 2006). These threshold criteria are arbitrary and no consensus has been 
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reached in the literature regarding the optimal threshold parameters (Roetenberg et al., 
2003).  
In recent years, mathematical and statistical models have been employed to improve the 
accuracy of activity detection and reduce the time required to visually process the signals. 
Two main methods have emerged, the AGLR (Staude and Wolf, 1999, Roetenberg et al., 
2003) and TKEO-based methods (Li et al., 2007, Solnik et al., 2010). AGLR uses a log-
likelihood ratio calculation to determine the statistical probability of muscle contraction 
based on probability density functions of the null hypothesis H0 (no change in the EMG 
signal) and the alternate hypothesis H1 (a change in the signal). A timed determinant 
window of fixed length 30 ms is moved along the data set, and the hypothesis is tested at 
each window. An alarm time is signalled when H1 is satisfied (Roetenberg et al., 2003). 
The use of AGLR to define onset and offset times was more accurate than threshold 
criteria when applied to the EMG data from multiple GCs (Roetenberg et al., 2003, Solnik 
et al., 2010). However, the detection of activity requires a distinct change in the log-
likelihood ratio from one 30 ms sample to the next, meaning that detection may be more 
difficult where the change in amplitude is less obvious. Both AGLR and the threshold 
(SD) method showed an increase in detection latencies as background noise within the 
EMG signal increased, though the AGLR method was less affected (Lee et al., 2007). 
Individuals with gait impairment may show high baseline activity and have lower 
amplitude bursts of activity (Lauer and Prosser, 2009). This can mimic the background 
noise examined by Lee et al. (2007), and could result in greater inaccuracies in burst 
activity detection for such populations, even with the more robust AGLR method. 
The TKEO was originally developed to compute the energy of sound. It was subsequently 
proposed as a method to treat EMG signals and aid in the detection of muscle activity by 
ensuring that both frequency and amplitude information from the EMG signal were 
incorporated into the detection process (Li et al., 2007). The discrete TKEO ! is defined 
in the time domain for signal amplitude " at time point n as follows (Li et al., 2007): 
Equation 1: #("n) = "n2 – ("n+1))("n–1) 
The TKEO is directly proportional to both the amplitude and the frequency of the input 
signal, and therefore it creates a greater distinction between muscle activity and baseline 
activity than methods based on signal amplitude alone (Li et al., 2007, Lauer and 
Prosser, 2009). Both AGLR and TKEO out-performed an arbitrary threshold when used 
with simulated EMG data (Li et al., 2007). The addition of TKEO to the previous three 
methods of burst detection (visual, threshold, and AGLR) improved the accuracy of all 
three methods (Solnik et al., 2010). Application of the TKEO to EMG signals from children 
with CP improved the detection of activity compared to a SD threshold method, despite 
the high levels of tonic baseline activity in the signals (Lauer and Prosser, 2009). This 
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improvement in activity detection is thought to be due to the incorporation of frequency 
information into the detection process. Recent studies have shown that the frequency 
component of EMG is a particularly sensitive measure in detecting differences between 
groups or following intervention (Lauer et al., 2007a, Lauer et al., 2007b, Wakeling et al., 
2007).  
Based on this evidence, it was decided to apply the TKEO equation to the filtered EMG 
signals to enhance the detection of muscle activity during gait in the current study. The 
TKEO-treated signals were then smoothed with a second order, 50 Hz Butterworth low-
pass filter to avoid errors in activity designation due to the rapid variations in the 
unsmoothed signal (Solnik et al., 2010). The periods of muscle activation were visually 
clearer in the TKEO-modified signal than in the original signal as expected. Figure 5.12 
shows an example. 
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TKEO = Teager Kaiser Energy Operator, ms = milliseconds, VHz2 = Volts times Hertz squared 
(units of TKEO) 
The next step in the process was to determine a TKEO-based threshold that would signal 
a period of muscle activation and then signal its cessation. Previous authors using the 
TKEO had described the use of a threshold based on a resting baseline. With this 
method, EMG signals from a muscle at rest were treated with the TKEO equation, and a 
threshold ! was determined using the following equation based on the mean, µ, a 
constant, ", and the standard deviation, #, of the resting trial. This method will be referred 
to as the Resting Threshold Method (RTM). 
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Equation 2: ! = µ + ".# 
The value of " varied among the studies, from 1 (Lauer and Prosser, 2009), 6–8 (Li et al., 
2007), and up to 15 (Solnik et al., 2010). No clear guidelines were available on the 
optimum value of ", as the studies had not reported the validity of a range of values. 
In relation to the CSM population, there were concerns regarding the validity of a 
threshold based on resting EMG activity. Variable resting tone could lead to difficulty in 
determining an optimum threshold for the participant group as a whole. Given the wide 
range of impairment among people with CSM, it was expected that participants would 
vary in the relationship between the amplitude of their EMG signals at rest and during 
activity. In the current study, preliminary tests were carried out to assess the applicability 
of the RTM algorithm to EMG signals from the CSM participants. It was found that the 
algorithm designated activation times that were not always consistent with visual 
interpretation. A second activation detection method was therefore required for 
comparison, to determine if it was possible to achieve more consistent parameters for the 
designation of activation while avoiding the need for visual analysis of all signals. 
To develop a new activation detection method, the characteristics of a TKEO-treated 
EMG signal from a GC were observed and analysed during bursts of activity and outside 
of these bursts to determine the parameters that might signify a burst of activity. During a 
visually determined activity burst, the TKEO amplitude was higher, and more rapidly 
changing, than during periods outside of these bursts. It was hypothesised that measures 
of TKEO amplitude and rate of change, measured by the slope of the relationship 
between TKEO amplitude and time, could be combined to create an alternative threshold 
for muscle activation. Amplitude could be determined by expressing a given point in the 
TKEO as a percentage of its maximum activity during the same GC. The change in TKEO 
amplitude between two successive data points could be described by measuring the 
slope of the line between the amplitudes of those two points.  
To determine more exact parameters, signals from each of the four muscles, taken from 
five participants with CSM during gait of varying mobility impairment, were examined for 
slope between successive time points and TKEO amplitude at each time point.  During 
periods when visual interpretation of the signal indicated that the muscle was not active, 
the amplitude of the smoothed TKEO varied from 0.1–1.5% of its maximum amplitude 
during that GC, and the slope between the amplitude at successive time points varied 
from 3x10-9 to 2x10-4 VHz2/ms. During activation, amplitude exceeded at least 6% of the 
maximum amplitude during that GC, while the slope of a line between the amplitude of 
successive time points ranged from 5x10-5 to 0.7 VHz2/ms. A novel “double threshold 
method” (DTM) was developed in the current study to signal activation when the 
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smoothed TKEO-treated signal exceeded 3% of its maximum amplitude during that GC 
and when the slope between two successive time points exceeded 10-6 VHz2/ms. 
!"#"#"$% &'()*'+),-%,.%'%/0+1,*%+,%*0+02+%+10%+)/)-3%,.%/452(0%'2+)6'+),-%
Validation of any new method requires comparison to a “gold standard”, which should be 
a widely accepted and proven method of performing the same task. There is no gold 
standard method to determine the timing of muscle activation from EMG signals. In 
clinical practice, visual interpretation is the most widely used method. It was previously 
used as a comparison in other validation studies of TKEO-based methods (Solnik et al., 
2010). A study was conducted to find the method that showed greatest agreement with 
visual interpretation. Two methods were compared, the RTM and the newly developed 
DTM.  
A subset of data, comprising the right TA signals from one GC of 12 participants with 
CSM, was used in the validation process. TA was chosen because it was the most 
superficial of the four muscles tested, and therefore the least likely to be affected by cross 
talk. To implement RTM, a sample of EMG data of one second’s duration, taken from the 
right TA at rest, was extracted using MATLAB. In some signals, the amplification gain had 
been altered from the resting trial to the gait trials. If this had occurred, the raw EMG data 
from the resting trial were scaled to the gain used in the gait trials, using a scaling system 
designed for the MA-300 shown in Appendix 5.3. The TKEO was then applied to the 
signals using a custom-built routine in MATLAB, detailed in Appendix 5.4. The mean and 
SD of the TKEO in the resting trial were obtained and three thresholds were determined, 
1) one SD above the mean (Lauer and Prosser, 2009), 2) seven SDs above the mean (Li 
et al., 2007), and 3) 15 SDs above the mean (Solnik et al., 2010).  
The filtered EMG signals from Section 5.4.3.1 were then treated with TKEO. The resulting 
output was smoothed using a second order, 50 Hz Butterworth filter as per Solnik et al. 
(2010). Using a MATLAB routine, shown in Appendix 5.5, the TKEO amplitude over the 
GC was compared to the activation threshold at each point in the signal. A window 25 ms 
in length was moved along each successive point in the signal. Activation was signalled 
at the central point of this window when at least 24 of 25 data points in the window 
exceeded the threshold. Cessation of activity was signalled when this condition was no 
longer satisfied. The resulting output of each threshold was then stored in MATLAB for 
later comparison with visual interpretation. 
DTM was then implemented for each gait trial using a MATLAB routine (Appendix 5.6). 
The activation threshold consisted of two components, a TKEO amplitude of 3% of the 
maximum smoothed TKEO amplitude within that trial, and a slope between successive 
data points of at least 10-6 VHz2/ms. The threshold was tested using a moving window of 
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25 ms, with activation signalled when 24 out of the 25 data points exceeded the double 
threshold. 
An independent observer (DM) examined the TKEO-treated signals visually and selected 
two portions of each signal, one during a clear period of activation and the other, during a 
clear period of inactivity. The MATLAB routines for both RTM (Appendix 5.5) and DTM 
(Appendix 5.6) then tested the outputs of the four chosen thresholds over these visually 
designated “on” and “off” periods. The validation test was set as an all-or-none result, in 
that the computerised methods were required to signal an “on” phase for the duration of 
the “on” portion designated by visual observation, and likewise for the “off” portion. Figure 
5.13 shows the steps in the validation process. 
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RTA = right tibialis anterior, TKEO = Teager Kaiser energy operator, DTM = double threshold 
method, RTM = resting threshold method, µ = mean, ! = standard deviation 
Results of the validation test are shown in Table 5.1. There was considerable variation in 
the designation of “on” and “off” phases by RTM compared to visual interpretation, 
depending on the value of ! used. The DTM method was more accurate, with 87.5% 
agreement with visual interpretation, compared to 58.33–79.17% with RTM. Figure 5.14 
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illustrates the difference in “on” and “off” designation between two participants’ TA signals 
using these methods. Part A and B show an over-estimation of activity duration in both 
participants. Part C shows that RTM with a ! value of 15 achieved a higher level of 
accuracy in Participant 1, but over-estimated activity in Participant 18. As seen in Part D, 
DTM designated activity periods that were more consistent with visual interpretation. 
!"#$%&'()*&+,-%%.%/0&#%01%%/&2345"$&6%43,/"037/&78&97/:&"/6&9788:&;<"4%4&"/6&875-&
=7.;50%-34%6&03.3/,&.%0<764&
RTM-1 RTM-7 RTM-15 DTM Case 
“On” “Off” “On” “Off” “On” “Off” “On” “Off” 
01 1 0 1 1 1 1 0 1 
02 1 1 1 1 1 1 1 1 
04 0 1 0 1 0 1 0 1 
05 1 1 1 1 1 1 1 1 
10 1 0 1 0 1 1 1 1 
11 0 1 0 1 0 1 0 1 
12 1 0 1 0 1 0 1 1 
13 1 0 1 1 1 1 1 1 
14 1 0 1 0 1 0 1 1 
15 1 0 1 1 1 1 1 1 
17 1 0 1 1 1 1 1 1 
18 1 0 1 0 1 0 1 1 
Total agreement (%) 58.33 75.00 79.17 87.50 
RTM, resting threshold method, DTM, double threshold method 
RTM thresholds for activation were 1, 7 and 15 standard deviations above mean resting TKEO, 
termed RTM-1, RTM-7 and RTM-15 respectively 
A value of 1 indicates that the computerised method agreed with visual designation for the duration 
of that “on” or “off” portion, and a value of 0 indicates a discrepancy 
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VHz2 = Volts times Hertz squared, TKEO = Teager Kaiser Energy Operator 
The raw TKEO (grey trace) was smoothed with a second order 50 Hz low pass Butterworth filter 
(black trace) to aid detection of activation  
Red line illustrates the designation of timing by the tested algorithm, with a value of 1 indicating 
activity and 0 indicating baseline 
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The validation study therefore found that, when a combined slope and amplitude 
activation threshold was applied to the TKEO-modified signal, it identified bursts of 
muscle activation that broadly corresponded with those designated by visual inspection. 
The activation threshold was set as a percentage of the maximum amplitude of the 
smoothed TKEO during that same GC, rather than as a number of SDs above a mean 
resting level as in RTM. This may have minimised the effect of variation in this resting 
baseline in the designation of activity. The addition of the slope threshold was designed 
to make the algorithm more specific to neurological problems, where there may be 
relatively high baseline signal and low peak amplitude during meaningful bursts of muscle 
activity. The requirement for the slope of the smoothed signal to exceed a threshold 
ensures that an unchanging baseline, even if abnormally high in amplitude, would not be 
designated as activation. 
The lack of a gold standard in distinguishing muscle activation from baseline signal during 
gait is a significant limitation in the development of computerised methods for this task. 
Clinically, visual observation is considered the optimal method of interpreting all aspects 
of EMG and is the standard against which computerised methods are assessed (Solnik et 
al., 2010). However, it is inherently subjective, and variation in the EMG signal that is not 
visible to the naked eye may be missed. Visual interpretation in research is limited by the 
excessive time needed to process large numbers of signals. A computerised method is 
therefore desirable for speed and objectivity, but has the disadvantage that it 
dichotomises the fine detail within the EMG signal into a simple “on” or “off”. The DTM 
method was the most consistent of the four methods in the designation of activity, but 
there were still discrepancies between its designation and that of visual observation in 
three cases. It was interesting that the “on” phase designated by the independent 
observer in two signals, cases 3 and 6, agreed with none of the computerised methods. 
On inspection of these signals, it was found that beginning of the visually designated “on” 
phase occurred just after a short (<20 ms) period of inactivity. All four algorithms required 
that the threshold be exceeded for at least 24 ms of a 25 ms window. This may have 
introduced latency in detecting a rapid change in the signal that would have been visible 
on visual inspection. However, removing the requirement for a 25 ms window might 
reduce the specificity of the detection algorithm, in that short insignificant spikes might be 
incorrectly designated as meaningful activity.  
It was concluded that the DTM showed best agreement with visual interpretation of 
muscle activation timing. This method was therefore selected to calculate timing 
parameters for EMG signals in the study.    
!"#"#"$% %&'()*+,-)+,'.%
Gait disturbances can be associated with impaired selective activation of functionally 
antagonist muscles due to pain inhibition, weakness, or changes in muscle tone, as 
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discussed in Chapter 4. Determination of co-activation from EMG data depends on the 
accuracy of the timing data extracted in Section 5.4.4.2. Co-activation between two 
muscles is reported as the percentage of the GC for which both are simultaneously 
active. For the current study, two antagonistic pairs were examined, BF and RF as one 
pair, and TA and MG as the second pair.  
!"#"#"#$ %&'()*)('+',-&$-.$'/($,&'(&0,'1$-.$23045($+4',6+',-&$
In people with neurological impairment, the representation of an EMG signal into its 
temporal components of “on” and “off” is insufficient to fully represent a person’s ability to 
scale motor output to the demands of a task (Roetenberg et al., 2003). The intensity of a 
muscle’s activation during a burst is also of importance, as it is gives an indication of the 
force produced (Bogey et al., 2005). Three parameters, peak ARV amplitude, timing of 
this peak, and area under the ARV curve during an activity burst, have been examined for 
repeatability in HCs with deliberate slight variations in electrode placement (Campanini et 
al., 2007). Burst durations in Campanini’s study were not extracted for individual GCs, but 
instead they were pre-determined based on data from a healthy population (Perry, 1992). 
These activation phases could not be assumed to be accurate in people with pathological 
gait.  
Another study used three amplitude parameters, maximum and median ARV during 
bursts of activation, and median ARV during baseline phases, to measure the intensity of 
activation in healthy people and people with CP and stroke (Roetenberg et al., 2003). 
Bursts of activation were determined using a computerised method, AGLR (see Section 
5.4.4.1). Roetenberg’s method was considered to have face validity in the evaluation of 
gait in CSM, as it was important to obtain a measure of activation intensity during the “off” 
(baseline) and “on” (activity) phases to fully characterise a muscle’s activation pattern.  
A literature search found no studies on the test-retest reliability of these parameters. 
Regarding validity, one study found significant differences in mean amplitudes during 
activity bursts of the erector spinae, vastus lateralis, tibialis anterior and gluteal muscles 
in people with stroke while walking with different gait aids (Buurke et al., 2005). This 
suggested that the mean amplitude within a burst was a valid measure of the intensity of 
muscle activation and was responsive to change under varying gait conditions. In the 
absence of a reliability study on these amplitude parameters, it was decided to examine 
the test-retest reliability of 1) maximum amplitude during a burst of activity, 2) mean 
amplitude during a burst of activity, and 3) mean amplitude of the baseline or “off” signal 
during gait. As the data would be used to compare between individuals and different test 
days, normalisation of the amplitude parameters was required. The parameters were 
normalised using both MVC and PDM methods, and the method with higher reliability 
was then for further use in the thesis. 
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The potential value of a locomotor-specific measure of spasticity (LSMS) was discussed 
in Chapter 4, Section 4.2.2.3. This measure was developed to evaluate muscle 
lengthening during gait in a cohort of children with CP (Crenna, 1998, Crenna, 1999), and 
then applied to an adult stroke population (Lamontagne et al., 2001). The LSMS in these 
studies extracted the phases in the GC when a muscle was lengthening, and examined 
the relationship between lengthening velocity and EMG amplitude.  
The method used by Crenna to determine muscle length differed somewhat from the 
method of Lamontagne. Crenna (1999) measured muscle length in millimetres by means 
of an anthropometric model for muscle kinematics. Lamontagne et al. (2001) used an 
equation based on the underlying joint kinematics to assess relative muscle length over 
the GC, validated in a previous study (Winter and Scott, 1991). Muscle length was 
compared relative to its length in the anatomical position where hip, knee and ankle joints 
were in neutral in all planes. Its lengthening velocity was then computed as the rate of 
change of relative muscle length over time. Lamontagne’s method was adopted for use in 
this study as it avoided the need for a separate anthropometric model and could be 
carried out using Vicon PiG®. The lack of actual units of muscle length measurement was 
not considered a disadvantage, as the hypothesis was concerned with the relationships 
between relative length, lengthening velocity and EMG output. 
The parameters used to evaluate the relationship between muscle length and EMG 
output also needed consideration. The development studies had described two 
approaches, 1) determination of the lengthening velocity threshold (LVT) for EMG 
recruitment (Crenna, 1999), and 2) measurement of the slope between lengthening 
velocity and EMG amplitude, such that a positive slope would indicate spasticity and its 
gradient would estimate the reflex gain (Lamontagne et al., 2001). Both approaches have 
been shown by their respective authors to be valid in discriminating pathological 
responses to lengthening from normal responses, though they have not been compared 
in the same population. It was considered that all three measures, 1) the LVT at which 
onset of EMG activity occurred, 2) the presence or absence of a positive slope, and 3) 
the gradient of the slope, would be of clinical benefit in distinguishing spasticity during 
locomotion in the CSM population. The three methods were therefore adopted for use in 
the current study. It was also considered that the timing of onset of EMG activity during a 
lengthening contraction would be of clinical importance, as it would indicate whether an 
abnormal response to lengthening contributed to a change in the timing of activation. The 
implementation of these measures in the cross-sectional and experimental studies would 
depend on their test-retest reliability. These results will be reported in Chapter 7. 
Some muscles undergo two or more periods of lengthening during the GC. To focus the 
analysis, it was decided to examine one key lengthening phase for each muscle. These 
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phases were 1) BF in terminal swing, 2) MG in mid stance, 3) TA in pre swing and 4) RF 
in pre swing. These phases were chosen because abnormal EMG activity by the 
lengthening muscles would be disruptive to the GC during these periods of lengthening. 
Furthermore, pathological responses to lengthening had been shown in other 
neurological populations to affect MG in mid stance (Lamontagne et al., 2001) and the 
hamstrings at terminal swing (Crenna, 1999), whereas other lengthening phases, such as 
that of MG in initial swing, did not show such responses (Lamontagne et al., 2001). It was 
considered that the analysis of one key phase of lengthening for each muscle would be 
sufficient to address the research question of whether spasticity was a contributory factor 
to gait impairment in CSM. 
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In addition to analysis of gait, quantification of disease severity, functional mobility, 
health-related quality of life (HRQOL) and spasticity were required as secondary outcome 
measures. The following sections describe the selection of the most suitable scales. 
!"!"1# 2-*(.343&*.3'(#'4#)30%*0%#0%5%+3.,#
A number of different scales to quantify the severity of CSM have been developed. A 
review of the literature identified eight scales, namely the Nurick scale (Nurick, 1972), 
Japanese Orthopaedic Association (JOA) scale (Japanese Orthopaedic Association, 
1994), Cooper myelopathy scale (Cooper and Epstein, 1985), European Myelopathy 
score (EMS) (Herdmann et al., 1994), Prolo score (Prolo et al., 1986), Myelopathy 
Disability Index (Casey et al., 1996), Ranawat score (Ranawat et al., 1979), and the 
Harsh scale (Harsh et al., 1987). Different scales emerged because the clinical symptoms 
of CSM have resulted in a variety of treatment methods, leading to the development of 
outcome measures specifically designed to evaluate these methods (Vitzthum and Dalitz, 
2007). The most appropriate measure of severity for the current study was selected from 
a literature review on the reliability and validity of the available scales. 
!"!"#"#$ %&'&()*+,$+-$).&$+/)*01'$2(1'&$+-$3%4$2&5&6*)7$
Vitzthum and Dalitz (2007) conducted a retrospective comparison of five scoring systems 
used for CSM, the Nurick score, the JOA score, the Cooper myelopathy score, the Prolo 
score, and the EMS. All five scores were found to be suitable for quantitatively assessing 
the clinical characteristics and progression of cervical myelopathy. Furthermore, all 
scales showed a significant correlation with one another using Spearman’s rho, with the 
significance of the correlations ranging from less than 0.05 (correlation between Cooper 
and Prolo scales) to less than 0.0001 (correlations between Nurick, JOA, lower limb 
Cooper scale and EMS). Actual values of Spearman’s rho were not given in the original 
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manuscript. The authors concluded that, because all the scales were found to be valid 
and responsive to change, it was not necessary to develop a new or universal score.  
It was concluded from the comparison study of Vitzthum and Dalitz (2007) and the 
original development studies that, as far as had been examined in the literature, no one 
particular scale showed superior validity or reliability. The Nurick and JOA scales were 
observed in the literature to be most commonly used in published reports, and were used 
in a recent multi-centre study of outcomes following surgery for CSM (Furlan et al., 2011). 
Comparison of participants of the current study to a wider cohort of people with CSM was 
desirable. For this reason, the Nurick and JOA were selected as measures of severity. 
!"!"#"$% &'()*+%,*-./%
The Nurick scale, detailed in Table 5.2, is the oldest outcome measure for CSM. It 
focuses on gait function and is therefore unable to detect changes in the upper extremity. 
A better-functioning score on Nurick was strongly associated with a higher score on the 
RAND Medical Outcomes Study 36-item Short Form Health Survey (SF36) (King and 
Roberts, 2002), indicating its validity. No studies of reliability were found. A limitation of 
Nurick is the influence of a person’s occupation on the score. Progression between a 
score of 2 and 3 on the scale may depend on the nature of a person’s employment rather 
than on the severity of neurological deficit. Its focus on gait impairment was however 
desirable because gait was the subject of the current study’s research and the scale was 
therefore immediately applicable to this cohort.  
0-1./%!"$2%&'()*+%,*-./%%
Score Description 
0 Signs and symptoms of root involvement, but without evidence of spinal cord 
disease 
1 Signs of spinal cord disease but no difficulty in walking 
2 Slight difficulty in walking which did not prevent full time employment 
3 Difficulty in walking which prevented full time employment or the ability to do all 
housework, but which was not so severe as to require someone’s help to walk 
4 Able to walk only with someone else’s help or with the aid of a frame 
5 Chairbound or bedridden 
!"!"#"3% 4-5-6/,/%7(89:5-/;)*%<,,:*)-8):6%,*-./%
The JOA score evaluates severity of myelopathy across four categories, motor 
dysfunction in the upper extremity, motor dysfunction in the lower extremity, sensory 
deficit, and sphincter dysfunction (Japanese Orthopaedic Association, 1975). Problems 
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were identified with the original scoring system, including the ranking of each category, 
the ratio of the score for categories, and the absence of a category for motor function of 
the shoulder and elbow (Yonenobu et al., 2001). The scoring system was revised in 1994 
to address these limitations (Japanese Orthopaedic Association, 1994). The inter- and 
intra-rater reliability of the new scoring system were found to be high, with intraclass 
correlation coefficients (ICCs) of 0.813 and 0.826, respectively (Yonenobu et al., 2001). 
King et al. (2003) found that the JOA moderately correlated with the SF36 in people with 
CSM. There were higher correlations between the SF36 and Nurick, Harsh, and Cooper 
scales, however this was attributed to the broader number of categories of dysfunction 
that the JOA assesses. When the lower limb sub-section of the JOA was evaluated as a 
separate entity, it showed strong correlation with the SF36 (King and Roberts, 2002). The 
JOA provides a wider assessment of CSM severity than most of the other scales as it 
includes both sensory and motor function of the upper and lower limbs, as well as 
sphincter dysfunction. The EMS assesses severity of myelopathy across similar domains 
(Herdmann et al., 1994), however a literature search using Medline found that it had 
fewer citations than the JOA. 
The JOA score was modified for use in Western populations, and there are two 
modifications. One version by Keller et al. (1993) removed the reference to the ability to 
eat with chopsticks from the original text and replaced it with a more generic description 
of upper limb function. A second modification to the original JOA changed the reference 
to the ability to use chopsticks to the use of Western feeding utensils (Chiles et al., 1999). 
In the absence of any pre-existing comparison of the validity and reliability of the two 
Western modifications, the JOA as modified by Chiles et al. (1999) was favoured above 
the earlier modification of Keller et al. (1993), because its content was considered to 
show greater similarity to the original JOA score that had been validated in previous 
studies (Yonenobu et al., 2001). Table 5.3 shows the modified JOA (mJOA) (Chiles et al., 
1999). 
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I. Motor Dysfunction of the Upper Extremity 
0 Unable to feed oneself 
1 Unable to use knife and fork, able to eat with a spoon 
2 Able to use knife and fork with much difficulty 
3 Able to use knife and fork with slight difficulty 
4 No dysfunction 
II. Motor dysfunction of the Lower Extremity 
0 Unable to walk 
1 Can walk on flat floor with walking aid 
2 Can walk up and / or down stairs with hand rail 
3 Lack of stability or smooth gait 
4 No dysfunction 
III (a). Sensory deficit, upper extremity 
0 Severe sensory loss or pain 
1 Mild sensory loss or pain 
2 No dysfunction 
III (b). Sensory deficit, lower extremity 
0 Severe sensory loss or pain 
1 Mild sensory loss or pain 
2 No dysfunction 
III (c). Sensory deficit, trunk 
0 Severe sensory loss or pain 
1 Mild sensory loss or pain 
2 No dysfunction 
IV. Bladder function 
0 Unable to void 
1 Marked difficulty in micturition (retention) 
2 Difficulty in micturition (frequency, hesitation) 
3 No dysfunction 
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The World Health Organisation’s International Classification of Functioning, Disability and 
Health (ICF) recommended the measurement of health-related quality of life (HRQOL), or 
participation restriction, to ensure that a complete profile of an individual’s health state is 
measured (World Health Organisation, 2001). To fulfil this requirement in this study, an 
outcome measure of HRQOL that had been validated for CSM was needed.  
The SF36 been validated for use in CSM by King and Roberts (2002), who confirmed its 
construct validity and internal consistency in this population. People with CSM exhibited 
significantly lower scores across all domains of the SF36 compared to a gender and age 
matched population, indicating poorer HRQOL (King et al., 2003). The results showed 
that people with CSM experienced problems in HRQOL that extended beyond the realm 
of physical deficits and included diminished emotional functioning and mental health. The 
authors recommended that the SF36 be used in conjunction with a disease-specific 
outcome measure for CSM such as the Nurick or mJOA to provide a complete picture, 
given that the SF36 was not designed specifically for CSM and may not be sensitive to its 
particular set of deficits. The applicability and reliability of the SF36, and its validity in this 
patient group, makes it the measure of choice for our study. Normal values for the SF36 
in the Irish population have been collated (Blake et al., 2000), allowing retrospective 
comparison with the CSM population in the current study relative to normative data. In the 
current study, the SF36 was scored using the guidelines of (Hays et al., 1993) 
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Assessment of gait impairment using kinematics, kinetics and EMG provides valuable 
information on the biomechanics and neuromuscular control of the locomotor system, but 
it does not measure the impact of a gait deficit on an individual’s functional mobility. The 
Modified Rivermead Mobility Index (MRMI), shown in Table 5.4, is an ordinal scale 
incorporating eight items related to functional mobility, with each item scored from 0 to 5 
depending on ability to perform the task with varying levels of assistance. Validity and 
reliability of the MRMI has been established in people with stroke (Lennon and Johnson, 
2000) and in a general neurological population in a study that reported an ICC for inter-
rater reliability of 0.93 and a Spearman’s rho correlation coefficient with the 10m timed 
walk test of 0.86 (Walsh et al., 2010). It has not been validated specifically for use in 
CSM, however it has been used to measure of functional mobility in adults with cervical 
or thoracic SCI (Opara et al., 2007). Its validity and reliability in a mixed neurological 
population (Walsh et al., 2010) suggested that it should transfer to CSM. Its face and 
content validity were considered appropriate for measurement of functional mobility in this 
population.  
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Item Task Score 
R L 1 Turning Over. 
Please turn over from your back to your side.   
2 Lying to Sitting. 
Please sit up on the edge of the bed. 
  
3 Sitting Balance. 
Please sit on the edge of the bed (10 seconds). 
 
4 Sitting to Standing. 
Please stand up from your chair (<15 seconds). 
 
5 Standing. 
Please remain standing (10 seconds). 
 
R L 6 Transfers. 
Please go from the plinth to the chair and back again.   
7 Walking Indoors. 
Please walk 10 metres in your usual way. 
 
8 Stairs. 
Please climb up and down this flight of stairs in your 
usual way. 
 
R L  TOTAL 
  
SCORING SYSTEM 
0 Unable to perform 
1 Assistance of two people required   
2 Assistance of one person required  
3 Requires supervision or verbal instruction 
4 Requires an aid or an appliance 
5 Independent 
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CSM is associated with increased muscle tone as one of the features of upper motor 
neurone pathology. There is considerable debate in the literature regarding the precise 
nature of spasticity (Pandyan et al., 2005). It has been defined as “a motor disorder 
characterised by a velocity-dependent increase in tonic stretch reflexes with exaggerated 
tendon jerks, resulting from hyperexcitability of the stretch reflex as one component of the 
upper motor neurone syndrome” (Lance, 1980), and as “disordered sensori-motor control, 
resulting from an upper motor neurone lesion, presenting as intermittent or sustained 
involuntary activation of muscles” (Pandyan et al., 2005). These two definitions present 
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somewhat different views of the concept, and illustrate the difficulty in capturing the 
nature of such a complex phenomenon. As discussed in Chapter 4, the use of a 
locomotor-based measure of muscle activity during lengthening was a key objective of 
the study of gait in this project. However, the inclusion of a clinical measure of spasticity 
was considered advantageous, as this forms part of the regular clinical objective 
assessment of CSM.  
The Ashworth scale was developed in 1964 to grade the resistance encountered in a 
muscle during passive stretch (Ashworth, 1964). It was modified in 1987, and inter-rater 
reliability of this modified scale, now known as the Modified Ashworth Scale (MAS), was 
demonstrated (Bohannon and Smith, 1987). It is the most widely used clinical scale of 
spasticity (Ansari et al., 2008). 
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  Description Score 
 No increase in muscle tone 0 
 Slight increase in muscle tone, manifested by a catch and release, or by minimal    
resistance at the end of the range of motion, when the affected part(s) is moved in 
flexion or extension 
1 
 Slight increase in muscle tone, manifested by a catch, followed by minimal 
resistance throughout the remainder (less than half) of the range of motion 
1+ 
 More marked increase in muscle tone through most of the ROM, but affected 
part(s) easily moved 
2 
 Considerable increase in muscle tone, passive movement difficult  3 
 Affected part(s) rigid in flexion or extension 4 
Several studies have since been carried out on its reliability and validity, with conflicting 
results (Ansari et al., 2008). One study showed it to be reliable for all muscle groups 
except the ankle plantarflexors (Gregson et al., 2000), while another found poor inter-
rater reliability for the elbow flexor and knee extensor muscles, with kappa values of 0.20 
(Fleuren et al., 2010). The validity of the MAS has also been questioned. The lower 
grades, 1, 1+, and 2 did not correspond with surface EMG readings of the elbow flexors 
in a trial of botulinum toxin efficacy (Pandyan et al., 2002). A further study found poor 
correlations between MAS scores and muscle activity in response to stretch, measured 
using root-mean-square EMG amplitudes, indicating that the MAS demonstrated 
insufficient construct validity for use as a measurement of spasticity (Fleuren et al., 2010). 
MAS scores were confounded by the presence of contracture in people more than three 
years after a stroke, such that the MAS could not distinguish between passive 
(contracture) and active (spasticity) resistance to stretch (Patrick and Ada, 2006). These 
findings raised considerable questions on what the MAS actually measures, and some 
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authors have proposed that it should not be used as a measurement of spasticity due to 
its limitations (Fleuren et al., 2010). However, a scale that demonstrates satisfactory 
correlation with EMG measurements in SCI has yet to be developed. 
Hsieh et al. (2008) carried out a review of a number of scales measuring spasticity in SCI. 
It was found that the scales measured different aspects of spasticity, and this could 
account for the poor correlation between individual tools. It was recommended that a 
battery of outcome measures be used when assessing spasticity in SCI. To date, no 
single measure of spasticity has been validated for use in the CSM population. The MAS 
has been used to grade spasticity in a study on gait impairment in CSM (Kuhtz-
Buschbeck et al., 1999), however its validity or reliability in this patient group was not 
examined.  
The studies quoted above indicate a lack of consensus in the literature regarding the 
reliability and validity of the MAS, and also regarding the optimal measurement of 
spasticity. However, for the current study, it was considered meaningful to include a 
measure that is familiar to therapists can be carried out easily in the clinical setting. 
Furthermore, the literature review in Chapter 2 found that an increase in resting muscle 
tone is generally accepted as an objective feature of CSM. It was of interest to quantify 
this change in muscle tone so that the features of gait analysis could be related to the 
clinical presentation. The inclusion of the MAS to measure spasticity, in combination with 
the surface EMG data, was therefore considered to provide a more comprehensive 
measure of this phenomenon than the use of either one of these measures in isolation.  
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The objectives of the study required further investigation of a number of methodological 
issues. The evidence relating to the methodology of 3DGA, SEMG, and the secondary 
outcome variables of CSM severity, quality of life, functional mobility and resting tone, 
was reviewed, and methods were developed based on a synthesis of the best available 
evidence. Chapter 6 will describe the application of the methodology to this study.    
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The processes described in Chapter 5 led to the development of methods to achieve the 
aims and objectives of the thesis. The project was divided into three studies as outlined in 
Chapter 4, Section 4.4. There were a number of general methods that were common to 
the three studies. All required the recruitment of people with CSM, assessment of the 
severity of CSM, and gait analysis using 3DGA and EMG technology. This chapter will 
describe these methods. Additional methods unique to the reliability, cross-sectional and 
experimental studies will be described in Chapters 7, 8 and 9, respectively.  
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Ethical approval for the thesis and its protocol was obtained from Beaumont Hospital 
Ethics (Medical Research) Committee in August 2008. Four amendments to the protocol 
were submitted to the Committee. In November 2008, the Committee granted approval 
for a second pre-operative 3DGA assessment to fulfil the aims of the reliability study. A 
second amendment was sought in December 2008 when it came to attention that one of 
the possible participants to the study was a staff member of Beaumont Hospital, who 
would normally have been exempt from taking part in research studies. The Committee 
approved the recruitment of the staff member in January 2009. In March 2009, approval 
was granted to include patients from the consultant’s rooms at Beaumont Private Clinic. 
In February 2010, a final amendment was approved to allow the recruitment of healthy 
controls for the cross-sectional study, the addition of a one-year follow-up assessment, 
and the extension of the study’s expected completion date to October 2011. The final 
version of the approval documentation is provided in Appendix 6.1. 
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Potential participants with CSM were identified at the outpatient neurosurgical Spinal 
Assessment Clinic and Beaumont Private Clinic at the national department of 
neurosurgery, Beaumont Hospital. CSM was diagnosed by a registrar or consultant 
neurosurgeon based on clinical examination and MRI, using the diagnostic criteria listed 
in Table 6.1. These criteria were in keeping with those used in other studies, for example 
Fehlings et al. (2008). 
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Criterion Description 
One of more of the following 
symptoms 
Clumsy hands 
Numb hands and / or feet 
Weakness of lower limbs 
Unsteady gait 
Bilateral upper and / or lower limb paraesthesiae 
One or more of the following signs Lower limb spasticity 
Unsteady gait 
Hyperreflexia, including inverted supinator sign or 
crossed adductor sign 
Upgoing plantar responses 
Clonus 
Weakness in corticospinal distribution 
MRI evidence of one or more of the 
following 
Cervical cord compression due to spondylosis, e.g. 
cord impingement or effacement of cerebrospinal fluid  
Signal change within cord 
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Participants with a diagnosis of symptomatic CSM using the criteria above were included 
in the study if they were aged over 18 years, able to give informed consent, and could 
stand independently and mobilise 10 metres without the need for physical assistance of 
another person, but with aids if required. 
Participants who met the inclusion criteria were excluded from the study if they suffered 
from 1) a co-existing neurological illness with physical deficits that could confound the 
assessment of CSM, including a history of stroke with physical deficits, 2) symptomatic 
lower limb osteoarthritis or rheumatoid arthritis affecting gait, or 3) any condition that 
would have hindered safe testing according to the study protocol, such as unstable 
cardiac conditions, severe respiratory difficulties, or severe pain. Skin sensitivity was also 
an exclusion criterion, if it would preclude the application of surface electrodes and 
reflective joint markers. Participants with a history of symptomatic tandem lumbar spine 
stenosis were excluded, as the coexistence of neurogenic claudication would confound 
the assessment of myelopathy (Lee et al., 2008). Finally, participants who had undergone 
previous surgical intervention for CSM were included in the reliability study only, and not 
in the cross-sectional comparison study with HCs or in the repeated-measures design 
post-operative follow-up study. 
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Inclusion and exclusion criteria were evaluated by reviewing the participant’s medical 
record, and by telephone interview prior to the scheduling of the first assessment. 
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When a consultant or registrar in neurosurgery confirmed a diagnosis of CSM, the 
principal investigator (PI) screened the patient’s medical record for inclusion and 
exclusion criteria. The PI then sent a letter of recruitment to the potential participant in the 
post. The letter highlighted the broad aims of the study, and is provided in Appendix 6.2. 
It included a response form with a stamped addressed envelope to facilitate a reply. The 
PI’s contact details were listed. Participants who indicated their interest in the study were 
contacted by telephone to discuss their participation and further check for exclusion 
criteria, and were then recruited if they wished to do so. If no contact was received from a 
potential participant, a follow-up phone call was conducted a month following the issue of 
the recruitment letter to determine whether the participant was willing to take part or 
preferred to decline.  
Participants were provided with a Participant Information Leaflet provided in Appendix 
6.3. Following the opportunity to ask questions about the study as they wished, they gave 
their informed consent using the Consent Form provided in Appendix 6.4. General 
Practitioner (GP) details were recorded, and each GP was sent a letter informing them of 
their patient’s participation (Appendix 6.5). 
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A number of classifications have been used in the literature to describe the events of a 
GC (Sutherland et al., 1988, Perry, 1992, Neptune et al., 2001). In the interpretation of a 
gait disorder, it is important that the terminology be used consistently to avoid confusion 
between similar, but not necessarily, equivalent terms such as heel strike and initial 
contact. This thesis adopted the traditional GC divisions of five stance and three swing 
phase periods, commonly known as the Ranchos classification (Perry, 1992). In this 
classification, the GC begins with the contact of one foot with the ground and ends when 
the same foot contacts the ground again. The event of toe off divides the GC into its two 
main phases, stance and swing.  
The stance phase is further divided into initial double support, single limb support, and 
second double support. These are defined by the events of opposite foot off, referring to 
toe-off of the contralateral limb, and opposite foot contact, referring to initial contact of the 
contralateral limb. To describe the tasks of weight acceptance, single limb support and 
limb advancement, the GC is further subdivided in the Ranchos classification into the 
following periods of stance, 1) initial contact, 2 loading response, 3) mid stance, 4) 
terminal stance, and 5) pre swing, and the following periods of swing, 6) initial swing, 7) 
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mid swing, and 8) terminal swing. These subdivisions are illustrated in Figure 6.1 and 
described in Table 6.2. 
!
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Black illustrates the lower limb of interest 
IC = initial contact, LR = loading response, GC = gait cycle 
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Phase Subdivision Description 
Initial contact Contact of foot with ground. 
Loading 
response 
Initial contact to opposite foot off. First double support 
phase. 
Mid stance Opposite foot off to heel rise of ipsilateral foot. First half of 
single limb support. 
Terminal 
stance 
Ipsilateral heel rise to opposite foot contact. Second half of 
single limb support.  
Stance 
Pre swing Contralateral foot contact to ipsilateral toe off. Second 
double support phase. 
Initial swing Foot off to point where swinging leg is adjacent to the 
contralateral stance limb 
Mid swing Swing leg moves from a position adjacent to contralateral 
stance limb to a forward position with tibia aligned vertically 
Swing 
Terminal 
swing 
Tibia vertical position to initial contact  
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Assessments were conducted for all CSM participants at baseline in the reliability and 
cross-sectional studies, and at six- and 12-month post-operative follow-up intervals in the 
experimental study. All assessments were carried out in the Movement Laboratory, RCSI. 
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A subjective assessment was carried out for each participant. The purpose of the 
subjective assessment was to ascertain 1) duration, severity and nature of myelopathic 
symptoms, 2) mobility status, including history of falls, 3) medical history and current 
medications, 4) social history and occupational activities. The information was recorded in 
a data collection form (Appendix 6.6), for subsequent analysis and coding. 
The severity of the participant’s CSM was graded using the Nurick classification (Nurick, 
1972) and the mJOA scale (Chiles et al., 1999). Scores were obtained from a structured 
interview. Scoring systems for these outcome measures are shown in Chapter 5, Table 
5.2 and Table 5.3. 
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Lower limb tone was measured in CSM participants using the Modified Ashworth Scale 
(MAS). Participants lay on a standard plinth. The muscle groups tested were hip 
adductors, hip flexors, quadriceps, hamstrings, and gastrocnemius. Each muscle group 
was tested by moving the joint through its full available range in one second, which was 
standardised by counting “one, one thousand” during the time taken to complete a 
repetition. Five repetitions were performed and the average resistance encountered was 
taken as the MAS score (Bohannon and Smith, 1987). The scoring system for the MAS is 
given in Chapter 5, Table 5.5. 
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The Modified Rivermead Mobility Index (MRMI) was assessed using a standard plinth 
and a flight of stairs with one handrail. Participants were given standard instructions 
according to the MRMI protocol, detailed in Chapter 5, Table 5.4. 
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Finally, participants completed the SF36 questionnaire to assess HRQOL. The SF36 also 
formed part of the standard assessment protocol of the Spinal Assessment Clinic at 
Beaumont Hospital. If participants had completed the SF36 at clinic within the previous 
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month, they were not required to complete it again, and the scores were taken from the 
most recent clinic records. 
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As described in Chapter 5, Section 5.3, 3DGA was conducted using a five-camera 
VICON ® 250 motion analysis system (VICON, Oxford Metrics Ltd., Oxford, UK) a Kistler 
multi-component force plate (Kistler Instruments Ltd., Winterthur, Switzerland), and a 
Motion Lab Systems MA-300 multi-channel surface EMG system (Motion Lab Systems 
Inc, Baton Rouge, Louisiana, USA). The capture volume was calibrated prior to each 
session using the manufacturer’s specified static and dynamic calibration procedures. 
Calibration residuals of less than 2 mm were accepted. 
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The measurement of anthropometric parameters followed the standard protocol of the 
RCSI Movement Laboratory.   
Height was measured with a stadiometer as shown in Figure 6.2. The head was 
positioned in the Frankfurt plane, a standard plane established by an imaginary line 
passing through the right tragion and the lowest point of the right eye. The vertical 
distance from the floor to the vertex of the head, its highest point in the mid-sagittal plane, 
was measured with the participant standing barefoot. 
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Weight was recorded in kilograms in unsupported barefoot standing using a Seca digital 
measuring scales. 
Leg length was measured with the participant in supine, lower limbs extended and pelvis 
in neutral. The inferior aspect of each ASIS was located by palpating caudally to cranially 
on the anterior hip to find its most inferior aspect. Leg length was measured from this 
point to the inferior aspect of the medial malleolus to the nearest millimetre. 
The distance between right and left ASIS was measured from the inferior aspect of each 
ASIS, located during measurement of leg length, using a tape measure, to the nearest 
millimetre. 
Knee joint width was measured with the participant lying supine with the knees flexed to 
75–80º. The lateral epicondyle was located at the lateral aspect of the knee joint line and 
the popliteal groove just beneath it was marked with a skin surface marker. The midpoint 
of the medial collateral ligament at its intersection with the knee joint line was marked 
medially. The distance between the medial and lateral marks was measured with callipers 
to the nearest millimetre. The average of three measurements was taken as the knee 
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joint width. Figure 6.3 demonstrates the measurement of knee joint width using the 
callipers. 
!
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Ankle width was measured in supine with knees extended, using callipers, from the most 
medial point of the medial malleolus to the most lateral point of the lateral malleolus. The 
average of three measurements was recorded to the nearest millimetre. 
Tibial torsion was measured in supine, with knees extended and the hip in neutral 
rotation. The arms of a gravity inclinometer known as a tibial torsion device were placed 
on the most medial point of the medial malleolus and on the most lateral point of the 
lateral malleolus. The tibial torsion device was held upright to allow the indicator arm to 
hang feely under gravity, and the number of degrees of tibial torsion was read from the 
dial with the device in this position, as shown in Figure 6.4. 
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SEMG electrodes were attached to four muscles on each leg, rectus femoris (RF), biceps 
femoris (BF), tibialis anterior (TA), and the medial head of gastrocnemius (MG). The area 
of skin in contact with the electrode was prepared by shaving and cleaning with an 
alcohol swab to reduce skin impedance, and allowed to dry prior to the attachment of the 
electrode. In participants with particularly dry skin, the area for electrode contact was 
further treated with gel to eliminate potential static interference with the signal from the 
skin surface. Electrodes were aligned along the direction of the muscle fibres insofar as 
this could be determined from their known anatomical orientation.  
Placement of the electrodes followed the SENIAM recommendations (Hermens and 
Freriks, 1997). To confirm the location for each electrode, the area identified by following 
the SENIAM guidelines was palpated while resisting the muscle’s action. This ensured 
that each electrode was placed over an area of muscle bulk. Electrodes were secured to 
the skin using surgical tape.  
The specifications used in the detection, recording, amplification and analogue-to-digital 
conversion of the EMG signal are listed in Table 6.3. 
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Electrodes  
Specification Double-differentiated pre-amplified surface electrodes 
Material Medical-grade stainless steel 
Shape Circular disks 
Size 12 mm 
Weight 10 g 
Reference contacts 12 mm x 3 mm bar 
Inter-electrode distance 18 mm 
Pre-amplifier body size 38 mm x 19 mm x 8 mm 
EMG Detection  
Detection mode Double differential 
Input impedance (pre-
amplifiers) 
> 100 M! 
Common mode rejection 
ratio (pre-amplifiers) 
> 100 dB at 65 Hz 
Signal-to-noise ratio > 50 dB 
Pre-amplifier gain 20 
Backpack gain range 10 to 500 
Low pass filter 500 Hz at -3 dB 
High pass filter 20 Hz at -3 dB 
Sampling  
Sampling rate 1000 Hz 
A/D Card and Resolution DATAQ® Instruments 32-channel DI-720 Data Acquisition 
System with 12 bit resolution (DATAQ Instruments Inc., 
Akron, Ohio, USA) 
Storage “.c3d” files on PC  
g = grams, mm = millimetres, M! = mega Ohms, dB = decibels, Hz = Hertz, PC = personal 
computer 
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A maximum voluntary isometric contraction (MVIC) was then recorded for each muscle 
using SEMG. A practice trial was carried out for each muscle to familiarise the participant 
with the procedure. At least one second of data from the muscle at rest was recorded 
prior to the initiation of MVIC, to ensure optimal SNR and to inspect the signal for 
interference. This data acted as a reference for the Resting Threshold Method timing 
algorithm described in Chapter 5, Section 5.4.4.2. Amplification gains were adjusted to 
achieve a signal amplitude of around 1 Volt (V) during MVIC. 
MVIC was carried out against manual resistance provided by the principal investigator 
(AM), using standardised test procedures for BF, RF, TA and MG muscles (Kendall et al., 
2005). The test positions and actions are shown in Table 6.4 and Figures 6.5–6.8. The 
contraction was held for 3 seconds with verbal encouragement to ensure that MVIC was 
reached. 
!"#$%&'()*&+%,-./012&-3&4"50464&7-$618".9&0:-4%8.0,&,-18.",80-1&
Muscle Position Command Action 
Biceps femoris Prone, knee in 70° 
flexion, hip in slight 
external rotation 
“Bend your 
knee as hard 
as you can” 
Tester applies strong 
extension force about 5 cm 
proximal to Achilles tendon, 
participant resists by 
attempting to flex knee 
maximally 
Gastrocnemius Prone, knee in 70° 
flexion, ankle in 
plantargrade 
position  
“Push up your 
foot as hard as 
you can” 
Tester applies a 
dorsiflexion force to the 
metatarsal heads, 
participant resists by 
pushing foot and toes up 
into tester’s hand  
Rectus femoris Sitting with thighs 
supported, hands 
placed at edge of 
plinth for support, 
knees in 90° flexion, 
feet clear of floor 
“Hold your 
knee up and 
straighten your 
leg as hard as 
you can” 
Participant flexes hip so 
that thigh clears the bed, 
tester places one hand on 
lower tibia proximal to ankle 
joint, participant attempts to 
strongly extend knee while 
maintaining flexed hip 
Tibialis 
anterior 
Sitting with thighs 
supported, feet clear 
of floor, ankle in 5° 
dorsiflexion and 
slight inversion 
“Hold your foot 
up” 
Tester attempts to push 
foot into plantarflexion and 
eversion, participant resists 
this action maximally 
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Fifteen retro-reflective markers of 25 mm diameter were placed on the participant’s lower 
limbs in standing in accordance with the MHH model (Davis et al., 1991). Marker 
placement is shown in Figure 6.9 and Figure 6.10. The PI was responsible for marker 
placement in all assessments. Table 6.5 describes the location and anatomical 
landmarks used in the placement of markers. Figure 6.11 shows the identification of the 
location for the heel marker.  
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Marker label Description 
Sacrum A wand marker was placed over the sacrum at the midpoint between the skin 
dimples of the posterior superior iliac spine. 
ASIS Markers were placed over each ASIS. 
Knee A KAD was attached to the lateral and medial femoral condyles. This was done 
initially in sitting, with the foot clear of the floor, to determine the location of the KAD 
at which minimal translation of the horizontal arm occurred during open kinetic chain 
knee flexion and extension. The KAD was then reapplied in standing at a point 
slightly posterior to its location in sitting, to compensate for movement of the skin 
over the knee joint from flexion in sitting to standing. 
Thigh A short wand was placed over the lateral aspect of the thigh in alignment with the 
most lateral aspect of the greater trochanter and the lateral knee joint axis marker on 
the KAD. 
Ankle Ankle markers were placed over the most lateral aspect of each lateral malleolus. 
Shank Marker wands were aligned with the ankle joint markers and the knee joint markers 
at the midpoint of an imaginary line between these markers. 
Forefoot Markers were attached to the heads of the second metatarsal bones, identified by 
asking the participant to flex their toes. 
Heel Markers were attached to the posterior aspect of the calcaneus, at the same height 
as the forefoot marker, determined by a calliper. 
KAD = knee alignment device, ASIS = anterior superior iliac spine 
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A static data capture was then performed with all markers in situ and the KAD placed at 
the knee joint line to calibrate the participant’s measurements and marker placement in 
the static position. The position for static calibration is shown in Figure 6.12. The 
participant was instructed to stand on the force plate for the static capture, with arms 
folded and knees slightly flexed. If the participant could not achieve stability in standing 
with slightly flexed knees, the knees were maintained in extension. Usual gait aids were 
used for participants who had difficulty with unsupported standing. Calibration was 
completed using PiG®.   
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The KADs were then removed and single markers were placed over the lateral aspect of 
the knee joint defined by KAD. A second static calibration was performed to facilitate 
marker labelling, retaining the rotation parameters defined in the previous calibration. 
This calibration is shown in Figure 6.13. 
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Participants were instructed to walk barefoot along the laboratory walkway at their usual, 
comfortable walking speed, using any habitual gait aids. Stand-by assistance was 
provided for safety by a co-investigator during the gait trials. Physical assistance was 
avoided unless the participant became unsteady, in which case that trial was not then 
used for further analysis. Although the force plate was visible in the centre of the 
walkway, participants were not informed of its purpose to ensure that their gait patterns 
were not altered by any attempt to target its location. Data were captured at 50 Hz. Raw 
data were monitored continuously on the Workstation screen to ensure optimal quality 
and to detect marker occlusion or displacement that may have occurred during walking. 
Gait trials were repeated until the participant had achieved ten trials with complete strikes 
to the force plate, five from each leg. The starting position for each trial was modified if 
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necessary to facilitate the collection of complete, uncontaminated force plate data. For 
some participants with more severe gait impairment, it was not possible to achieve the 
required number of force plate strikes, due to short stride length or the onset of fatigue. In 
these cases, ten trials were collected as normal for TSPs, kinematics, and EMG, but the 
number of trials containing valid kinetic data may have been less than five. Participants 
were monitored for fatigue during the assessment by subjective questioning, and given 
rest breaks as required between trials to minimise fatigue. 
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The raw video and analogue data, captured by the Vicon cameras and Kistler force plate 
in Section 6.5, required further processing in Vicon Workstation to generate temporal-
spatial, kinematic and kinetic data. Anthropometric data, obtained in Section 6.6.2, were 
inputted into Workstation. The markers in the static calibration trial were then labelled and 
Vicon’s “static gait model” procedure was applied to the calibration trial to determine the 
lower limb joint centres from the anthropometric data and marker locations. This 
calibration formed the basis of the PiG routine that calculated kinematics and kinetics for 
the remaining trials in that session.   
Individual gait trials were then processed in Workstation. Three-dimensional trajectories 
were reconstructed from the raw video files, shown in Figure 6.14 and labelled, as shown 
in Figure 6.15.  
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Gaps in the trajectories were inspected and filled using inbuilt commands in Workstation, 
either by interpolation for small gaps, or by copying the pattern of an adjacent trajectory if 
the gaps were large. The trajectories were then filtered using a Woltring filter with a MSE 
of 15 mm2. PiG then calculated the joint centres and computed the underlying joint 
motion. GRFs, captured in three planes by the Kistler force plate, were integrated with 
kinematic data to calculate joint moments and powers using inverse dynamics. Kinetic 
parameters were normalised to body weight to enable comparison between participants.  
GC events of heel strike and toe off were then defined in Workstation to facilitate the 
calculation of TSPs. These events were derived from force plate data where the 
participant had achieved a complete strike of the foot to the force plate, without 
contacting the force plate with the opposite foot. A threshold of 20 Newtons was used to 
determine the points of heel strike and toe off. Trials without force plate data, or where 
force plate data were contaminated, were defined by observation of the patterns of the 
heel and forefoot trajectories, for one GC of each lower limb. Figure 6.16 shows the 
inspection of heel and forefoot trajectories to determine GC events. The remaining GCs 
were then computed by Vicon’s auto-correlation system, using the ankle trajectory as a 
reference, and verified by visual inspection. Errors in the auto-correlation of GC events 
were manually corrected. TSPs were then calculated for that trial.  
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The next step in data processing involved the importing of gait trials from Workstation into 
Vicon Polygon®, a software package for visualisation of temporal-spatial, kinematic and 
kinetic data. Ten gait trials from each participant were imported into Polygon, comprising 
five trials each with force plate data from the left and right lower limbs. If a participant 
could not achieve the specified number of force plate strikes, 10 gait trials were still 
imported to Polygon, but some of these contained kinematic data only. The Polygon 
software normalised each GC in time to 51 data points from heel strike (0%) to ipsilateral 
heel strike (100%) at intervals of 2%. If a gait trial contained data from more than one 
complete GC for one or both lower limbs, the GC from each lower limb with the best 
quality data was selected for further analysis, and data from other GCs in that trial were 
discarded using Polygon’s graphical user interface. The temporal-spatial, kinematic and 
kinetic data for each trial were then exported to Microsoft Excel using a macro routine in 
Polygon. An average was obtained for that assessment of each TSP, and of time-
normalised kinematic and kinetic curves. Figure 6.17 shows the Polygon interface and 
the visualisation of kinematic and kinetic graphs. Table 6.6 lists the TSPs and Table 6.7 
details the kinematic and kinetic curves that were exported from Polygon. 
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Variable Description Units of 
measurement 
Cadence Number of steps taken in one minute Steps / minute 
Double 
support 
Time for which both lower limbs are in stance Seconds  
Double 
support 
duration 
Duration of double support as a percentage of GC  % GC duration 
Foot off Percentage of GC at which transition from stance 
to swing occurs 
% GC duration 
Gait speed Distance covered over time Metres per 
second 
Opposite foot 
contact 
Time during stance phase of one limb that the 
opposite limb begins stance, i.e. beginning of 
second double support phase 
% GC duration 
Opposite foot 
off 
Time during stance phase of one limb that the 
opposite limb begins swing, i.e. completion of first 
double support phase  
% GC duration 
Single 
support 
Time for which only ipsilateral limb is in contact 
with the ground  
Seconds 
Single 
support 
duration 
Duration of single support as a percentage of GC  % GC duration 
Step length Distance covered from heel strike of ipsilateral 
limb to heel strike of the contralateral limb 
Metres 
Step time Time from heel strike of ipsilateral limb to heel 
strike of the contralateral limb 
Seconds 
Step width Lateral distance between right and left forefoot 
markers during double support 
Metres 
Stride length Distance covered from heel strike of one limb to 
heel strike of the same limb 
Metres 
Stride time Time from heel strike of one limb to heel strike of 
the same limb  
Seconds 
GC = gait cycle 
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Name Description Positive 
orientation 
Units 
Pelvic tilt Movement of the pelvis in 
the sagittal plane 
Anterior tilt 
Pelvic obliquity Movement of the pelvis in 
the frontal plane 
Upward obliquity 
Pelvic rotation Movement of the pelvis in 
the transverse plane 
Internal rotation 
Hip flexion / extension Movement of the hip in the 
sagittal plane 
Flexion 
Hip abduction / 
adduction 
Movement of the hip in the 
frontal plane 
Abduction 
Hip rotation Movement of the hip in the 
transverse plane 
Internal rotation 
Knee flexion / 
extension 
Movement of the knee in 
the sagittal plane 
Flexion 
Ankle dorsiflexion / 
plantarflexion 
Movement of the ankle in 
the sagittal plane 
Dorsiflexion 
Degrees 
Hip flexor / extensor 
moment 
Net moment of force about 
the hip in the sagittal 
plane 
External extensor 
moment 
Hip abduction / 
adduction moment 
Net moment of force about 
the hip in the tranverse 
plane 
External abductor 
moment 
Knee flexor / extensor 
moment 
Net moment of force about 
the knee in the sagittal 
plane 
External extensor 
moment 
Ankle dorsiflexor / 
plantarflexor moment 
Net moment of force about 
the ankle in the sagittal 
plane 
External 
plantarflexor 
moment 
Newton 
metres 
Hip power Net power at the hip 
across three planes 
Knee power Net power at the knee 
across three planes 
Ankle power Net power at the ankle 
across three planes 
Power generation Watts per 
kilogram  
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The kinematic and kinetic variables, extracted from Polygon for each participant’s 
assessment and listed in Table 6.7 above, consisted of time-varying curves normalised to 
51 data points, each representing the GC at 2% intervals. Key points from each kinematic 
and kinetic curve were selected based on data from previous studies in CSM (Kuhtz-
Buschbeck et al., 1999, Maezawa et al., 2001, Suzuki et al., 2002) and on their clinical 
relevance (Kirtley, 2006). A large number of variables were included to facilitate 
exploration of the data in the reliability and cross-sectional studies. This approach was 
used by a number of studies using 3DGA, particularly in populations whose gait 
characteristics had not previously been assessed in detail with this technology 
(Mahaudens et al., 2009, Williams et al., 2009b, Gil-Agudo et al., 2011). Tables 6.8 and 
6.9 list and define these kinematic and kinetic key points, respectively. Extraction of the 
key points from the time-normalised average of each assessment was performed using a 
customised routine in MATLAB, shown in Appendix 6.7.  
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Joint Description 
Peak pelvic tilt 
Range of pelvic tilt 
Average pelvic tilt 
Peak pelvic obliquity 
Range of pelvic obliquity 
Pelvis 
Range of pelvic rotation 
Hip position in the sagittal plane at initial contact 
Peak hip flexion 
Peak hip extension 
Total range of hip excursion in the sagittal plane 
Peak hip abduction in swing 
Total range of hip excursion in the frontal plane 
Peak hip internal rotation 
Hip 
Total range of hip rotation 
Knee position at initial contact 
Peak knee flexion in stance, loading response  
Peak knee flexion in swing 
Peak knee extension in midstance 
Knee 
Total range of knee excursion in the sagittal plane 
Ankle position at initial contact 
Peak ankle dorsiflexion in stance 
Peak ankle dorsiflexion in swing 
Ankle 
Peak ankle plantarflexion 
&
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Type of Data Description 
Peak mediolateral GRF 
Peak negative antero-posterior GRF (braking) 
Peak positive antero-posterior GRF (propulsion) 
First vertical GRF peak, loading  
Minimum value of GRF during stance 
Ground 
reaction force 
(GRF) (N/kg) 
Second vertical GRF peak, propulsion  
Peak hip flexor moment 
Peak hip extensor moment 
Peak hip abductor moment 
Peak knee flexor moment 
Peak knee extensor moment 
Moments 
(Nm/kg) 
Peak ankle plantarflexor moment 
Peak concentric hip extensor power during loading response (H1) 
Peak eccentric hip flexor power during mid-stance (H2) 
Peak concentric hip flexor power during terminal stance (H3) 
Peak eccentric knee extensor power during loading response (K1) 
Peak concentric knee extensor power during mid-stance (K2) 
Peak eccentric knee extensor power in terminal stance (K3) 
Peak eccentric knee flexor power, terminal swing (K4) 
Peak eccentric ankle power in loading response through to mid 
stance (A1) 
Powers (W/kg) 
Peak concentric ankle plantarflexor power at terminal stance (A2) 
Abbreviations: W = Watts, kg = kilograms, N = Newtons, Nm = Newton metres 
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EMG analogue data from each trial were exported to a comma separated values (CSV) 
text file in ASCII (American Standard Code for Information Interchange) format. A custom 
built routine in MATLAB, detailed in Appendix 6.8, extracted EMG signals from each 
channel for the duration of the GCs defined and used in Polygon in section 6.7.1 above. 
The signals were then filtered with a second-order Butterworth high-pass filter with a cut-
off of 25 Hz and a fourth-order Butterworth low-pass filter with a cut-off of 400 Hz, applied 
in forward and reverse directions using a MATLAB routine, previously shown in Appendix 
5.2. The filtered signals were stored in MATLAB ‘mat’ format for further analysis.  
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As outlined in Chapter 5, Section 5.4.4.2, the TKEO-based Double Threshold Method 
(DTM) for detection of muscle activation showed the highest agreement with visual 
interpretation. It was used for detection of the timing of muscle activation for all EMG 
signals in the current study. Using a custom built routine in MATLAB, shown in Appendix 
6.9, the filtered signals of Section 6.7.3.1 were treated with the TKEO equation. Activation 
was signalled when the TKEO amplitude at a given time point exceeded 3% of the 
maximum TKEO amplitude of that trial, in Volts times Hertz squared, and when the slope, 
or rate of change of the TKEO-treated signal over time, exceeded 10-6, for at least 24 
time points in a 25 point moving window. Cessation of activation was signalled when this 
condition was no longer satisfied. The application of this algorithm generated two outputs, 
1) a vector, termed “ON”, of a series of logical 1’s and 0’s denoting periods of muscle 
activity and no activity, respectively, and 2) the time points in the GC at which the signal 
changed from an “on” to an “off” state, and vice versa. 
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The amplitude of each EMG signal was extracted using the RMS method. RMS was 
generated over a time interval of 30 ms with 20 ms overlap using a previously written 
routine in MATLAB (Ajiboye, 2006), provided in Appendix 6.10. The resulting output was 
interpolated to 101 data points using one-dimensional linear interpolation, thereby 
normalising the data in time to the GC at successive percentage points from 0 to 100. 
This facilitated the interpretation of RMS amplitude in relation to timing data, kinematics 
and kinetics.  
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Normalisation of a signal’s RMS amplitude to a given reference amplitude is necessary to 
facilitate comparison between participants on different test days, and between groups of 
participants. As outlined in Chapter 5, Section 5.4.4.4, both the maximum amplitude of a 
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muscle’s EMG signal in one session of gait analysis and a muscle’s signal during MVC, 
have been used as normalisation references, but their reliability has not been tested. It 
was therefore necessary to test both methods for reliability and to choose the most 
reliable method for further analysis.  
To obtain the PDM reference, the maximum value of each muscle’s time-normalised 
RMS, over the ten extracted trials in that session, was identified using MATLAB. For MVC 
normalisation, MVC signals obtained in Section 6.6.4 were exported to MATLAB and their 
RMS were calculated. In some cases, the MVC trial was recorded using different 
amplification gains to those used in gait trials. If this had occurred, raw data from the 
MVC trial was scaled to the gains used in the gait trials for that session, using a scaling 
system designed for the MA-300 (Appendix 5.3). The maximum RMS value over the 0.5 s 
interval with the highest mean amplitude was then extracted and used as the MVC 
normalisation reference (Hsu et al., 2006). 
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The total duration of activation for each muscle in a GC was summed and expressed as a 
percentage of GC duration to allow for comparison between GCs of varying length and 
between individuals. The mean activation time of ten gait trials in one session was used 
for further analysis. 
To determine co-activation, the activation of antagonistic muscle pairs, RF–BF and TA–
MG, were compared at each time point in the GC. Co-activation was defined as 
simultaneous activation of both muscles, when the “ON” vector of Section 6.6.3.2 
denoted “1” for both muscles at a particular data point. The duration of co-activation for 
each pair was then summed and expressed as a percentage of GC duration. The mean 
co-activation of 10 trials in one session was used for further analysis. 
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The RMS of each signal over the GC was further processed to extract the peak and 
mean RMS amplitude of each burst of muscle activity, as well as the mean RMS during 
the periods of the GC when the muscle in a baseline state (“off”). Phases of activity for 
each muscle were determined based on their relevance to the GC from the work of 
(Perry, 1992). The phases used for analysis of each muscle are listed in Table 6.10. 
Stance and swing were determined from the point at which toe-off occurred in each 
individual GC, previously obtained as a TSP in Section 6.7.1. 
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Muscle Activity burst 
Medial gastrocnemius Stance 
Loading response Tibialis anterior 
Swing 
Stance Biceps femoris 
Swing 
Loading response 
Pre swing to initial swing 
Rectus femoris 
Swing 
Figure 6.18 illustrates the process of extracting amplitude data for each activity burst. The 
timing of muscle activation within each phase was extracted based on the data of Section 
6.6.4.1. The timing was then applied to the RMS of the signal obtained in Section 6.6.3.2. 
For each phase listed in Table 6.10, the RMS values at the time points in which the 
muscle was active in that phase were extracted, and the peak and mean RMS were 
calculated from this data. The RMS of the “off” phases was calculated by extracting the 
RMS values at the time points in the GC when the muscle was not active, and calculating 
the mean of these values.  
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A) Raw signal, extracted over the gait cycle from heel strike to heel strike  
B) Signal after filtering off-line with a Butterworth filter to remove motion artefact 
C) TKEO-treated signal with the straight grey line (Y axis) showing the periods in which the muscle 
was “on” (active) or “off” in the gait cycle 
D) the root-mean-square (RMS) of the signal, normalised to the gait cycle from 0 to 100% 
E) extraction of RMS from the bursts of each clinically-relevant phase 
V, Volts, ms, milliseconds, VHz2, Volts times Hertz squared, RMS, root-mean-square amplitude, 
TO, toe off, RF, rectus femoris 
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As discussed in Chapter 5, Section 5.4.4.5, a locomotor specific measure of spasticity 
(LSMS) was developed according to the methods of Lamontagne et al. (2001) and 
Crenna (1999). The LSMS evaluated the relationship between a muscle’s EMG signal 
and its lengthening velocity over the GC. The relative length and lengthening velocities of 
TA, MG, BF and RF during the GC were calculated using formulae derived by Winter and 
Scott (1991). The resting length of each muscle was defined as its length in the 
anatomical position, with hips, knees and ankles at 0º flexion and extension. The 
muscle’s length at any given point during the GC was a function of the angle of the joint 
or joints it crossed, its angle of pennation, and three (for single joint muscles) or six (for 
multi joint muscles) constants. Length was expressed in relation to the resting length in 
the anatomical position. Lengthening velocity was then calculated as a function of the GC 
duration. Equations are listed in Appendix 6.11. Calculations of muscle length and 
lengthening velocity were performed using a custom-built routine in MATLAB (Appendix 
6.12). Lengthening velocity was interpolated to 101 data points to facilitate interpretation 
with the EMG signal. 
One key lengthening phase was examined for each muscle, namely, BF lengthening 
contraction during terminal swing, MG during mid stance, TA during terminal stance 
through initial swing, and RF during the same period. Three parameters were extracted 
as part of the LSMS, 1) the lengthening velocity at the point of onset of EMG activity 
during the lengthening contraction, namely LVT, 2) the time point at which EMG activity 
onset occurred, termed the “critical time” and expressed as a percentage of GC duration, 
and 3) the slope of the line of EMG RMS, expressed as a percentage of the maximum 
RMS in that session, plotted against lengthening velocity, with positive slopes indicating 
an abnormal response (Lamontagne et al., 2001). The onset of EMG activity during 
lengthening was extracted from the timing data of Section 6.7.4.1 
!"#$ %&'()*+,&'$
This chapter has described the general methods of recruitment, data collection, and 
processing that were common to all studies in the project. The next three chapters will 
detail the methods and results of the individual reliability, cross-sectional and 
experimental studies.    
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Before a measurement instrument can be applied to a clinical population, it is good 
scientific practice to estimate its reliability in that population. This ensures that the results 
can be interpreted within the context of the variation in scores that occurs from test to 
retest (Bruton et al., 2000). In the absence of previous studies of reliability on 3DGA and 
EMG in the CSM population, it was necessary for the current study to undertake this task. 
About 70% of reliability studies conducted to date have evaluated healthy participants 
(McGinley et al., 2009). Each clinical population will have its own characteristics 
regarding variability (Bruton et al., 2000), and therefore estimates of reliability from 
healthy participants cannot be extrapolated to those with a specific impairment such as 
CSM. Reliability is a key concern where the data will be used to compare participants and 
to evaluate the outcome of an intervention (Dankaerts et al., 2004), as was the case with 
the current study. 
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A number of studies have evaluated the reliability of temporal-spatial, kinematic and 
kinetic parameters in populations including healthy participants, CP, and stroke. 
Approaches to the analysis of reliability in 3DGA have differed among studies. Some 
studies examined the reliability of kinematic and kinetic curves over the complete GC 
(Kadaba et al., 1989, Steinwender et al., 2000, Schwartz et al., 2004, Delval et al., 2008), 
while others extracted key points from those curves, such as a peak value or a range 
(Maynard et al., 2003, Monaghan et al., 2007, Yavuzer et al., 2008). Key points have 
been considered more meaningful, as they are easier to compare and interpret than 
complete curves, and tend to include the most clinically relevant features of the curves 
(Redekop et al., 2008).  
A systematic review, based on the results of fifteen studies of 3DGA, found highest 
reliability for kinematic parameters in the sagittal plane (ICC 0.8), with the exception of 
pelvic tilt (ICC 0.6), and lowest reliability in the transverse plane (ICC <0.7). Standard 
errors of measurement (SEM) of around 4º in the sagittal plane and 2º in the frontal plane 
were calculated. The review concluded that most kinematic parameters showed 
moderate to good reliability, however the measurement errors were not small enough to 
be ignored in clinical interpretation (McGinley et al., 2009). In neurological populations, 
intra-session reliability was found to be higher in children with better-functioning scores 
 
121 
on the Gross Motor Function Classification Scale, and lower in those with more severe 
CP (Redekop et al., 2008), suggesting that the severity of a mobility disorder impacts 
negatively on reliability. Studies have found kinetic parameters to be more reliable than 
kinematics in children with CP (Steinwender et al., 2000), adults with stroke (Campanini 
and Merlo, 2009), and healthy adults (Kadaba et al., 1989, Monaghan et al., 2007). In 
healthy adults, GRFs were more repeatable than joint moments, possibly due to variation 
in marker placement contributing to moments (Kadaba et al., 1989).   
No studies on the reliability of 3DGA in SCI have been reported to date. It would be 
expected that some of the trends shown in previous studies would apply to the current 
study in CSM. Variation in marker placement is considered the most important source of 
extrinsic or measurement error in test-retest reliability (McGinley et al., 2009). Efforts to 
minimise this error in the current study were discussed in Chapter 5, Section 5.3.3.1. 
Intrinsic variability, or true inherent variation in a participant’s gait, may also be a factor in 
people who have limited mobility (Schwartz et al., 2004), such as those with CSM, and 
may increase the minimal detectable change of the 3DGA in this population (Haley and 
Fragala-Pinkham, 2006). 
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To date, no studies have examined the reliability of SEMG timing data in gait in a 
neurological population. In healthy participants, the timing of the peak value of the linear 
envelope, normalised to GC duration, was found to vary by less than 10% GC duration 
for peroneus longus, TA, MG and soleus, despite deliberate changes in electrode location 
(Campanini et al., 2007). This would suggest that timing is relatively robust to slight 
differences in electrode placement from test to retest. However, Campanini’s study did 
not consider variability in estimates of the total duration of bursts of muscle activation 
over the GC, which may be affected by the relative location of innervation zones and 
tendons with respect to the overlying electrodes, and may therefore vary from test to 
retest (Farina et al., 2001). 
In neurological populations, the timing and amplitude of bursts of activity may be prone to 
greater levels of intrinsic variability (Schwartz et al., 2004). This may be due to the 
presence of spasticity with its variable manifestations depending on pain, temperature, or 
fatigue, or to inconsistencies in achieving the optimum motor strategy for a task in gait. 
Therefore, it cannot be assumed that the duration of muscle activation over the GC will 
be robust in the current study’s CSM population, and an estimate of test-retest variability 
is required. 
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Test-retest reliability of SEMG amplitude data was also a key concern for the current 
study. Conflicting results have been found by studies in addressing this issue, and as yet, 
there are no findings relating to the reliability of amplitude data from EMG signals in a 
neurological population. Three factors need to be considered in the reliability of amplitude 
data: 1) the effect of test-retest variability when electrodes are removed and re-applied, 
as opposed to intra-test reliability, where electrodes are not usually removed and 
environmental changes will not affect the final signal, 2) the units reported, that is, 
whether the RMS or average rectified value (ARV) amplitude in Volts is examined for 
reliability or whether normalisation is applied, 3) if normalisation is applied, which method 
is used. 
The most reliable normalisation reference has not yet been determined. Norcross et al. 
(2010) compared the reliability of ARV amplitude of EMG of the gluteal muscles, RF, 
vastus lateralis, BF and adductors at the hip from two normalisation tasks, conventional 
MVC and muscle activity during single leg stance. Both methods demonstrated good-to-
excellent reliability (ICC, 0.85–0.95, SEM, 8.5–201 mV). However, the effect of removing 
and reapplying the electrodes was not examined, a factor which must be considered in 
clinical interpretation of EMG data where results will usually be compared on different test 
days. A study of test-retest reliability of non-normalised ARV amplitudes in a maximal and 
sub-maximal test of trunk muscle function found higher test-retest reliability in the sub-
maximal test (ICC, 0.88, SEM, 8%) compared to the maximal test (ICC 0.7, SEM 17%) 
(Dankaerts et al., 2004). A study of reliability in healthy people and those with knee 
pathology found high variability in non-normalised RMS parameters, with ICCs ranging 
from 0.23 to 0.84, and SEM of up to 0.28 mV (Callaghan et al., 2009). Although these 
studies examined the reliability of the normalisation reference itself, they did not examine 
the reliability of EMG signals from other tasks that were scaled to that reference value. 
This was the key question for the current study, which was not so much concerned with 
the reliability of the amplitude of SEMG signals in the reference test, but rather, the 
amplitude of signals during gait when normalised to that reference. 
In relation to normalised SEMG amplitude data, Knutson et al. (1994) found that 
normalising gastrocnemius activity to MVC provided more repeatable results in people 
with anterior cruciate ligament injuries, than normalisation to mean and peak amplitudes 
from gait. Reliability of the MVC method was also found to be superior to PDM and MDM 
methods for EMG assessment of the hip musculature in HCs during open and closed 
kinetic chain exercises (Bolgla and Uhl, 2007). 
These studies show that reliability of amplitude parameters varies considerably, 
depending on the population studied, the normalisation method used, and the time 
interval between tests. In the absence of any definitive data on reliability, it was 
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necessary that the current study evaluate reliability of both PDM-normalised and MVC-
normalised bursts amplitudes during gait in CSM. The most reliable method could then be 
used for analysis in the cross-sectional and experimental studies.  
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As discussed in Chapter 5, Section 5.4.4.5, a measure of the lower limb muscles’ 
responses to lengthening during the GC was required to fulfil the objective of determining 
if spasticity was a factor in gait impairment. Although aspects of the LSMS have been 
validated in children with CP (Crenna, 1999) and in adults following stroke (Lamontagne 
et al., 2001), its repeatability has not been assessed. This has limited its use in 
monitoring locomotor recovery (Lamontagne, 2006). The current study therefore included 
analysis of the test-retest reliability of three aspects of the LSMS, namely 1) the 
lengthening velocity threshold (LVT) for muscle activation, 2) the critical time during 
lengthening at which activation occurred, and 3) the slope of the relationship between 
EMG amplitude and lengthening velocity, in the CSM group. The methods involved in 
calculation of the LSMS have been described in Chapter 6, Section 6.7.4.3. 
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A number of statistical methods have been used in the evaluation of reliability. Of these, 
the coefficient of variation, the coefficient of multiple correlation (CMC), and its derivate 
for curves, the coefficient of multiple determination (CMD), have been criticised because 
they are influenced by the size of the parameter itself. Parameters with a larger range, for 
example knee flexion in swing, will invariably record higher reliability than parameters 
with a smaller range, such as pelvic obliquity, using these methods (McGinley et al., 
2009). The ICC is a more commonly used measure of relative reliability, and has been 
recommended for use in reliability studies (Fleiss, 1986, Rankin and Stokes, 1998).  
Recent literature has recognised that correlation indices alone do not determine whether 
a measure is sufficiently reliable for clinical use. It is therefore necessary to obtain a 
measure of absolute reliability, reported in the same units as the parameter itself, to 
ensure that the results can be interpreted in a clinical context (Bruton et al., 2000, 
McGinley et al., 2009). Absolute measures of reliability include the SEM (Streiner and 
Norman, 2008), which is based on the ICC (Shrout and Fleiss, 1979), and Bland–Altman 
95% limits of agreement (LOA) (Bland and Altman, 1986).  
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The aims of the reliability study were 1) to evaluate the reliability of temporal-spatial, 
kinematic, kinetic, and EMG parameters in a cohort of people with clinical and 
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radiological evidence of CSM, and 2) to estimate the change required to exceed 
measurement error for parameters used in the evaluation of gait impairment in CSM.  
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The reliability study was a prospective cohort design with consecutive recruitment of 
participants from a neurosurgical clinic. This design has been recommended for reliability 
studies of gait analysis (McGinley et al., 2009). 
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Participants were recruited from a neurosurgical clinic between December 2008 and 
February 2010. The inclusion and exclusion criteria described in Chapter 6, Section 6.3 
were applied. As discussed in Chapter 5, section 5.32, previous surgery for CSM was not 
an exclusion criterion for participation in the reliability study.  
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Participants attended the RCSI Movement Laboratory on two separate test days, 
between two and seven days apart. This time interval was considered short enough to 
avoid a true change in a participant’s gait pattern, an important factor in a potentially 
progressive condition such as CSM. It was also long enough to minimise recall bias on 
the part of the PI, for example, with respect to marker placement or anthropometric 
measurements. It aimed to avoid a potential learning effect on the part of the participant 
who might recall a self-generated cue in relation to gait. The time interval was in keeping 
with recommendations from other reliability studies (McGinley et al., 2009).  
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Motion analysis and EMG data were captured according to the methods described in 
Chapter 6, Section 6.6. The PI performed anthropometric measurements, marker 
application and data processing for all assessments, and was blinded to the results of the 
participants’ first assessment on the second test day.$Data were processed according to 
the methods described in Chapter 6, Section 6.7.  
Reliability was calculated on the average of ten gait trials from each session. The use of 
multiple gait trials within one 3DGA assessment has been shown to improve reliability by 
stabilising the average of a number of slightly variable trials, and a figure of ten trials for 
kinematics has been reported (Monaghan et al., 2007). Kinetic data are generally more 
reliable (Kadaba et al., 1989, Campanini and Merlo, 2009), but also more difficult to 
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obtain because a complete and uncontaminated strike to the force plate is required. For 
this study, it was decided to capture ten trials for temporal-spatial, kinematic, and EMG 
data, and five trials from each lower limb for kinetic data, to achieve a stable average for 
reliability tests while avoiding excessive data collection time and possible participant 
fatigue.   
The parameters examined for reliability were listed in Chapter 6, Tables 6.6, 6.8 and 6.9. 
Data for the participants’ left lower limbs were analysed for reliability of TSPs, kinematics 
and kinetics, while data from the right lower limbs were analysed for reliability of EMG 
parameters. These sides were chosen by coin toss to condense the analysis, as it was 
not expected that there would be systematic differences in reliability between lower limbs. 
Furthermore, each individual contributes their own intrinsic variability to the data set, 
regardless of whether left or right is analysed, and including both in the data set may 
have artificially increased reliability by reducing the variability of the overall scores.  
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A sample size calculation was based on a formula provided by Streiner and Norman 
(2008), shown in Appendix 7.1. The lower acceptable limit for reliability was set at an ICC 
of 0.70, the minimum recommended level when using a measurement in research 
(Nunnally, 1978). The desired level of reliability was set at 0.85, leaving a predicted 
confidence interval width of 0.7–1.0. The levels for type I and type II statistical errors were 
set at 0.05 and 0.8, respectively. Each patient performed ten trials to enhance reliability 
as previously recommended (Monaghan et al., 2007), thereby generating five trials with 
kinetic data for each lower limb. A sample size of 13 was calculated. 
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The distribution of each variable was tested for normality using quantile-quantile (QQ) 
plots, stem-and-leaf plots and the Shapiro-Wilk test in Stata 11 (StataCorp, Texas, USA). 
Test-retest reliability was examined for each parameter using three statistical methods, 1) 
the ICC one-way random effects model for single measures, recommended for use in 
test-retest reliability studies (Fleiss, 1986), 2) the SEM calculated from the ICC and the 
parameter’s SD, using the formula described by (Streiner and Norman, 2008): SEM = SD 
x !(1–ICC), and 3) Bland–Altman plots and 95% LOA (Bland and Altman, 1986). ICC 
values were calculated in Predictive Analytical Software (PASW) 18 (IBM Corporation, 
Armonk, NY, USA), while SEM and LOA were calculated in Excel for Macintosh 2008 
(Microsoft Corporation, Redmond, WA, USA).  
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Twenty-six people met the inclusion criteria between December 2008 and February 2010, 
and 13 of these, seven female and six male, agreed to participate. Of the 13 who did not 
take part, five participated in the cross-sectional and experimental studies, but declined to 
attend a second baseline assessment for reliability. Five declined to participate in any 
aspect of the study, and the remaining three participants were excluded, two due to pre-
existing neurological conditions, and one due to inability to mobilise. In accordance with 
the inclusion criteria, all 13 had signs and symptoms of CSM, MRI evidence of cord 
compression, and no history of co-existing neurological problems or other medical 
conditions affecting gait. Three participants had a history of previous surgery for CSM. 
Their participation was limited to the reliability study only, and they did not go on to 
participate in the cross-sectional study or the experimental study. One participant 
complained of a painful knee on the second test day, resulting in an alteration in his gait 
pattern. His data were therefore excluded, as an appreciable change in his gait had 
occurred that was not related to CSM.  
The characteristics of the remaining 12 participants are shown in Table 7.1. The mean 
age of the cohort was 54.3 years (range, 34–73 years). Participants had a median Nurick 
score of 2 (range, 1–4), a median mJOA score of 10.5 (range, 8–14), and a median 
MRMI score of 39 (range, 34–40). One participant (case 14) required the use of a crutch 
to mobilise independently. The remaining 11 could walk unaided. Kinetic data were not 
collected for two participants, as one failed to strike the force plate cleanly due to a short 
stride length, while the other used a crutch that contacted the force plate, contaminating 
the data. 
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Case Age 
(years) 
Gender Duration of 
symptoms 
(months) 
Previous 
surgery 
(Y/N) 
Nurick mJOA MRMI 
01 50 F 12 Y 3 12 38 
02 67 F 12 N 3 8 34 
04 49 F 5 N 1 14 40 
05 34 M 24 N 2 10 40 
10 52 F 204 Y 2 12 40 
11 53 M 108 N 2 10 39 
12 50 F 48 N 2 10 40 
13 73 M 420 N 3 12 38 
14 51 M 60 N 4 10 35 
15 72 F 10 N 2 10 40 
17 54 F 36 Y 2 14 39 
18 47 M 12 N 3 11 39 
mJOA = modified Japanese Orthopaedic Association score, MRMI = Modified Rivermead Mobility 
Index 
Case numbers reflect sequential recruitment to the overall study 
Missing values from the sequence are those participants who did not attend for a second pre-
operative or baseline assessment for reliability 
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TSPs showed excellent test-retest reliability. As shown in Table 7.2, ICCs were above 0.9 
for all parameters with the exception of opposite foot contact (ICC 0.61). SEM values and 
Bland–Altman 95% LOA were low for all parameters. Figure 7.1 shows Bland–Altman 
plots for each TSP. 
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ICC Bland–Altman 95% LOA Parameter 
ICC 95% CI 
SEM 
D SD(D) 95% LOA 
Cadence (steps/min) 0.99 0.95 0.99 1.70 -1.03 2.55 -6.14 4.07 
Double Support (s) 0.99 0.96 0.99 0.01 0.00 0.02 -0.04 0.04 
Foot Off (%) 0.97 0.90 0.99 0.81 0.25 1.15 -2.04 2.54 
Opposite Foot 
Contact (%) 0.61 0.11 0.87 1.01 0.69 1.50 -2.31 3.70 
Opposite Foot Off 
(%) 0.91 0.72 0.97 0.77 0.18 1.07 -1.97 2.33 
Single Support (s) 0.96 0.86 0.99 0.01 0.01 0.01 -0.01 0.04 
Step Length (m) 0.99 0.98 0.99 0.01 0.00 0.01 -0.03 0.03 
Step Width (m) 0.91 0.72 0.97 0.01 0.00 0.01 -0.02 0.03 
Stride Length (m) 0.99 0.98 0.99 0.02 0.00 0.03 -0.05 0.05 
Stride Time (s) 0.99 0.96 0.99 0.02 0.01 0.03 -0.04 0.06 
Step Time (s) 0.97 0.89 0.99 0.02 0.00 0.02 -0.05 0.04 
Gait Speed (m/s) 0.99 0.98 0.99 0.02 -0.01 0.04 -0.08 0.06 
ICC = Intraclass correlation coefficient, CI = 95% confidence intervals for ICCs, SEM = standard 
error of measurement, LOA = Bland–Altman 95% limits of agreement, D = mean difference, SD(D) 
= standard deviation of the difference, s = seconds, m = metres, m/s = metres per second 
Bland–Altman LOA were calculated using the formula 95% LOA = D ± 2 x SD(D) (Bland and 
Altman, 1986) 
All values are rounded up to two decimal places for presentation in the table 
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The x-axis shows the mean score and the y-axis shows the difference in scores 
Dashed lines indicate 95% limits of agreement 
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Reliability indices of kinematic parameters showed greater variation than those of TSPs. 
In general, total joint ROM in a plane was more reliable than a peak or specific point 
within that range, for example, the ICC for total hip sagittal plane motion was 0.95, 
whereas peak hip flexion and extension had ICC values of 0.89 and 0.74, respectively. 
Two parameters had ICC values below 0.6, and these were peak hip internal rotation 
(0.54) and ankle position at initial contact (0.33). SEMs were below 4º for all parameters 
except peak hip internal rotation (5.81°). Bland–Altman plots with 95% LOA are shown in 
Figures 7.2, 7.3 and 7.4. LOA values ranged from -1.63º ! 1.73º for pelvic tilt range, to -
20.44º ! 18.47º for peak hip internal rotation. Reliability statistics for each parameter are 
listed in Table 7.3.  
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ICC Bland–Altman 95% LOA  
Parameter 
ICC 95% CI 
SEM 
 D SD(D) 95% LOA 
Peak pelvic tilt 0.84 0.56 0.95 2.38 -0.69 3.59 -7.87 6.50 
Total range pelvic tilt 0.87 0.63 0.96 0.55 0.05 0.84 -1.63 1.73 
Average pelvic tilt 0.78 0.43 0.93 2.57 -0.73 3.95 -8.64 7.18 
Peak pelvic obliquity 0.64 0.16 0.88 1.62 -0.27 2.63 -5.53 4.99 
Total range pelvic 
obliquity 0.92 0.74 0.98 0.92 -0.76 1.13 -3.02 1.50 
Total range pelvic 
rotation 0.87 0.62 0.96 1.14 0.58 1.64 -2.70 3.85 
Peak hip flexion 0.89 0.68 0.97 2.99 -0.77 4.47 -9.71 8.18 
Peak hip extension 0.74 0.33 0.92 3.19 -0.03 5.06 -10.1 10.08 
Total hip range in sagittal 
plane 0.95 0.84 0.99 1.28 -0.69 1.77 -4.24 2.85 
Peak hip abduction 0.69 0.24 0.90 2.25 0.42 3.59 -6.77 7.60 
Total hip range in frontal 
plane 0.85 0.58 0.95 1.05 -0.94 1.27 -1.75 -0.14 
Peak hip internal rotation 0.54 0.000 0.84 5.81 -0.99 9.73 -20.4 18.47 
Total range hip rotation 0.87 0.62 0.96 3.66 1.01 5.49 -9.97 11.99 
Knee position at initial 
contact  0.66 0.19 0.89 3.11 0.42 5.02 -9.61 10.46 
Peak knee flexion in 
stance 0.62 0.12 0.87 3.67 0.17 4.42 -8.67 9.01 
Peak knee flexion in 
swing 0.65 0.17 0.88 3.32 1.68 5.10 -8.52 11.89 
Peak knee extension 0.62 0.12 0.87 3.12 0.69 5.07 -9.44 10.83 
Total knee range in 
sagittal plane 0.87 0.62 0.96 2.62 0.99 3.87 -6.75 8.73 
Ankle position at initial 
contact 0.33 -0.25 0.74 2.35 1.61 3.91 -6.22 9.44 
Peak ankle dorsiflexion 
in stance 0.62 0.12 0.87 1.37 0.16 2.24 -4.33 4.65 
Peak ankle dorsiflexion 
in swing 0.79 0.43 0.93 2.00 0.55 3.08 -5.61 6.71 
Peak ankle plantarflexion 0.76 0.37 0.92 2.90 1.37 4.34 -7.30 10.05 
ICC = Intraclass correlation coefficient, CI = 95% confidence intervals for ICCs, SEM = standard 
error of measurement, LOA = Bland–Altman 95% limits of agreement, D = mean difference, SD(D) 
= standard deviation of the difference 
Bland–Altman LOA calculated using the formula 95% LOA = D ± 2 x SD(D) (Bland and Altman, 
1986) 
All values are rounded up to two decimal places for presentation in the table 
Abbreviations:  o, degrees 
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The x-axis shows the mean score and the y-axis shows the difference in scores 
Dashed lines indicate 95% limits of agreement 
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The x-axis shows the mean score and the y-axis shows the difference in scores 
Dashed lines indicate 95% limits of agreement 
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The x-axis shows the mean score and the y-axis, the difference in scores 
Dashed lines indicate 95% limits of agreement 
 
135 
!"#"#"#$ %&'()*('(+,$-.$/(0&+(1$2)3)4&+&35$
Kinetic parameters generally showed excellent reliability, with most ICCs at least 0.85, as 
shown in Table 7.4. However, low ICCs were found for medio-lateral GRF (0.12), peak 
hip abductor moment (0.54), and peak eccentric power at the knee during loading 
response, K1 (0.56). SEM values for kinetic parameters are listed in Table 7.4, and 
Bland–Altman plots with 95% LOA are provided in Figures 7.5, 7.6 and 7.7. SEMs were 
generally small when referenced to the mean values for each parameter shown in the 
Bland–Altman plots. Bland–Altman 95% LOA are significantly larger than SEM values for 
the same parameters. Outliers are visible in some plots, including knee power at loading 
response and peak hip abductor moments.  
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ICC SEM Bland–Altman 95% LOA 
Parameter 
ICC 95% CI  D SD (D) 95% LOA 
Medio-lateral GRF 0.12 -0.50 0.67 0.05 0.00 0.10 -0.20 0.20 
First peak, antero-
posterior GRF 0.87 0.60 0.97 0.16 -0.05 0.24 -0.53 0.42 
Second peak, antero-
posterior GRF 0.95 0.81 0.99 0.10 0.05 0.28 -0.52 0.61 
First peak, vertical GRF 0.84 0.51 0.96 0.40 -0.20 0.59 -1.38 0.97 
Minimum vertical GRF in 
midstance 0.92 0.72 0.98 0.36 0.19 0.51 -0.84 1.22 
Second peak, vertical GRF 0.86 0.56 0.96 0.23 -0.14 0.33 -0.79 0.51 
Hip extensor moment 0.66 0.13 0.90 122 -63 189 -441 314 
Hip flexor moment 0.91 0.70 0.98 88 -8 134 -275 259 
Hip abductor moment 0.54 -0.06 0.86 69 -13 117 -247 221 
Knee extensor moment 0.89 0.63 0.97 56 -16 85 -186 155 
Knee flexor moment 0.91 0.70 0.98 58 30 82 -135 195 
Ankle plantarflexor 
moment 0.94 0.79 0.98 53 -29 75 -179 121 
Hip concentric power, 
loading (H1) 0.76 0.31 0.93 0.19 -0.09 0.28 -0.65 0.47 
Hip eccentric power, 
midstance (H2) 0.86 0.56 0.96 0.10 0.02 0.16 -0.30 0.34 
Hip concentric power, 
terminal stance (H3) 0.95 0.82 0.99 0.12 0.03 0.17 -0.32 0.37 
Knee eccentric power, 
loading response (K1) 0.56 -0.03 0.87 0.42 0.27 0.65 -1.03 1.57 
Knee concentric power, 
midstance (K2) 0.80 0.40 0.94 0.17 -0.03 0.27 -0.56 0.50 
Knee eccentric power, 
terminal stance (K3) 0.92 0.73 0.98 0.11 -0.01 0.17 -0.34 0.33 
Knee eccentric power, 
terminal swing (K4) 0.81 0.43 0.95 0.12 0.05 0.18 -0.31 0.40 
Ankle eccentric power, 
loading (A1) 0.91 0.69 0.98 0.12 0.04 0.17 -0.31 0.39 
Ankle concentric power, 
terminal stance (A2) 0.91 0.71 0.98 0.36 -0.06 0.54 -1.14 1.03 
ICC = Intraclass correlation coefficient, CI = 95% confidence intervals for ICCs, SEM = standard 
errors of measurement, LOA = Bland–Altman 95% limits of agreement, D = mean difference, SD(D) 
= standard deviation of the difference, GRF = ground reaction force 
Bland–Altman LOA calculated using the formula 95% LOA = D ± 2 x SD(D) (Bland and Altman, 
1986) 
Units of measurement: GRF, Newtons per kilogram (N/kg), moments, Newton millimetres per 
kilogram (Nmm/kg), powers, Watts per kilogram (W/kg) 
All values are rounded up to two decimal places for presentation in the table 
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The x-axis shows the mean score and the y-axis, the difference in scores 
Dashed lines indicate 95% limits of agreement 
GRF = ground reaction force, N = Newtons, kg = kilograms
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The x-axis shows the mean score and the y-axis, the difference in scores 
95% limits of agreement (LOA) are shown in the dashed lines 
Nmm = Newton millimetres, kg = kilograms 
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The x-axis shows the mean score and the y-axis, the difference in scores 
95% limits of agreement (LOA) are shown in the dashed lines 
W = Watts, kg = kilograms 
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The total duration of each muscle’s activation time was calculated for individual GCs 
using the DTM based on the TKEO equation, as previously described in Chapter 6, 
Section 6.7.3.2. Reliability indices of the mean activation times of 10 GCs in each of the 
two test days were then calculated. Results are shown in Table 7.5. Timing of TA 
demonstrated the highest test-retest reliability overall, with an ICC of 0.81 and a SEM of 
5.5% GC duration. RF, BF and MG had ICCs of 0.59, 0.56 and 0.55 respectively. SEMs 
were 5.5% GC duration or below for three of the four muscles with the exception of BF, 
which had a SEM of 9.3% GC duration. Bland–Altman 95% LOA were larger than the 
corresponding SEMs. Bland–Altman plots are shown in Figure 7.8. 
:+,)(&!"#;&'()*+,*)*-.&/0&-<(&-/-+)&-*4*56&/0&4=9>)(&+>-*?*-.&*5&-<(&6+*-&>.>)(&
ICC Bland–Altman LOA (% GC) Muscle 
ICC 95% CI 
SEM  
(% GC) D SD (D) 95% LOA 
Rectus femoris 0.59 .080 .861 5.5 0.73 9.15 -17.6 19.0 
Biceps femoris 0.56 .030 .847 9.3 -0.32 15.51 -31.3 30.7 
Tibialis anterior 0.81 .474 .939 5.5 2.95 7.96 -13 18.9 
Medial gastrocnemius 0.55 .015 .843 4.4 0.14 7.4 -14.7 14.9 
ICC = intraclass correlation coefficient, SEM = standard error of measurement, CI = confidence 
interval, GC = gait cycle, LOA = limits of agreement, D = difference, SD (D) = standard deviation of 
the difference 
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The x-axis shows the mean activation time of the muscle across the two assessments, and the y-
axis shows the difference in activation time between the two assessments 
Dashed lines indicate 95% limits of agreement 
Mean and difference are expressed as a percentage of gait cycle duration (% GC) 
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Reliability of mean and peak RMS amplitudes of key bursts of muscle activity, and the 
mean RMS amplitude during a muscle’s baseline phases of inactivity over the GC, were 
analysed. Two sets of amplitude data were generated, one normalised to MVC, and the 
other normalised using PDM. Both methods were described in Chapter 6, Section 6.7.3.3. 
The reliability of amplitude parameters normalised to the two methods will be presented 
separately. 
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The MVC normalisation method yielded poor results for reliability. Cronbach’s alpha was 
negative for some variables, including the peak amplitude of the stance and swing bursts 
of activity of TA, MG and RF, and the mean amplitude of the stance bursts of TA and RF. 
This indicated a lack of internal consistency between the values obtained in the two test 
days, and therefore ICC and SEM were not calculated for these variables. ICCs were 
poor for the remaining parameters. Three of these, peak amplitude of BF stance burst, 
peak amplitude of BF swing burst, and mean amplitude of BF swing burst, achieved ICC 
values above 0.6. SEM values and 95% LOA were of the order of 30% MVC for mean 
and peak burst amplitudes for all muscles. The SEM values for amplitude during baseline 
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phases were less than 5% MVC for BF and RF, but close to 19% for TA, and could not be 
calculated for MG. Results of the reliability of amplitude variables using MVC 
normalisation are shown in Table 7.6.  
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ICC Bland–Altman 95% limits of agreement 
Muscle Amplitude 
ICC 95% CI 
SEM 
D SD (D) 95% LOA 
Mean burst amplitude, stance * * * * 35.14 92.00 -148.85 219.14 
Mean burst amplitude, swing * * * * 80.42 180.06 -279.70 440.55 
Peak burst amplitude, stance * * * * 12.59 26.73 -40.87 66.05 
Peak burst amplitude, swing * * * * -21.66 171.13 -363.93 320.61 
Mean amplitude, baseline 0.07 -0.49 0.59 4.82 4.02 95.74 -187.46 195.50 
Mean burst amplitude, pre swing 0.00 -0.58 0.60 15.43 -30.29 236.62 -503.52 442.95 
Rectus femoris 
Peak burst amplitude, pre swing -0.07 -0.62 0.55 22.30 1.78 167.67 -333.56 337.11 
Mean burst amplitude, stance 0.54 0.00 0.84 13.65 -0.52 37.42 -75.36 74.32 
Mean burst amplitude, swing 0.62 0.13 0.87 15.00 -3.80 22.66 -49.13 41.53 
Peak burst amplitude, stance 0.64 0.16 0.88 23.37 11.19 21.65 -32.10 54.48 
Peak burst amplitude, swing 0.60 0.09 0.86 26.66 -10.16 36.56 -83.29 62.96 
Biceps femoris 
Mean amplitude, baseline 0.57 0.05 0.85 4.74 17.20 40.24 -63.27 97.67 
Mean burst amplitude, stance * * * * -0.02 7.90 -15.82 15.78 
Mean burst amplitude, swing 0.20 -0.38 0.68 50.28 18.68 56.40 -94.12 131.48 
Peak burst amplitude, stance 0.18 -0.39 0.66 87.28 7.93 19.65 -31.38 47.24 
Peak burst amplitude, swing * * * * 33.54 92.19 -150.85 217.93 
Tibialis anterior 
Mean amplitude, baseline 0.12 -0.45 0.63 18.95 40.36 110.80 -181.23 261.96 
Mean burst amplitude, stance 0.08 -0.48 0.60 49.18 3.68 8.96 -14.23 21.60 
Peak burst amplitude, stance * * * * 11.73 23.22 -34.72 58.18 Medial gastrocnemius 
Mean activity, baseline * * * * 18.37 34.41 -50.45 87.20 
Results for SEM and Bland–Altman 95% LOA are expressed as a percentage of MVC 
* indicates that Cronbach’s alpha was negative for internal consistency, therefore ICC and SEM were not calculated 
ICC = intraclass correlation coefficient, SEM = standard error of measurement, CI = confidence interval, D = mean difference between scores of first and second 
assessment, SD(D) = standard deviation of the difference between scores of the first and second assessment
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PDM normalisation yielded higher reliability results than the MVC method. Four 
parameters, mean amplitude of RF stance burst, peak amplitude of BF stance burst, and 
mean amplitude during MG and TA baseline phases, had ICCs of 0.7 or higher. However, 
one of these, peak amplitude of BF stance burst, had a high SEM of over 30% RMSMAX, 
indicating high absolute variability of test-retest scores. SEM values for other variables 
were of the order of 1% RMSMAX for mean activity at baseline during gait, 4–10% RMSMAX 
for mean amplitude during bursts, and 7–15% RMSMAX for peak amplitude during bursts. 
The mean and peak amplitudes during RF swing were not internally consistent according 
to Cronbach’s alpha, and therefore their ICC and SEM were not calculated. The peak 
amplitude of MG during stance had a constant value of 100% RMSMAX for all participants, 
and therefore reliability statistics could not be calculated. Table 7.7 shows the reliability 
results for amplitude parameters normalised using PDM. Bland–Altman plots with 95% 
LOA are shown in Figures 7.9 and 7.10. 
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ICC Bland–Altman 95% limits of agreement 
Muscle Amplitude 
ICC 95% CI 
SEM 
D SD (D) 95% LOA 
Mean burst amplitude, stance 0.70 0.25 0.90 5.85 2.06 9.13 -16.19 20.31 
Mean burst amplitude, swing * * * * 2.25 15.63 -29.00 33.51 
Peak burst amplitude, stance 0.63 0.15 0.88 7.86 2.89 12.49 -22.09 27.86 
Peak burst amplitude, swing * * * * 10.44 27.55 -44.65 65.53 
Mean amplitude, baseline 0.25 -0.33 0.70 2.62 -1.14 4.76 -10.66 8.39 
Mean burst amplitude, pre swing 0.32 -0.33 0.77 9.29 2.22 16.91 -31.61 36.05 
Rectus femoris 
Peak burst amplitude, pre swing 0.18 -0.45 0.70 14.94 5.72 28.36 -51.01 62.45 
Mean burst amplitude, stance 0.63 0.14 0.88 6.09 -3.06 9.43 -21.92 15.80 
Mean burst amplitude, swing 0.46 -0.11 0.80 10.08 9.37 14.44 -19.51 38.25 
Peak burst amplitude, stance 0.79 0.43 0.93 31.92 -7.55 15.25 -38.06 22.95 
Peak burst amplitude, swing 0.36 -0.22 0.76 15.44 15.18 22.70 -30.21 60.58 
Biceps femoris 
Mean amplitude, baseline 0.54 0.00 0.84 3.53 1.11 5.83 -10.55 12.77 
Mean burst amplitude, stance 0.55 0.02 0.84 7.67 -1.67 12.75 -27.17 23.83 
Mean burst amplitude, swing 0.50 -0.05 0.82 5.64 -0.99 9.56 -20.11 18.13 
Peak burst amplitude, stance 0.47 -0.09 0.81 6.95 1.49 11.88 -22.27 25.24 
Peak burst amplitude, swing 0.41 -0.16 0.78 10.15 -2.03 17.73 -37.49 33.42 
Tibialis anterior 
Mean amplitude, baseline 0.89 0.67 0.97 1.51 0.43 2.25 -4.06 4.92 
Mean burst amplitude, stance 0.39 -0.18 0.77 4.31 -2.81 7.04 -16.90 11.27 
Peak burst amplitude, stance ** ** ** ** ** ** ** ** Medial gastrocnemius 
Mean activity, baseline 0.79 0.44 0.93 1.60 -0.09 2.50 -5.09 4.91 
ICC = intraclass correlation coefficient, SEM = standard error of measurement, CI = confidence interval, D = mean difference between scores, SD(D) = standard 
deviation of the difference between scores, LOA = limits of agreement 
SEM and Bland–Altman 95% LOA are expressed as a percentage of RMSMAX 
* indicates that Cronbach’s alpha was negative for internal consistency, therefore ICC and SEM were not calculated 
** The peak activity during MG stance was 100% RMSMAX for all participants and had zero variability, therefore reliability could not be calculated
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The x-axis shows the mean activation time of the muscle across the two assessments, and the y-
axis shows the difference in activation time between the two assessments 
Dashed lines indicate 95% limits of agreement 
Mean and difference are expressed as a percentage of gait cycle duration (% GC) 
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The x-axis shows the mean activation time of the muscle across the two assessments, and the y-
axis shows the difference in activation time between the two assessments 
Dashed lines indicate 95% limits of agreement 
Mean and difference are expressed as a percentage of gait cycle duration (% GC) 
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The reliability of three indices to describe a muscle’s response to lengthening were 
examined, 1) critical time of EMG onset during lengthening, 2) LVT, the lengthening 
velocity at onset of EMG activity during muscle lengthening, and 3) the slope of the 
muscle’s time- and amplitude-normalised EMG signal versus its lengthening velocity, 
indicating the rate of change of EMG amplitude with respect to lengthening velocity. A full 
description of these indices was provided in Chapter 6, Section 6.7.4.3. LVT was the 
most reliable of the three indices, with ICCs ranging from 0.77 (MG) to 0.89 (BF). SEM 
values ranged from 0.18 normalised lengths per second (l0/s) for BF to 0.42 l0/s for RF. 
The critical time of EMG onset was very reliable for TA (ICC 0.91, SEM 2.36% GC 
duration), but less reliable (ICC 0.35) for BF and MG. Reliability of the slope index was 
the least favourable of the three indices, with ICC values below 0.6 for all muscles and 
large SEM and LOA values, particularly for TA (SEM 11.18 % RMSMAX/ms, LOA -29.59 ! 
42.61 % RMSMAX/ms). Table 7.8 shows the ICC, SEM and LOA values for each muscle’s 
critical time, LVT and slope. Bland–Altman plots are shown in Figure 7.11. 
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ICC Bland–Altman 95% LOA 
Muscle Index 
ICC 95% CI 
SEM 
D SD (D) 95% LOA 
Critical 
time 0.63 0.13 0.87 3.70 0.63 6.02 -11.40 12.67 
LVT 0.81 0.49 0.94 0.41 0.05 0.63 -1.21 1.31 
Rectus 
femoris 
Slope 0.43 -0.14 0.79 1.60 0.61 2.71 -4.81 6.03 
Critical 
time 0.35 -0.23 0.75 3.04 1.42 5.27 -9.11 11.95 
LVT 0.89 0.68 0.97 0.17 0.06 0.25 -0.44 0.56 
Biceps 
femoris 
Slope 0.56 0.04 0.85 6.90 -8.18 7.76 -23.69 7.33 
Critical 
time 0.91 0.72 0.97 2.24 -0.91 3.26 -7.42 5.61 
LVT 0.85 0.57 0.95 0.29 -0.18 0.41 -1.00 0.64 
Tibialis 
anterior 
Slope 0.37 -0.21 0.76 9.55 5.87 15.90 -25.93 37.68 
Critical 
time 0.35 -0.23 0.75 3.54 1.53 6.16 -10.79 13.86 
LVT 0.77 0.40 0.93 0.22 -0.12 0.31 -0.75 0.51 
Medial 
gastroc-
nemius 
Slope 0.59 0.08 0.86 1.19 -0.04 1.96 -3.97 3.88 
LVT = lengthening velocity threshold, LOA = limits of agreement 
Critical time is the time, as a percentage of gait cycle duration, at which EMG onset occurs during 
lengthening 
LVT is the lengthening velocity (in normalised lengths per second) at which EMG onset occurs 
Slope is the change in EMG amplitude per unit change in lengthening velocity during the phase of 
lengthening (see Section 6.7.4.3 for a detailed description)
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The x-axis shows the mean activation time of the muscle across the two assessments, and the y-
axis shows the difference in activation time between the two assessments 
Dashed lines indicate 95% limits of agreement (LOA) 
Mean and difference are expressed as a percentage of gait cycle duration  
GC = gait cycle, l0/s = normalised muscle lengths per second, % RMSMAX = normalised amplitude  
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The aims of this study were to evaluate the reliability of 3DGA and SEMG in measuring 
gait in CSM, and to estimate the change required to exceed measurement error when 
applying these variables to clinical practice and research. It was found that TSPs 
demonstrated high reliability, with SEM values below what would be considered 
meaningful change in clinical practice. For example, the SEM for gait speed, an outcome 
measure commonly used to evaluate severity of CSM (Singh and Crockard, 1999), was 
0.02 m/s, whereas a change of 0.1 m/s, five times the magnitude of the SEM, has been 
suggested as a clinically-meaningful change (Judge et al., 1996b).  
When measuring kinematic parameters, it has been suggested that errors larger than 5° 
could mislead clinical interpretation (McGinley et al., 2009). With the exception of peak 
hip internal rotation, the SEMs for kinematic key points in this CSM cohort were all below 
4°, and most were below 3°. This indicates a sufficiently high level of reliability for use in 
clinical practice. Similarly, kinetic parameters showed a general trend of high ICCs and 
low SEMs. Medio-lateral GRF had a low ICC, consistent with other studies (Rabuffetti 
and Frigo, 2001), but its SEM of 0.05 Newtons per kilogram (N/kg) was also low, 
indicating a high degree of absolute agreement between test-retest scores. 
Bland–Altman 95% LOA were reported for all parameters, however these values are 
significantly greater than the corresponding SEM. This may be explained by the small 
sample size in this study. Sample sizes of at least 50 have been recommended when 
calculating LOA (Rankin and Stokes, 1998). In the current study, Bland–Altman plots for 
some parameters revealed a number of outliers that may have contributed to a large 
standard deviation of the difference. The effect of these outliers might be reduced in a 
larger sample size. There are no general guidelines on the interpretation of the 95% LOA, 
and each must be considered with reference to the range of the raw data (Monaghan et 
al., 2007). 
The ICC has been recommended for use in reliability studies because of its flexibility in 
evaluating different study designs, and its ability to isolate factors affecting reliability, such 
as intra-tester compared to inter-tester variation (Streiner and Norman, 2008). A criticism 
of the ICC is the extent to which it is influenced by between-subjects variance. It 
measures the ratio of true score variance to true variance plus error, and as such it will 
invariably be low in situations where there is little variation among subjects. This limitation 
is illustrated by ankle position at initial contact, which had a low ICC of 0.33 but a SEM of 
2.35°, still within an acceptable error range. Similarly, the low ICC of peak medio-lateral 
GRF was also associated with an acceptable SEM (0.05 N/kg). The important factor is 
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not the value of the reliability coefficient, but rather, whether the measurement error 
renders the instrument practical for clinical use (Bruton et al., 2000). 
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The reproducibility of many EMG indices of locomotor function was previously unknown 
and limited their applicability in repeated measures design studies (Lamontagne, 2006). 
The current study provides some evidence for the reproducibility of timing and amplitude 
parameters, and the LSMS. With regard to timing, the SEM values for RF, MG and TA 
indicated that a change in activation time of around 5.5% GC duration could be 
considered a real change. This represents a change of about 55 ms, based on an 
average GC duration of one second. Activity bursts of 30 ms or less are have little effect 
on the resulting kinetic output (Bogey et al., 1992). It is therefore likely that a SEM of 5% 
would not cause clinically relevant differences to be masked by error. 
The large SEM for BF timing was not in keeping with the results from the other muscles. 
Bland–Altman plots of Figure 7.8 show some outlying data points that may have 
adversely affected the reliability analysis. It is possible that the effect of outliers on the 
timing data of BF, and indeed the other muscles, would be reduced if a larger sample 
size were employed. BF is less superficial than the other muscles, and may be more 
prone to greater test-retest variation in electrode placement. It is also possible that its 
timing may be more intrinsically variable in this neurological population. Further 
investigation in larger sample sizes and in other populations could identify the 
contributory factors to this finding. 
Reliability analysis of the amplitude of EMG activity, an indirect measure of the intensity 
of muscle activation, yielded mixed results. Inter-session and inter-participant variations 
in electrode placement, the variable number and size of motor units sampled, and 
environmental conditions, preclude the analysis of the absolute measurement of signal 
amplitude in Volts (Lehman and McGill, 1999). Normalisation to a reference level of EMG 
amplitude is therefore required for reproducibility, however the reliability of the resulting 
normalised parameters has not previously been examined in relation to gait in a 
neurological population. This study found that, with the possible exception of BF, 
normalisation to MVC yielded unacceptably poor test-retest reliability in determining EMG 
amplitude parameters in gait in CSM. No parameter had an ICC above 0.7, and only 
three parameters, pertaining to BF, had ICCs above 0.6. SEM values were below 5% 
MVC for two parameters, the mean amplitude of the “off” phases of BF and RF, but 
generally of the order of at least 15–20%, and in some cases up to 50%, MVC.  
It is likely that the high variability in the results between test days is due to variation in the 
performance of MVC itself. The ability of people with neurological impairment to reliably 
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produce MVC has been questioned (Perry, 1992, Damiano et al., 2000), but its relevance 
to gait has not previously been tested. The current study was limited by the lack of a 
dynamometer to ensure that a consistent force was produced during the performance of 
MVC on both days. This might have established whether the source of error was the 
production of MVC, or the recording of its associated EMG activity. However, from a 
clinical point of view, the methodology of this study was carefully applied using 
standardised test procedures and instructions to participants. Aside from the variation in 
electrode placement, which in theory should not be a factor for the normalised signal as 
the gait signals are referenced to a maximum value obtained with the same electrode 
location, the most plausible reason for variation in test-retest scores was variability in the 
number of motor units activated, and their intensity, in performing MVC on the two test 
days.     
PDM normalisation uses the peak amplitude obtained during gait itself as the 
normalisation reference. This method has been used in studies of gait in neurological 
populations, such as Lamontagne et al. (2001). The current study took the PDM 
normalisation reference for each test day to be the maximum RMS value achieved over 
the ten gait trials from that session, designated RMSMAX. Each data point in the time-
normalised RMS of the signal was then expressed as a percentage of RMSMAX . Test-
retest reliability analysis yielded somewhat more favourable results for PDM compared to 
MVC normalisation. ICCs of 0.7 or higher were achieved for the mean amplitude of the 
RF loading response burst, peak amplitude of the BF stance burst, and mean amplitude 
of TA and MG during baseline phases. However, a number of parameters achieved ICC 
values of 0.6 or lower. SEM values were of the order of 1% RMSMAX for mean activity 
during the baseline phases, 4–10% RMSMAX for mean activity during bursts, and 7–15% 
RMSMAX for peak activity during bursts. The results suggest that mean normalised RMS 
amplitude during a burst of activity may be a more reliable indicator of the intensity of 
muscle activation, than the peak RMS amplitude. Although the signal’s RMS was 
smoothed by the use of a 30 ms time window, it is not possible, or indeed desirable, to 
remove all signal fluctuations. It is possible that the peak amplitude in a burst is more 
prone to variation due to these inherent fluctuations in the signal, and that mean 
amplitude is a more consistent indicator of the intensity of a burst of activity, as it reflects 
the overall work done by a muscle during that burst of activity. 
Finally, test-retest reliability of indices of a muscle’s response to lengthening, the LSMS, 
showed that LVT was the most repeatable measure. Its ICCs ranged from 0.77 to 0.89, 
indicating good to excellent reliability. SEM values for LVT were 0.17–0.41 l0/s. Clinically 
meaningful change for this measure in CSM is as yet unknown. A study of medial 
hamstrings activity in gait in children with spastic CP and typically-developing children 
found a statistically significant difference in LVT of 0.6 l0/s (reported in percentages as 
60% total length per second) between the two groups (Crenna, 1999). This value of 0.6 
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l0/s is more than three times the SEM of BF LVT in this study, 0.17 l0/s, indicating that 
clinically meaningful change would probably not be masked by measurement error.  
The critical time of EMG activity onset during lengthening showed mixed relative 
reliability, with ICCs of 0.35–0.91, but better absolute reliability, with SEMs of 2.24–3.7% 
GC duration for all muscles. This parameter is less useful than LVT as an indicator of 
spasticity, as it measures only the time at which muscle activation occurs during muscle 
lengthening, and not the length of the muscle or its lengthening velocity. However, it may 
serve as a useful indicator of premature activity in relation to timing of the GC, and allow 
correlations to be generated with the timing of other parameters. Its SEM of 2–3% GC 
duration equates to around 20–30 ms based on an average GC duration of one second. 
This is considered below the time of a clinically meaningful change in muscle activation 
(Bogey et al., 1992), suggesting that critical time is sufficiently reliable for use in clinical 
studies and research.  
The slope parameter, adapted for use from Lamontagne et al. (2001), showed the 
poorest reliability of the three LSMS indices. As a measure of rate of change of one 
normalised parameter (RMS amplitude) with respect to another normalised parameter 
(muscle lengthening velocity), it is more difficult to interpret intuitively than LVT. It showed 
greater absolute variability, as indicated by the variation in the mean scores of the Bland–
Altman plots shown in Figure 7.11. Its poorer reliability may be due to the fact that it 
depends on RMS amplitude, which in itself shows poor test-retest reliability as discussed 
in the previous paragraphs, whereas LVT is based on the time at which muscle activation 
occurs and not the amplitude of this activation.  
Lamontagne et al. (2001) suggested that the frequency of positive slopes, rather than the 
magnitude of the slope itself, could be used as an indicator of spasticity, as a positive 
slope is considered to represent a pathological response to lengthening. As shown in the 
Bland–Altman plots, positive slopes were evident in one participant for BF, six 
participants for TA, and all participants for MG, while no participant had a positive slope 
for RF. It is possible that the direction of the slope, rather than its magnitude, could 
distinguish between people with pathological responses to lengthening and those with 
normal responses. In people with stroke, the frequency of positive slopes was 
significantly higher in MG during gait than in matched HCs at the same speed 
(Lamontagne et al., 2001). Further research is necessary to determine whether this is 
true of all muscles, and whether it applies equally to other neurological populations, 
including CSM.  
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Variability in gait data can be attributed to two sources, intrinsic variability or true variation 
in the patient’s gait pattern, and extrinsic variability due to methodological errors in 
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marker application, anthropometric measurements, or calibration of the motion capture 
system (Schwartz et al., 2004). It is generally accepted that the major source of extrinsic 
error in 3DGA data is in marker application (McGinley et al., 2009). We found that total 
ROM in a plane was generally more reliable than peaks within that range, for example, 
total sagittal plane range at the knee joint had an ICC of 0.87 and a SEM of 2.62°, 
whereas the values for peak flexion in swing were 0.65 and 3.32°, and for peak 
extension, 0.62 and 3.12°. This might be due to variations in marker placement, resulting 
in an offset from flexion to extension where the total range is in fact unchanged.  
Intrinsic variability can be estimated by measuring the reliability of gait trials within the 
same session, when methodological issues such as marker placement and calibration 
errors would not influence gait variability (Schwartz et al., 2004). There may also be some 
intrinsic variability in gait performance from day to day, particularly in patients with 
neurological conditions, where factors such as spasticity or fatigue may influence the 
strategies used in gait (Redekop et al., 2008). This intrinsic variability can provide 
valuable information about the condition of the patient, however it may be difficult to 
distinguish from measurement error. The current study found that two parameters 
pertaining to the action of the plantarflexors, peak ankle plantarflexion angle and 
concentric ankle power at terminal stance, were less reliable than other peak values in 
the same curves. This may suggest that certain phases of the GC could be inherently 
more variable in the CSM population. Further studies will be needed to investigate these 
findings, and to establish the characteristics of CSM gait in people with different levels of 
disease severity. 
It is known that reliability will vary for the same instrument across populations and across 
different levels of severity (Streiner and Norman, 2008). Our study included a wide range 
of CSM severity, from those with little or no difficulty in walking (Nurick grade 1), to one 
patient who required an aid (Nurick grade 4). A previous study found that reliability of gait 
data was lower in children with more severe CP (Redekop et al., 2008). The current study 
was not sufficiently powered to examine reliability within sub-groups. However, such a 
wide range of impairment represents the spectrum of disease severity in the CSM 
population. It has been recommended that studies of reliability should recruit samples 
that represent the populations of interest (McGinley et al., 2009). 
The lower reliability, and thus greater variability, of EMG indices compared to TSP, 
kinematic and kinetic data, is of interest in the interpretation of gait. The inherent 
limitations of EMG in relation to electrode placement, including variable sampling of motor 
units, and the need for filtering and extraction of key parameters from an inherently 
variable signal, have been discussed in Chapter 5, Section 5.4. These extrinsic factors 
may have affected the test-retest reliability, and have previously been acknowledged as 
the most important source of variability in EMG studies (Lehman and McGill, 1999). 
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However, it is possible that other factors contribute to the changes in EMG 
measurements from test to retest. TSPs, kinematics and kinetics represent the end 
products of an interaction between the biological signals responsible for muscle activation 
and the musculoskeletal system. Reliability analysis demonstrates that this end product is 
relatively consistent from test to retest, so the question must then be posed as to why 
there is so much variability in the underlying EMG signals. There are a number of 
possible reasons for this. The first possibility is that the level of processing needed to 
extract clinically relevant parameters from the EMG signal’s random series of spikes 
reduces the accuracy of the relationship between the extracted parameter and the clinical 
entity it is designed to measure. This may be the case particularly with measures of EMG 
amplitude, when condensing a rapidly varying signal into a mean or peak value over a 
large burst of activity may not reflect the complexities of the task achieved by the smaller 
peaks and troughs within that burst. In other words, the problem may be one of validity, in 
that the calculation of EMG amplitude over a burst does not measure the intensity of 
muscle activation, as it is designed to do.  
The second possibility is that there is greater intrinsic variability in muscle activation as 
measured by EMG, perhaps relating to fatigue or pain, than the outputted kinematic and 
TSPs would indicate. In other words, the locomotor system may be very adept at 
producing a consistent output using motor strategies that are not necessarily constructed 
in a consistent manner. However, it is difficult to understand the extent of this without 
similar studies of reliability in healthy populations. In addition to these factors, which are 
intrinsic to the muscles themselves, there may also be slight fluctuations in the orientation 
of the limbs and the centre of mass, and in the activation of other untested agonist 
muscles. These would require varying degrees of compensation by the tested muscles, 
but are not reflected in the calculation of lower limb kinematics and kinetics. Muscles 
need to respond to changes in posture, the environment, and sensory input from the 
supporting surface, and in people with neurological injuries, these responses may not be 
consistent. These inconsistencies could be reflected in the variable amplitude parameters 
measured by EMG. 
Variation in test-retest scores cannot therefore be dismissed entirely as measurement 
error, particularly in this neurological population. However, intrinsic variability has the 
effect of increasing the minimal detectable change of a measure, the minimal amount of 
change that is not likely to be due to chance or measurement error (Haley and Fragala-
Pinkham, 2006). Therefore, a true improvement cannot be reported with certainty until the 
post-intervention test result exceeds the variability of the pre-intervention test by at least 
one SEM, regardless of whether the source of that variation is intrinsic or extrinsic.  
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The relative (ICC) and absolute (SEM) reliability of an array of TSP, kinematic, kinetic 
and EMG parameters showed acceptable reliability for use in clinical practice and in 
repeated measures design studies, with the exception of some parameters such as MVC 
normalisation and peak hip internal rotation range. The choice of parameters from the list 
of those tested for reliability depends on the aspects of gait that are of greatest clinical 
interest in the CSM population. On review of the kinematic parameters, it was decided to 
exclude peak and range of pelvic tilt from the remainder of the thesis, as the average 
position of the pelvis in the sagittal plane, average pelvic tilt, has been quoted in previous 
studies of gait in neurological populations (Williams et al., 2009b), and is of greater 
clinical interest. Peak hip internal rotation and peak hip abduction were also excluded, as 
the total ranges in these planes were more reliable than the peaks. The remaining TSP, 
kinematic and kinetic parameters were retained for further analysis in the cross sectional 
and repeated measures design studies.  
In relation to EMG, the reliability of timing parameters, extracted using the TKEO-based 
DTM routine, was considered acceptable. The high SEM of BF timing parameters meant 
that changes in test-retest scores would need to exceed almost 10% GC duration to be 
deemed clinically meaningful. However, as no superior method to determine timing in this 
muscle had been identified, and changes of this magnitude could occur in people with 
more severe CSM compared to HCs, it was considered acceptable to include BF timing 
as a parameter. 
Amplitude parameters showed high test-retest variability and comparatively low reliability, 
compared to other parameters. Of the two methods of normalisation, amplitude 
parameters normalised using PDM showed higher reliability than when normalised to 
MVC. From a validity point of view, PDM lacks a clear physiological reference, which is a 
potential advantage of MVC. However, the poor reliability results of MVC normalisation 
suggest that the ability of people with CSM to produce a true maximum voluntary 
activation should be questioned, and that MVC may not be a valid normalisation 
reference in this population. Therefore, despite its limitations, PDM was chosen as the 
normalisation method for further use in the current study. The bursts of activation that 
were tested in the reliability study were included in the cross-sectional and repeated 
measures design studies, but limited to the analysis of mean amplitude, rather than 
peaks, of these bursts due to the superior reliability of the mean values. The results, 
however, will need to be interpreted in the context of limited reliability and the potential 
contributing factors to test-retest variability discussed in Section 7.4.4. 
Finally, of the possible parameters included in the LSMS, LVT showed highest reliability, 
and SEM values suggested that the measurement error was small enough to avoid 
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masking clinically relevant change. Critical time of activation onset was more variable, but 
it was decided to include it as a descriptive indicator of muscle response to lengthening, 
as it is of clinical interest to know the point during lengthening at which muscle activation 
occurs. The slope criterion demonstrated poor reliability, and therefore it was decided not 
to test this parameter for statistically significant differences in the cross-sectional or 
repeated measures studies. However it was decided to retain the presence or absence of 
positive slopes as a descriptive indicator, as recommended in the original paper 
(Lamontagne et al., 2001). Observation of trends in the CSM cohort suggested that there 
may be a tendency towards positive slopes in some muscles during gait, so it may be 
useful to compare this trend to healthy controls and to evaluate pre- to post-operative 
changes. 
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This chapter determined the relative and absolute test-retest reliability of TSPs, 
kinematic, kinetic and EMG parameters in CSM. Most parameters demonstrated 
acceptable reliability for use in the cross-sectional and experimental studies. Some 
parameters, such as EMG amplitude normalised to MVC, were discarded from further 
use in the thesis due to unacceptable reliability. An estimate of the change required to 
exceed measurement error is now known. This information will inform the interpretation of 
differences in gait between the CSM participants and HCs in the cross-sectional study, 
and the change scores following surgery in the experimental study. 
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This chapter reports the results of a cross-sectional study to address the second aim of 
the thesis, the comparison of gait patterns of people with CSM to those of age- and 
gender-matched HCs. The objectives of this study were 1) to describe the gait patterns of 
people with CSM with reference to age- and gender-based norms, and 2) to identify key 
areas of impairment in gait in CSM. 
);>(( ?&@&1+$7&0%(+5($'+%+.+1(5+'("&#1%"4(.+0%'+1,(
);>;<( :#%."/06(+5("&#1%"4(.+0%'+1,(%+(!9:($#'%/./$#0%,(
A number of factors were considered in the selection of a cohort of HCs, aiming 1) to 
ensure that the HC group was an accurate match for the CSM participants, and 2) to 
avoid confounding of the kinematic, kinetic and SEMG data by extraneous factors. 
Functional data analysis of gait in 48 healthy individuals found that age, gender and gait 
speed had statistically significant influences on kinematic data (Roislien et al., 2009). Gait 
speed was unaffected by the presence of other variables, including height and weight in 
the regression models. It was therefore decided to match HCs based on age and gender. 
Previous studies using age-matched HCs to evaluate neurological gait impairment had an 
age criterion of within five years (Williams et al., 2009b), and this was considered 
achievable. 
The literature indicated conflicting opinions on the need to match gait speed when 
comparing gait data between groups. Gait speed is a known confounding variable for 
kinematics and kinetics, particularly in the sagittal plane (Lelas et al., 2003, Roislien et al., 
2009, Chung and Wang, 2010). Some authors have cautioned that, unless gait analysis 
is carried out at matched speed, conclusions cannot be drawn on the cause and effect 
relationship between speed and speed sensitive parameters (Chen et al., 2005). A 
reduction in gait speed, especially in older people, could be due to biomechanical 
changes (DeVita and Hortobagyi, 2000) or to the conscious choice of a more cautious 
gait pattern (Winter et al., 1990), rather than to an inability to generate the moments and 
powers required for a faster gait. Many studies of gait in neurological populations have 
matched the speed of the HC group to the group with pathological gait for these reasons 
(Lamontagne et al., 2002, Chen et al., 2005, Williams et al., 2009b).  
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On the other hand, it is known that individual preference for a particular gait speed occurs 
at the point where energy consumption per unit distance is minimised. This allows the 
locomotor system to take advantage of the passive mechanical properties of the lower 
limb in the absorption and generation of power (Jordan et al., 2007). Therefore, the 
imposition of a slower gait speed on healthy people may be counter-productive. Although 
the end product, gait speed, is the same, the neuromuscular and biomechanical 
strategies required to achieve this speed are not. This poses difficulties in the 
interpretation of the results of a matched speed comparison. A study of 30 healthy people 
walking at different percentages of preferred gait speed found that energy cost of walking 
and sagittal plane kinematics did not show any statistically significant differences 
between 80% and 120% of preferred walking speed (PWS), indicating that 80% PWS is 
not slow enough to change the demands of the locomotion task (Chung and Wang, 
2010). This study did not compare the effect of actual gait speed, but instead focused on 
the use of a percentage of PWS as the speed criterion. 
Based on the above studies, it appeared that there were advantages and disadvantages 
to the comparison of gait data at comfortable and matched speeds. Both methods 
appeared to have validity for different aspects of gait performance. As a result, it was 
decided to assess gait in HCs at both self-selected comfortable walking speed and at the 
speed of the participant with CSM to whom they were matched. 
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The interdependence of many gait variables can lead to difficulties in the interpretation of 
data. The relationships between variables may not be clear from assessing them 
individually. Furthermore, the large number of variables increases the likelihood of a type 
two statistical error, or finding a significant result by chance. 
Principal components analysis (PCA) is a multivariate statistical technique designed to 
reduce the number of variables in a data set into a smaller number of dimensions or 
principal components (PCs). Each PC is a linear weighted combination of the original 
variables (Vyas and Kumaranayake, 2006). PCA has been used to classify gait patterns 
in children with CP (Schutte et al., 2000, Carriero et al., 2009) and in adults with 
osteoarthritis of the hip (Gaudreault et al., 2011). In the current study, its advantage was 
that it could be implemented on the pooled data of the CSM and HC participants at 
comfortable gait speed, as it would account for the interdependence of gait speed and 
other parameters. Stability tests of PCA on gait data from two groups of children found 
that the PCs were robust to changes in the data sets (Carriero et al., 2009), therefore it 
could reasonably be assumed that the exclusion of matched speed data would not affect 
the output of PCA.  
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The aim of PCA was to identify the dominant variability of the data and reduce its 
dimensionality into smaller numbers of PC variables. This would improve the 
understanding of the differences in gait between HC and CSM participants, and 
contribute to the identification of key areas of impairment that might otherwise be masked 
by the inter-dependency of variables in the original data set. 
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Participants with CSM were recruited from a neurosurgical clinic between December 
2008 and December 2010. The diagnosis of CSM was confirmed by a neurosurgeon, 
either consultant or registrar, using the criteria outlined in Chapter 6, Table 6.1. Inclusion 
and exclusion criteria were described in Chapter 6, Section 6.4.1.1. 
HCs were recruited from a local population. The need for participants was advertised via 
email at the PI’s workplace. Recipients were encouraged to forward the email to others. 
The inclusion criteria for HCs were 1) age within 5 years of a recruited CSM participant, 
2) same gender as that participant, 3) ability to attend for assessment at the Movement 
Laboratory. HCs were excluded if they had a history of lower limb joint replacement 
surgery, complained of acute or chronic musculoskeletal injuries affecting gait, suffered a 
cardiovascular or respiratory impairment hindering mobilisation, or had a history of 
neurological disorders with physical deficits. 
Upon recruitment, HCs were provided with a Controls Information Leaflet (Appendix 8.1). 
All HCs gave informed consent using the Healthy Controls Consent Form (Appendix 8.2). 
Beaumont Hospital Ethics (Medical Research) Committee granted ethical approval 
(Appendix 6.1). 
!"#"4$ 5.0'$.3.67+0+$
CSM and HC participants attended the Movement Laboratory for 3DGA and EMG 
assessment, following the procedures described in Chapter 6, Section 6.6. Gait analysis 
was firstly conducted at self-selected comfortable walking speed for both groups. Ten 
trials, comprising five left and five right force plate strikes, were captured.  
Each HC then completed a second assessment at the walking speed of the CSM 
participant to whom he or she was matched, termed the matched speed assessment. 
Each trial was timed with a stopwatch. The goal speed was indicated by verbal feedback 
at the end of each trial, and not by external cues during the trial itself. Trials were 
included in the representative average if they were within 0.1 m/s of the goal speed. The 
assessment concluded when ten trials at goal speed were achieved. 
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Gait trials were processed and TSP, kinematic, kinetic and EMG parameters extracted 
according to the methods described in Chapter 6, Section 6.7. The average of ten 
captured trials of each condition, comfortable and matched speeds, was used to 
represent the gait pattern of each participant at that speed. Data from each CSM 
participant’s more affected lower limb were analysed, and compared to data from the 
same leg of his or her HC match, as previously reported in a neurological population 
(Williams et al., 2009b). The more affected lower limb was determined by subjective 
questioning.  
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A sample size calculation was performed in Stata. At a significance level of 0.05, 13 pairs 
of participants were required for 90% power to detect a difference in gait speed of 0.1 m/s 
between CSM and HC participants, based on a SD of 0.11 m/s. 
Two sets of statistical analysis were conducted, the first comparing CSM with HC 
participants at comfortable speed, and the second comparing the pairs at matched 
speed. The distribution of the difference between paired CSM and HC scores of each 
variable was checked visually using QQ plots and stem and leaf plots, and theoretically 
using the Shapiro-Wilk test and tests of skewness and kurtosis in Stata. Data from CSM 
and HC participants were compared using two-tailed paired t-tests. The non-parametric 
Wilcoxon signed-rank test was used to compare variables that were not normally 
distributed. In the case of the LSMS (see Chapter 5, Section 5.4.4.5 and Chapter 6, 
Section 6.7.4.3), the incidence of positive slopes between CSM and HC participants was 
compared for each muscle using Fisher’s exact test of proportions. Significance for all 
tests was established a priori at a probability (p) level of 0.05.  
PCA of the temporal-spatial, kinematic and kinetic variables was performed in Stata on 
the pooled data of the CSM and HC participants at comfortable gait speed. The groups 
were not defined a priori when pooling the data (Carriero et al., 2009). EMG data were 
excluded from the first PCA in order to determine the PCs that emerged from a smaller 
data set of more correlated variables. A second PCA was then performed with EMG data 
included.  
The contribution of each independent variable to the PCs was examined in both 
analyses. A variable was considered to contribute to a PC if its prediction score for that 
PC exceeded 0.15. Previous studies incorporating kinematic data had used a threshold 
prediction score of 0.2 (Carriero et al., 2009). Prediction scores in the current study were 
expected to be lower due to the larger number of parameters in the data set. The aspect 
of gait that was represented by each PC was then interpreted. Scatter plots of the scores 
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of the PCs were generated to visualise differences between the HC and CSM 
participants.  
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Forty-four people with CSM met the inclusion criteria for the study over the 24-month 
recruitment period. A total of 15 were excluded for reasons of pre- or co-existing 
neurological conditions (six), immobility (four), previous surgery for CSM (four), and 
rheumatoid arthritis affecting gait (one). Ten people declined to participate in the study, 
leaving a total of 19 participants in the CSM group. One participant was later diagnosed 
with a co-existing neurological disorder. His data were excluded from analysis in 
accordance with the exclusion criteria. Age- and gender-matched HCs were recruited for 
16 of the remaining 18 participants. One participant was not matched to a HC because he 
habitually mobilised with an aid. The effects of this would have confounded comparison 
with an independently mobile HC. A match was not found within the required time frame 
for the oldest participant in the CSM group, who was 77 years old. However, as the 
power calculation indicated the need for 13 pairs of participants to detect a difference in 
gait speed of 0.1 m/s, it was considered that 16 participants in each group would be 
sufficient for statistical analysis. The two participants who were not matched to HCs 
participated in the experimental study, presented in Chapter 9. 
Characteristics of the participants in the CSM and HC groups are shown in Table 8.1. 
Paired t-tests confirmed that there were no statistically significant differences between the 
CSM and HC pairs in height (p = 0.08) or weight (p = 0.75).  
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CSM HC 
Case Gender Age (years) 
Height 
(metres) 
Weight 
(kg) 
Duration of 
symptoms (months) Nurick mJOA MRMI 
Age 
(years) 
Height 
(metres) 
Weight 
(kg) 
02 F 68 1.52 85.2 12 3 8 34 68 1.69 74.4 
03 M 57 1.66 80.3 12 3 11 38 59 1.76 78.4 
04 F 50 1.61 57.7 5 1 14 40 45 1.67 62.8 
05 M 35 1.93 100.7 24 2 10 40 33 1.76 85.5 
06 F 43 1.46 80.2 48 3 12 39 41 1.73 67.1 
07 F 46 1.5 56.4 60 3 13 39 41 1.67 61.5 
08 F 63 1.6 70.4 36 3 9 39 58 1.71 71.7 
11 M 53 1.56 54.6 108 2 10 39 53 1.73 76 
12 F 51 1.72 74.8 48 2 10 40 55 1.63 57.5 
13 M 74 1.69 61.5 420 3 12 38 73 1.71 63.9 
15 F 73 1.64 54.1 10 2 10 40 68 1.56 61.3 
16 F 48 1.72 89.8 48 1 13 40 50 1.59 74.5 
18 M 47 1.67 78.7 12 3 11 39 52 1.89 89.5 
19 M 64 1.83 91.1 180 2 14 40 65 1.8 81 
20 M 54 1.79 96.3 18 3 10 39 54 1.79 69.7 
22 M 58 1.66 75.6 10 4 12 39 62 1.66 94.2 
Mean / median  55.25 1.66 75.5 36 3 11 39 54.8 1.71 73.1 
mJOA = modified Japanese Orthopaedic Association score, MRMI = Modified Rivermead Mobility Index, kg = kilograms, M = male, F = female
 
165 
!"#"$% &'()*+,-./),01,-%),+,('0'+/%
!"#"$"%& '()*(+,-./0&12003&
The comfortable gait speed of HC participants was 1.49 m/s, significantly faster than that 
of their CSM counterparts, 1.12 m/s (p < 0.0001). This faster speed resulted from both a 
longer mean stride length of 1.45 m compared to 1.19 m (p = 0.0001), and a higher mean 
cadence of 122 steps per minute compared to 113 steps per minute (p = 0.005). CSM 
participants spent a longer proportion of the GC in double support, 26%, compared to 
20% GC duration for HCs (p = 0.0001). This was associated with shorter single support 
duration of 36.7% in CSM compared to 39.9% in HCs (p < 0.0001). The decrease in 
single support duration was caused by both a delay in opposite foot off, which occurred at 
12.9% GC in CSM compared to 10.4% GC in HC (p = 0.0006), and in foot off, at 62.7% 
GC in CSM compared to 60.2% GC in HC (p = 0.003), as illustrated in Figure 8.1. There 
were no significant differences in step width between pairs (CSM 16.9 cm, HC 15.9, p = 
0.4). Full data are presented in Table 8.2. 
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DS1 = first phase of double support, OFO = opposite foot off, SS = single support phase, OFC = 
opposite foot contact, DS2 = second phase of double support, FO = foot off
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CSM HC Difference Variable 
 Mean SD Mean SD Mean SD 
95% 
Confidence 
Intervals 
p value 
Cadence 
(steps / 
min) 
113.22 10.40 122.97 8.62 -9.75 12.05 -16.17 -3.3 0.006 
Double 
support (s) 0.28 0.06 0.20 0.03 0.08 0.06 0.05 0.11 0.0001 
Single 
support (s) 0.39 0.04 0.39 0.02 0.00 0.04 -0.02 0.02 0.9 
Double 
support 
duration 
(% GC) 
26.06 3.82 20.32 2.03 5.74 4.14 3.54 7.95 0.0001 
Single 
support 
duration 
(% GC) 
36.66 2.06 39.86 0.85 -3.20 1.99 -4.26 -2.1 <0.0001 
Foot off (% 
GC) 62.71 2.19 60.18 1.33 2.53 2.81 1.03 4.03 0.003 
Gait speed 
(m/s) 1.12 0.24 1.49 0.18 -0.36 0.24 -0.49 -0.2 <0.0001 
Opposite 
foot 
contact (% 
GC) 
49.56 1.25 50.26 0.59 -0.69 1.57 -1.53 0.14 0.09 
Opposite 
foot off (% 
GC) 
12.91 2.14 10.40 1.13 2.51 2.33 1.27 3.75 0.0006 
Step length 
(m) 0.59 0.10 0.73 0.06 -0.14 0.11 -0.19 -0.1 0.0001 
Step time 
(s) 0.54 0.05 0.49 0.03 0.05 0.06 0.02 0.08 0.002 
Step width 
(m) 0.17 0.04 0.16 0.03 0.01 0.04 -0.01 0.03 0.4 
Stride 
length (m) 1.19 0.19 1.45 0.11 -0.26 0.20 -0.37 -0.2 0.0001 
Stride time 
(s) 1.07 0.11 0.98 0.06 0.09 0.11 0.03 0.15 0.006 
SD = standard deviation, GC = gait cycle, m = metres, s = seconds 
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In the matched speed trials, HCs walked at a mean gait speed of 1.11 m/s to match their 
CSM counterparts at 1.12 m/s. There were differences in how this speed was achieved. 
HCs had a lower cadence (104 steps per minute) compared to CSM participants (113 
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steps per minute, p = 0.0009), and a longer stride length (1.27 m compared to 1.19 m, p 
= 0.03). In keeping with the lower cadence, HCs had a significantly longer stride time 
(CSM 1.07 s, HC 1.17 s, p = 0.0008), and achieved this by spending longer portion of the 
GC in single support (CSM 36.7% GC, HC 37.6% GC, p = 0.049) rather than in double 
support (CSM 26.1% GC, HC 24.9% GC, p = 0.14). Full results are shown in Table 8.3. 
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CSM HC Difference Variable 
Mean SD Mean SD Mean SD 
95% 
Confidence 
Intervals 
p 
value 
Cadence 
(steps / 
min) 
113.22 10.40 103.91 12.02 9.31 9.00 4.52 14.11 0.0009 
Double 
support (s) 
0.28 0.06 0.30 0.07 -0.02 0.03 -0.03 0.00 0.07 
Single 
support (s) 
0.39 0.04 0.44 0.04 -0.05 0.04 -0.07 -0.02 0.0005 
Double 
support 
duration (% 
GC) 
26.06 3.82 24.94 3.32 1.12 2.84 -0.40 2.64 0.14 
Single 
support 
duration (% 
GC) 
36.66 2.06 37.56 1.66 -0.90 1.67 -1.79 0.00 0.049 
Foot off (% 
GC) 
62.71 2.19 62.49 1.76 0.21 2.01 -0.85 1.28 0.7 
Gait speed 
(m/s) 
1.12 0.24 1.11 0.21 0.02 0.07 -0.02 0.06 0.3 
Opposite 
foot contact 
(% GC) 
49.56 1.25 50.27 0.65 -0.71 1.41 -1.46 0.04 0.06 
Opposite 
foot off (% 
GC) 
12.91 2.14 12.69 1.73 0.22 1.54 -0.61 1.04 0.6 
Step length 
(m) 
0.59 0.10 0.64 0.06 -0.05 0.07 -0.09 -0.01 0.02 
Step time 
(s) 
0.54 0.05 0.58 0.06 -0.04 0.05 -0.07 -0.01 0.007 
Step width 
(m) 
0.17 0.04 0.16 0.04 0.01 0.05 -0.02 0.03 0.5 
Stride 
length (m) 
1.19 0.19 1.27 0.13 -0.08 0.14 -0.16 -0.01 0.03 
Stride time 
(s) 
1.07 0.11 1.17 0.13 -0.10 0.10 -0.15 -0.05 0.0008 
SD = standard deviation, GC = gait cycle, m = metres, s = seconds 
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Paired t-tests were used to compare all kinematic variables, with the exception of peak 
ankle dorsiflexion in swing. This variable was tested using a Wilcoxon signed-rank test 
because the differences between HC and CSM pairs did not satisfy a normal distribution.  
At the pelvis, there were no differences in average pelvic tilt (CSM 9.37°, HC 8.76°, p = 
0.75) or in range of pelvic rotation (CSM 8.2°, HC 10.76°, p = 0.48). However, HCs had a 
significantly greater range of pelvic obliquity (8.78°) compared to CSM (6.34°, p = 0.003).  
At the hip, HCs had significantly greater total sagittal plane excursion than the CSM 
participants (HC 49.1°, CSM 44.3°, p = 0.004). There were no significant differences in 
peak hip extension, hip position at initial contact, or in hip ROM in the frontal or 
transverse planes.  
At the knee, HCs showed significantly greater peak flexion in stance (HC 22.1°, CSM 
13.7°, p = 0.0005), peak flexion in swing (HC 57.5°, CSM 48.6°, p = 0.0005), and total 
sagittal plane motion of the knee (HC 59.9°, CSM 51.9°, p = 0.004), but no significant 
difference in peak knee extension. 
There was no significant difference in ankle position in the sagittal plane at initial contact, 
though the CSM group tended to strike with slight plantarflexion (CSM –0.61, HC 0.52°, p 
= 0.3). Peak ankle dorsiflexion was not different between the groups in either stance or 
swing, however the graph of ankle movement over the GC, shown in Figure 8.2, “Ankle 
Dorsi / Plantar ROM”, indicated that HCs achieved dorsiflexion earlier in the mid stance 
phase than CSM participants. HCs had significantly greater peak plantarflexion of -18.4° 
compared to CSM, -11.3° (p = 0.013). Table 8.4 shows the full results. Figure 8.2 
illustrates kinematic curves over the GC. 
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CSM HC Difference Variable 
Mean  SD  Mean SD Mean SD 
95% 
Confidence 
Intervals  
p 
value 
Pelvic obliquity 
range 6.3 3.2 8.8 2.8 -2.4 2.7 -3.9 -1.0 0.003 
Pelvic rotation 
range 8.2 3.6 10.8 4.1 -0.6 3.2 -2.3 1.1 0.5 
Average pelvic 
tilt 9.4 5.9 8.8 4.2 0.6 7.5 -3.4 4.6 0.75 
Hip position at 
initial contact 30.3 6.9 31.3 5.6 -1.0 9.5 -6.0 4.1 0.7 
Peak hip 
extension -13.4 6.3 -16.5 5.3 3.1 8.8 -1.6 7.9 0.17 
Total sagittal 
plane excursion 
of hip 
44.3 5.3 49.1 4.9 -4.8 5.7 -7.8 -1.8 0.004 
Range of hip 
abduction / 
adduction 
12.0 3.2 13.0 3.0 -1.1 3.6 -3.0 0.9 0.27 
Range of hip 
rotation 19.1 10.1 16.2 4.8 2.9 11.6 -3.3 9.1 0.33 
Knee position at 
initial contact 4.2 6.0 3.3 3.7 0.9 6.3 -2.4 4.3 0.57 
Peak knee 
flexion in stance 13.7 6.4 22.1 6.9 -8.3 7.5 -12.3 -4.3 0.0005 
Peak knee 
extension -3.3 4.4 -2.4 4.4 -0.9 5.8 -4.0 2.1 0.52 
Peak knee 
flexion in swing 48.6 5.6 57.5 4.2 -8.9 8.1 -13.2 -4.6 0.0005 
Total sagittal 
plane excursion 
of knee 
51.9 6.9 59.9 5.4 -8.0 9.4 -13.0 -3.0 0.004 
Ankle position at 
initial contact -0.6 3.7 0.5 3.1 -1.1 4.2 -3.4 1.1 0.3 
Peak ankle 
dorsiflexion in 
stance 
14.3 2.6 14.4 2.7 -0.1 3.2 * * 0.92 * 
Peak ankle 
plantarflexion -11.3 6.9 -18.4 7.6 7.1 10.0 1.7 12.4 0.013 
Peak ankle 
dorsiflexion in 
swing 
6.2 4.2 4.7 2.5 1.5 4.1 -0.7 3.7 0.16 
* denotes a non-normally distributed variable with p value calculated using Wilcoxon signed rank 
test  
Confidence intervals were not calculated for non-normally distributed variables 
SD = standard deviation 
All variables are measured in degrees
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Significant differences between HC (green) and CSM (red) are indicated using boxes and arrows 
Ant = anterior, Post = posterior, Flex = flexion, Ext = extension, Plantar = plantarflexion, Dorsi = 
dorsiflexion, Abd = abduction, Add = adduction, Int = internal, Ex = external 
The vertical dashed lines indicate toe-off for CSM (red) and HC (green) 
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There were no significant differences in kinematics at the hip or pelvis at matched speed. 
At the knee, HCs showed greater peak flexion during swing (HC 54.6°, CSM 48.6°, p = 
0.006), and this resulted in greater total sagittal plane excursion (HC 56.8°, CSM 51.9°, p 
= 0.03). At the ankle, HCs achieved greater peak ankle dorsiflexion during stance (HC 
16.2°, CSM 14.3°, p = 0.02) and greater peak plantarflexion at pre swing (HC –16.6°, 
CSM –11.3°, p = 0.02). Full results are listed in Table 8.5. Graphs of GC curves are 
shown in Figure 8.3. 
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CSM HC Difference Variable 
Mean SD  Mean  SD Mean  SD  
95% 
Confidence 
Intervals  
p 
value 
Pelvic obliquity 
range 6.3 3.2 7.0 2.3 -0.7 2.3 -1.9 0.5 0.2 
Pelvic rotation 
range 8.2 3.6 8.4 2.1 1.2 3.5 -0.7 3.0 0.2 
Average pelvic tilt 9.4 5.8 8.8 4.0 0.6 7.2 -3.2 4.5 0.74 
Hip position at 
initial contact 30.3 6.9 29.3 5.3 1.0 9.4 -4.0 6.0 0.67 
Peak hip 
extension -13.4 6.3 -13.5 5.9 0.1 8.6 -4.5 4.7 0.97 
Total sagittal 
plane excursion 
of hip 
44.3 5.3 43.7 3.2 0.6 4.2 -1.6 2.9 0.55 
Range of hip 
abduction / 
adduction 
12.0 3.2 11.4 2.6 0.5 3.0 -1.1 2.1 0.49 
Range of hip 
rotation 19.1 10.1 17.0 4.6 2.1 10.8 -3.6 7.9 0.45 
Knee position at 
initial contact 4.2 6.0 1.7 4.5 2.5 6.9 -1.2 6.1 0.17 
Peak knee flexion 
in stance 13.7 6.4 16.2 7.9 -2.5 7.3 -6.4 1.4 0.19 
Peak knee 
extension -3.3 4.4 -2.2 4.0 -1.1 5.3 -3.9 1.7 0.4 
Peak knee flexion 
in swing 48.6 5.6 54.6 5.0 -6.0 7.5 -10.0 -2.0 0.006 
Total sagittal 
plane excursion 
of knee 
51.9 6.9 56.8 5.2 -4.9 8.0 -9.2 -0.6 0.03 
Ankle position at 
initial contact -0.6 3.7 -0.7 3.5 0.1 4.0 -2.1 2.2 0.95 
Peak ankle 
dorsiflexion in 
stance 
14.3 2.6 16.2 2.5 -2.0 3.0 -3.6 -0.4 0.02 
Peak ankle 
plantarflexion -11.3 6.9 -16.6 6.4 5.3 8.0 1.1 9.6 0.02 
Peak ankle 
dorsiflexion in 
swing 
6.2 4.2 6.2 4.0 0.1 4.5 -2.3 2.5 0.96 
SD = standard deviation 
All variables are measured in degrees
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Significant differences are indicated using boxes and arrows 
Ant = anterior, Post = posterior, Flex = flexion, Ext = extension, Plantar = plantarflexion, Dorsi = 
dorsiflexion, Abd = abduction, Add = adduction, Int = internal, Ex = external 
Vertical dashed lines indicate toe-off for both groups 
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Full results for kinetic parameters are listed in Table 8.6. Analysis of GRF showed no 
difference in peak medio-lateral shear force between HC and CSM pairs (p = 0.3). 
Differences in peak vertical GRF were not normally distributed, however when analysed 
with a Wilcoxon signed-rank test, there were significantly higher forces in HCs (p = 
0.0004). Analysis of the AP GRF showed significant differences in both the deceleration 
(CSM 1.39 N/kg, HC 2.1 N/kg, p = 0.0003) and acceleration components (CSM –1.6 
N/kg, HC –2.53 N/kg, p < 0.0001). Figure 8.4 illustrates the GRF curves. 
Peak hip abductor and extensor moments showed a trend towards lower scores in CSM. 
There were significant differences in peak hip flexor moments (HC –0.81 Newton metres 
per kilogram (Nm/kg), CSM –0.62 Nm/kg, p = 0.02). At the knee, peak extensor moments 
were significantly higher in HCs (0.56 Nm/kg) than in CSM (0.27 Nm/kg, p = 0.0005), 
however there were no differences in peak flexor moments. Peak ankle plantarflexor 
moments were significantly higher in HC (1.6 Nm/kg) than in CSM (1.41 Nm/kg, p = 
0.0007). Figure 8.4 illustrates the hip, knee and ankle moments. 
Figure 8.5 shows net power at the hip, knee and ankle, summed across the three axes of 
rotation, over the GC. Analysis revealed significant differences in hip power absorption in 
mid stance, H2 (HC –0.96 Watts per kilogram (W/kg), CSM –0.61 W/kg, p = 0.004) and 
hip power generation in pre swing, H3 (HC1.71 W/kg, CSM 1.0 W/kg, p = 0.0001). There 
were significant differences between pairs in all of four power peaks at the knee, with 
greater power generation and absorption by the HC participants. Ankle power generation 
at pre swing, A2, was higher in HC (4.85 N/kg) than in CSM (2.82 N/kg, p = 0.0001), 
whereas there was no difference in power absorption at the ankle in mid stance, A1. 
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CSM HC Difference Variable 
Mean SD Mean SD Mean SD 
95% 
Confidence 
Intervals 
p value 
Medio-lateral 
GRF  0.66 0.19 0.59 0.19 0.07 0.27 -0.07 0.21 0.3 
Antero-
posterior GRF, 
deceleration 
1.39 0.46 2.10 0.53 -0.71 0.61 -1.03 -0.38 0.0003 
Antero-
posterior GRF, 
acceleration 
-1.60 0.52 -2.53 0.41 0.93 0.59 0.61 1.24 <0.0001 
Vertical GRF 10.58 0.74 12.23 1.42 -1.65 1.57 * * 0.0004* 
Hip extensor 
moment 0.78 0.20 0.88 0.22 -0.10 0.21 -0.21 0.01 0.075 
Hip flexor 
moment  -0.62 0.27 -0.81 0.23 0.19 0.28 0.04 0.34 0.02 
Hip abductor 
moment 0.84 0.18 0.98 0.22 -0.14 0.30 -0.30 0.02 0.08 
Knee extensor 
moment  0.27 0.18 0.56 0.26 -0.30 0.27 -0.44 -0.15 0.0005 
Knee flexor 
moment  -0.52 0.11 -0.57 0.14 0.06 0.17 -0.03 0.14 0.2 
Ankle 
plantarflexor 
moment 
1.41 0.21 1.60 0.12 -0.18 0.18 -0.28 -0.09 0.0007 
Hip power 
generation, H1 0.51 0.29 0.58 0.41 -0.07 0.45 -0.31 0.17 0.5 
Hip power 
absorption, H2 -0.61 0.27 -0.96 0.39 0.35 0.41 0.13 0.56 0.004 
Hip power 
generation, H3 1.00 0.45 1.71 0.47 -0.71 0.54 -1.00 -0.42 0.0001 
Knee power 
absorption, K1 -0.70 0.87 -2.10 1.36 1.40 1.47 0.62 2.18 0.002 
Knee power 
generation, K2  0.59 0.28 0.97 0.33 -0.38 0.39 -0.58 -0.17 0.0015 
Knee power 
absorption, K3  -0.68 0.42 -1.21 0.50 0.53 0.63 0.20 0.87 0.004 
Knee power 
absorption, K4  -0.70 0.27 -1.56 0.63 0.86 0.69 0.49 1.22 0.0002 
Ankle power 
absorption, A1 -0.99 0.34 -0.92 0.24 -0.07 0.29 -0.22 0.09 0.37 
Ankle power 
generation, A2  2.82 1.34 4.85 1.19 -2.03 1.56 -2.86 -1.20 0.0001 
* denotes a non-normally distributed variable analysed using Wilcoxon signed rank test 
Ground reaction forces (GRF) are reported in Newtons per kilogram, moments in Newton metres 
per kilogram, and powers in Watts per kilogram 
SD = standard deviation, GRF = ground reaction force 
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Med = medial, Lat = lateral, N = Newtons, kg = kilograms, Nm = Newton metres, Ant = anterior, 
Post = posterior, Ext = extensor, Flex = flexor 
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W = Watts, kg = kilograms, Gen = generation, Abs = absorption, H = Hip power peak, K = knee 
power peak, A = ankle power peak 
&
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Table 8.7 shows the kinetic parameters of CSM and HC participants at matched speed. 
There were fewer differences between pairs at this speed. The acceleration component 
of AP GRF was higher in HC, with a peak of –1.9 N/kg, compared to –1.6 N/kg in CSM (p 
= 0.02). The CSM group generated higher peak hip extensor moments (CSM 0.78 
Nm/kg, HC 0.61 Nm/kg, p = 0.013), a parameter that was not different at comfortable 
speed. In keeping with this finding, peak hip power generation during loading response 
(H1) was higher in the CSM group (0.51 W/kg) compared to HCs (0.25 W/kg, p = 0.05). 
There were no differences in power generation and absorption at the knee, although 
there was a non-significant tendency for greater absorption peaks at K1 and K4 in HCs. 
At the ankle, the CSM participants absorbed significantly more power at the A1 peak in 
mid stance (CSM –0.91 W/kg, HC –0.8 W/kg, p = 0.03). There was a trend towards 
higher power generation at the ankle at toe-off in HC (3.32 W/kg) compared to CSM (2.82 
W/kg), however this did not reach statistical significance (p = 0.075). Figures 8.6 and 8.7 
show kinetic curves over the GC for CSM and HC participants. 
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CSM HC Difference 
Variable 
Mean SD Mean SD Mean SD 
95% 
Confidence 
Intervals 
p 
value 
Medio-lateral 
GRF 0.66 0.19 0.59 0.19 0.07 0.27 -0.07 0.21 0.3 
Antero-posterior 
GRF, 
deceleration 
1.39 0.46 1.53 0.45 -0.13 0.44 -0.37 0.10 0.24 
Antero-posterior 
GRF, 
acceleration 
-1.60 0.52 -1.90 0.45 0.30 0.45 0.05 0.54 0.02 
Vertical GRF 10.58 0.74 10.82 0.57 -0.24 0.60 -0.56 0.08 0.12 
Hip extensor 
moment 0.78 0.20 0.61 0.23 0.16 0.23 0.04 0.29 0.01 
Hip flexor 
moment -0.62 0.27 -0.58 0.27 -0.04 0.26 -0.18 0.10 0.5 
Hip abductor 
moment 0.84 0.18 0.90 0.21 -0.06 0.25 -0.19 0.07 0.3 
Knee extensor 
moment 0.27 0.18 0.33 0.22 -0.06 0.21 -0.18 0.05 0.25 
Knee flexor 
moment -0.52 0.11 -0.51 0.16 0.00 0.18 -0.10 0.09 0.95 
Ankle 
plantarflexor 
moment 
1.41 0.21 1.48 0.13 -0.07 0.17 -0.16 0.02 0.12 
Hip power 
generation, H1 0.51 0.29 0.32 0.25 0.19 0.36 0.00 0.38 0.05 
Hip power 
absorption, H2 -0.61 0.27 -0.57 0.31 -0.05 0.28 -0.20 0.10 0.5 
Hip power 
generation, H3 1.00 0.45 0.94 0.45 0.06 0.40 -0.15 0.28 0.54 
Knee power 
absorption, K1 -0.70 0.87 -0.84 0.56 0.15 0.73 -0.24 0.53 0.43 
Knee power 
generation, K2 0.59 0.28 0.56 0.25 0.03 0.31 -0.13 0.19 0.7 
Knee power 
absorption, K3 -0.68 0.42 -0.66 0.44 -0.02 0.50 -0.28 0.25 0.9 
Knee power 
absorption, K4 -0.70 0.27 -0.84 0.44 0.14 0.41 -0.08 0.36 0.19 
Ankle power 
absorption, A1 -0.99 0.34 -0.80 0.24 -0.19 0.31 -0.36 -0.02 0.03 
Ankle power 
generation, A2 2.82 1.34 3.32 1.09 -0.50 1.04 -1.06 0.06 0.075 
SD = standard deviation, GRF = ground reaction force 
GRFs are reported in Newtons per kilogram, moments in Newton metres per kilogram, and powers 
in Watts per kilogram 
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Med = medial, Lat = lateral, N = Newtons, kg = kilograms, Nm = Newton metres, Ant = anterior, 
Post = posterior, Ext = extensor, Flex = flexor 
Significant differences at key points are highlighted with text and arrows 
Vertical dashed lines indicate toe-off for both groups 
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Gen = power generation, Abs = power absorption, W = Watts, kg = kilograms 
Significant differences at key points are highlighted with text and arrows 
Vertical dashed lines indicate toe-off for both groups 
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The total duration of activation of RF, BF, TA and MG muscles over the GC was 
determined using the TKEO-based DTM algorithm described in Chapter 5, Section 
5.4.4.2. Paired t-tests found that the duration of RF, BF and TA activation was 
significantly longer in CSM particpants. MG showed no differences between pairs. The 
actual differences of 10.9% for RF, 9.8% for BF and 11.2% for TA exceeded the SEM for 
timing of those muscles, previously discussed in Chapter 7, Section 7.5.3.1. Timing 
parameters are listed in Table 8.8.  
The CSM group showed significantly greater co-activation between RF and BF, 14.5% 
GC duration compared to the HCs’ 9.3% GC duration (p = 0.04). There was a non-
significant trend for greater co-activation between TA and MG in CSM (7.5% GC) than in 
HC (4% GC, p = 0.17). Table 8.8 shows the results of the analysis of co-activation. 
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CSM HC Difference Muscle 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
p 
value 
Rectus 
femoris 32.97 18.22 22.06 6.00 10.92 18.92 0.84 21.00 0.04 
Biceps 
femoris 31.81 10.96 21.93 5.09 9.88 9.78 4.67 15.09 0.001 
Tibialis 
anterior 42.16 9.86 30.93 8.84 11.23 14.32 3.60 18.86 0.007 
Medial 
gastrocnemius 31.75 9.68 28.88 8.09 2.88 13.26 -4.19 9.94 0.4 
Rectus–biceps 
co-activation 14.44 8.73 9.32 4.38 5.12 9.49 0.07 10.18 0.04 
Tibialis–
gastrocnemius 
co-activation 
7.47 7.91 4.02 4.03 3.45 9.66 -1.70 8.59 0.17 
Activation times are expressed as a percentage of gait cycle duration 
SD = standard deviation 
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Analysis of timing parameters at matched speed mirrored the results of the comfortable 
speed analysis. The CSM group had significantly greater total activation time of RF, BF 
and TA, though RF did not reach statistical significance (p = 0.07). The timing of MG 
showed no significant differences between groups, though there was a non-significant 
trend of longer activation time in CSM (31.75% GC) than in HC (26.81% GC, p = 0.14). 
Co-activation between RF and BF was of significantly greater duration in CSM compared 
to HC. There was no difference between pairs in relation to MG and TA co-activation. 
Table 8.9 shows the results of analysis of timing and co-activation at matched speed. 
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CSM HC Difference Muscle 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
p 
value 
Rectus 
femoris 32.97 18.22 24.45 6.50 8.53 17.22 
-
0.65 17.70 0.07 
Biceps 
femoris 31.81 10.96 19.30 6.52 12.51 9.58 7.40 17.61 0.0001 
Tibialis 
anterior 42.16 9.86 29.76 10.88 12.40 15.64 4.06 20.74 0.006 
Medial 
gastrocnemius 31.75 9.68 26.81 8.03 4.95 12.75 
-
1.85 11.74 0.14 
Rectus–biceps 
co-activation 14.44 8.73 9.30 3.79 5.14 7.26 1.27 9.01 0.013 
Tibialis–
gastrocnemius 
co-activation 
7.47 7.91 3.93 3.60 3.54 9.15 -1.34 8.41 0.14 
Activation times are expressed as a percentage of GC duration 
SD = standard deviation 
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The mean amplitude of a muscle’s EMG signal during bursts of activity and during “off” 
phases were extracted according to the methods described in Chapter 6, Section 6.7.3.3. 
Mean amplitudes were normalised using the PDM method described in Section 6.7.3.4. 
The CSM group had significantly higher mean amplitude in the “off” or baseline phases of 
RF (CSM 17.9% RMSMAX, HC 13.7% RMSMAX, p = 0.02) and BF (CSM 15.6% RMSMAX, 
HC 11% RMSMAX, p = 0.006). The CSM group also showed significantly lower BF activity 
during stance (CSM 47.6% RMSMAX, HC 58.5% RMSMAX, p = 0.04). There were no 
differences in mean amplitude of MG or TA. Results are shown in Table 8.10 and Figure 
8.8. 
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CSM HC Difference Muscle 
Burst 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
p 
value 
RF loading 
response  56.15 9.82 60.88 7.89 -4.72 11.06 -10.62 1.17 0.11 
RF pre 
swing 45.70 15.86 43.36 12.93 -5.78 13.84 * * * 0.25 
RF swing 19.34 12.21 25.11 9.63 5.44 18.96 -13.15 1.60 0.12 
RF baseline 17.86 6.08 13.71 3.73 4.15 6.65 0.61 7.70 0.02 
BF stance 47.63 11.10 58.50 15.10 -9.56 16.54 -18.72 -0.40 0.04 
BF swing 43.87 12.88 39.67 12.03 4.20 14.56 -3.56 11.96 0.27 
BF baseline 15.55 4.03 10.97 3.93 4.58 5.52 1.64 7.52 0.005 
TA stance 55.78 8.68 55.61 14.02 0.18 18.41 -9.63 9.98 0.97 
TA swing 47.73 6.72 45.25 9.49 2.48 12.91 -4.40 9.36 0.45 
TA baseline 15.91 4.23 14.16 2.70 1.75 4.92 -0.87 4.38 0.18 
MG stance 57.35 6.97 62.03 4.66 -4.68 9.13 -9.54 0.19 0.06 
MG baseline 13.29 3.42 11.84 6.60 1.46 8.11 -2.86 5.78 0.48 
Amplitude of each burst is expressed as a percentage of the muscle’s peak root-mean-square 
(RMS) amplitude during gait  
RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius, SD = 
standard deviation  
The symbol * denotes results of a Wilcoxon signed-rank test 
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Amplitude is expressed as a percentage of maximum root-mean-square (RMS) amplitude obtained 
during 10 gait trials of each session (%RMSMAX) 
* denotes statistically significant difference between CSM and HC 
 
185 
!"#"J"$& @-,B>03&12003&
At matched speed, CSM participants showed statistically higher normalised amplitudes 
during the “off” phases of RF (p = 0.02) and BF (p = 0.01), in keeping with the findings at 
comfortable speed. No other differences in amplitude were found at matched speed. 
Differences in RF activity during swing and pre swing did not follow a normal distribution. 
These activity bursts were examined with the non-parametric Wilcoxon signed-rank test. 
The results of EMG amplitude analysis at matched speed are shown in Table 8.11. 
C-./0&!"%%8&S)2/5,730&(*&)71B/0&-B,5:5,H&.7+1,1&-;3&.-10/5;0&2>-101&37+5;6&6-5,&(*&'?@&
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CSM HC Difference Muscle 
Burst 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
p 
value 
RF 
loading 
response  
56.15 9.82 57.25 6.39 -1.10 7.80 -5.26 3.06 0.58 
RF pre 
swing 45.70 15.86 38.10 14.57 -10.72 17.99 * * *0.58 
RF swing 19.34 12.21 30.06 10.56 8.89 25.93 * * *0.11 
RF 
baseline 17.86 6.08 13.28 3.18 4.59 6.69 1.02 8.16 0.02 
BF 
stance 47.63 11.10 53.99 8.32 -5.05 11.12 -11.20 1.11 0.1 
BF swing 43.87 12.88 38.49 13.35 5.38 15.38 -2.82 13.57 0.18 
BF 
baseline 15.55 4.03 11.70 3.29 3.85 5.54 0.90 6.80 0.014 
TA 
stance 55.78 8.68 58.66 11.81 -2.88 18.28 -12.62 6.86 0.54 
TA swing 47.73 6.72 42.44 7.84 5.29 11.34 -0.75 11.33 0.08 
TA 
baseline 15.91 4.23 13.35 3.11 2.56 5.19 -0.21 5.33 0.07 
MG 
stance 57.35 6.97 58.93 5.10 -1.58 9.31 -6.54 3.38 0.51 
MG 
baseline 13.29 3.42 10.93 5.33 2.37 6.68 -1.20 5.93 0.18 
RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius, SD = 
standard deviation 
Amplitude is expressed as a percentage of peak root-mean-square (RMS) amplitude during gait 
* denotes that the groups were compared using the Wilcoxon signed rank test 
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Methods to derive a locomotor-specific measure of spasticity (LSMS) were implemented 
as described in Chapter 6, Section 6.7.4.3. Two quantitative parameters were extracted, 
1) the lengthening velocity threshold (LVT) that triggered muscle activation during a 
lengthening phase for that muscle, and 2) the time (percentage GC duration) at which this 
activation was initiated, termed the critical time, tC. The frequency of a positive slope 
between the EMG RMS and lengthening velocity was also presented for descriptive 
analysis. The CSM group showed a trend of lower LVT during lengthening, indicating 
greater velocity-related sensitivity to stretch, in all muscles except MG. This trend was 
significant for TA (p = 0.05). Similarly, the time of EMG activity onset during the GC was 
earlier in RF and BF in CSM, but not in MG or TA, however this trend was not significant. 
The results of the LSMS are presented in Table 8.12. 
C-./0&!"%$8&W(B()(,(+D120B5*5B&)0-17+0&(*&12-1,5B5,H&(*&A'&-;3&'?@&2-+,5B52-;,1&-,&
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CSM HC Difference Measure 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
 p 
value 
RF LVT (l0/s) 2.78 1.12 3.52 1.56 -0.74 1.82 -1.71 0.23 0.12 
RT tc (% GC) 84.08 6.70 87.82 6.06 -3.74 8.72 -8.39 0.90 0.11 
BF LVT (l0/s) 1.47 0.43 1.59 0.47 -0.13 0.63 -0.46 0.21 0.44 
BF tc (% GC) 79.49 3.86 81.41 4.81 -1.91 6.55 -5.40 1.58 0.26 
TA LVT (l0/s) 1.02 0.71 1.67 1.09 -0.65 1.20 -1.29 -0.01 0.05 
TA tc (% GC) 56.83 5.24 55.92 4.37 0.91 8.18 -3.45 5.27 0.66 
MG LVT 
(l0/s) 
0.50 0.71 0.47 1.46 0.03 1.54 -0.79 0.85 0.94 
MG tc (% GC) 20.39 9.13 20.97 8.90 -0.58 10.86 -6.36 5.21 0.83 
RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius, lo/s  = 
normalised muscle lengths per second, GC = gait cycle 
 
Data on the direction of the slope between lengthening velocity and EMG amplitude are 
shown in Figure 8.9. The dominant direction of the slope out of ten trials for each 
participant was analysed, such that if five or more trials showed a positive slope during 
lengthening, then the dominant direction for that participant was deemed to be positive. A 
noteworthy finding was the predominance of positive slopes in MG in both groups, 
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indicating a velocity-sensitive response to lengthening. This was in keeping with this 
muscle’s lower LVT (Table 8.10). For each muscle, the proportions of dominantly positive 
slopes in CSM and HC participants were compared using Fisher’s exact test. Participants 
with CSM showed a higher incidence of dominant positive slopes in TA, however this did 
not reach statistical significance (p = 0.07). No differences in dominant slope direction 
were found for MG, RF or BF, suggesting that the gain of the stretch reflex was not 
different between CSM and HC participants in these muscles during gait. 
4567+0&!"Q8&P()5;-;,&35+0B,5(;&(*&,>0&1/(20&(*&)71B/0&/0;6,>0;5;6&:0/(B5,H&=5,>&+0120B,&
,(&V@L&-)2/5,730&XY&9@?@SZ[&*(+&'?@&-;3&A'&2-+,5B52-;,1&-,&B()*(+,-./0&12003&&
Positive slopes suggest a velocity sensitive response to lengthening 
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The critical time of onset of RF and TA activity during lengthening occurred significantly 
earlier in CSM than in HCs (RF: CSM 84% GC, HC 89.4% GC, p = 0.02; TA: CSM 56.8% 
GC, HC 61.3%, p = 0.03). There were no differences in the LVT of these muscles, in 
contrast to the results at comfortable speed. The findings for MG were consistent with 
comfortable speed analysis, with no differences in either LVT or tC. However, the LVT of 
BF was significantly lower in HC, 1.11 lo/s, compared to 1.47 lo/s in CSM. Results are 
shown in Table 8.13. 
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CSM HC Difference Measure 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
 p 
value 
RF LVT (l0/s) 2.78 1.12 3.26 1.20 -0.49 1.46 -1.26 0.29 0.2 
RT tC (% GC) 84.08 6.70 89.40 5.07 -5.32 8.06 -9.62 -1.02 0.02 
BF LVT (l0/s) 1.47 0.43 1.11 0.40 0.36 0.51 0.09 0.63 0.01 
BF tC (% GC) 79.49 3.86 82.76 5.53 -3.26 7.64 -7.33 0.81 0.11 
TA LVT (l0/s) 1.02 0.71 1.44 0.94 -0.42 0.96 -0.93 0.10 0.1 
TA tC (% GC) 56.83 5.24 61.27 4.27 -4.45 7.21 -8.29 -0.61 0.03 
MG LVT 
(l0/s) 
0.50 0.71 0.71 0.49 -0.21 0.76 -0.61 0.20 0.29 
MG tC (% 
GC) 20.39 9.13 18.33 4.43 2.06 9.02 -2.75 6.87 0.38 
RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius, 
lengthening velocity threshold = LVT, normalised lengths per second = l0/s, GC = gait cycle 
The slope of the relationship between EMG amplitude and lengthening velocity was also 
calculated for each trial, and the dominant slope direction was determined for each 
participant. Results on slope direction were identical to those at comfortable speed, 
presented in Section 8.4.7.1. In other words, the dominant slope direction did not change 
in HCs when speed was reduced.  
!"#"!% C+1451),-%5*()*4'40/%,4,-8/1/%*9%=,10%@,0,%
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PCA was conducted on the pooled data of temporal-spatial, kinematic and kinetic 
variables listed in Tables 8.2, 8.4 and 8.6. In total, 50 variables were included in the PCA 
algorithm. The first PC, labelled PC1, accounted for 44.4% of the total variability of the 
data, the second, PC2, accounted for a further 9.8% of the variability, and the third PC, 
PC3, accounted for a further 8.2%. In all, 62.3% of the total variability of the data set was 
accounted for by the first three PCs. The remaining PCs each accounted for no more 
than 6.9% of the total variability of the data set, and these were not considered further. 
Table 8.14 shows the first 3 PCs and their contributing variables. 
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PC Proportion Positive Variables Score Negative Variables Score 
PC1 42.9% Gait speed 0.207 Anteroposterior 
acceleration GRF 
-0.199 
  Step length 0.197 Double support time, 
seconds 
-0.196 
  Stride length 0.196 Double support duration, % 
GC 
-0.189 
  Single support duration, 
% GC 
0.193 Opposite foot off, % GC -0.184 
  Anteroposterior 
deceleration GRF 
0.185 Hip absorption power, H2 -0.170 
  Vertical GRF 0.182 Knee absorption power, K1 -0.168 
  Hip power, pre swing 
(H3) 
0.181 Foot off, % GC -0.167 
  Ankle power generation, 
stance (A2) 
0.178 Step time -0.165 
  Knee sagittal plane 
range 
0.172 Knee absorption power, K4 -0.164 
  Hip sagittal plane range 0.166 Stride time -0.160 
  Knee power generation, 
K2 
0.165 Knee absorption power, K3 -0.158 
  Cadence 0.163   
  Knee flexion in swing 0.160   
  Pelvic obliquity range 0.158   
  Ankle plantarflexor 
moment 
0.151   
PC2 9.8% Average pelvic tilt 0.386 Single support time, 
seconds 
-0.323 
  Hip position, initial 
contact 
0.371 Ankle position, initial 
contact 
-0.260 
  Hip rotation range 0.247 Ankle plantarflexor moment -0.207 
  Hip extension 0.225 Stride time -0.173 
  Hip extensor moment 0.165 Step time -0.166 
  Cadence 0.165   
  Pelvic rotation range 0.162   
  Foot off, % GC 0.159   
  Pelvic obliquity range 0.159   
PC3 8.5% Knee extension 0.380 Knee absorption power, K1 -0.199 
  Knee flexion in stance 0.360 Knee sagittal plane range -0.166 
  Hip power generation, 
H1 
0.276   
  Knee position, initial 
contact 
0.273   
  Knee extensor moment 0.257   
  Medio-lateral GRF 0.235   
  Hip extension 0.224   
  Hip flexor moment 0.223   
  Hip position, initial 
contact 
0.222   
  Knee flexor moment 0.182   
Positive variables are those that increase as the PC increases 
Negative variables are those that have an inverse relationship with the PC score 
Kinematic and kinetic variables refer to peak values unless range is stated 
GRF = ground reaction force, PC = principal component, GC = gait cycle 
The symbol * denotes variable with a negative sign by convention 
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A review of the component scores indicated that the variables contributing to PC1 were 
functions of propulsion and the generation of momentum. PC1 was influenced by the 
relationship between walking speed and sagittal plane range at the hip and knee, as well 
as the power bursts associated with gait speed. The variables contributing to PC2 and 
PC3 occurred during the stance phase of gait, and this suggested that PC2 and PC3 
reflected different aspects of stability in stance. Many of PC2’s contributing variables 
centred on the mid and terminal stance phases of gait, while PC3 variables tended to 
centre on the loading response to mid stance phases. Individual PC scores are shown in 
Figure 8.10. The differences between the groups were not tested for significance 
because the aim of PCA was to explore the relationships between the variables, and not 
to test a hypothesis. Figure 8.11 illustrates the dispersion of scores of CSM and HC 
participants in the PC1 and PC2 components, and shows a pattern of clustering with 
CSM participants generally showing lower scores on PC1 and greater variability on PC2. 
4567+0&!"%R8&T(UD-;3D=>51G0+&2/(,1&(*&,>0&,>+00&2+5;B52-/&B()2(;0;,&:-+5-./01&*+()&
EPLS&3-,-&5;&'?@&-;3&A'&2-+,5B52-;,1&&
Mean scores are shown by the central line, standard deviations by the boxes, and minimum and 
maximum values by the whiskers 
PC = principal component 
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The arrows and boxed variables show the relationship between these individual variables and the 
overall PC score 
A-P GRF = antero-posterior ground reaction force, GC = gait cycle, PC = principal component 
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PCA was then repeated with the inclusion of EMG timing, co-activation, amplitude, and 
lengthening data. A higher total number of PCs were extracted compared to PCA without 
EMG data. The first three PCs remained dominant, representing 30.9%, 8.9% and 7.4% 
of the total variability in the data, respectively. The 3DGA variables contributing to the 
PCs were consistent with those of the first PCA, albeit with some differences in the order 
of contribution. This suggested that the PCs were consistent in their representation of the 
components of gait, and were relatively stable to the inclusion of the EMG data. The 
overall scores on PC3, however, were slightly different when EMG data were included 
(see Figure 8.12), suggesting that the inclusion of EMG data had a greater effect on this 
PC than on PC1 and PC2. PC1 was negatively influenced by RF–BF co-activation 
duration and by BF duration, although the weightings for these variables, –0.124 and –
0.142, did not reach the threshold of 0.15 required for significant contributions. PC2 was 
positively influenced by duration of RF activity, amplitude of RF during stance, and BF 
duration, suggesting that RF and BF had a role in increasing the components of stability 
in stance represented by PC2. PC3 was positively affected by TA burst amplitude in 
stance and by the critical time of MG activity onset during lengthening, suggesting that 
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the EMG variables contributing to PC3 reflected stability during stance at the lower leg 
and foot. The variables contributing to the PCs of the combined TSP, kinematic, kinetic 
and EMG data set are listed in Table 8.15. Figure 8.12 shows the dispersion of scores on 
PC1 and PC2 for CSM and HC participants. Figure 8.13 illustrates box-and-whisker plots 
of the HC and CSM scores on the first three PCs. As illustrated by these graphs, the 
overall clustering of HC and CSM scores is well preserved compared to the first PCA 
without EMG. 
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PC Score Positive Variables Score Negative Variables Score 
PC1 30.9% Gait speed 0.200 Antero-posterior GRF, deceleration -0.192 
   Step length 0.190 Double support time, seconds -0.184 
   Stride length 0.189 Double support duration, % GC -0.179 
   Single support duration, % GC 0.184 Opposite foot off, % GC -0.170 
   Antero-posterior GRF, deceleration 0.176 
Knee power absorption, 
K1* -0.165 
   Hip power generation, H3 0.176 Knee power absorption, K4* -0.162 
   Ankle power generation, A2 0.175 Hip power generation, H1 -0.155 
  Vertical GRF 0.174 Step time -0.155 
  Knee flexion, swing 0.163 Knee power absorption, K3* -0.154 
  Knee sagittal plane range 0.162 Foot off, % GC -0.152 
  Knee power generation, K2 0.155    
   Cadence 0.150    
PC2 8.9% RF pre swing burst amplitude 0.231 
Single support time, 
seconds -0.301 
   BF LVT 0.206 RF swing burst amplitude -0.231 
   Cadence 0.195 Stride time -0.212 
   Hip rotation, range 0.186 Knee extension* -0.191 
   BF swing burst amplitude 0.183 Step time -0.188 
   Average pelvic tilt 0.168 Ankle plantarflexor moment -0.179 
   BF duration 0.166    
   Pelvic obliquity range 0.157    
   Pelvic rotation range 0.156    
   Hip extensor moment 0.155    
   RF duration 0.150    
PC3 7.4% Hip position, initial contact 0.331 Ankle position, initial contact -0.248 
   Average pelvic tilt 0.291 Ankle plantarflexion* -0.164 
   Hip power generation, H1 0.253    
   BF critical time 0.214    
   Hip extension* 0.202    
   Hip flexor moment* 0.196    
   TA stance burst amplitude 0.186    
   Hip sagittal plane range 0.175    
   MG critical time 0.166    
   Foot off, % GC 0.151    
Positive variables are those that increase as the PC increases 
Negative variables are those that have an inverse relationship with the PC score 
Kinematic and kinetic variables refer to peak values unless range or position is stated 
GRF = ground reaction force, MG = medial gastrocnemius, RF = rectus femoris, BF = biceps 
femoris, TA = tibialis anterior, GC = gait cycle, PC = principal component 
The symbol * denotes that variable has a negative sign by convention 
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RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, PC = principal component 
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PC = principal component 
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The aim of this cross-sectional study was to compare the gait patterns of people with 
untreated CSM to those of healthy age- and gender-matched controls. The first 
comparison was conducted at the comfortable gait speed of both groups to illustrate the 
natural walking pattern adopted by each participant. In keeping with other studies (Kuhtz-
Buschbeck et al., 1999, Singh and Crockard, 1999, Maezawa et al., 2001, Suzuki et al., 
2002, Lee et al., 2011), the current study also found that people with CSM walked at a 
significantly slower comfortable walking speed, representing a decrease of 0.36 m/s on 
the speed of the HCs (1.48 m/s). The fact that the comfortable gait speed of the slowest 
HC, 1.22 m/s, was still 0.1 m/s faster than the mean of the CSM group, 1.12 m/s, 
illustrates the severity of loss of natural gait speed in CSM.  
Analysis of TSPs at comfortable speed indicated that CSM participants had difficulty in 
generating adequate stride and step length, and also required a longer time to complete 
each stride. They spent a longer proportion of the GC in double support and less in single 
support and swing, suggesting either a lack of stability in single leg stance, weak 
contralateral push off at pre swing, premature cessation of swing due to hyperactivity of 
the hamstrings, or limited hip extension on the stance leg (Winter, 1985, Kirtley, 2006). 
Analysis of kinematics and kinetics provided further insight into the underlying movement 
patterns. CSM participants differed from their HC counterparts in their range of pelvic 
obliquity over the GC, with HCs showing an average of 2.4° more obliquity, which 
appeared to be due to reduced upward rather than downward movement as shown in 
Figure 8.2. The difference between groups exceeded the SEM of pelvic obliquity range of 
0.92°, as per Chapter 7, Section 7.5.2.2. This was partly in keeping with the findings of a 
previous study, which found that pelvic obliquity was reduced in people who had a history 
of CSM for less than one year, but normal in those who had CSM for more than a year, 
compared to HCs (Suzuki et al., 2002). The significance of the reduction in pelvic 
obliquity in the current study was unclear. Upward pelvic obliquity was considered to 
increase the effective leg length of the trail limb during stance, and was deemed to be 
one of the six determinants of gait (Saunders et al., 1953). It was later shown that this 
movement occurred too late in the GC to have such an effect (Della Croce et al., 2001). It 
was possible that reduced pelvic obliquity in CSM was a secondary effect of other factors 
affecting stability in stance.  
At the hip, there were no differences in ROM in the frontal or transverse planes. Peak hip 
extension showed a mean reduction of 3° in CSM compared to HC. This did not reach 
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statistical significance, nor did it exceed the SEM of peak hip extension of 3.2°. However, 
it led to a significant overall reduction in total sagittal plane range at the hip in CSM. 
Stimulation of afferent receptors in the hip joint occurs during hip extension and signals 
the transition from stance to swing, contributing to appropriate muscle activation. If the 
hip is prevented from reaching an extended position, the generation of the flexor burst 
and the onset of swing may be inhibited (Dietz, 2002). There were significant decreases 
in the H2 and H3 hip powers during terminal stance and pre swing in the CSM cohort. 
This may have been a feature of the reduced speed of the CSM group (Kirtley, 2006). It 
may also have resulted from decreased hip extension, which then impaired the 
generation of propulsion into swing. 
Significant differences were found in knee flexion in stance, swing, and total knee sagittal 
plane range, in keeping with the findings of previous studies on gait in CSM (Kuhtz-
Buschbeck et al., 1999, Maezawa et al., 2001, Suzuki et al., 2002, Lee et al., 2011). As 
discussed in Chapter 3, Section 3.2.4, a previous study found reduced knee flexion 
during swing in people with symptoms of CSM who did not have a reduction in gait 
speed, suggesting that it was an early sign of gait impairment in CSM (Maezawa et al., 
2001). The current study also found lower power absorption peaks of the knee at loading 
response (K1) and initial swing (K3) in CSM, confirming that the losses of knee flexion in 
stance and swing were associated with reduced eccentric activity. In particular, loss of 
the K1 peak at loading response indicated impairment of the loading response due to 
weak quadriceps (Kirtley, 2006). 
At the ankle, CSM participants reached significantly lower peak plantarflexion than their 
HC counterparts at the terminal stance and pre swing phases of gait. This was 
associated with reduction in the ankle plantarflexor moment and the A2 power generation 
peak, with a decrease of more than 2 W/kg in the latter. The plantarflexors have been 
shown to provide most of the body’s support during terminal stance (Anderson and 
Pandy, 2003). The loss of their concentric power burst at this point would have limited the 
propulsion of the leg into swing (Kirtley, 2006). This loss of propulsion was not 
compensated by an increase in the H3 hip power generation peak, as noted in other 
populations such as stroke (Nadeau et al., 1999). An effective swing phase, and therefore 
stride length, depends on the generation of sufficient momentum at the toe-off phase of 
gait (Kirtley, 2006). The lack of plantarflexion and A2 power at pre swing in CSM could 
have contributed to the shorter stride length and reduced single support time noted in the 
analysis of the TSPs.  
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There is some difficulty in the interpretation of kinematic and kinetics between two sets of 
participants walking at different speeds. Despite the obvious advantage that it reflects the 
natural capabilities of each participant, many variables, particularly kinetics, have a 
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predictive dependency with gait speed (Riley et al., 2001, Lelas et al., 2003). Other 
variables, such as sagittal plane kinematics, show a positive correlation with speed 
(Kirtley et al., 1985). The differences between CSM and HC kinematics and kinetics could 
simply restate the fact that people with CSM walk more slowly, rather than providing 
insight into the causes of the slower gait, as suggested in stroke (Chen et al., 2005). 
To control for the potential confounding effects of gait speed, each HC performed ten 
trials at the walking speed of the CSM participant to whom he or she was paired. This 
necessitated a mean reduction in walking speed of 0.36 m/s, with a range of 0–0.68 m/s, 
depending on the severity of the CSM participant’s mobility limitation. HCs achieved the 
target speed by reducing cadence, while maintaining a stride length close to that of their 
comfortable speed. The proportion of the GC spent in single support was significantly 
shorter in CSM than in HC participants at matched speed, confirming the analysis at 
comfortable speed that people with CSM lacked either stability in stance or the propulsive 
power to initiate swing (Kirtley, 2006).  
Analysis of kinematics and kinetics further highlighted the differences between groups. 
Motion at the pelvis and hip were similar at matched speed, however peak power 
generation at the hip in loading response, H1, and peak hip extensor moment at loading 
response, were higher in the CSM group. A pathological increase in H1 power can 
compensate for a disruption of forward progression during stance (Kirtley, 2006).  
The HC group demonstrated greater peaks of ankle dorsiflexion during stance, ankle 
plantarflexion at toe-off and AP GRF at pre swing, as well as higher knee flexion in swing. 
These findings indicated an impairment of the CSM participants’ ability to 1) control 
forward progression and generate propulsion through initial lengthening of the Achilles 
tendon in dorsiflexion, and 2) release that energy through ankle plantarflexion at pre 
swing (Kirtley, 2006). This was not just a consequence of slower gait speed. The finding 
of reduced knee flexion in swing was also consistent with impaired swing initiation caused 
by inadequate propulsion (Gage, 1991). The combination of reduced ankle plantarflexion 
at pre swing and reduced knee flexion in swing has previously been reported in the 
paretic limbs of people with stroke (Chen et al., 2005) and with traumatic central cord 
syndrome (Gil-Agudo et al., 2009). Anecdotally, people with CSM commonly cite toe 
catching as a cause of falls. This could be related to reduced knee flexion in swing 
because this variable is a key component in ensuring adequate foot clearance (Gage et 
al., 1995).  
The condition of matched speed aimed to control for the association of many kinematic 
and kinetic variables with gait speed, however it had the disadvantage of imposing an 
unfamiliar locomotor pattern on one set of participants. Individual preference for a 
particular gait speed occurs close to the speed at which energy consumption per unit 
distance is minimised, allowing the locomotor system to take advantage of the passive 
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mechanical properties of the lower limb in the absorption and generation of power 
(Jordan et al., 2007). The strategies used by the HCs in the current study to achieve 
slower speeds did not reflect the natural preferences of their neuromusculoskeletal 
systems. The deliberate enforcement of a reduced speed may have had confounding 
effects on the kinematic and kinetic patterns of the HCs because they may have adopted 
alternative and unfamiliar strategies to impede the generation of their natural momentum. 
Some evidence of this was noted in the EMG analysis. 
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Further insight into the muscular activation patterns that produced the observed 
kinematics and kinetics was gleaned from EMG analysis of four lower limb muscles. 
There were key differences between HC and CSM participants in the timing of muscle 
activation. In CSM, the duration of activation of RF, BF and TA was prolonged by around 
10% GC duration. The increases in duration of RF and BF activation were associated 
with an increase in their co-activation of more than 5% GC duration, with HCs showing 
BF–RF co-activation of 9.3% GC duration and CSM participants, 14.4% GC duration. The 
timing of muscle activation in HCs was relatively robust to changes in speed. Total 
activation duration varied for each muscle by around 1–2% GC duration, even though gait 
speed varied by a significantly greater amount under the comfortable and matched speed 
conditions. This provided further evidence that the timing of activation in CSM was a 
feature of abnormal neuromuscular control, and not a consequence of slower gait speed. 
This was the first study to quantify timing abnormalities in gait in CSM. 
Co-activation occurs during normal movement and may improve movement efficiency 
during performance of lower limb activities by providing increased joint stabilisation 
(Busse et al., 2006). However, a point is reached when increased co-activation will 
excessively stiffen a joint and impair its movement (Damiano, 1993). Prolonged duration 
of muscle activation and excessive co-activation have been attributed to an inability to 
voluntarily activate intended muscles due to impaired corticospinal function and defective 
motor commands (Shiavi et al., 1987). This interpretation suggests that timing 
abnormalities are a direct consequence of the CNS lesion.  
In contrast, recent research has provided evidence for prolonged activation and co-
activation as adaptive compensatory strategies. In one study of people with orthopaedic 
problems, prolonged duration of muscle activity during gait was found in 66% of the lower 
limbs studied (Brunner and Romkes, 2008). This finding was attributed to the need to 
compensate for weakness. The patterns of prolonged muscle activation were similar to 
those reported in neurological disorders, such as CP. This led to the hypothesis that 
people with neurological disorders essentially used the same adaptive strategies for 
muscle weakness as people without neurological dysfunction, and that weakness was the 
primary impairment underlying the timing abnormalities (Brunner and Romkes, 2008). A 
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finding of particular interest to the current study was that co-activation between 
hamstrings and quadriceps was the second most common timing abnormality noted in 
people with orthopaedic conditions, present in 17% of the lower limbs studied. This was 
attributed to the need for increased proximal stabilisation during stance. It is possible that 
people with CSM used this co-activation strategy for similar reasons. The most common 
timing abnormality in the orthopaedic population was prolonged duration of MG 
activation, but this was not observed in the current study. 
Further evidence of co-activation as an adapative strategy was found in a study of gait 
following stroke. People with stroke had less co-activation during gait on the paretic side, 
but greater co-activation on the non-paretic side, compared to HCs (Lamontagne et al., 
2000b). There was little evidence to suggest that increased co-activation on the non-
paretic side resulted from ipsilaterally mediated effects of the CNS lesion. Rather, it was 
considered more likely that this was an adaptive behaviour by the non-paretic limb to help 
maintain postural stability, particularly in the double support phases of gait when it was 
assisting the paretic limb in the support function (Lamontagne et al., 2000b). This 
provided further evidence for the hypothesis that co-activation and prolonged timing of 
muscle activation are compensatory mechanisms, rather than primary consequences of 
the CNS injury.  
Comparison between the findings of the current study and other studies was limited by 
the differences in the methods used to determine the timing of muscle activation. Brunner 
and Romkes (2008) used semi-quantitative visual analysis. This facilitated assessment of 
subtle changes in the signal, but may have led to greater variation in the results than if a 
computerised algorithm had been used. Lamontagne et al. (2001) used an amplitude 
threshold of 20 microvolts (!V) to designate activation, however this method may have 
been confounded by the higher baseline activity of people with neurological impairment 
(Roetenberg et al., 2003). Future studies could address this problem by consistently 
applying a validated timing detection method, such as the DTM method of the current 
study. 
In addition to the timing of activation of a particular muscle, a measure of its intensity was 
also required. The intensity of muscle activation over the GC was indicated by the mean 
amplitudes of bursts of activity and inactivity, normalised to the maximum amplitude 
obtained during the GC in that session. The BF activity burst in stance was of higher 
normalised mean amplitude in HC at comfortable speed than in CSM, but this difference 
did not occur at matched speed. Other muscle activity bursts showed no difference 
between pairs. In contrast, the mean baseline amplitudes of BF and RF were significantly 
higher in CSM than in HCs at both comfortable and matched speeds.  
Normalisation of a muscle’s EMG amplitude to the peak amplitude from the GC posed 
some difficulty in the interpretation of the results. Lower peak amplitude would over-
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emphasise the amplitude at other phases of the GC. This meant that the higher amplitude 
of the inactive phases could have been caused by an inability to scale down the intensity 
of a muscle’s output when its activation was not required, or by an inability to increase the 
intensity during periods when activation was required. The use of a gait-based 
normalisation reference may have diluted the variability between participants, as there 
was no way to know whether each individual’s peak amplitude was high or low compared 
to normal. 
Some authors have reported the absolute value of the amplitude at specific phases of the 
GC in V, and have found significant differences in burst amplitudes of people with 
neurological gait impairment compared to HCs (Lamontagne et al., 2002). However, there 
are difficulties with this approach. The absolute value of the EMG signal amplitude can be 
affected by intrinsic participant characteristics, such as subcutaneous fat thickness 
(Lehman and McGill, 1999), as well as extrinsic factors such as heat, humidity, and the 
location of the electrode over the muscle (Hogrel, 2005). Although muscle morphology in 
CSM has not been studied with reference to atrophy or soft tissue infiltration, in the 
current study it was subjectively more difficult to palpate the lower limb muscles of CSM 
compared to HC participants during the placement of electrodes described in Chapter 6, 
Section 6.6.3. The muscles of HCs tended to be more prominent, and identification of the 
optimum location for electrode placement was therefore easier. If the absolute amplitude 
of the EMG signal had been studied, it would not be possible to know whether a reduced 
amplitude in CSM were due to inability to generate a signal of higher intensity, or whether 
the signal had been attenuated by a higher ratio of non-contractile soft tissue to muscle 
tissue.  
In the absence of clear indication of the intensity of muscle activation, some authors 
suggested that the ratio of the mean amplitude of bursts of activity to baseline activity 
provided a relevant indication of the motor control capacities of the patient (Roetenberg et 
al., 2003). Compared to HCs at both matched and comfortable speed, the higher mean 
amplitude of BF and RF of CSM participants during the “off” phases suggested that these 
muscles were less efficient at scaling their intensity appropriately. Unfortunately, the 
limitations of the amplitude normalisation method prevented any further interpretation of 
whether this were due to higher baseline signal, reduced peak output, or a combination of 
both. 
Abnormal timing and amplitude parameters appeared to affect the proximal lower limb 
muscles of RF and BF, with less effect on MG and TA. This was in keeping with the 
findings of other studies on the manifestation of motor problems following incomplete 
SCI. In a study of 27 people with incomplete SCI, including six with CSM, timing of 
activation and accuracy of movement of dorsi- and plantarflexors were relatively 
unaffected compared to a comparison group of people with stroke, even though the peak 
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torques of these muscles were similarly reduced in both groups (van Hedel et al., 2010). 
Similar findings were shown using smaller sample sizes of the same populations by 
(Wirth et al., 2008). Van Hedel’s study evaluated a task involving the application of 
dorsiflexor and plantarflexor torque to move a visual target. The findings from the current 
study suggested that the timing of activation of MG and co-activation between TA and 
MG were relatively preserved during gait in CSM. The scaling of motor output by MG and 
TA, as measured by the mean amplitude during and outside their key bursts, was 
comparable to that of HCs. 
It was of interest that timing and amplitude abnormalities appeared to affect the muscles 
of the thigh, while most kinematic and kinetic differences between CSM and HC 
participants occurred at the knee and ankle. This may be explained by the need for 
greater proximal co-activaiton and activation duration to stabilise the lower limb due to a 
loss of distal power absorption and generation capability. Prolonged activation of BF may, 
for example, have produced the higher hip extensor moment and H1 power at loading 
response. As discussed in Section 8.5.1.2, increased H1 is a compensatory strategy to 
facilitate forward translation of the trunk over the supporting limb where the contralateral 
pre swing phase has failed to generate adequate propulsion (Kirtley, 2006).  
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EMG analysis then progressed to the interpretation of the LSMS, which described a 
muscle’s response to lengthening during the GC. Hyperexcitability of the stretch reflex is 
just one component of the abnormal muscle activity observed in spasticity, and is 
associated with both an increase in the gain of the stretch reflex and a reduction in the 
stretch receptors’ threshold for activation (Pandyan et al., 2005). If stretch reflex 
hyperexcitability contributed to the abnormal muscle activity observed in CSM, it would be 
expected that 1) EMG activity would occur at a lower lengthening velocity in CSM than in 
HC, indicating reduced stretch receptor threshold, and 2) a given lengthening velocity 
would elicit a greater efferent response in EMG activity, indicating increased reflex gain.   
At comfortable speed, CSM participants showed a trend of lower LVTs for all muscles 
with the exception of MG. Differences were significant only for TA during the terminal 
stance phase of gait, where TA activity was initiated during at a lengthening velocity of 
just over 1 l0/s compared to the HC threshold of 1.7 l0/s. The incidence and frequency of 
positive slopes of TA were also significantly higher in CSM than in HC participants. This 
confirmed that the TA showed earlier activation during lengthening, indicating higher 
sensitivity of the stretch reflex, and greater EMG activity as lengthening velocity 
increased, indicating an increase in the gain of the stretch reflex compared to HCs. It is 
possible that this activation of TA impeded the progression of the ankle into plantarflexion 
and contributed to the limitation of the A2 power burst, two findings that were noted in the 
analysis of kinematics and kinetics compared to HC at comfortable speed.  
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It was previously suggested that the slope of the relationship between normalised EMG 
amplitude and lengthening velocity determined whether the response to lengthening was 
normal, indicated by a negative slope, or pathological, indicated by a positive slope. This 
was shown to have discriminative validity in stroke when compared to data from HCs 
(Lamontagne et al., 2001). However, the current study found that the dominant slope 
direction was positive in a number of HCs, indicating that slope direction alone did not 
distinguish between pathological and non-pathological responses to lengthening. In the 
case of MG, a positive slope was the dominant direction in both HC and CSM 
participants. The reasons for this may lie in the nature of the eccentric contraction to be 
studied. In the evaluation of spasticity, the question is whether muscle activation allows 
normal physiological lengthening to take place in a controlled manner, or whether the 
activation, through premature timing or excessive amplitude, impedes joint movement 
and thus interferes with the tasks of the GC. It has been proven that the H reflex, a 
measure of the excitability of the monosynaptic stretch reflex, increases towards the end 
of stance, allowing the stretch reflex to assist in the push-off phase of gait (Capaday and 
Stein, 1987). The dominance of positive slopes in MG in HCs suggested that, rather than 
being an abnormal response, it was normal for EMG activity to increase during this 
lengthening phase in the GC. This reinforced the fact that the monosynaptic stretch reflex 
was more excitable at the end of stance. In contrast, the dominant slope direction for TA, 
BF and RF was negative in HCs, indicating that a normal gait allowed some yield to occur 
during lengthening before muscle activity was initiated to control or halt this movement. 
The current study therefore provided no evidence for hyperexcitability of the stretch reflex 
of MG as a factor in the abnormal gait of CSM. 
Analysis of the LSMS at matched speed yielded largely similar findings for TA, RF and 
MG responses to lengthening, although the difference in LVT of TA did not reach 
statistical significance, as it had done at comfortable speed. An unexpected finding was 
the reversal of the expected relationship in BF LVT at terminal swing, which was 
significantly lower in HCs than their CSM counterparts. As HCs by definition had no 
neurological impairment, this lower LVT could not be due to spasticity. This highlighted a 
limitation of LVT as an indicator of spasticity during locomotion at an imposed speed. LVT 
measured the velocity at which a muscle activated to control its lengthening by initiating 
an eccentric contraction, but it did not give an indication of whether this activation was 
due to a reduction in the threshold of the stretch receptors, or a voluntary activation. In 
response to the imposition of the unnaturally slow gait required by the matched speed 
condition, it was likely that HCs were consciously trying to slow the advancement of the 
tibia to increase their stride time, reduce cadence and ensure that the slower speed was 
achieved. They may have activated their hamstring muscles deliberately at a lower than 
normal lengthening velocity to impair the progression of the swing phase, thereby 
delaying initial contact and lowering cadence.  
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In addition to the lack of distinction of voluntary versus reflexive activation on lengthening, 
the LSMS was considered to have a further limitation. Calculations of muscle lengthening 
by this method did not discriminate between lengthening of the muscle belly and 
lengthening of its tendon, but instead they were analysed as one unit. Studies using 
ultrasound technology revealed key differences in the behaviour of muscles and tendons 
in response to lengthening. In healthy children, lengthening of the gastrocnemius–soleus 
complex was characterised by near-isometric muscle contraction and passive stretching 
of the Achilles tendon by up to 7 mm, followed by an elastic recoil of the tendon at push-
off to contribute to the A2 power generation peak (Fukunaga et al., 2001). Prior to the 
publication of Fukunaga’s findings, it was thought that gastrocnemius contracted 
eccentrically, not isometrically, during the mid stance phase of gait. However, it is not 
known whether this relationship holds true in children or adults with neurological 
dysfunction. It has been hypothesised that children with CP may have insufficient ability 
to control lengthening with an isometric contraction, and this may force their 
gastrocnemius muscles to act eccentrically (Shortland, 2011).  
The objective of the LSMS in the current study was to examine the lower limb muscles for 
evidence of hyperexcitability of the stretch reflex as a manifestation of spasticity during 
gait. It was beyond the scope of the study to examine relative lengthening of the various 
components of the musculotendinous units. The lack of distinction between lengthening 
of muscle versus tendon is acknowledged as a limitation. Nonetheless, the LSMS 
provided quantitative data on the responses of a muscle when a lengthening force was 
imposed on it, even if it did not identify the structures that actually lengthened, or whether 
the associated contraction was reflexive or voluntary. The evaluation of spasticity during 
gait is a complex task, and the method used in this study was the best available at the 
time of study design. Its specificity to gait and avoidance of the need for unnatural stimuli 
were considered advantages to this method (Lamontagne et al., 2001).  
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Principal components analysis (PCA) was performed on the pooled TSP, kinematic and 
kinetic parameters of the CSM and HC participants to explore the data, identify its 
dominant variability, and reduce its dimensionality into smaller numbers of principal 
component variables (PCs). This approach has been used successfully in CP, resulting in 
the classification of gait patterns that were broadly consistent with those identified by 
observation (Carriero et al., 2009). In the current study, three dominant PCs were 
extracted from the pooled data. In keeping with the findings of Carriero et al. (2009), the 
first PC, accounting for 42.9% of the total variability of the data, was a function of gait 
speed, sagittal plane kinematics and the absorptive and propulsive powers associated 
with speed. This suggested that PC1 represented the ability of the locomotor system to 
generate momentum. CSM participants tended to score below zero on this PC, while HC 
participants scored above zero. This was not surprising, given the slower gait speed of 
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CSM participants and their lower scores on many of the variables contributing to PC1. 
PCA did not determine whether the lower peak powers and sagittal plane motion were 
the cause or the result of the slower gait speed, however it provided support to the 
findings that the generation of momentum was a deficiency in the CSM gait. 
The second PC included variables that were associated with the single support phase of 
gait. Interpretation of these as a group suggested that PC2 represented stability in single 
leg stance. Earlier analysis of TSPs had shown that CSM participants spent a shorter 
proportion of the GC in single support compared to HCs at both matched and comfortable 
speed. It was not clear from kinematics and kinetics whether this was due to lack of 
stability in single leg stance, or to reduced generation of momentum at toe-off affecting 
the duration of swing and consequently the contralateral single support phase. Visual 
interpretation of PC2 suggested that there were differences between HC and CSM pairs 
in stability in single leg stance, but that these differences were not as pronounced as 
those of PC1. The lack of clear differences suggested that, although stability in single leg 
stance was somewhat impaired in CSM and contributed to the relationship between 
single and double support duration, it was not the key factor in this relationship.  
The inclusion of EMG variables in the PCA data set resulted in higher overall variability in 
the data. This was reflected by the reduction in the overall percentage of variability 
accounted for by each PC. The first two PCs retained their overall profile of contributing 
variables and showed consistency in scores of CSM and HC participants with the first 
PCA. PC3 showed a greater change in its contributing variables and its overall scores 
when EMG data were included. This rendered it more difficult to interpret the aspect of 
gait that it represented. In relation to PC1 and PC2, the scores were much more stable, 
allowing some insight to be gleaned into the aspects of EMG that influence these PCs. 
The momentum generation represented by PC1 was negatively influenced by duration of 
BF activation and RF–BF co-activation. However, these variables did not achieve the 
weighting threshold to contribute significantly to that PC. In contrast, the stability 
component PC2 was positively influenced by both of these variables, as well as by the 
duration of RF activation and its amplitude during its stance phase burst. These findings 
could reflect the contribution of prolonged duration of muscle activation, particularly of BF 
and RF, to the task of stability in stance. To date, no studies could be found that included 
both 3DGA and EMG data in a PCA for gait analysis, so it is not known whether the EMG 
variables would contribute to the PCs in this way in other populations. 
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In an UMNL, impaired movement is not merely the direct consequence of a central lesion, 
as evidenced by defective programming and reflex function. It also reflects the secondary 
compensatory processes induced by the primary lesion (Dietz, 2002). It is known that an 
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UMNL leads to an increase in the excitability of the short latency monosynaptic reflexes, 
a decrease in the functionally more important long latency reflexes, and a decrease in 
supraspinal drive. These neurophysiological changes are expressed during movement by 
a lack of force generating capability (paresis), abnormal muscle tone, and reduced 
proprioceptive input to the lower limb muscles (Dietz, 2002, Dietz, 2003). The locomotor 
system then adopts a movement pattern that best preserves the ability to ambulate under 
the constraints imposed by these impairments, and that represents the best integration 
between the biomechanical system and the control properties of the CNS (Taga, 1995). 
The challenge for the current study was to evaluate the influences of these 
neuromuscular and biomechanical interactions, and to determine the primary and 
secondary compensatory mechanisms underlying gait impairment in CSM.   
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In a physical examination, a finding of spasticity is one of a cluster of signs that can 
indicate the presence of an upper motor neurone lesion and eventually lead to a 
diagnosis of myelopathy (Baron and Young, 2007). The characteristic gait of CSM has 
been described in observational gait analysis as a “spastic pattern” (Suzuki et al., 2002). 
However, in relation to neurological disorders in general, Pandyan et al. (2005) noted that 
there was insufficient evidence in the literature to support the hypothesis that the 
abnormal muscle activity observed in people with spastic movement disorders resulted 
from stretch reflex hyperexcitability. 
The current study did not find strong evidence of stretch reflex hyperexcitability as a 
contributing factor to gait impairment in CSM. There was some indication of velocity-
related sensitivity to lengthening in TA from its lower LVT during terminal stance and pre 
swing, and its higher percentage of positive slopes. Abnormal activation of TA at this 
point could have contributed to the reductions in peak ankle plantarflexion and the A2 
power, thereby impairing propulsion and leading to the observed shortened step and 
stride lengths and shortened swing phase duration. It was noted that TA LVT did not 
feature as a contributing variable to any of the first three PCs, meaning that it probably 
had little influence on the tasks of momentum generation and stability in stance. It is also 
unlikely that it contributed to the prolonged duration of activation of TA that was 
determined in the analysis of timing, as the lower LVT did not cause the TA to activate 
earlier in the GC in CSM. 
Evidence of spasticity of the plantarflexor muscles has been found in gait in other 
neurological conditions (Crenna, 1998, Lamontagne et al., 2001). The current study found 
evidence of neither hyperexcitability of the MG stretch reflex nor premature activation of 
MG during stance. LVTs for activation were similar between HC and CSM participants. 
The incidence and frequency of positive slopes were also similar. Previous studies have 
shown that the presence of excessive EMG activity during passive lengthening of a 
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muscle in stroke was not associated with excessive activity during lengthening under 
dynamic conditions (Ada et al., 1998). The current study did not examine the EMG 
responses to passive lengthening in the CSM cohort, however the finding of a lack of MG 
spasticity during gait were similar to those of Ada et al. (1998), but in contrast to those of 
Lamontagne et al. (2001), both studies in stroke. 
Similarly, there was no conclusive evidence of spasticity in RF and BF muscles. Both 
muscles showed prolonged duration of activation, excessive co-activation and 
excessively high EMG amplitude outside of bursts of muscle activity, compared to HCs. 
The phenomenon of “sustained involuntary activation of muscles”, such as might be 
indicated by excessive activation duration or co-activation, was included in the revised 
definition of spasticity by the SPASM consortium (Pandyan et al., 2005). This finding 
could reflect spasticity in the CSM cohort, but this assumption is confounded by the 
identification of similar activation patterns in people without neurological disorders 
(Brunner and Romkes, 2008).  
In summary, the current study identified limited evidence of hyperexcitability of the stretch 
reflex of TA only, not of the other muscles, as a possible limiting factor to the generation 
of push-off at the pre swing phase of gait. It was not clear whether the abnormal timing of 
muscle activation or sustained activation outside of functional bursts of activity were due 
to primary manifestations of spasticity as defined by Pandyan et al. (2005), or whether 
they were compensatory mechanisms. However again, these findings must be 
considered within the limitations of the LSMS outlined in Section 8.5.1.4, and within the 
lack of clear consensus on the manifestation of spasticity during gait.  
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The definition of spasticity of Pandyan et al. (2005) included the signs and symptoms of 
the positive features of an UMNL, but excluded the negative features. These include 
paresis, defined as a lack of force-producing capability, and lack of dexterity, defined as a 
reduced ability to accurately activate selected muscle groups within the available strength 
range (Pandyan et al., 2005, van Hedel et al., 2010).  
The evidence for paresis as a factor in gait impairment in CSM was more compelling than 
that of spasticity. There were significant differences in several peak kinetic and kinematic 
parameters, particularly at the knee and ankle, suggesting an inability to generate and co-
ordinate sufficient muscular force to walk at a speed typical of people of similar age and 
gender. Compared to HCs at matched speed, CSM participants showed reductions in 
peak ankle plantarflexion, the acceleration component of AP GRF, and peak knee flexion 
in swing, three variables that are associated with the generation of propulsive power. 
These findings indicated that CSM participants had difficulty in generating momentum at 
this critical phase of the GC, and that the lack of momentum was not simply due to a 
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slower gait speed. Furthermore, at matched speed, CSM participants showed an 
increase in the first hip power peak at H1, a known compensatory strategy for loss of 
forward progression during stance (Kirtley, 2006). The principal component PC1 was a 
function of progression and generation of momentum, and showed the largest difference 
between CSM and HC participants of the three PCs.   
Evidence from EMG analysis also supported the hypothesis that paresis was a factor. 
Mean normalised EMG amplitudes outside the key bursts of activity of RF, BF, and, at 
comfortable speed, TA, were abnormally high. This may have been due to excessive 
background activity or to lower peak activation intensity, or both. Although the exact 
nature of this relationship could not be determined, it pointed to an impairment of the 
motor control capabilities of the CSM participants (Roetenberg et al., 2003).  
Differences in the timing of muscle activation were more conclusive than analysis of 
amplitude, as the TKEO-based DTM routine had shown high validity and reliability. The 
increases in BF and RF duration of activation and in their co-activation were of sufficient 
magnitude to be of clinical interest. Their persistence at matched speed suggested that 
these findings were important features of the control of ambulation in CSM and not just 
the result of a slower gait speed. Co-activation of proximal musculature during gait is a 
known compensatory strategy for muscle weakness in people with orthopaedic problems 
(Brunner and Romkes, 2008) and for contralateral lower limb paresis (Lamontagne et al., 
2000b) and may have been used as a similar compensatory strategy here.  
In summary, there was strong evidence for paresis as a primary contributory factor to gait 
impairment in CSM. This was evidenced by reduced ability to generate power, reduced 
scaling of motor output in the accomplishment of the tasks of the GC, and the need for 
co-activation to enhance stability and compensate for weakness. 
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Complex movements are programmed by the CNS and adapted by proprioceptive 
feedback (Dietz, 2002). Impairment of one aspect of proprioception has been shown in 
previous studies of people with CSM using joint position sense of the knee as an 
outcome measure (Takayama et al., 2005b, Okuda et al., 2006). The single support 
phase provides the greatest proprioceptive challenge to the locomotor system during gait. 
Parameters related to single leg stance have been used as measures of stability in stroke 
(Lamontagne et al., 2002). However, the single support phase also depends on the ability 
of the stance leg to generate sufficient muscle power (Anderson and Pandy, 2003), as 
well as its ability to receive proprioceptive input and adjust the alignment of the body 
accordingly. It is therefore not possible to separate the various influences of paresis and 
proprioception in the single support phase of gait.      
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Whether the reduction in single support duration in CSM was due to a lack of power or a 
lack of proprioceptive input was unclear. Riley et al. (1990) hypothesised that it is during 
the double support phase that the CNS integrates the afferent signals of proprioceptive 
input and relays the information to the neuromuscular system to make the required 
postural adjustments and produce the intended movement. Lack of proprioceptive input 
at this point would require more time to co-ordinate the postural adjustments needed to 
initiate forward progression of the centre of mass and change from bipedal to unilateral 
stance (Buckley et al., 2005). It is possible that the decrease in single support and 
associated increase in double support duration reflected a lack of reliable proprioceptive 
input during stance.  
In addition to single leg support, instability during walking is primarily assessed by key 
parameters in the medio-lateral direction (Judge et al., 1996a). People with CSM tended 
to have a slightly higher step width and medio-lateral GRF, but these differences did not 
reach statistical significance. There was therefore no clear evidence of impaired medio-
lateral stability in CSM. However, some studies have not found step width to be an 
indicator of impaired balance (Krebs et al., 2002, Moe-Nilssen and Helbostad, 2005). 
Further studies are needed to determine indicators of reduced stability in CSM, as the 
lack of difference in step width cannot rule out an instability component in this population. 
The second PC was a function of stability in single leg stance. Its scores were more 
variable among CSM participants, who tended towards positive scores while HCs had a 
mean negative score. Other studies using PCA have dichotomised their populations in 
sub-groups based on whether the scores on a PC variable were above or below zero. 
The scores of the PCs on the pooled data of all participants are centred on a zero mean, 
and therefore the sign of the score could be considered to reflect distinct sub-groupings 
(Gaudreault et al., 2011). It is possible that the difference in sign of the mean PC2 score 
of CSM and HC participants reflected fundamental differences in the stability in single leg 
stance of both groups, however the magnitude of the difference was small compared to 
that of PC1.  
It was also possible that the deficiencies in the generation of momentum and propulsion 
at terminal stance and pre swing were not just related to paresis, but were also a 
compensatory strategy for loss of proprioceptive input. The CSM participants may have 
decreased the time spent in the unstable situation of single leg support by using less 
muscle force to avoid the generation of momentum and base of support excursions 
associated with propulsion, in an effort to protect the locomotor system from these 
proprioceptive challenges.  
The current study was limited in its ability to evaluate instability during gait. It examined 
gait in CSM participants at comfortable speed only. The locomotor systems were not 
challenged by faster gait speeds, or other tasks such as obstacle avoidance or tandem 
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walking. These conditions would have allowed further discrimination of the ability of 
people with CSM to control their centre of mass in more challenging conditions (Schrager 
et al., 2008). Furthermore, evaluation of stride-to-stride variability, an independent 
predictor of falls in the elderly (Hausdorff et al., 2001, Maki and McIlroy, 2006), may also 
have provided further information on instability. However, the aim of this study centred on 
the evaluation of habitual gait patterns in CSM. Many participants were challenged by 
normal locomotion at comfortable speed, and did not have the capacity to increase their 
speed further or achieve tasks such as tandem walking.  
!">% H*45-?/1*4%%%%%%%
This chapter has presented and discussed the findings of gait impairment in CSM 
compared to HCs at comfortable and matched gait speeds. Key biomechanical and 
neuromuscular changes in the CSM gait were identified, and their significance as primary 
impairments or compensatory strategies was evaluated. This information has provided a 
profile of gait impairment in CSM and highlighted key deficits that contributed to this 
impairment.  
The next chapter will evaluate the ability of the CNS in CSM to recover its locomotor 
ability following surgical decompression of the spinal cord.  
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Surgery is widely used as a treatment for CSM, particularly in people whose symptoms 
show neurological progression over time. The aim of surgical intervention is to stabilise 
the disease by minimising spinal cord compression at the spondylotic levels, thereby 
preventing further neurological deterioration (Rao et al., 2006). However, surgery itself 
carries numerous risks including vertebral artery injuries, damage to neural structures, 
and instrumentation failure (Rao et al., 2006). For many people with CSM, the decision to 
undergo surgery can be a difficult one. The lack of anticipated improvement in symptoms 
and the risk of adverse events must be weighed against the possibility of further 
irreversible neurological deterioration if the cord is not decompressed. 
Gait impairment is one of the cardinal symptoms of CSM. General measures of gait 
performance, such as speed and the ability to mobilise with or without an aid, are often 
used as general indicators of CSM severity. There is some evidence from follow-up 
studies that temporal-spatial and kinematic variables can improve after surgery (Kuhtz-
Buschbeck et al., 1999, Maezawa et al., 2001). The clinical significance of these 
improvements is not known. A more detailed examination of gait before and after surgical 
intervention is required to assess the true potential for recovery, as well as the clinical 
significance of that recovery. This would provide further information to surgeons and 
patients on the expected outcomes of surgery, and contribute to the expanding base of 
knowledge on the potential for changes in gait following spinal cord injury. 
The aim of this study was to determine changes in temporal-spatial, kinematic, kinetic, 
and EMG variables in gait in people with CSM at six months and one year following 
surgery. The study was also concerned with the following secondary objectives: 1) to 
determine if an association existed between measures of gait impairment and severity of 
CSM, 2) to compare functional mobility in people with CSM to measures of gait 
impairment, and 3) to determine the impact of gait impairment on HRQOL. 
M"$% ;'0L*@/%
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Participants with CSM were recruited from the neurosurgical spinal assessment clinic at 
Beaumont Hospital over a two-year period from December 2008 to December 2010. The 
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procedures used for the diagnosis of CSM and the inclusion and exclusion criteria for the 
study were described in Chapter 6, Section 6.3. 
M"$"$% D,0,%5*--'501*4%
Participants attended the Movement Laboratory, RCSI, for assessment on three 
occasions, once before surgery, and twice after surgery at six and twelve months post-
operatively. Gait analysis was conducted using 3DGA and EMG as described in Chapter 
6, Section 6.6. Secondary outcome measures of CSM severity, spasticity, functional 
mobility and HRQOL were examined, using to the procedures described in Chapter 6, 
Section 6.5. 
3DGA and EMG data were processed as described in Chapter 6, Section 6.7. Ten gait 
trials were extracted from each assessment to create a representative average.  
M"$"2% I0,01/015,-%,4,-8/1/%%
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The literature review in Chapter 3 found that gait speed was the most commonly used 
outcome measure for gait in CSM. Reports have considered the minimal clinically 
important difference in gait speed to be 0.1 m/s, and although this is not specific to CSM, 
it shows a good correlation with the ability to carry out functional activities of daily living 
(Judge et al., 1996b). A power calculation based on a paired t-test found that a sample 
size of 13 participants would have 90% power at the 5% significant level to detect a 
change in gait speed of 0.1 m/s from pre- to post-operative assessment, with a SD of the 
difference of 0.11 m/s. The power calculation was conducted in Stata. 
Q"$"E"$& AH2(,>0151&,01,5;6&
Univariate analysis was conducted on individual clinically meaningful gait parameters, 
comprising the key points, ranges and EMG parameters previously selected and outlined 
in Chapter 6, Sections 6.7.2 and 6.7.4. A number of considerations were made in relation 
to the optimal method to test the pre- and post-operative individual parameters for 
statistically significant changes post surgery. Data from two follow-up assessments at six 
and twelve months following surgery were available. Analysis of the differences between 
mean scores at three time points would normally require a repeated measures analysis of 
variance (ANOVA). There were a number of difficulties with the application of this test to 
the current study. A repeated measures ANOVA assumes the property of sphericity, 
namely that the variance in the difference in scores between two time points is the same 
as the variance between two other time points (Park et al., 2009). It was expected that 
this assumption would not be satisfied by the small sample size of the current study, 
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particularly as one set of time points, baseline to six month follow-up, included surgical 
intervention, whereas the second time points, six and 12-month follow-up, had no 
intervention. Analysis of the differences in mean scores at multiple time points was further 
complicated by the possibility that not all participants would attend a one-year follow-up 
by September 2011.  
In relation to the primary research question, the differences at individual time points were 
of less interest than the overall changes in gait, and the secondary outcome measures, 
over the entire follow-up period. To address this question, and to avoid the limitations of 
the repeated-measures ANOVA test, it was decided to conduct hypothesis testing on the 
differences between baseline scores and last follow-up, using paired t-tests. This would 
achieve the aim of identifying overall changes in gait following surgery. Descriptive and 
visual analysis of scores at six and twelve months would allow for interpretation of 
progress over the follow-up period. Prior to the application of a paired t-test, the 
assumption of normal distribution was verified for each variable using QQ plots and stem-
and-leaf plots in Stata. The Shapiro-Wilk test and tests of skewness and kurtosis were 
carried out as numerical tests of normal distribution. 
Secondary outcome measures of MRMI, MAS, mJOA and Nurick were non-parametric in 
nature. Changes in these scores from baseline to last follow-up were tested for 
significance using the Wilcoxon signed rank test. 
The null hypothesis of the current study could therefore be stated as follows: 1) the CSM 
cohort would not experience change in key gait parameters following surgery, and 2) no 
significant differences would be found from pre-operative assessment to latest post-
operative follow-up.   
Q"$"E"E& K(1,&>(B&B()2-+51(;&=5,>&>0-/,>H&B(;,+(/&3-,-&
If a significant change was found in a variable from pre- to post-operative assessment, 
post hoc comparison of the changed score with HC data was carried out. Two of the 13 
participants in the experimental study did not have a matched HC for reasons outlined in 
Chapter 8, Section 8.4.1. An independent t-test was therefore required to compare the 
groups, as they no longer represented matched pairs. To assess the impact of change of 
any variable post-operatively, its mean value from 16 HCs and 13 CSM participants post-
operatively were compared using an independent t-test, once the assumption of normal 
distribution was satisfied. The null hypothesis, that there would be no difference between 
the post-operative CSM cohort and HCs, was in this case considered a positive outcome. 
Q"$"E"#& K+5;B52-/&B()2(;0;,1&-;-/H151&(*&6-5,&3-,-&
PCA was conducted on the pooled 3DGA and EMG data of the CSM participants before 
and after surgery and the cohort of 16 HCs who participated in the cross-sectional study. 
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HCs were included to provide a normal reference. It was expected that the PCs extracted 
from this multivariate analysis would reflect those found in the cross-sectional study. Data 
were plotted and interpreted visually. The purpose of PCA was to assess the interaction 
between individual gait parameters and their contributions to the overall aspects of gait 
represented by the PCs. Differences in PCs themselves from pre- to post-surgery were 
not tested for statistical significance, because although the PCs gave an overall 
numerical impression of performance in an aspect of gait, it was not known whether 
changes in the contributing parameters represented improvement, deterioration, or 
compensation. Furthermore, the PC scores are dimensionless and have no clear 
interpretation in the clinical setting, and therefore tests of statistically significant change 
could not be interpreted for their clinical relevance.    
Q"$"E"I& K+035B,(+1&(*&(7,B()0&*(//(=5;6&17+60+H&*(+&'?@&
Three variables, age, symptom duration, and severity of symptoms at baseline, were 
considered possible predictors of outcome following surgery. Previous studies reported 
that older age and longer symptom duration were associated with poorer outcomes after 
surgery for CSM (Morio et al., 2001, Suri et al., 2003). The severity of symptoms at 
baseline did not show significant correlation with post-operative recovery in previous 
studies (Morio et al., 2001), however many studies analysed the mJOA score as a 
parametric test using percentage recovery rates as the primary outcome measure 
(Hirabayashi et al., 1981), rather than using gait data. The effect of these possible 
predictor variables on gait data was not known prior to the current study. Severity of 
symptoms at baseline was measured using the pre-operative mJOA score and pre-
operative gait speed. 
These three predictor variables were examined for correlation with post-operative change 
in gait speed as the response variable. Pearson’s correlation coefficient was used to 
examine correlation between age and symptom duration and the independent variable of 
change in gait speed, while Spearman’s correlation coefficient was used for the non-
parametric mJOA score. If a significant correlation was found to exist, the variables, with 
the exception of the non-parametric variable mJOA, were entered into a linear regression 
model to determine whether a dependency existed between the two variables. The 
dependency was quantified using hypothesis tests of the significance of the regression 
coefficient R2, and by calculating its confidence interval. 
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The participants identified in the cross-sectional study were also eligible to participate in 
the experimental study, as the same inclusion and exclusion criteria applied. As 
previously described in Chapter 8, Section 8.4.1, there were 44 people who met the 
inclusion criteria over the 24-month recruitment period. Fifteen were excluded for reasons 
previously described in Chapter 8, Section 8.4.1, and a further ten declined to participate. 
The remaining 19 participated in the study. One participant was diagnosed with a co-
existing neurological disorder after the first assessment, and his data were therefore 
excluded as the neurological disorder may have confounded the gait data. Five 
participants did not undergo surgery within the time frame of the thesis, which required 
that surgery take place before March 2011 to ensure a six-month follow-up prior to 
September 2011. Their pre-operative baseline data were included in the cross-sectional 
study. The experimental study therefore includes the data of the 13 participants who 
underwent surgery between December 2008 and March 2011. Eleven had also 
participated in the cross-sectional study and eight had participated in the reliability study. 
The flow chart in Figure 9.1 illustrates the recruitment process and participation of the 
CSM cohort in the three studies. 
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One participant of the cohort of 13 was unable to attend for six-month follow-up 
assessment, but attended the 12-month assessment as scheduled. Three participants 
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attended follow-up at six months but were unavailable to attend at 12 months. Last post-
operative follow-up therefore took place at six months for three participants and at 12 
months for 10 participants. 
The protocol aimed to schedule the pre-operative assessment as close as possible to the 
date of surgery, however a number of difficulties arose with this. Many participants 
received less than 24 hours’ notice of their admission. Several planned admissions were 
cancelled due to lack of availability of beds, theatre time, or the emergency admission of 
other patients. It was therefore not possible to know the date of surgery in advance with 
certainty. The mean time from pre-operative assessment to surgery was 2.2 months 
(range, 0–4.9 months).  
Q"E"%"E& '>-+-B,0+51,5B1&(*&2-+,5B52-;,1&
The characteristics of the 13 participants are detailed in Table 9.1. The mean age was 
56.6 years (range, 34–77 years). Participants reported a history of myelopathic symptoms 
for a mean of 59 months (range, 9–420 months). The median Nurick score was 3 (range, 
1–4), median mJOA score, 10 (range, 8–13), and median MRMI score, 39 (range, 34–
40). Two participants had a history of lower limb osteoarthritis, and three had a history of 
low back pain, however these problems were not acutely symptomatic and therefore did 
not preclude participation in the study. Two participants had non-insulin dependent 
diabetes mellitus with no history of associated lower limb neuropathy. One participant had 
a history of myocardial infarction, treated at the time with angiographic stenting, and had 
no persistent cardiac symptoms or signs since that event.  
M"2"$% I?+=15,-%140'+P'401*4%
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The most commonly involved cervical levels were C3/4, C4/5 and C5/6. Eleven 
participants underwent surgery at one or more of these levels (85%). One participant had 
additional involvement of C6/7, and one participant had compression of the spinal cord at 
C0/1 and C1/2. Seven participants underwent surgery via an anterior approach, involving 
an anterior cervical discectomy and fusion (ACDF) in six cases and an anterior cervical 
corpectomy and fusion (ACCF) in one case. The remaining six participants had a 
posterior approach, three of which involved laminectomy and lateral mass plating (LLMP), 
one, a decompression and lateral mass screws, and two, an occipital-cervical fusion. 
Q"E"$"$& K(1,D(20+-,5:0&B()2/5B-,5(;1&-;3&-3:0+10&0:0;,1&
Three participants of the cohort of 13 (23%) suffered adverse events relating to their 
CSM. One participant sustained a fractured neck of femur following a fall. This was 
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reduced and fixed with a hemiarthroplasty. Surgery to the cervical spine followed three 
weeks later.  
Two participants (15%) suffered post-operative complications, one involving wound 
infection at the surgical site and subsequent sepsis, and the other involving 
instrumentation failure. In both cases, the instrumentation was removed and the cervical 
spine stabilised in a halo ring and brace. The second participant then underwent a repeat 
fusion following the removal of the halo brace. Follow-up for this participant was 
scheduled from the date of this repeat surgery, rather than from the date of the original 
surgery. The first participant achieved adequate decompression from the halo brace and 
did not require further surgery, and therefore no adjustments to follow-up dates were 
required in this case.  
Q"E"$"E& K>H15(,>0+-2H&5;,0+:0;,5(;&*(//(=5;6&17+60+H&
One participant (8%) had no physiotherapy intervention following surgery. Three 
participants (23%) were assessed by a physiotherapist during their in-patient stay in the 
days immediately following surgery and given general post-operative advice, but received 
no further out-patient follow-up. The remaining nine participants (69%) had multiple 
sessions of outpatient or domiciliary physiotherapy following surgery. 
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Case Age Duration of 
symptoms 
(months) 
PMH Nurick mJOA MRMI Surgical 
Approach 
Level Procedure Complications 
02 67 12 OA hip & knee 3 8 34 Anterior C4/5, C5/6 C5 ACCF Fracture NOF 
03 57 12 Lumbar discectomy, 
OA knee 
3 11 38 Anterior C4/5, C5/6 ACDF  
05 34 24 Nil 2 10 40 Anterior C4/5, C5/6 ACDF  
07 45 60 Nil 3 12 39 Posterior C0/1, C1/2 OCF Instrumentation 
failure * ** 
08 62 36 LBP 3 9 39 Anterior C4/5, C5/6 ACDF  
12 50 48 Nil 2 10 40 Anterior C3/4, C4/5, 
C5/6 
ACDF  
13 73 420 Angina 3 12 38 Posterior C3/4, C4/5, 
C5/6 
LLMP  
14 51 60 MI & angioplasty, 
NIDDM 
4 10 35 Posterior C3/4, C4/5, 
C5/6, C6/7 
LLMP Infection * 
15 72 10 Nil 2 10 40 Posterior C3/4 LLMP  
16 47 48 LBP 1 13 40 Anterior C4/5, C5/6 ACDF  
18 47 12 GORD 3 11 39 Posterior C3/4, C4/5, 
C5/6 
Lateral mass screws, 
decompression 
 
20 54 18 NIDDM 3 10 39 Anterior C5/6 ACDF  
21 77 9 Nil 3 12 39 Posterior C1/2 OCF  
PMH = past medical history, mJOA = Japanese Orthopaedic Association score, MRMI = Modified Rivermead Mobility Index, OA = osteoarthritis, LBP = low back 
pain, MI = myocardial infarction, NIDDM = non insulin dependent diabetes mellitus, GORD = gastro-oesophageal reflux disorder, ACCF = anterior cervical 
corpectomy & fusion, ACDF = anterior cervical discectomy & fusion, OCF = occipital-cervical fusion, LLMP = laminectomy & lateral mass plating, NOF = neck of 
femur 
* removal of instrumentation and fusion with halo brace, ** re-do of surgery and replacement of instrumentation following removal of halo brace 
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Standard verbal questions were used to assess each participant’s subjective impression 
of their gait pattern and general symptoms following surgery. At last post-operative follow-
up, eight participants (62%) stated that their gait had improved, while three (23%) 
reported deterioration. Two participants (15%) reported no change. When asked about 
symptoms in general, excluding gait, nine (69%) reported that they had generally 
improved, while one (8%) noted an overall deterioration. Two participants (15%) reported 
no change.  
Six participants (46%) reported a history of at least one fall in the six months prior to the 
pre-operative assessment. All pre-operative falls were reported to be as a result of 
unsteady gait and mobility impairment, rather than adverse environmental circumstances. 
Following surgery, two participants (15%) had sustained a fall by their last follow-up, 
however in both cases, the participants felt that the falls were unrelated to their CSM gait 
impairment, as one (a previous faller) had slipped on ice and the other (no history of pre-
operative falls) had tripped on an unexpected obstacle. Results are depicted in Figure 
9.2. 
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Results of the secondary outcome measures are shown in Table 9.2.  
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Scale Pre-op 6 months post-op 
12 months 
post-op 
Last follow-
up 
p 
value 
mJOA 10 (8–13) 13.5 (8–17) 14 (10–17) 14 (10–17) 0.005 
Nurick 3 (1–4) 2 (0–4) 1.5 (0–4) 2 (0–4) 0.009 
MRMI 39 (34–40) 40 (35–40) 40 (36–40) 40 (35–40) 0.03 
SF36       
Physical 
functioning 
40 (10–
80) 60 (15–90) 65 (25–90) 60 (15–90) 0.009 
Physical role 
functioning 50 (0–75) 50 (0–93.75) 53.13 (13–94) 
56.25 (12.5–
93.75) 0.06 
Bodily pain 32.5 (0–100) 
67.5 (22.5–
100) 
46.25 (10–
100) 65 (10–100) 0.02 
General health 50 (20–95) 55 (15–85) 65 (20–80) 65 (20–85) 0.06 
Vitality 50 (19–94) 
56.25 (6.25–
81.25) 50 (19–81) 
56.25 (6.25–
81.25) 0.57 
Social functioning 50 (0–100) 62.5 (0–100) 43.75 (38–88) 50 (0–100) 0.61 
Emotional role 
functioning 
66.7 (0–
100) 75 (0–100) 79.2 (25–100) 92 (25–100) 0.07 
Mental health 65 (50–90) 75 (30–100) 67.5 (35–90) 75 (35–90) 0.16 
Health transition 25 (0–50) 75 (25–100) 50 (25–100) 75 (25–100) 0.004 
mJOA = Japanese Orthopaedic Association score, MRMI = Modified Rivermead Mobility Index, 
SF36 = RAND Medical Outcomes Study 36-Item Short Form Health Survey 
()E)F)G' ,&1&%"09'35'?9&632;0=9'
Figure 9.3 shows mJOA and Nurick scores before, six months and twelve months 
following surgery. MJOA scores improved from a median of 10 before surgery to a 
median of 13.5 at six months and 14 at 12 months following surgery. Of the ten 
participants who attended 12-month follow-up, two were unchanged, one had 
deteriorated, and the remaining seven had improved. Six-month follow-up of the other 
three participants found one unchanged and two improved. The median Nurick score was 
3 before surgery, 2 at six months and 1.5 at 12 months. Six participants had no change in 
Nurick score and seven showed an improvement at their latest follow-up. 
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* denotes statistically significant difference between pre- and post-operative scores (Wilcoxon 
signed rank test) 
 
When last follow-up scores were pooled as post-operative scores, the Wilcoxon signed 
rank test showed a statistically significant improvement in mJOA scores (p = 0.005) and 
in Nurick scores (p = 0.009) following surgery. 
()E)F)*' !$8/0"38;6'?3-"6"09'
Functional mobility was assessed using the MRMI. A significant ceiling effect was noted 
with this outcome measure. At pre-operative assessment, four of 13 participants scored 
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the maximum score of 40, while at post-operative assessment, eight of 13 participants 
reached the maximum score. The median MRMI score was 39 (range, 34–40) pre-
operatively and 40 (range, 35–40) post-operatively. The Wilcoxon signed rank test found 
this change to be statistically significant (p = 0.03), but it did not exceed the minimal 
detectable change of the MRMI of four points (Lennon and Johnson, 2000).  
()E)F)E' M&;60=B%&6;0&>'N$;6"09'35'6"5&'
HRQOL was assessed using the SF36. The nine domain scales of physical functioning, 
physical role functioning, bodily pain, general health, vitality, social functioning, emotional 
role functioning, mental health and health transition were compared separately from pre- 
to post-operative assessment using a Wilcoxon signed rank test. There were statistically 
significant improvements in physical functioning, bodily pain and health transition. No 
significant changes occurred in the other domains, although physical role functioning, 
emotional role functioning and general health showed trends of improvement. 
()E)F)F' O&40"8#'?$4/6&'038&'
Tone in the lower limb muscles of RF, BF, TA and MG was assessed using the Modified 
Ashworth Scale (MAS). The numbers of participants scoring at each point on the MAS 
before and after surgery are depicted in Figure 9.4. Post-operative MAS scores of RF 
were lower, depicting lower resting tone, in three participants, while one participant’s 
score increased. Two participants had a lower score of BF after surgery, while one had a 
higher score. TA scores increased post-operatively in one participant. Finally, in MG, 
post-operative MAS scores were lower in five participants and higher in two participants. 
A Wilcoxon signed rank test found no difference in MAS scores of RF (p = 0.34), BF (p = 
0.6), TA (p = 0.3) or MG (p = 0.27), from pre- to post-operative assessment.  
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Columns show the number of participants who scored at each point on the Modified Ashworth 
Scale before and after surgery 
See Chapter 5, Table 5.5 for an explanation of the tone depicted by each score 
!"#"=$ >4,+$454791,1$
()E)P)G' C&?23%;6B42;0";6'2;%;?&0&%4'
Individual participant trends in gait speed, cadence, double support duration, single 
support duration, stride length and step width are shown in Figure 9.5. 
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?380=';8>'G*B?380=';44&44?&80'
Gait speed increased from a mean of 1.05 m/s pre-operatively to 1.08 m/s at last post-
operative assessment. This was not statistically significant (p = 0.62). There were no 
changes in stride length (mean difference, 0.02 m, p = 0.57), cadence (mean difference, 
1.1 steps per minute, p = 0.83) or single support as a percentage of GC duration (mean 
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difference, 0.2% GC duration, p = 0.82). No differences were found in the individual 
timing of the events of opposite foot off, opposite foot contact or foot off, or in step width. 
The results are summarised in Table 9.3. 
C;-6&'()E+'@=;8#&4'"8'0&?23%;6B42;0";6'2;%;?&0&%4'536637"8#'4$%#&%9'
Pre Op Post Op Difference Variable 
Mean SD Mean SD Mean SD 
95% 
Confidence 
Intervals 
p 
value 
Gait speed 
(m/s) 1.05 0.32 1.08 0.37 -0.03 0.20 
-
0.15 0.09 0.62 
Cadence 
(steps / min) 110.30 12.44 111.37 14.87 -1.06 17.96 
-
11.9 9.79 0.83 
Stride length 
(m) 1.12 0.26 1.14 0.31 -0.02 0.11 
-
0.09 0.05 0.57 
Double 
support 
duration (% 
GC) 
27.99 6.90 28.72 8.93 -0.72 4.88 * * *0.75 
Single 
support 
duration (% 
GC) 
35.89 2.82 35.68 4.46 0.22 3.27 -1.76 2.19 0.82 
Opposite foot 
off (% GC) 13.38 2.78 13.79 3.88 -0.41 2.83 
-
2.12 1.30 0.61 
Opposite foot 
contact (% 
GC) 
49.27 1.31 49.48 1.38 -0.21 1.25 -0.96 0.55 0.56 
Foot off (% 
GC) 63.87 4.57 64.39 4.66 -0.52 2.20 
-
1.85 0.81 0.41 
Step width 
(m) 0.16 0.04 0.17 0.05 -0.01 0.02 
-
0.02 0.01 0.26 
SD = standard deviation, m = metres, s = seconds, min = minute, GC = gait cycle 
* denotes non-normally distributed variable tested with Wilcoxon signed rank test 
()E)P)*' R"8&?;0"/'2;%;?&0&%4'
Figure 9.6 shows kinematics of the pelvis, hip, knee and ankle over the GC at pre-
operative, six-month and 12-month assessments.  
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;8>'G*B?380=';44&44?&804'
Ant = anterior, Int = internal, Ex = external, Flex = flexion, Ext = extension, Abd = abduction, Add = 
adduction, Dorsi = dorsiflexion, Plantar = plantarflexion 
Dashed grey lines show one standard deviation of HC data 
The graphs indicate a small decrease in pelvic tilt, an increase in peak hip extension, and 
an increase in peak knee flexion in swing. Results of the analysis of pre- to post-operative 
assessments are provided in Table 9.4. Paired t tests found no significant differences in 
the kinematic key points tested.  
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Pre Op Post Op Difference Variable 
Mean SD Mean SD Mean SD 
95% 
Confidence 
Intervals 
p 
value 
Pelvic 
obliquity 
range 
6.17 3.49 6.84 3.04 -0.67 2.11 -1.95 0.60 0.27 
Average 
pelvic tilt 8.76 5.43 8.10 6.48 0.67 4.79 -2.23 3.56 0.63 
Peak hip 
extension -12.24 7.10 -13.10 7.34 0.85 5.68 -2.58 4.29 0.6 
Hip total 
sagittal plane 
excursion 
42.46 7.62 42.52 8.03 -0.07 5.48 -3.38 3.24 0.97 
Hip 
abduction 
adduction 
range 
12.00 3.47 11.07 4.07 0.93 3.00 -0.88 2.74 0.29 
Peak knee 
flexion in 
stance 
14.82 5.83 16.20 6.27 -1.39 1.28 -4.17 1.40 0.3 
Peak knee 
flexion in 
swing 
47.80 1.73 50.07 2.21 -2.26 1.40 -5.32 0.79 0.13 
Knee total 
sagittal plane 
excursion 
49.59 8.67 50.37 8.94 -0.79 3.49 -2.89 1.32 0.43 
Peak ankle 
dorsiflexion 
in stance 
15.08 2.73 15.79 2.53 -0.71 2.54 13.42 16.73 0.33 
Peak ankle 
dorsiflexion 
in swing 
8.31 6.14 10.34 4.41 -2.03 5.16 -5.15 1.08 0.18 
Peak ankle 
plantarflexion -10.50 7.36 -9.86 5.25 -0.64 4.37 -3.28 2.00 0.61 
Means, standard deviations (SD) and confidence intervals are reported in degrees  
()E)P)E' R"8&0"/'2;%;?&0&%4'
Figure 9.7 shows GRFs and joint moments at the hip, knee and ankle at the three time 
points. Figure 9.8 shows the joint powers. The graphs indicated some increases in hip, 
knee and ankle powers, particularly in the terminal stance and pre swing phases of gait, 
from pre- to post-operative assessment. Increases were noted in peak knee extensor 
moment during loading response and in its corresponding power, K1. 
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?380='2340B32&%;0"1&';44&44?&804'
N/kg = Newtons per kilogram, Nm/kg = Newton metres per kilogram, Lat = lateral, Med = medial, 
Ext = extensor, Flex = Flexor 
Dashed grey lines show one standard deviation of HC data 
Arrows indicate statistically significant differences between CSM participants at pre-operative and 
last post-operative assessment  
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!"#$%&'()V+'H3"80'237&%4'31&%'0=&'#;"0'/9/6&';0'2%&B32&%;0"1&:'4"QB?380=';8>'G*B?380='
2340B32&%;0"1&';44&44?&804'
Gen = generation, Abs = absorption, W/kg = Watts per kilogram 
Arrows indicate statistically significant differences between CSM participants at pre-operative and 
last post-operative assessment 
Dashed grey lines show one standard deviation of HC data 
 
Paired t tests comparing pre-operative with last post-operative assessments found a 
significant increase in ankle A2 power at pre-swing from 2.63 W/kg before surgery to 3.18 
W/kg after surgery (p = 0.03). There was also a statistically significant increase in the 
magnitude of the knee K4 power at terminal swing from 0.66 W/kg at pre-operative 
assessment to 1.08 W/kg post-operatively (p = 0.01). Knee power in initial swing, K3, 
increased from 0.69 W/kg pre-surgery to 0.93 W/kg after surgery, but this did not reach 
statistical significance at the two-tailed level (p = 0.099). Similarly, hip H3 power at pre-
swing increased from 0.89 W/kg to 1.24 W/kg, again without reaching statistical 
significance (p = 0.098).  
Peak hip extensor moments increased from 0.72 Nm/kg to 0.81 Nm/kg, but this was not 
significant (p = 0.15). There were no differences in peak hip abductor (p = 0.82) or peak 
knee extensor moments (p = 0.32). Peak ankle plantarflexor moment did not satisfy the 
assumption of a normal distribution, and was tested with a Wilcoxon signed rank test. 
This showed towards higher peak plantarflexor moments in the post-operative 
assessment (1.34 Nm/kg pre-operatively, 1.44 Nm/kg post-operatively, p = 0.05), and the 
difference of 0.1 Nm/kg exceeded the SEM of this variable of 53 Nmm/kg (0.053 Nm/kg). 
 
231 
The acceleration component of AP GRF increased from 1.48 N/kg to 1.57 N/kg at post-
operative assessment, but this was not significant (p = 0.28). Results are shown in Table 
9.5. 
C;-6&'()P+'R"8&0"/'L&9'23"804'-&53%&';8>';50&%'4$%#&%9'
Pre Op Post Op Difference Variable 
Mean SD Mean SD Mean SD 
95% 
Confidence 
Intervals 
p value 
Vertical GRF, 
peak 1 10.50 0.82 10.83 0.78 -0.33 0.87 * * * 0.07 
Antero-
posterior GRF, 
acceleration 
-1.48 0.62 -1.57 0.67 0.09 0.28 -0.08 0.26 0.29 
Peak hip 
extensor 
moment 
0.72 0.24 0.81 0.24 -0.09 0.21 -0.21 0.04 0.15 
Peak hip 
abductor 
moment 
0.85 0.17 0.86 0.28 -0.01 0.22 -0.15 0.12 0.82 
Peak knee 
extensor 
moment 
0.27 0.19 0.32 0.22 -0.05 0.17 -0.16 0.06 0.32 
Peak ankle 
plantarflexor 
moment 
1.34 0.28 1.44 0.36 -0.10 0.23 * * * 0.05 
Hip power 
generation, H1 0.48 0.26 0.42 0.34 0.06 0.20 -0.06 0.18 0.29 
Hip power 
absorption, H2 -0.56 0.32 -0.63 0.32 0.07 0.32 -0.12 0.27 0.44 
Hip power 
generation, H3 0.89 0.48 1.24 0.95 -0.35 0.70 -0.77 0.08 0.099 
Knee power 
absorption, K1 -0.69 0.95 -0.93 1.11 0.24 0.57 -0.10 0.59 0.15 
Knee power 
absorption, K3 -0.61 0.43 -0.91 0.77 0.31 0.62 -0.07 0.68 0.098 
Knee power 
absorption, K4 -0.66 0.28 -1.08 0.55 0.42 0.52 0.10 0.73 0.01 
Ankle power 
generation, A2 2.63 1.58 3.18 1.61 -0.55 0.80 -1.04 -0.07 0.03 
The symbol * denotes a non-normally distributed variable with p value calculated using Wilcoxon 
signed rank test 
Ground reaction forces (GRF) are reported in Newtons per kilogram, moments in Newton metres 
per kilogram, and powers in Watts per kilogram 
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Figure 9.9 shows the total duration of muscle activation during the GC at pre-operative, 
six-month and 12-month assessments. Table 9.6 shows the results of statistical analysis 
from pre-operative assessment to last follow-up. The duration of activation of TA 
increased from 37% GC duration pre-operatively to 41.7% post-operatively (p = 0.02). 
There was a non-significant decrease in RF activation duration from 34% to 30% GC 
duration at post-operative assessment, however this was associated with a large 
dispersion (SD, 18% GC duration) and did not reach statistical significance (p = 0.46). No 
other changes in the activation duration of individual muscles were noted. There was a 
0.9% GC duration decrease in BF–RF co-activation following surgery, and a 1.9% 
increase in TA–MG co-activation, however these changes were not significant. Figure 
9.10 shows representative pre-operative and post-operative EMG signals from an 
individual participant, with the timing parameters highlighted.  
C;-6&'()S+'W$%;0"38'35'?$4/6&';/0"1;0"38';8>'/3B;/0"1;0"38'-&53%&';8>';50&%'4$%#&%9'
Pre Op Post Op Difference Muscle 
Mean SD Mean SD Mean SD 
95% 
confidence 
intervals 
p 
value 
Rectus 
femoris 33.97 19.11 29.99 16.14 3.97 18.63 
-
7.28 15.23 0.46 
Biceps 
femoris 32.15 11.97 31.81 10.13 0.34 13.77 
-
7.98 8.66 0.93 
Tibialis 
anterior 36.99 11.16 41.67 10.83 -4.68 6.46 
-
8.58 -0.78 0.02 
Medial 
gastrocne-
mius 
26.90 10.83 28.30 6.09 -1.40 7.42 -5.89 3.08 0.51 
RF / BF co-
activation 13.64 8.69 12.71 10.90 0.93 8.99 
-
4.50 6.36 0.72 
TA / MG co-
activation 3.97 3.79 5.83 5.65 -1.85 5.00 * * *0.22 
* denotes variable tested with non-parametric Wilcoxon signed rank test 
Duration of activation is expressed as a percentage of gait cycle duration 
RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius 
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Signals were treated with a Butterworth filter to remove motion artefact 
RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius 
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The EMG amplitudes of key bursts of muscle activity during the GC before and after 
surgery are shown in Figures 9.11 and 9.12. Pre- and last post-operative comparisons 
are detailed in Table 9.7. There were no significant changes after surgery. In the cross-
sectional study, RF and BF baseline activity was shown to be higher in CSM than in HCs. 
The amplitude of RF baseline activity reduced from 18.2% to 17.2% GC duration, and BF 
reduced from 16.8% to 15.2% GC duration, however these were not statistically 
significant (p = 0.5 and p = 0.24, respectively).  
C;-6&'()T+'J?26"0$>&'35'?$4/6&';/0"1"09'-$%404'>$%"8#'0=&'#;"0'/9/6&'-&53%&';8>';50&%'
4$%#&%9'
Pre Op Post Op Difference Muscle 
Burst 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
p 
value 
RF loading 
response  56.40 8.87 56.31 11.87 0.09 7.67 -4.55 4.72 0.97 
RF pre 
swing 52.10 11.88 44.79 13.67 7.31 14.99 -2.22 16.83 0.12 
RF swing 17.46 12.59 21.31 9.06 -3.85 11.60 -10.86 3.16 0.25 
RF baseline 18.18 6.64 17.03 4.83 1.15 6.01 -2.48 4.79 0.5 
BF stance 43.76 9.22 45.21 8.26 -1.46 10.77 -7.97 5.05 0.64 
BF swing 46.13 10.12 44.39 16.87 1.74 19.30 -9.92 13.40 0.75 
BF baseline 16.81 3.95 15.17 3.93 1.64 4.82 -1.28 4.55 0.24 
TA stance 55.46 8.89 55.01 9.33 0.45 4.30 -2.15 3.05 0.71 
TA swing 48.73 8.50 48.99 4.69 -0.26 7.15 -4.58 4.07 0.9 
TA baseline 15.42 4.28 16.84 3.57 -1.41 3.69 -3.64 0.82 0.19 
MG stance 59.19 4.39 57.27 4.90 1.92 6.87 -2.23 6.07 0.33 
MG baseline 12.40 3.77 11.93 3.71 0.47 3.90 -1.88 2.83 0.67 
Amplitude of each muscle is expressed as a percentage of its peak root-mean-square (RMS) 
amplitude during gait 
RF = rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius, SD = 
standard deviation  
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Amplitude is expressed as a percentage of maximum root-mean-square (RMS) amplitude obtained 
during 10 gait trials of each session 
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Amplitude is expressed as a percentage of maximum root-mean-square (RMS) amplitude obtained 
during 10 gait trials of each session 
 
()E)S)E' [3/3?303%B42&/"5"/'?&;4$%&'35'42;40"/"09'
Table 9.8 shows the lengthening velocity threshold (LVT) and time of onset of EMG 
activity during lengthening, critical time (tC), of the four lower limb muscles during gait 
before and after surgery. There was a significant increase in LVT of RF from 2.74 lo/s to 
3.2 lo/s after surgery (p = 0.02), indicating a reduction in velocity-related sensitivity to 
lengthening. There were no significant changes in the LVT or tC of the remaining 
muscles.  
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Pre Op Post Op Difference Measure 
Mean SD Mean SD Mean SD 
Confidence 
Interval 
p 
value 
RF LVT (lo/s) 2.74 1.12 3.20 1.21 -0.46 0.61 -0.83 -0.09 0.02 
RT tc (% GC) 83.55 8.03 85.51 6.20 -1.96 7.51 -6.50 2.57 0.36 
BF LVT (lo/s) 1.43 0.44 1.31 0.48 0.12 0.40 -0.12 0.37 0.3 
BF tc (% GC) 78.79 5.83 78.68 6.16 0.11 4.27 -2.46 2.69 0.92 
TA LVT (lo/s) 1.16 0.73 1.13 0.68 0.03 0.28 -0.14 0.20 0.72 
TA tc (% GC) 57.33 7.50 57.19 5.63 0.14 3.89 -2.21 2.49 0.9 
MG LVT (lo/s) 0.63 0.62 0.59 0.83 0.03 0.93 * * * 0.81 
MG tc (% GC) 20.11 12.39 18.78 10.43 1.33 15.47 -8.02 10.67 0.76 
LVT = lengthening velocity threshold, normalised lengths per second = l0/s, GC = gait cycle, RF = 
rectus femoris, BF = biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius 
 
Data on the direction of the slope of lengthening velocity versus EMG amplitude are 
shown in Figure 9.13. The dominant direction of the slope over ten trials from each 
participant was analysed. There was a slight reduction in the number of participants with 
dominant positive slopes of TA and MG post-operatively, and a slight increase in 
dominant positive slopes of RF. However, these resulted from changes in dominant slope 
direction for one (TA) and two (MG and RF) participants, and did not reach statistical 
significance on Fisher’s exact test. 
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Positive slopes suggest a velocity sensitive response to lengthening  
!"#"B$ C01+$30*$*0</4.,105$8,+3$3)47+39$*05+.071$
Comparison of 3DGA and EMG variables in participants with CSM before and after 
surgery showed statistically significant differences in five variables, peak ankle 
plantarflexor moment, A2 and K4 powers, duration of activation of TA, and LVT of RF. 
The post-operative measurements from these variables were compared to the HC cohort 
of the cross-sectional study. Results are shown in Table 9.9. There were statistically 
significant differences between the CSM participants post-operatively and the HCs in K4 
and A2 power and TA duration of activation. There were no significant differences 
between the groups with respect to RF LVT or peak ankle plantarflexor moment. K4 
power and peak ankle plantarflexor moment did not follow a normal distribution, and were 
tested using the non-parametric Mann Whitney U test. 
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CSM post op HC Difference 
Variable 
Mean SD Mean SD Mean 
Confidence 
interval 
p 
value 
Ankle 
plantarflexor 
moment (Nm/kg) 
1.44 0.36 1.6 0.12 0.16 * * *0.75 
K4 power (W/kg) -1.08 0.55 -1.56 0.63 -0.48 * * *0.025 
A2 power (W/kg) 3.18 1.61 4.85 1.19 1.67 0.60 2.74 0.003 
TA activation 
duration (% GC) 41.67 10.83 30.93 8.84 -10.74 -18.23 -3.3 0.007 
RF LVT (lo/s) 3.20 1.21 3.52 1.56 0.32 -0.76 1.40 0.55 
Nm/kg = Newton metres per kilogram, W/kg = Watts per kilogram, G = gait cycle, TA = tibialis 
anterior, RF = rectus femoris, LVT = lengthening velocity threshold, lo/s = relative lengths per 
second 
* denotes non normally distributed variable tested with Mann Whitney U test 
!"#"D$ C.,5*,/47$*0</05)5+1$454791,1$02$#E>F$45;$@A>$;4+4$
PCA was conducted on the pooled 3DGA and EMG data of the 13 participants pre- and 
post-surgery (last follow-up) and the 16 HCs from the cross-sectional study. The PCs 
extracted were similar to those of the cross-sectional study, with the first three PCs 
accounting for 33.5%, 6.9% and 6.6% of the variability in the data set, respectively. Table 
9.10 lists the 3DGA and EMG variables contributing to each PC and their weightings.  
Figure 9.14 shows the clustering of scores on PC1 and PC2 before and after surgery. 
Figure 9.15 shows box and whisker plots of each PC. The plot of PC1 indicated that post-
operative scores moved towards HC scores, although mean PC1 scores remained below 
zero. There was little change in PC2 and PC3 scores from pre- to post-operative 
assessments. 
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PC Score Positive Weight Negative Weight 
PC1 33.5% Gait speed 0.194 Antero-posterior GRF, acceleration*  -0.188 
  Step length 0.186 Double support, seconds -0.174 
  Stride length 0.186 Double support duration, % GC -0.171 
  Antero-posterior GRF, deceleration 0.176 Opposite foot off, % GC -0.164 
  Single support duration, % GC 0.173 Step time -0.159 
  Ankle power generation, A2 0.171 Foot off, % GC -0.158 
  Knee sagittal plane range 0.169 Stride time -0.157 
  Vertical GRF 0.161 Knee absorption power, K1* -0.151 
  Cadence 0.159    
  Hip sagittal plane range 0.158    
  Hip power generation, H3 0.156    
  Knee power generation, K2 0.156    
PC2 6.9% Hip position, initial contact 0.302 Ankle position, initial contact -0.218 
  Average pelvic tilt 0.295 Ankle plantarflexor moment -0.165 
  Hip rotation range 0.259    
  TA critical time 0.254    
  BF critical time 0.224    
  BF LVT 0.221    
  RF-BF co-activation duration 0.209    
  Pelvic rotation range 0.169    
  Hip power generation, H1 0.160   
  Hip sagittal plane range 0.158   
  Hip extension* 0.151   
PC3 6.6% BF critical time 0.250 RF pre-swing burst amplitude -0.256 
  Knee flexion, stance 0.243 MG LVT -0.215 
  RF swing burst amplitude 0.242 RF baseline amplitude -0.202 
  TA stance burst amplitude 0.222 TA duration -0.194 
  Hip power generation, H1 0.204 BF baseline amplitude -0.165 
  Knee extension* 0.197 TA baseline amplitude -0.164 
  Hip flexor moment* 0.163 BF duration -0.164 
  MG critical time 0.159     
  Opposite foot contact, % GC 0.153     
GRF = ground reaction force, GC = gait cycle, PC = principal component, RF = rectus femoris, BF 
= biceps femoris, TA = tibialis anterior, MG = medial gastrocnemius, LVT = lengthening velocity 
threshold 
Kinematic and kinetic variable names refer to peak values unless range or position is stated 
* denotes a variable with a negative sign by convention 
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PC = principal component, GRF = ground reaction force 
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Zero denotes the mean score of the pooled HC, CSM pre-operative, and CSM post-operative data 
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Scatter plots, shown in Figure 9.16, were generated to examine the relationship between 
post-operative change in gait speed and four potential predictors, age, symptom duration, 
baseline mJOA and baseline gait speed. The relationships were examined using tests of 
correlation. Pearson’s correlation coefficient found no statistically significant associations 
between age and change in gait speed (correlation coefficient R = 0.076, p = 0.8) or 
baseline gait speed and change in gait speed (R = –0.047, p = 0.88). Symptom duration 
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was not normally distributed and its relationship with change in gait speed was tested for 
significance using Spearman’s rho, as was the case for mJOA, an ordinal scale. 
Spearman’s rho found no correlation between baseline mJOA and change in speed (rho 
= 0.102, p = 0.74) or between symptom duration and change in gait speed (rho = –0.03, p 
= 0.92). These pairs of variables were not entered into a linear regression model to 
assess for dependency because they did not satisfy the assumption of a linear 
association between predictor and response variables. 
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Symptom duration is shown with the outlier at 420 months removed to illustrate the relationship 
between the variables at the lower end of the x-axis 
JOA = Japanese Orthopaedic Association score 
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As discussed in Section 9.3.1.5, three participants experienced adverse events resulting 
from either CSM itself or surgical treatment for it. One participant, case 02, sustained a 
fractured neck of femur as a result of a fall that occurred after her baseline assessment 
and three weeks before her planned surgery. She underwent a hemiarthroplasty and 
post-operative rehabilitation, and then had decompressive surgery to the cervical spine 
as planned. At six-month follow-up, she was mobilising independently. She reported no 
falls in the time since surgery, however her gait speed had decreased from 0.83 m/s to 
0.61 m/s. Her mJOA score increased from 8 to 14, showing an overall improvement in 
myelopathic symptoms. The same participant did not attend a one-year follow-up 
because she had sustained an injury to her ankle that significantly hindered mobilisation 
at that time.  
Another participant, case 07, suffered post-operative failure of her cervical 
instrumentation. She deteriorated medically and required intubation and mechanical 
ventilation in the intensive care unit. Following removal of instrumentation, her cervical 
spine was immobilised in a halo ring and vest for four months. She then underwent 
repeat occipital-cervical fusion five months after the first surgery. She was unavailable for 
follow-up at six months following that surgery, but returned at 12 months. Her gait speed 
decreased from 1.04 m/s pre-operatively to 0.61 m/s post-operatively, while mJOA score 
decreased from 13 to 12. 
The third participant, case 14, experienced a post-operative infection at the surgical site 
with progression to sepsis. He underwent removal of surgical instrumentation and 
multiple wound debridement procedures, and was subsequently immobilised in a halo 
vest and jacket. This was removed after 12 weeks and he had no further operative 
intervention after that event. At six-month follow-up, there was a decrease in gait speed 
from 0.53 m/s to 0.38 m/s, and a decrease in mJOA from 10 to 8. At 12-month follow-up, 
gait speed increased to 0.6 m/s, and mJOA returned to the baseline score of 10. He 
attended a rehabilitation centre for a four-week period of in-patient rehabilitation in the 
time between his six-month and twelve-month follow-up assessments. 
In total, three participants with adverse events experienced a mean decrease in gait 
speed of 0.19 m/s (SD, 0.25 m/s). The ten participants who did not experience 
complications showed a mean increase of 0.09 m/s (SD, 0.14 m/s). The differences were 
not tested for statistical significance due to the small number of participants with 
complications.  
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This was the first study to comprehensively evaluate gait in CSM before and after surgery 
using 3DGA and EMG technology. The aim of the study was to determine whether people 
with CSM experienced changes in gait following surgery. The first part of the discussion 
will be addressed under three clinical questions: 1) Did surgery stabilise the gait 
impairment? 2) Did gait improve following surgery? 3) If gait improved, was it comparable 
to normal healthy gait? The second part of the discussion will examine the implications of 
the findings for the management of CSM.  
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The aim of surgical decompression in CSM is to halt the progression of neurological 
deterioration by decompressing the spinal cord and stabilising the affected spondylotic 
cervical levels (Rao et al., 2006). Although there are no long-term prospective studies on 
the natural history of CSM, step-wise deterioration over time has been described in the 
literature (Clarke and Robinson, 1956). If the course of CSM is one of progressive 
neurological deterioration, then a lack of improvement in gait following surgery is not 
necessarily a negative outcome. Rather, a lack of deterioration implies that the goal of 
stabilisation of the deficit has been achieved. 
The results found no evidence of deterioration in gait following surgery over the three 
time points. Considering the cohort as a whole, there was a mean increase in gait speed 
of 0.03 m/s. This change was neither statistically nor clinically significant, but this small 
increase shows a trend contrary to what would be expected in a situation of worsening 
CSM. Similarly, other kinematic key points that had been different to HCs in the cross-
sectional study, such as hip total sagittal plane range, peak knee flexion in swing, peak 
ankle plantarflexion in stance, and range of pelvic obliquity, showed no significant change 
following surgery, indicating that the kinematics of the gait pattern were preserved. In 
relation to kinetics, any statistically significant changes were due to increases rather than 
decreases in peak values. There were no negative changes in kinetic key points or 
curves over the GC. EMG data were more difficult to interpret in the context of 
stabilisation of the gait impairment, as some changes may have been compensatory and 
there was no obvious direction of improvement or deterioration in timing and amplitude 
parameters. LVT did not significantly decrease, however, which suggests no increase in 
spasticity-related effects on gait.  
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In summary, it can be concluded that in this cohort of 13 participants, gait showed on 
average no deterioration in the six- to 12-month post-operative period.  
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The primary goal of surgery is to prevent deterioration in neurological function, however 
in some cases, a secondary goal may be to facilitate improvement (Rao et al., 2006). 
Statistical analysis of TSPs and kinematic key points revealed no differences in post-
operative scores. Visual inspection of the graphs did not reveal trends that may have 
been undetected due to lack of statistical power. In this respect, the time, distance and 
movement features that characterised the participants’ gait patterns did not improve. 
However, the kinetics and neuromuscular control that contributed to these gait patterns 
showed some post-operative changes. Power generation at the ankle in pre swing (A2), 
power absorption by the knee in terminal swing (K4), and peak ankle plantarflexor 
moment were significantly higher post-operatively. The H3 propulsive power of the hip at 
pre-swing and the knee absorption powers of K1 in loading response and K3 in terminal 
swing all showed mean post-operative increases that were of clinical interest and 
exceeded SEM, although they did not reach statistical significance. On the whole, these 
changes indicated that the locomotor system had become more adept at absorbing and 
generating power at the hip, knee and ankle at appropriate times during gait.  
EMG data on the neuromuscular control of force production yielded somewhat 
inconclusive results. The significant increase in the duration of activation of TA over the 
GC was unlikely to have produced the increased A2 power, as this is normally a function 
of the gastrocnemius–soleus complex. No changes in gastrocnemius function were noted 
in the EMG data, although these parameters had not differed from HCs at baseline. 
There was a statistically significant increase in the LVT of RF, indicating an improvement 
in the ability of that muscle to yield to stretch. This indicated reduced hyperexcitability of 
the stretch reflex and therefore reduced RF spasticity. This was not associated with a 
significant reduction in the duration of activation of RF. Similarly, peak knee flexion angle 
in swing, a parameter often impaired by spasticity of RF (Sutherland and Davids, 1993), 
was not different following surgery. In other words, if it was the case that RF was 
responding more appropriately to lengthening as the post-operative change in its LVT 
suggested, then this improvement was not reflected in the corresponding kinematics or in 
the duration of activation of RF over the GC. 
In summary, there was evidence of some improvement in kinetic data in the CSM cohort 
following surgery, however this did not result in measurable improvements in kinematics 
or TSPs. Participants appeared to be in better control of power absorption and 
generation, but did not use this control to increase the excursion of the lower limb joints in 
the sagittal plane and walk faster.  
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The next research question considered whether the improved kinetic and EMG 
parameters had returned to normal levels. Visual interpretation of the hip, knee and ankle 
powers and ankle plantarflexor moment over the GC indicated that the post-operative 
curves were closer to those of HCs. Two parameters that were significantly improved in 
CSM post-operatively, A2 and K4 peak powers, continued to show significant differences 
from HC data, while there were no differences in peak ankle plantarflexor moment 
between post-operative CSM data and HCs. 
Chapter 8, Section 8.4.5, reported that the pre-operative duration of activation of TA was 
significantly prolonged compared to HCs. Post-operatively, TA activation duration had 
further increased from 37% to 41.7% GC duration, compared to HC duration of 31%. This 
parameter was therefore more “abnormal” than it had been pre-operatively. The LVT of 
RF increased significantly following surgery, and its post-operative value was not 
significantly different to that of HCs. Interpretation of this change was hindered by the 
lack of significant difference between CSM participants and HCs pre-operatively, despite 
the large mean difference in scores at that time (HC 3.5 l0/s, CSM 2.8 l0/s pre-operatively, 
3.2 l0/s post-operatively). Analysis of the implications of these changes in EMG will be 
considered in Section 9.5.4. 
PCA allowed further exploration of the relationships between gait variables. The first PC, 
representing propulsion and momentum generation, showed clear differences between 
HC and CSM participants pre-operatively. Post-operatively, the mean score for the CSM 
cohort moved closer to that of HC participants, but differences remained in the clustering 
of the groups, as shown in Figures 9.14 and 9.15. In contrast, the CSM participants’ post-
operative score on PC2, representing aspects of stability in stance, showed a small 
decrease on the pre-operative scores. This change was in the opposite direction to HC 
data. PCA therefore indicated a change in momentum generation following surgery that 
brought CSM participants closer to their HC counterparts, but also indicated an opposite 
change in the aspects of stability in stance represented by PC2. 
In summary, there was little evidence that gait in CSM participants returned to normal 
following surgery. There was a trend of improvement towards normal values in kinetic 
variables, though significant differences between CSM and HCs remained. The first PC, 
reflecting propulsion and generation of momentum, followed this trend. For the most part, 
the features of the myelopathic gait that were identified in Chapter 8 were still present 
following surgery. 
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The current study found no significant change in gait speed in people with CSM after 
decompressive surgery. This finding is in contrast to previous reports. Post-operative 
increases in gait speed of 0.12 m/s (Singh and Crockard, 1999), 0.15 m/s (Kuhtz-
Buschbeck et al., 1999, Maezawa et al., 2001) and 0.19 m/s (Singh et al., 2009) have 
been reported, although one study of six participants found no significant change 
(Moorthy et al., 2005). Similarly, other studies found significant post-operative changes in 
kinematics. One reported a 5.6° increase in total sagittal plane excursion of the knee 
(Moorthy et al., 2005). A further study identified an 8° increase in peak hip flexion, a 4° 
increase in peak knee flexion in stance, and a 5° increase in peak ankle dorsiflexion in 
stance (Maezawa et al., 2001). None of these features were apparent from the data of 
the current study. The increase in speed in the cohort was just 0.03 m/s (95% CI from 
pre- to post-operative assessment, -0.15–0.09 m/s), and would not be considered to be of 
clinical importance.  
There is a possibility that the 0.03 m/s increase in speed could reflect the beginning of 
further increases after the twelfth post-operative month. Anecdotally, it has been reported 
that any neurological improvement following surgery for CSM could take up to 24 months 
to manifest. However, Singh et al. (2009) assessed performance on a 30m timed walk 
test at 6, 12, 24 and 36 months post-surgery in CSM, and found that most improvement 
in gait speed occurred in the first six months. This was supported by a recent prospective 
study, which found the greatest increase in Berg Balance Scale scores in the first six 
post-operative months (Furlan et al., 2011). It is worth noting that while Singh et al. 
(2009) found a significant increase in 30m timed walk scores from pre- to post-operative 
follow-up, their participants may have represented a more severely affected population. 
Their mean pre-operative gait speed was 0.56 m/s, in contrast to the current study, in 
which participants walked at a mean speed of 1.05 m/s before surgery.  
In relation to kinematics, non-significant increases were found in the current study in 
some parameters including peak knee flexion in swing, peak ankle dorsiflexion in swing, 
and peak hip extension. These were increases of 1–2° and did not exceed the SEM of 
those variables, suggesting that they were within the realm of measurement error. Even if 
one could be confident of exceeding measurement error, changes of this magnitude 
could not be considered of clinical importance. The lack of statistical significance of these 
findings was therefore considered to reflect the true state of the participants, and was not 
a type two statistical error. 
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The overall finding was that the temporal-spatial and kinematic features of gait in CSM 
were unchanged following surgery, but there were some changes in how these features 
were produced by kinetics and EMG. Significant increases in ankle power generation at 
pre-swing, knee power absorption in terminal swing, and peak ankle plantarflexor 
moment were found. A strong predictive relationship between peak powers and gait 
speed has been shown, with regression coefficients of above 0.8 for A2 and K4 (Lelas et 
al., 2003). In the current study, the mean increases of 0.55 W/kg in A2 and 0.42 W/kg in 
K4 did not significantly affect gait speed. This was a surprising finding. Winter (1983) 
reported that the A2 power at pre swing was responsible for generating around 30% of 
the total energy of the GC. The K4 power at terminal swing reflects the eccentric 
contraction of the hamstring muscles to control forward advancement of the swinging tibia 
and prevent abrupt hyperextension of the knee (Kirtley, 2006). It is clear that, in the post-
operative assessment, the stance leg underwent greater propulsion into swing by the 
ankle plantarflexors and the hamstrings then dampened this additional momentum in 
terminal swing. These changes were reflected in the increase in PC1 scores. However, it 
is not clear why the additional forward momentum created by these power peaks did not 
translate into faster gait speed or increased stride length. It was not the case that the 
greater propulsion in swing was offset by longer period in stance, as double support 
duration and cadence were unchanged.    
EMG identified a significant increase in the duration of activation of TA post-operatively. 
TA duration had already been abnormally prolonged at baseline compared to HCs. This 
further increase was a trend away from HC data. It is possible that this reflected 
neurological deterioration and further impaired selective control of muscle activation, 
however there was no other evidence of neurological deterioration in this cohort. That TA 
duration was even more prolonged following surgery, despite a trend to improvement of 
other gait parameters, suggested that it was a compensatory feature of gait in CSM. 
Visual analysis of individual TA signals showed that, across a number of signals, the 
additional duration of activation occurred mainly in stance. It may have reflected a 
strategy to improve control around the ankle during weight bearing, creating a more 
stable ankle joint and allowing the A2 power to be transmitted more effectively in 
propulsion. TA did not show increased co-activation with MG following surgery. Its 
additional activation therefore must have occurred during times when MG was not active. 
This supports the theory that its purpose was to create stability in loading response and 
mid stance. However, without EMG signals from other muscles acting about the ankle 
joint for stability, including peroneus longus and tibialis posterior, the exact function of this 
additional TA activation can only be speculated upon. Increases in the duration of muscle 
activity have been noted as compensatory strategies in the non-paretic lower limb after 
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stroke (Lamontagne et al., 2000b), and this finding suggests that similar strategies are 
possible in CSM. 
Changes in the effects of spasticity during the GC were assessed using the LSMS. RF 
did not show a significantly lower LVT compared to HCs pre-operatively, suggesting that 
it wasn’t impaired by spasticity, although the SD of the difference of 1.82 lo/s between HC 
and CSM pairs indicated a large dispersion in the scores. Following surgery, there was a 
significant increase in RF LVT, indicating less spasticity of RF post-operatively compared 
to the pre-operative assessment. It could be the case that this spasticity of RF had little 
effect on the kinematics of the gait pattern at baseline, and therefore a higher LVT was 
not reflected in the motion of the hip or knee. RF spasticity is usually associated with 
prolonged activation time (Sutherland and Davids, 1993). This was the case compared to 
HCs at baseline, and post-operatively, there was a mean decrease in RF activation 
duration of close to 4% GC duration. This was not statistically significant and did not 
exceed SEM, but could reflect a slight change in neuromuscular function that did not 
affect kinematics. 
The lack of quantitative change in TSPs and kinematics despite changes in other aspects 
of biomechanical and neuromuscular function, merits further discussion. The consistency 
of the kinematics of gait from pre- to post-operative assessment was not in keeping with 
the subjective finding that 62% of participants felt an improvement in their gait, the 
reduction in falls incidence from 46% in the pre-operative year to 15% in the post-
operative year, and the improvements in MRMI and SF36 physical functioning scores. An 
abnormal gait pattern in a person with neurological impairment reflects the direct 
consequences of the primary CNS lesion and the secondary compensatory processes 
that determine the optimal gait pattern for a given CNS lesion (Dietz, 2002). It could be 
the case that this gait pattern becomes embedded into the CNS, even if the 
biomechanical and neuromuscular factors contributing to this pattern have the potential to 
change their output. Similar findings have been reported in people with hip osteoarthritis, 
who have reported relief of pain and improved HRQOL following total hip arthroplasty, but 
without changes in gait kinematics and kinetics of either the affected or contralateral 
lower limb (Beaulieu et al., 2010). This lack of change in gait has been attributed to the 
preservation of the pain-avoidance strategies that characterised gait prior to joint 
replacement (Beaulieu et al., 2010). In the current study, it is possible that fear of falling 
or perceived lack of stability may have caused the CSM participants to retain a gait 
pattern characterised by slower gait speed with shorter stride lengths, less time in single 
support duration and smaller kinematic joint excursions. Their subjective improvement in 
gait could reflect that the kinetics and neuromuscular activity were more efficient, even if 
not more effective, at producing movement. Most people with CSM experience a 
neurological deficit for a number of months or, in some cases years, prior to operative 
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intervention, and this would allow time for the abnormal gait pattern to embed itself in the 
CNS.   
Another possibility is that the increases in powers in the current study were of insufficient 
magnitude to induce changes in kinematics. There may be a threshold beyond which A2 
and K4 must improve before they affect the kinematic and temporal-spatial output. This 
hypothesis would not be supported by previous studies of the dependency between 
powers and gait speed, which suggested a quadratic predictive relationship (Lelas et al., 
2003). However, the relationship between these variables has not been studied in gait in 
people with neurological disorders. Interestingly, even though these powers improved 
significantly in the CSM cohort following surgery, they still differed from HCs, albeit at a 
faster speed. This may indicate that they were a significant but insufficient improvement 
on the pre-operative assessment. The differences in gait in the cross-sectional study of 
people with CSM and HCs at matched speed, reported in Chapter 8, suggested that 
equal gait speeds do not result from equal kinematic and kinetic parameters when one 
cohort has a neurological impairment.  
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Although the current study evaluated gait before and after surgical intervention, it was 
observational in nature and did not set out to evaluate the effect of that intervention. 
Without an RCT and sufficient statistical power for two groups, it cannot be known 
whether the changes in gait resulted directly from surgery. However, from an 
observational viewpoint, the study shows with relative certainty that gait did not 
deteriorate over the 12-month (in three cases, six month) follow-up period, in contrast to 
the generally accepted trend of progressive deterioration in untreated CSM. In addition, 
there was a mean post-operative improvement in mJOA scores, improved subjective 
perception of gait, and a reduced incidence of falls in the cohort, suggesting that, if a 
change does occur, it tends to be in the positive direction. This is the first study to provide 
quantitative data on the biomechanical and neuromuscular changes in gait following 
surgery. This new information may assist surgeons in effectively counselling people with 
CSM who seek greater clarity on the balance of risks and benefits in advance of a 
decision to undergo surgical intervention. 
The issue of adverse events deserves further consideration. Three of the 13 participants 
experienced adverse events, representing 23% of the cohort. One of these adverse 
events, a fall leading to a fractured neck of femur and subsequent hemiarthroplasty, was 
not a direct result of surgery. Surgical complications occurred in two participants, 15% of 
the cohort. As might be expected, there was a general trend of poorer outcomes in those 
who experienced complications, but the number was too small for sub-group analysis. 
Furthermore, additional factors were likely to have impacted on these outcomes, 
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including the prolonged intensive care unit stays in two participants, and lengthy periods 
of time of immobility for all three participants that would have adversely affected gait, 
regardless of the neurological state. However, not all participants who experienced 
complications had an overall negative outcome. One improved his gait speed by 0.07 m/s 
at one-year follow-up compared to his pre-operative speed, despite initial deteriorations in 
his gait at six months. However, prospective surgical candidates should probably be 
advised that the likelihood of preservation of gait performance and possible improvement 
in some aspects of gait appears to be linked to an uncomplicated pre- and post-operative 
course.   
The results of the current study hold important implications for the rehabilitation of gait in 
people with CSM following surgery. The improvements in kinetics and changes in EMG 
parameters suggested that some adaptation had taken place over the post-operative time 
period, although these did not translate into temporal-spatial or kinematic changes. Even 
if surgery does not directly alter the CNS lesion or lead to an improvement in neurological 
impairment, as found by Sampath et al. (2000), the capacity for improvement in gait by 
neuroplasticity and compensation may be preserved (Dietz and Harkema, 2004). Studies 
using functional MRI in CSM have provided evidence of reorganisation in the 
sensorimotor cortices following surgical decompression of cervical spine stenosis (Holly 
et al., 2007, Duggal et al., 2010). The current study’s findings of improvement in aspects 
of gait are in keeping with these studies’ evidence of adaptation within the CNS following 
surgery. In a systematic review, Kokotilo et al. (2009) described the reorganisation of 
brain function in people with CNS damage as one of the fundamental mechanisms 
involved in recovery of sensorimotor function, and commented that the brain networks 
involved in different aspects of motor control remain responsive, even in chronic 
paralysis. Therapeutic strategies aimed at restoring spinal cord function, such as body-
weight supported treadmill training, could build on this cortical reorganisation, even in 
people with chronic SCI (Lucareli et al., 2011).  
The participants in the current study received variable levels of rehabilitation input, 
depending on the severity of their gait deficit. All participants were otherwise 
independently mobile, with deficits that were probably not as severe as those of people 
with other neurological disorders. This, along with the expectation that surgery stabilises 
rather than improves gait, may cause patients and clinicians to accept a gait pattern that 
has changed little following surgery. An RCT of more intensive rehabilitation intervention, 
targeted at locomotor recovery following surgery for CSM, is necessary to determine 
whether people with CSM can build on the changes in kinetics and EMG to maximise 
their potential to improve. The changes in gait outlined in the current study, coupled with 
developing knowledge on the ability of the spinal cord to recover its locomotor capacity 
after injury, suggest that there is potential for further improvement in gait in CSM.      
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This experimental study aimed to assess gait in people with CSM before and after 
surgical intervention. Its goal was not to determine whether surgery was superior to 
conservative management, and as such, the changes in gait cannot be causally attributed 
to surgical intervention without comparison to a control (non-surgical) group. Instead, the 
study can be considered within its remit as an observational study of change following an 
intervention. An RCT of the effects of surgery compared with conservative management 
would not be ethical, as surgery has over time become accepted as the gold standard for 
treatment in CSM, particularly in people with a deteriorating neurological status 
(Jankowitz and Gerszten, 2006, Rao et al., 2006). All participants in the current study had 
experienced deterioration in their gait since the onset of their symptoms, and all chose 
surgical intervention after the option was presented to them with the known risks and 
benefits. The current study adds an additional dimension to knowledge of these risk and 
benefits by confirming that, for the most part, gait does not deteriorate, and that positive 
changes are possible, particularly in an uncomplicated post-operative course.  
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The study examined gait in freely moving participants with CSM at their comfortable gait 
speed to gain an insight into the preferred locomotor strategy of the CNS in response to 
the neurological lesion. The features of an UMNL, namely spasticity, paresis, impaired 
sensation and proprioception, would have influenced these locomotor patterns to varying 
degrees. The study did not include measurements of impairment of proprioception or 
muscle strength. The influences of these impairments therefore cannot be quantified. 
However, only weak associations between voluntary muscle strength and gait have been 
shown in other neurological conditions, such as CP (Dallmeijer et al., 2011).  
An outcome measure of one aspect of the UMNL, spasticity, was used, but again this 
was known to have poor association with changes in tone observed during gait and 
during active movement in general (Ada et al., 1998, Dietz, 2003). In the current study, 
the MAS provided information on resting tone as a separate entity. It was not used to 
inform the analysis of gait.  
With regard to measurement of proprioception, the complex interaction between the 
various sensory pathways involved in the regulation of gait could not have been inferred 
by simple clinical tests of sensation and joint position sense. More intensive tests, such 
as static posturography, would be informative and should be considered for future 
studies. However, for the current study, the addition of such measures would have 
significantly increased the research burden on participants who were already required to 
 
254 
contribute significant time to multiple gait analysis assessments with several repeated 
trials.  
The assessment of various aspects of neurological function in locomotion is complex and 
time-consuming, with a long list of potential research questions. The study needed to 
focus its methods to its primary question, the performance of gait. Information on signs of 
impairment, such as power and sensation, can lead to a diagnosis and an overall 
impression of the severity of CNS involvement, but give little information about the cause 
and effect of a locomotor disorder (Dietz, 2003). Now that the key aspects of gait 
impairment in CSM have been identified, and their response to surgery documented, 
future studies could further assess the contributions of impaired proprioception, paresis 
and spasticity to the observed gait patterns. 
()P)S)E' Z55&/0'35'=&0&%3#&8&"09';?38#'2;%0"/"2;804'
Finally, although the study was statistically powered to detect change following surgery 
with gait speed as the primary outcome measure, the sample size of 13 was vulnerable to 
the effects of heterogeneity within the cohort. The standard deviation of the difference for 
gait speed was 0.2 m/s, almost twice the predicted variance of 0.11 m/s. Much of this 
increased variance was contributed by two of the participants with complications, who 
experienced deterioration in gait speed that was not in keeping with the trend of the 
cohort in general. However, post-operative complications are a feature of surgery, and 
were reported in 18.5% of cases in a recent prospective study of 81 people with CSM 
(Furlan et al., 2011). The incidence of complications in the current study was in keeping 
with general trends.  
!"?$ L05*7&1,05$
The study concludes that, at one-year follow-up after surgical decompression, people 
with CSM experienced subjective improvements in their ability to mobilise and the 
severity of their CSM. This was associated with improved functional mobility and health-
related quality of life. TSPs and kinematic patterns showed no change following surgery, 
however there were increases in the absorption and generation of power, particularly by 
the knee and ankle, at key phases of the GC. EMG data indicated preservation of the 
potential for neuromuscular adaptation by altering the duration of activation of key muscle 
groups. Future studies of gait in CSM should focus on analysis of gait in more challenging 
environments, and the implementation of rehabilitation strategies to maximise the 
changes in kinetic and EMG parameters in improving locomotor performance following 
surgery. 
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The aims of this thesis were 1) to examine the repeatability of 3DGA and EMG measures 
of gait in CSM, 2) to evaluate gait impairment in people with CSM compared to healthy 
age- and gender-matched controls, and 3) to investigate changes in gait following 
decompressive surgery. There were a number of novel aspects to this thesis. The 
repeatability of 3DGA had not previously been examined in CSM or other forms of 
incomplete SCI. Furthermore, this was the first known investigation of the repeatability of 
EMG indices of timing, amplitude and response to lengthening in gait in a neurological 
population. This was the first study to compare gait in CSM to age- and gender-matched 
HCs, and to account for the speed dependency of gait parameters. It was also the first 
study of gait in CSM to systematically evaluate a range of kinematic key points, to 
investigate joint moments and powers, and to quantify muscle activity by EMG in a CSM 
cohort before and after decompressive surgery.  
HN"J$ K-).-,)8$02$+3)$+3)1,1$
The literature review was divided into three chapters. The first of these, Chapter 2, 
presented an overview of the aetiology, pathophysiology and clinical signs and symptoms 
of CSM. This review highlighted the difficulties in diagnosing CSM due to its variable 
presentation and MRI findings. The emergence of surgery as the mainstay of treatment 
was discussed. The goal of surgery in most cases was to prevent further deterioration in 
neurological function (Rao et al., 2006). Prediction of post-operative outcome was limited 
by the absence of evidence on the natural history of CSM, lack of RCTs comparing 
different surgical approaches, and inadequate follow-up after surgery in the published 
studies. The review highlighted the need for quantitative, sensitive outcome measures, 
such as 3DGA, over standardised follow-up intervals to improve knowledge on the effect 
of surgery in CSM.  
Chapter 3 focused on gait impairment as one of the primary symptoms of CSM. Previous 
research had identified some of its features. People with CSM tended to walk more slowly 
than HCs, with prolonged double support duration and shorter stride length (Kuhtz-
Buschbeck et al., 1999, Maezawa et al., 2001, Lee et al., 2011). Kinematic analysis 
identified reduced ROM at the knee in early stage disease. Reduced ankle plantarflexion 
and knee hyperextension in stance were features of more severe CSM (Maezawa et al., 
2001, Kim et al., 2010, Lee et al., 2011). Although these earlier studies contributed to the 
understanding of gait in CSM, the literature review identified a number of gaps in current 
knowledge. These were 1) absence of kinetic and EMG analysis, 2) lack of matched 
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speed comparisons, 3) follow-up assessments at non-standardised intervals following 
surgery, and 4) lack of concurrent assessment of outcome measures of CSM severity, 
HRQOL and functional mobility.  
Evidence for the role of 3DGA in other pathologies was reviewed in Chapter 4. It was 
shown that kinetic analysis determined compensatory strategies for weakness of specific 
lower limb muscles in children with myelomeningocele (Gutierrez et al., 2005). EMG-
based measures of the timing of muscle activation and co-activation identified key 
neuromuscular adaptations underpinning the recovery of mobility after stroke (Buurke et 
al., 2008), and showed that people with orthopaedic problems used similar strategies to 
compensate for weakness (Heiden et al., 2009). A locomotor-based measure of spasticity 
objectively quantified abnormal responses to muscle lengthening in CP and stroke, 
bridging the gap between passive measures of spasticity and its effect on gait (Crenna, 
1999, Lamontagne et al., 2001). Such studies had contributed to the understanding of the 
biomechanical and neuromuscular mechanisms that influenced gait in these conditions, 
and had implications for rehabilitation and outcome assessment. The methods and 
findings of these studies, and the gaps in the understanding of gait in CSM identified in 
Chapter 3, provided the basis for the aims and objectives of the thesis.  
The methods of the thesis were developed in Chapter 5 and described in Chapter 6. Of 
particular interest was the validation of a novel method to determine the timing of muscle 
activation from EMG signals in gait. This “double threshold method”, based on the Teager 
Kaiser Energy Operator function, built on the work of previous authors in the field. It 
showed 87.5% agreement with visual interpretation of muscle activation, the highest 
accuracy of the four methods tested. The selection of 3DGA and EMG parameters for the 
thesis was based on their use in previous studies in neurological conditions, however 
information on their test-retest reliability in CSM was lacking. It was decided to test the 
reliability of a wide range of possible parameters, and select those with sufficient 
repeatability for use in the remainder of the thesis. 
The results and discussion of the thesis were divided into its component studies, the 
reliability study in Chapter 7, the cross-sectional study in Chapter 8, and the experimental 
study of post-operative changes in CSM in Chapter 9. The reliability study showed that 
most TSPs, kinematic and kinetic parameters were sufficiently reliable for clinical and 
research purposes. Variation in scores from test to retest was considered to result from a 
combination of marker placement error and intrinsic variability in the gait patterns of the 
participants. EMG data yielded more variable reliability. Timing parameters were 
generally reliable, although BF showed a larger SEM of than RF, TA and MG. Amplitude 
parameters showed poor reliability with the MVC normalisation method. The peak 
dynamic method (PDM) showed higher, but still variable, reliability. The PDM method was 
therefore chosen for use in the cross-sectional and experimental studies, while 
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acknowledging the limitation that it diluted inter-individual variability due to its lack of a 
quantifiable physiological reference. Finally, of the parameters used in the LSMS, the 
LVT and critical time of EMG onset during lengthening showed better reliability than the 
slope criterion of Lamontagne et al. (2001). It was decided to retain the direction of the 
slope, positive or negative, as an outcome measure, but not the slope gradient. The 
reliability study aided in the interpretation of the results of the cross-sectional and 
experimental studies, as it estimated the change in each parameter that would be 
required to exceed measurement error. 
The results of the cross-sectional study were presented in Chapter 8. The CSM 
participants had a significantly slower comfortable walking speed. Stride length and single 
support duration were reduced compared to HCs at both comfortable and matched 
speeds. Kinematic and kinetic data showed multiple differences between groups at 
comfortable speed. At matched speed, significant decreases persisted in the CSM cohort 
in peak ankle plantarflexion and peak knee flexion in swing. Non-significant reductions in 
ankle power generation and knee power absorption peaks were noted. The CSM group 
showed prolonged EMG activation duration of BF, RF and TA, and prolonged RF–BF co-
activation, at both speeds. Of interest was the finding that timing parameters changed 
little in HCs from comfortable to matched speed, indicating that the timing of muscle 
activation as measured by EMG is innate and not speed dependent. The LSMS found 
evidence of increased velocity-related sensitivity to lengthening in TA, but not in RF, BF 
or MG. Many of the findings provided evidence for paresis as a cause of impairment in 
gait in CSM. The evidence for spasticity as a contributing feature was less convincing, 
though this was interpreted within the limitations of the LSMS. Participants in the study 
were not assessed under conditions that would challenge balance and stability, and 
therefore impairment of proprioception as a contributing feature could not be fully 
evaluated. Impaired proprioception was suggested by the reduced single support 
duration, however were no differences in step width or medio-lateral GRF, variables that 
might indicate instability (Judge et al., 1996a). PCA revealed more differences in the PC 
representing momentum generation and propulsion, than in the PC representing stability 
in stance. It was therefore postulated that paresis was the main contributory impairment 
to gait in CSM. 
Chapter 9 presented the results of the experimental study. Pre to post-operative 3DGA 
and EMG analysis of gait in 13 CSM participants found no changes in TSPs or 
kinematics. Kinetic analysis showed statistically significant post-operative increases in K4 
absorption power at terminal swing, A2 power generation in pre-swing, and ankle 
plantarflexor moment, although the first two of these variables had not reached the range 
of HC data. EMG analysis showed compensatory responses in the timing of TA, which 
had further prolonged its duration of activation from pre-operative assessment. The 
LSMS showed a significant increase in LVT of RF, indicating reduced sensitivity to 
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lengthening. PCA revealed small improvements in the first PC representing propulsion, 
but not in the second PC, representing stability in stance. The gait analysis findings were 
associated with significant improvements in CSM severity, functional mobility and 
HRQOL. Overall, the experimental study indicated that gait did not deteriorate post-
operatively. The aim of surgery to stabilise function had therefore been achieved. The 
improvements in kinetic parameters suggested that power was absorbed and generated 
more effectively at key points in the GC. This was interpreted as an indicator of some 
neurological recovery. The improvements in the secondary outcome measures supported 
this trend of recovery. 
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Although 3DGA had been used previously to evaluate kinematics in CSM, its reliability in 
this population had not been established. The reliability study in this thesis contributed to 
this gap in the literature. It found that most 3DGA and EMG parameters had the 
psychometric properties to differentiate change from measurement error, and quantified 
the likely test-retest error ranges. It also highlighted those measures that were 
insufficiently reliable. The results have applicability to other neurological populations, 
particularly the findings pertaining to EMG. Several studies have used EMG measures of 
timing, amplitude and response to lengthening of muscle activity, without considering the 
influence of measurement error or intrinsic variability on the observed scores. Future 
studies are required to determine whether reliability is similar in other pathologies, 
however comparisons can be made between the population of this thesis and other 
conditions. 
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Previous studies of gait in CSM focused only on temporal-spatial and kinematic 
parameters, but not on the underlying biomechanical and neuromuscular strategies that 
produced movement during walking. The association between gait speed and many 
kinematic key parameters had not been considered. The current study identified several 
abnormalities in the CSM cohort that persisted when compared to HCs at matched 
speed. Generation of momentum from stance to swing was particularly affected, and this 
was confirmed by multivariate analysis using PCA. EMG analysis highlighted significant 
differences in the duration of muscle activation and co-activation in the lower limbs during 
gait. The study identified strong evidence for paresis as a contributing factor to gait 
impairment in CSM. This was the first study to describe the key characteristics of gait in 
CSM, and to ascertain its underlying contributory factors.  
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Literature on the effects of surgical decompression of the spinal cord in CSM has been 
mixed to date. Reports have stated that surgery aimed to prevent further neurological 
deterioration, and that improvement in function could be expected only in the minority of 
cases (Rao et al., 2006). However, a number of studies showed improvements in aspects 
of mobility such as gait speed (Singh et al., 2009). The current study was the first to 
evaluate changes in gait using a detailed gait analysis protocol involving three-
dimensional motion analysis and EMG study of muscle activation patterns. Follow-up was 
conducted at standardised intervals, although final analysis included a six-month follow-
up for three participants who could not complete the 12-month post-operative 
assessment. Secondary outcome measures of functional limitation and participation 
restriction were evaluated concurrently. The findings showed an improvement in 
secondary outcome measures, but no changes in gait speed, TSPs, or kinematic 
parameters. There were, however, significant changes in power generation and 
absorption at key phases of the GC, compensatory responses in muscle activation, and 
improvements in the principal component reflecting momentum generation and 
propulsion. The fact that these did not affect TSPs and kinematics could be explained by 
two possible mechanisms, 1) the increased power peaks were of insufficient magnitude 
to improve joint ROM, stride length and speed, and 2) the pre-operative gait pattern had 
become embedded in the CNS, despite the capacity for improved momentum generation 
and adaptation of EMG parameters. In either case, the experimental study concluded that 
surgery had impacted the biomechanical and neuromuscular features of gait impairment. 
Capacity for further improvement should be explored through rehabilitation strategies 
aimed at locomotor function. 
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This need for this thesis was prompted by a lack of evidence on expected outcomes 
following surgery in CSM, and the absence of definitive rehabilitation protocols or 
guidelines in managing the condition. The expectation that surgery would stabilise rather 
than improve gait impairment meant that the potential of patients to respond to post-
operative rehabilitation was uncertain. Recently, there has been growing evidence on the 
ability to improve gait in people with SCI by neuroplasticity, neurological recovery and 
compensation (Dietz, 2010). This thesis identified key aspects of gait impairment in CSM, 
with many implications for physiotherapists. Firstly, the biomechanical and neuromuscular 
patterns underlying gait impairment have been described in greater detail, and therapists 
can improve their understanding of this condition as a result. Secondly, the role of paresis 
as a contributing factor implies that rehabilitation programmes should focus on 
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strengthening of the lower limb muscles. Finally, it is possible that a targeted post-
operative rehabilitation programme could facilitate the translation of improved kinetics into 
faster walking with more normal kinematics. Future RCTs will be necessary to evaluate 
such programmes. However, until these emerge, the evidence suggests that there is 
potential for improved gait patterns in people with CSM following surgery. Locomotor 
strategies aimed at maximising the improved kinetics, harnessing the ability of the CNS to 
compensate for deficits, and preventing the hardwiring of pre-operative gait patterns into 
the CNS, should be trialled with individual patients to facilitate recovery. 
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Surgeons face a significant problem in the lack of sensitive, quantitative published data 
on outcomes following surgical intervention for CSM (Jankowitz and Gerszten, 2006). In 
deciding the optimal management for any given patient, the risk of intra-operative 
complications must be weighed against the prospect of future neurological deterioration if 
surgery is not undertaken. The 3DGA and EMG assessment of gait in this thesis is a 
significant contribution to knowledge of post-operative changes. The findings should 
inform the pre-operative decision-making process by providing surgeons with greater 
clarity on the aspects of gait that can be affected by surgery. Furthermore, the evidence 
for further potential improvements in gait, outlined in Section 10.4.1 above, suggests that 
surgeons should encourage their patients to pursue active rehabilitation following 
surgery. The significant post-operative improvements in the secondary outcome 
measures of severity of CSM, functional mobility and HRQOL are encouraging, as they 
suggest that the potential benefits of surgery are multi-dimensional. Finally, the lack of 
evidence to implicate spasticity as a causative factor of gait impairment suggests that 
people with CSM may be unlikely to benefit from anti-spasmodic medication as a means 
of improving their gait. This is in line with expert opinion on the nature of spasticity (Dietz, 
2003). 
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Individuals with CSM are faced with the uncertainty of future progressive neurological 
deterioration due to ongoing degenerative processes in the cervical spine. Surgery is 
often presented as the only option to prevent this deterioration. Its goal to stabilise rather 
than improve neurological function, coupled with the risk of major surgical complications, 
creates a situation of potentially undesirable outcomes regardless of whether operative or 
conservative management is chosen. This thesis confirms the stabilisation of a gait deficit 
at one year following surgery, even with the inclusion of participants who experienced 
complications. Furthermore, changes in kinetics and EMG suggest that further 
improvement in gait is possible with targeted rehabilitation intervention, in line with recent 
studies on the recovery of mobility in incomplete SCI. The findings indicate that the post-
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operative course for people with CSM may be more optimistic than previously expected, 
and suggest that they should pursue more active rehabilitation following surgery.  
HN"=$ M,<,+4+,051$02$+3)$+3)1,1$
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The study had 90% statistical power to detect a difference of 0.1 m/s at the 0.05 
significance level with 13 participants in the experimental study, and 13 participants in 
each group in the cross-sectional study. This was in keeping with the recommendation 
that studies using multiple outcome measures should have a minimum power of 90% to 
detect change in the primary measures (Borm et al., 2006). The power calculation was 
based on gait speed because it was the most widely reported measure of gait in CSM, 
has a clear relationship with functional performance (Judge et al., 1996b), and is a 
predictor of many outcomes (Bohannon and Williams Andrews, 2011). The variance of 
other gait parameters, particularly in EMG, is not widely known. The power of the study to 
detect change in kinematic, kinetic or EMG variables cannot be assumed, and it is 
possible that some type two statistical errors occurred in the analysis. 
The participants in the experimental study had greater variance than expected. Three of 
13 participants experienced complications that affected their recovery from surgery, 
leading to a larger than expected standard deviation of the pre- to post-operative 
difference in gait speed. All small sample sizes are vulnerable to the effects of 
heterogeneity, so it is possible that type two errors may have occurred. However, the 
participants in this study represented a large proportion of the eligible population who 
were approached on a continuous prospective basis over a two-year period. Furthermore, 
the rate of complications in the current study was in keeping with larger international 
studies (Furlan et al., 2011). These facts suggest that the participants can be considered 
representative of the wider population of people with CSM. 
The inter-dependence of many gait parameters also deserves consideration from a 
statistical point of view. Each variable was considered of benefit in the description and 
analysis of gait impairment, and as a result, multiple comparisons were made using 
paired t tests. The possibility of a chance finding of significance due to a type one error 
cannot be out-ruled. The strong correlations between individual gait variables precluded 
the use of Bonferroni adjustments (Perneger, 1998). The problem of a possible chance 
finding was addressed by evaluating the relationships between gait variables that were 
found to be significantly different, with the rationale that a chance finding of significance 
would not be associated with significant differences in its contributing variables. 
Multivariate analysis was also employed to focus the discussion to the principal 
components of gait that showed greatest deviation.  
 
262 
HN"="J$ C.0+0*07$;)-,4+,051$
The interval between pre-operative assessment and surgical intervention could not be 
standardised among participants, as this was beyond the control of the PI. Some 
participants experienced delays in their planned admission to hospital. The mean interval 
from pre-operative assessment to surgery was 2.2 months. The possibility of further 
deterioration in gait during this time, not captured by the pre-operative assessment, 
cannot be out-ruled. If a further deterioration had occurred, it is possible that the true 
changes in gait following surgery were under-represented. 
Three participants were unavailable for follow-up at the 12-month post-operative 
assessment. Their six-month data were used for the pre- to post-operative analysis. 
Further change could have occurred between six and 12 months. However, graphs of gait 
data of the 10 participants who completed the protocol suggested that the greatest 
improvement occurred in the first six months, with smaller improvements thereafter. This 
temporal trend was not tested for significance due to the already high volume of 
hypothesis tests, though similar findings were reported in a previous study (Singh et al., 
2009).  
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The thesis focused on the analysis of overground barefoot walking at comfortable gait 
speed to indicate the natural preferences of the locomotor system. Functional walking 
requires nervous system control for three tasks, 1) equilibrium during propulsive 
movement, 2) basic reciprocal movement strategy, and 3) adaptation to behavioural 
goals and external constraints (Behrman et al., 2006). The current study did not evaluate 
the third task. The subjective improvement in gait reported by the participants, and the 
reduction in falls incidence, could reflect an improvement in walking ability associated 
with activities of daily living and the ability to adapt the motor program to varying 
demands. Future studies could address this issue by including gait analysis of a range of 
gait speeds, tandem gait, and obstacle avoidance (van Hedel et al., 2007). This would 
evaluate the ability to control centre of mass in more unpredictable conditions (Schrager 
et al., 2008), giving a greater indication of instability and proprioceptive deficits in CSM. 
Evaluation of the sensory, vestibular and visual components of balance using 
posturography is also recommended, as this technology has shown the ability to 
discriminate the causes of balance deficits (Yardley et al., 1998). Finally, future studies 
should assess the ability to ambulate within the community, a skill that is not adequately 
predicted by gait speed (Lord and Rochester, 2005).  
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The literature review identified a lack of evidence to guide the rehabilitation of people with 
CSM. There is a need for studies of rehabilitation intervention in this population, given 
that many patients will be limited by a gait impairment that, based on the evidence of the 
experimental study, shows potential to improve after surgery. The cross-sectional study 
deduced that paresis was the most evident contributory factor, suggesting that 
strengthening programmes may be beneficial. Rehabilitation should also specifically 
target locomotor function. Adjuncts such as body weight supported treadmill training have 
shown promise in incomplete SCI (Lucareli et al., 2011). The current study showed 
evidence for biomechanical and neuromuscular changes following surgery that had not 
translated into improved gait speed or kinematics. Targeted locomotor training could 
bridge this gap, resulting in more positive outcomes for people with CSM. 
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The thesis focused on the evaluation of neuromuscular control using EMG measures of 
timing, amplitude, and response to lengthening. Apart from TKEO, little processing was 
applied to the EMG signals. Measures of timing showed good discriminative validity and 
were repeatable and accurate compared to visual interpretation. However, measures of 
amplitude in particular showed limited ability to distinguish people with CSM from HCs, 
due to the dilution of inter-participant variation by normalisation. Visual interpretation 
suggests that much detail is contained within the EMG signal. The challenge is to remove 
clinically meaningful information from the signal in a manner that facilitates comparison 
between different individuals and on different test days. Recent studies of more complex 
EMG processing techniques, such as wavelet decomposition of signals into time-
frequency space and subsequent PCA, have shown promising results. These methods 
have the potential to provide new information on the nature of muscle adaptation to a 
CNS lesion (Wakeling et al., 2007). As with any technique, test-retest reliability of the 
parameters obtained in wavelet transformation or other complex EMG processing should 
be established, prior to their application in clinical and research practice. 
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The thesis aimed to address the lack of knowledge on gait impairment in CSM, and to 
evaluate changes in gait following decompressive surgery. The chosen outcome 
measures, 3DGA and EMG, were found to be sufficiently reliable for use in clinical and 
research practice in the evaluation of gait impairment in CSM. Comparison with age- and 
gender-matched HCs, including a matched speed analysis and PCA, indicated key 
deficits in gait in CSM, particularly in relation to generation of momentum at terminal 
stance and pre swing. Compensatory EMG responses of prolonged activation and co-
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activation were evident. The deficits were considered to be due primarily to paresis. 
Repeat analysis at six and twelve months following surgery indicated that decompression 
of the spinal cord had succeeded in stabilising the gait deficit. Some kinetic features of 
gait improved significantly following surgery, though these had not translated into 
temporal-spatial and kinematic changes. There may be potential for further improvement 
in gait in CSM through rehabilitation protocols focused on strengthening, as well as the 
targeting of locomotor strategies to maximise the improved kinetics and facilitate 
adaptation within the CNS to a more normal gait pattern. 
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Equipment Trolley 
Name     Description 
Measuring tape    cloth, 1.5m in length 
Calipers     measuring up to 14cm widths 
Single-use disposable razors   1 per subject trial  
Alcohol swabs     (Sterets) 3-4 per subject  
Black kohl pencil    for surface marking 
Leucopore fixing tape    (Mueller) 2.5cm width 
3mm Screwdriver   to alter gain settings on the EMG system 
tibial torsion device   for measurement of tibial torsion  
 
EMG 
16 Channel (MA-300-16) EMG Back Pack Unit (Motion Lab Systems), plus gait waistcoat 
8 pre-amplified surface electrodes, (Motion Lab Systems) 
Ground electrode (Motion Lab Systems) 
 
Marker placement 
Double-sided adhesive tape  (2.5 cm, Motion Lab Systems) 
Scissors 
10 Vicon markers and 5 wands    
Knee alignment devices   (Motion Lab Systems) 
 
Other 
Wooden step with rubber cover  (21cm high, to allow more accurate visualisation of Vicon 
markers) 
Full length mirror 
Height-adjustable plinth plus 2 pillows. 
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Anthropometric Measurements 
Height 
Measured with a stadiometer. The head is positioned in the Frankfurt Plane, a standard plane 
for orientation of the head. It is established by an imaginary line passing through the right 
tragion (the front of the ear) and the lowest point of the right eye socket. Subject is barefoot.  
Measure the vertical distance from the floor to the vertex (the highest point on the head in the 
mid-sagittal plane).  
 
Weight 
Calculated using Seca digital measuring scales, and record in kilogrammes. Subject is 
barefoot. 
 
Leg length 
Subject lies supine and is asked to bridge and swing pelvis from side to side and then lower 
pelvis. Both lower limbs are then extended. 
Pen mark (X) placed on each ASIS - located by palpating caudally to cranially on anterior hip 
to find inferior aspect of ASIS.  The most inferior bony point is marked. 
Leg length is measured from the mark to the inferior aspect of the medial malleolus.  It is 
measured in cm to nearest 0.1cm 
 
Inter-ASIS distance 
Subject supine, knees extended, measure distance from each marker point on the ASIS 
using measuring tape, measured in cm to nearest 0.1cm 
 
Knee width 
Subject in supine lying, knee flexed (75–80°) 
Lateral knee: Palpate lateral epicondyle and locate popliteal groove, which is a groove just 
below the lateral epicondyle.  Mark position with skin surface marker. 
Medial knee: Palpate the medial femoral condyle, locate the medial collateral ligament and 
place a mark where the midpoint of the medial collateral ligament intersects with the joint line.  
Mark this point with a skin surface marker, the knee joint axis is downwards and medially. 
Knee width is measured with a callipers, one arm is placed on the medial and the other on 
the lateral knee joint mark. This is measured in cm to nearest 0.1cm, recording the average 
of three measurements.   
Double–sided tape is applied to the medial and lateral aspects of the knee to allow better 
attachment of the knee alignment device during Vicon marker placement.  
 
Ankle width 
Subject in supine lying, knee flexed (75–80°). Measured with callipers, one arm on the most 
medial point of the medial malleolus and one arm on the most lateral point of the lateral 
malleolus. This the widest part of the ankle joint.  Measured in cm to nearest 0.1cm, 
recording average of three measurements to nearest 0.1cm 
 
Tibial Torsion 
With the subject supine, rotate the thigh and shank (around the long axis of the thigh and 
shank) until the knee axis lies horizontal (if you have marked the knee axis on the medial and 
lateral side then these marks should now be the same vertical height above the couch 
surface). 
Sit at the end of the couch facing the plantar surface of the feet. 
With the preferred hand place the device tips up on the malleoli marks, adjusting the width of 
the tips of the device with the fingers through the two ring-holes on each of the legs. 
Ensure that the device is held with the plane of the dial-face vertical allowing the angle 
indicating arm to hang freely under gravity. The degree of tibial torsion is indicated by the 
angle indicating arm when the device is held in this position. It is a measure of the angular 
difference between the knee axis and the ankle axis in the vertical plane. It is otherwise 
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expressed as the amount of rotation around the long axis of the shank between the projection 
of the knee flexion/extension and the bimalleolar (ankle) axes onto the plane perpendicular to 
the long axis of the shank. 
 
Fig 1: Measurement of Tibial Torsion 
Procedure for SEMG electrode Placement 
Equipment  
• 16 Channel (MA-300-16) EMG system (Motion Lab Systems), plus gait waistcoat 
• 8 Active surface electrodes, pre-amplified and labeled for each muscle and 
corresponding channel. 
• Ground electrode (Motion Lab Systems) 
• Leucopore fixing tape (1.25cm & 2.5cm widths) Alcohol swabs (sterets),  
• Single-use disposable razors 
• Black kohl pencil for surface marking 
• Measuring tape 
 
Protocol 
Subject dressed appropriately in shorts, supine on plinth for limb measurements and anterior 
surface electrode marking.  
 
1. Check all attachments to MA-300 desk top unit and ensure all leads are in place. 
2. Attach SEMG electrodes to their specific channels (1-8) in the MA-300 before attaching 
to patient. 
3. Bring the wires of the 8 leads down the sides of the patient’s shorts (4 on the left and 4 
on the right side).  Rest the MA-300 Back Pack Unit on the subject’s torso. 
4. Clean all electrodes with an alcohol swab and leave to dry with contact area facing 
upwards. 
5. Identify location for electrode placement on muscle (see below: “Electrode Placement”). 
Locate muscle bulk to be tested (e.g. gastrocnemius), and engage muscle by resisting its 
action (resist ankle plantarflexion). Mark borders of the location for the electrode with skin 
marker.  
6. Prepare the skin by shaving the area for the electrode until all hair is removed. 
7. Wipe area with alcohol swab 6 times forward and back and leave to dry. 
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8. Secure the body of the electrode to the muscle using Micropore surgical tape or 
Leucotape. Secure the wire with a separate strip of tape approximately 2cm from the 
base of the electrode. 
9. Connect the black transmission wire from the MA-300 desktop unit to the backpack unit 
and turn on the desktop unit. Ensure green “power” light is glowing at front of desktop 
unit. 
10. Note the gain of each electrode channel.  
11. Open “Windaq USB0” application and check the quality of the output signal from the 8 
channels, firstly at rest, and secondly with the subject moving the lower limbs to activate 
the corresponding muscle channels. 
o If interference is noted on a channel’s output when the corresponding muscle is 
at rest: 
! Remove electrode from skin, shave and swab the area again, leave to 
dry and re-apply electrode. If the skin is very dry, hydrate the area using 
Eko-Gel™ ultrasound gel after shaving and cleaning to minimise static 
interference from the skin surface. 
! Disconnect and re-connect the electrode to its corresponding channel. 
! Re-check all wires and connections to the MA-300 desktop unit. 
! Ensure ground electrode is in contact with an electrically neutral area 
(e.g. bony prominence). 
o When the subject moves the lower limbs, ensure each channel is registering an 
electrical signal with muscle activity. If no signal is observed: 
! Ensure electrode is correctly connected to its channel by removing and 
re-connecting if necessary. 
! Increase the gain on the corresponding channel and repeat contraction. 
! Check that electrode is in contact with skin and is over the muscle belly. 
! Remove the electrode from its channel and test in another channel. 
! If all of the above measures fail to elicit an electrical signal with muscle 
contraction, remove the electrode, mark as faulty, and use a spare 
electrode. 
o If the signal from a channel appears “saturated”, reduce the gain of the channel 
on the MA-300 Back Pack Unit using a 3mm screwdriver.   
Electrode Placement 
1. Rectus Femoris (knee extensor and hip flexor) 
Patient supine. 
Activate muscle by resisting knee extension and hip flexion. 
Measure distance from ASIS to the superior border of the patella, place electrode halfway 
between these surface markings parallel to the orientation of the fibres. 
 
2. Tibialis Anterior (ankle dorsiflexor) 
Patient supine. 
Activate muscle by resisting ankle dorsiflexion.   
Measure the distance between the lateral joint line of the knee and the medial malleolus. 
Place electrode just lateral to medial shaft of tibia at one third distance from the knee to the 
ankle marker (over area of greatest muscle bulk). 
 
3. Biceps Femoris (knee flexor, hip extensor and lateral rotator of tibia in relation to 
femur) 
Patient prone. 
Activate muscle by resisting further flexion of knee held in flexion and slight lateral rotation. 
Palpate muscle bulk and place electrode parallel to muscle fibres midway between gluteal 
fold to the lateral knee on postero-lateral aspect of thigh. 
 
4. Gastrocnemius Medial Head (ankle plantarflexor) 
Patient prone. 
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Activate muscle by resisting plantarflexion of the ankle. 
Measure distance between the medial knee joint line and the medial malleolus. Apply 
electrode one third distance from the knee, 2cm medial to the midline of the posterior aspect 
of the leg.  Apply parallel to muscle fibre orientation over area of greatest muscle bulk. 
 
5. Ground electrode (green) is applied to the right shoulder of the subject and attached to 
the back of the EMG recorder. 
 
Order of Placement of electrodes 
Supine 
Left Rectus Femoris   Channel 1 
Left Tibialis Anterior   Channel 5 
Right Rectus Femoris   Channel 2  
Right Tibialis Anterior   Channel 6 
 
Prone 
Right Biceps Femoris   Channel 4 
Right Gastrocnemius   Channel 8 
Left Biceps Femoris   Channel 3 
Left Gastrocnemius   Channel 7 
MVIC (Maximum Voluntary Isometric Contraction) 
MVIC recordings are taken from each muscle in turn, since the patient is already in prone, left 
biceps femoris and left gastrocnemius are tested first followed by the right side.  The patient 
is asked to hold the limb in position and contract “as hard as you can” for 3 seconds against 
the testers applied resistance.  Each subject is allowed a practice trial on each muscle before 
recordings are taken using the Workstation programme.  SEMG gain channels are usually 
set to 1 for MVIC, but should be increased if the signal is too small to be readable at this 
setting when observed in Windaq. 
 
Prone  
Biceps Femoris: knee in 70 degrees flexion, tester applies strong extension force just 
proximal to the tendo-achilles.  Subject resists and attempts to flex knee maximally “bend 
your knee, hard as you can” 
 
Gastrocnemius:  knee in 70 degrees flexion and ankle in mid-plantarflexion.  Patient is 
asked to push foot and toes up into testers hand at the ball of the foot; tester applies a 
dorsiflexion force and instructs “push your foot up, hard as you can” 
 
The subject is asked to sit over the edge of the bed (taking care that electrode leads and tape 
are not pulled or displaced).  The subject is allowed a practice MVIC trial of each of the 
anterior muscles before recording takes place.  The subject is asked to stabilise with their 
hands at the side of the bed with the back of the knees against the edge. 
 
Sitting 
Rectus Femoris: Participant sits with thighs supported, hands placed at edge of plinth for 
support, knees in 90° flexion, feet clear of floor. Participant flexes hip so that thigh clears the 
bed, tester places one hand on lower tibia proximal to ankle joint, participant attempts to 
strongly extend knee while maintaining flexed hip. Instruction is “hold your knee up and 
straighten your leg as hard as you can” 
Tibialis Anterior: ankle in 5-10 degrees dorsiflexion and slight inversion.  The tester 
attempts to pull the foot out of this position and the subject tries to keep their foot in this 
position.  Pressure is applied by the tester at the dorsum of the foot at the level of the 
metatarsal heads.   
Avoid stress on the wires by making sure that the wires are not taut when the limb fully 
extends. 
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Protocol for Vicon Marker Placement 
Equipment:   
15 lightweight retro-reflective markers 2cm in diameter (Vicon) (includes 5 wand markers) 
Knee Alignment Device (KAD) x2 (Motion Lab Systems) 
Double sided-adhesive tape (2.5cm) (Motion Lab Systems) 
Black kohl pencil for surface marking 
Full length mirror 
 
Protocol: 
Subject standing, on wooden box with rubber grip.  The extra height of the subject allows for 
more accurate placement of the foot markers and alignment of the ankle, knee and thigh 
markers 
 
1. Forefoot Markers:  Attach to the heads of the 2nd metatarsal bones.  To assist in 
identifying them, ask the subject flex their toes. 
 
2. Ankle Joint Markers:  Attach directly over the lateral malleoli. 
 
3. Heel Markers:  Attach over the os calcis at 
the same height as the forefoot marker.  A 
caliper (which was used to measure knee 
widths) can be used to measure the distance 
from the uppermost point of the forefoot and 
heel markers to the floor (Figure 2).  These 
should be equal.  The mirror should also be 
used to check that the markers are in 
alignment along transverse plane.    
 
Figure 2:  Photograph demonstrating how a calipers is 
used to ensure that the retro reflective markers of the 
forefoot and heel are placed at the same height. 
 
4. ASIS: Markers are placed over each anterior superior iliac spine, left then right.  
These have been marked previously leg-length measurement (on the iliac crest 
palpate caudal to cranial, the marker is placed over the most anterior part). 
 
5. Knee Joint Axis:  The axis is determined using a knee alignment device (KAD) and 
the markers for the lateral and medial femoral condyles.  The KAD is attached with 
the subject standing away from the bed. The horizontal wands are aligned parallel to 
the floor.  The back of the KAD is adjusted so that it gradually falls into the back of 
the calf whist tightening the lateral side of the device and letting the back of it to rest 
on the back of the subject’s leg. 
The subject is then asked to actively flex and extend each knee in turn; the location 
of the device is altered by the principal tester until the flexion/extension wand shows 
minimum movement. 
 
6. Thigh Markers:  The shorter wand markers are placed at the lateral aspect of the 
thigh, in alignment with the greater trochanter (hip joint centre) and the lateral knee 
joint axis marker.  A full length mirror is placed 2 metres from the subject to aide the 
examiner to accurately line up the markers.  This is done firstly on the left side, then 
the right.  The left thigh marker is lower than the right. 
 
7. Shank Markers:  The longer wand markers are used for the shank; these are 
aligned with the ankle joint markers and the knee joint markers, again using the 
mirror for reference.  The left thigh marker is lower than the right 
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8. Sacral Marker:  The sacral wand marker is placed at the midpoint between the skin 
dimples formed by the PSIS (level of S2) 
 
Data Capture 
Static Trial:  The subject stands quietly on the force platform (at the centre of the walkway) 
with KADs attached facing towards the workstation.  Subject is asked to place arms across 
chest for the calibration and to remain as still as possible with knees extended fully.  Up to 
three seconds of video data is recorded. 
 
The KADs are removed and the lateral joint markers are placed over the points where the 
KADs had been attached - there should be some temporary marks on the skin where the 
arms of the KAD’s were attached to the lateral knee. A second static trial is then taken with 
the lateral joint markers in place of the KADs. 
 
Gait Analysis 
Once the subject is ready for testing, he/she will have a trial walk down the walkway towards 
the workstation, without recording.  During this trial walk: 
• The outputs of the electrodes are checked and gains are increased or decreased to 
ensure a readable signal which is not saturated (aim for amplitude of one Volt at the 
signal’s maximum point during the gait cycle). 
• The cameras are checked so that they are detecting all the reflective markers whilst 
the subject is walking over the forceplate.   
 
The subject begins the walk from different point of the walkway good heel strike is achieved.  
Coloured start positions allow the subject to start at the correct position.  To achieve sufficient 
data, 5 good strikes are required on each foot.  Poor strikes are discarded, thus more than 14 
walks may be required to achieve desired number of strikes.  The assistant advises the 
subject of the point to start at.  At this point the subject should be unaware of the forceplate.  
If the subject knows that the forceplate is there, then he/she may change the gait pattern in 
an attempt to strike the forceplate – this may lead to inaccurate and inconsistent results. 
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function mf = Butterworth(signal) 
% Butterworth(signal) calculates the filtered EMG signal (musclef) 
for a single muscle using set filtering parameters decided in PhD 
Development of Methodology 
% Ailish McDermott, 18 Aug 2010, RCSI Movement Lab 
% fs = 1kHz 
% Signal is a 1-D vector 
% Butterworth takes the raw EMG data and filters using a 4th order 
Butterworth low 
% pass filter with 400 Hz cut-off frequency followed by a 2nd order 
% high-pass filter with a 25 Hz cut-off frequency 
% All filters are dual pass (i.e. applied in forward and backward 
% directions to avoid phase distortion) and zero lag 
% Note: If fs is not = 1Khz, then divide HP cut and LP cut by new fs 
(in kHz) 
% ---------------------------------------------------------%  
% ------ Butterworth filters low-pass and high-pass -------% 
[B1 A1]=butter(4,0.4,'low'); % 4th order LP filter, LP cut = 400 Hz 
[B2 A2]=butter(2,0.025,'high'); % 2nd order HP filter, HP cut = 25 
Hz 
% ------ Butterworth filters low-pass and high-pass -------% 
% ------ Resulting Filter ---------------------------------% 
b=cconv(B1,B2); % cconv function to convolve vectors B1 and B2 
a=cconv(A1,A2); % cconv function to convolve vectors A1 and A2 
mf=filtfilt(b,a,signal); 
end 
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MA-300 EMG scale calculation for volts at skin surface       
                
  ADC input range 20 
 Volts (+10 volts to -10 
volts)       
  ADC channel gain (x1) 2   
Signal range is 
+/- 5 Volts   
  ADC resolution 12  bit   4096 bits   
  One bit represents 0.0024414  Volts         
          
Preamplifier 
gain 20   
  ANALOG:GEN_SCALE 1.000000     
Desk Top Unit 
gain 2   
                
  MA-300 Gain switch settings for a GEN_SCALE of ……………   1.000000   
  Switch 
Input 
(mV) 
Total 
Gain BPU Gain   ANALOG:SCALE   
  0 28.82 347 8.68 0.0000070358   
  1 5.17 1934 48.35 0.0000012624   
  2 2.55 3921 98.03 0.0000006226   
  3 1.82 5508 137.70 0.0000004432   
  4 1.30 7696 192.40 0.0000003172   
  5 1.08 9278 231.95 0.0000002631   
  6 0.90 11132 278.30 0.0000002193   
  7 0.78 12772 319.30 0.0000001912   
  8 0.61 16524 413.10 0.0000001477   
  9 0.55 18104 452.60 0.0000001349   
                
 
Source: www.c3d.org
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function TKEO = tkeo(signal) 
 
% Applies Teager Kaiser Energy Operator to a signal and returns 
the output 
% Created by Ailish McDermott, RCSI Movement Lab 02-Nov-2010 
% Last modified 10-Nov-2010 
 
mod_signal = [zeros(1,1); signal; zeros(1,1)]; % zero pads start 
and end of signal 
signal_nplus1 = [zeros(2,1); signal]; % Creates vector of n+1 
values for signal 
signal_nminus1 = [signal; zeros(2,1)]; % Creates vector of n-1 
values for signal 
signal_tkeo1 = (mod_signal.^2) - (signal_nplus1.*signal_nminus1); 
TKEO_long = abs(signal_tkeo1); % zero padded version of original 
signal  
a = length(TKEO_long); 
TKEO = TKEO_long(2:a-1); % returns signal to its original length 
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function rest_threshold_method(th) 
% ------------------------ % 
% Part of the validation of EMG timing 
% This function represents Method 1-3, the testing of various 
thresholds, th (1, 7 and 15) above resting EMG signal TKEO 
% Compares against a pre-defined standard from visual 
interpretation of the signal 
% Created by Ailish Malone (McDermott), RCSI Movement Lab, 06-Apr-
2011 
% Inputs: Threshold 
% Outputs: logical "pass" (1) or "fail" (0) values to output 
matrices, ON and OFF, the result 
% Folder “TimingValidation” contains files ‘On_Result.mat’ and 
‘Off_Result.mat’, the results of visual interpretation 
% ----------------------- % 
root = '/Users/ailish/Documents/MATLAB/TimingValidation/'; 
load([root,'On_Result.mat']); 
load([root,'Off_Result.mat']); 
for n = 1:12 
    % first load file, apply TKEO and filter 
    load([root,'TA',int2str(n),'.mat']); 
    sig = tkeo(rtaf); 
    [B,A] = butter(2,0.05,'low'); 
    sig2 = filtfilt(B,A,sig); 
    % Now find the resting signal and apply threshold algorithm 
    load([root,'TA_rest',int2str(n),'.mat']); 
    rtaf = Butterworth(rta); 
    rest_tkeo = tkeo(rtaf);  
    rest_mean = mean(rest_tkeo); 
    rest_sd = std(rest_tkeo); 
    threshold = rest_mean + (th*rest_sd); 
    % Now find points were gait signal exceeds threshold 
    sig_on = sig2 > threshold; 
    % Now see where threshold is exceeded for ≥ 24 / 25 data 
points 
    TIME = [sig_on(end-12:end); sig_on; sig_on(1:12)]; 
    t = length(sig_on); 
    R = zeros(t,1); 
    for k = 1:t 
        R(k) = sum(TIME(k:k+24)); 
    end 
    ACTIVE = R > 23; 
    % Now we have our ON values - save before moving on to test 
against visual interpretatiion 
    folder = 
'/Users/ailish/Documents/MATLAB/TimingValidation/TestResults/'; 
    outputfile = 
[folder,'TA_th',int2str(th),'.',int2str(n),'.mat']; 
    eval(['save ',outputfile,' ACTIVE sig2 sig rest_mean 
rest_sd']); 
    % Now compare to visual interpretation 
    StandardFile = [root,'VisualResult_TA',int2str(n),'.mat']; 
    load(StandardFile); 
    tc = b - a; 
    test = sum(ACTIVE(a:b)); 
    if test == tc + 1 
        result = 1; 
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    else result = 0; 
    end 
    % Now output this result to ON matrix in On_Result.mat 
    if th == 1 
        ON(n+1,2) = result; 
    elseif th == 7 
        ON(n+1,3) = result; 
    else ON(n+1,4) = result; 
    end 
    ResultOutput1 = [root,'On_Result.mat']; 
    eval(['save ',ResultOutput1,' ON']); 
    % Repeat above for OFF matrix 
    if sum(ACTIVE(c:d)) == 0 
        result2 = 1; 
    else result2 = 0; 
    end 
    if th == 1 
        OFF(n+1,2) = result2; 
    elseif th == 7 
        OFF(n+1,3) = result2; 
    else OFF(n+1,4) = result2; 
    end 
    ResultOutput2 = [root,'Off_Result.mat']; 
    eval(['save ',ResultOutput2,' OFF']); 
end  
clear all 
end 
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% double_threshold_method 
% A script file to test the accuracy of the "double threshold 
method", incorporating slope and amplitude parameters of the TKEO 
modified signal, in determining timing of muscle activation 
compared to visual interpretation as a "gold standard" 
% Written by Ailish Malone, 14-Apr-2011 
% Last modified 14-Apr-2011 
% Inputs = signal from file 'TA',int2str(p),'.mat' [p = 1:12] 
% Outputs = logical "pass" (1) or "fail" (0) values to output 
matrices, ON and OFF 
% --------------------------- % 
 
root = '/Users/ailish/Documents/MATLAB/TimingValidation/'; 
load([root,'On_Result.mat']); 
load([root,'Off_Result.mat']); 
for n = 1:12 
    load([root,'TA',int2str(n),'.mat']); 
    sig = tkeo(rtaf);               % Apply TKEO to filtered gait 
data 
    [B,A] = butter(2,0.05,'low');   % Get vectors for dual-pass 
filter for smoothing 
    sig2 = filtfilt(B,A,sig);       % Smooths the signal 
    slope = gradient(sig2);         % Gets the slope of the 
smoothed signal 
    sig_on = abs(slope) > 1e-6;     % Creates logical index where 
the absolute value of the slope is above a threshold 
    th = (max(sig2))*0.03;          % Sets a threshold at 3% 
maximum value of signal 
    sig_on2 = sig2 > th;            % Finds points where sig2 
exceeds threshold value 
    % ------------------------ % 
 
    % Now put sig_on and sig_on2 side by side and sum the values 
    % Create new logical matrix where both sig_on and sig_on2 
declare 1, i.e. 
    % both slope and amplitude exceed threshold 
    isiton = [sig_on sig_on2]';     % Creates matrix of both "on" 
conditions in rows for summing columns 
    both_on = sum(isiton);          % Sums the columns of the 2 
row vectors 
    timeon = both_on';              % Transposes the resulting 
vector back to a column instead of a row 
    changetime = timeon == 2;       % Creates a new logical vector 
where both conditions are satisfied for slope and threshold 
    % ------------------------ % 
 
    % Now see if both conditions are satisfied for at least 24 of 
25 
    % consecutive samples 
    % May need to change value of 23 if it leads to false 
positives 
    % 25 consecutives led to false off signals where there was a 
slight blip in 
    % contraction 
    TIME = [changetime(end-12:end); changetime; changetime(1:12)];    
% Appends the last 12 values to the beginning and first 12 values 
to end to create new vector TIME 
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    t = length(changetime);   % Gets the number of data points for 
new matrix containing 25 consecutive ON values 
    R = zeros(t,1); % Initialises a matrix that will contain 
logical values of TIME 
    for k = 1:t 
        R(k) = sum(TIME(k:k+24));   % Sums each consecutive set of 
25 data points 
    end 
    ACTIVE = R > 23;    % If 24 of 25 consecutive points are 
satisfying the on condition, then consider muscle to be on (allows 
for blips in middle of contraction) 
    % ------------------------ % 
 
    % Now we have our ON values - save before moving on to test 
against 
    % visual interpretatiion 
    folder = 
'/Users/ailish/Documents/MATLAB/TimingValidation/TestResults/'; 
    outputfile = [folder,'TA_dtm',int2str(n),'.mat']; 
    eval(['save ',outputfile,' ACTIVE sig2 sig']); 
 
    % Now test against visual interpretation % 
    StandardFile = [root,'VisualResult_TA',int2str(n),'.mat']; 
    load(StandardFile); 
    % First test against ON values 
    tc = b - a; 
    test = sum(ACTIVE(a:b)); 
    if test == tc + 1 
        result = 1; 
    else result = 0; 
    end 
    % Now output this result to ON matrix in On_Result.mat 
    ON(n+1,5) = result; 
    ResultOutput1 = [root,'On_Result.mat']; 
    eval(['save ',ResultOutput1,' ON']); 
    % Now test against OFF values % 
    if sum(ACTIVE(c:d)) == 0 
        result2 = 1; 
    else result2 = 0; 
    end 
    % Now output this result to OFF matrix in Off_Result.mat 
    OFF(n+1,5) = result2; 
    ResultOutput2 = [root,'Off_Result.mat']; 
    eval(['save ',ResultOutput2,' OFF']); 
end 
clear all 
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[Name of Subject 
Address Line 1 
Address Line 2 
Address Line 3] 
 
Date 
 
Dear ___________________, 
 
Following your recent consultation with Professor Ciaran Bolger, consultant 
neurosurgeon at Beaumont Hospital, I would like to inform you about a research project 
currently taking place in collaboration with Professor Bolger and the Royal College of 
Surgeons in Ireland.  
 
The aim of the project is to examine walking patterns in people who are experiencing 
symptoms related to “wear and tear” in the neck which causes pressure on the spinal cord. 
(The medical term for this is “cervical spondylotic myelopathy”). These symptoms may 
include clumsiness or awkwardness of the hands, changes in feeling in the hands or feet, 
or inability to walk as far or with the same ease as normal. If you are experiencing any of 
these symptoms, and if you are currently awaiting surgery to your neck as a result, it is 
likely that you will be eligible to take part in this project. 
 
So what would taking part involve? In brief, a detailed assessment of your walking 
pattern would be conducted using a VICON™ motion analysis system. This would take 
place in the Physiotherapy Movement Laboratory in the Royal College of Surgeons in 
Ireland, St. Stephen’s Green, Dublin 2. Using this technology, we can examine your 
walking pattern in detail, measuring many aspects such as your walking speed, the 
position of your feet as you walk, the forces going through each of your joints, the 
movement available at your joints, and the activity in your muscles. The assessment is 
painless and involves simply attaching some markers to your legs, which the computer 
then records as you walk along a walkway. The protocol would require you to attend for 
[one / two] initial assessments – [less than a week apart from one another] – and then a 
[NUMBER] assessment six months after your neck surgery and a [NUMBER] 
assessment twelve months after your surgery to evaluate any changes in your walking 
pattern as a result of the surgery. The results of your assessments would all be provided to 
you on a CD, which we hope would be of interest and benefit to you and to the healthcare 
professionals involved in your care. 
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At present, there is very little research on why the symptoms relating to this condition 
develop, or on how they change over time. We hope that, by recruiting as many people as 
possible to this project, we will improve knowledge and understanding of the condition 
among healthcare professionals, so that patients will get the best possible care. The 
project is funded by the Health Research Board (www.hrb.ie). 
 
I wish to emphasise that participation in this research project is purely voluntary, and you 
are under no obligation to take part. If you decide take part, you have the right to 
withdraw from the study at any stage if you no longer wish to continue your participation. 
Your care at Beaumont Hospital will not be affected in any way.  
 
If you think you may be interested in taking part in this study, or if you would like further 
information, I would be delighted to hear from you. Please do not hesitate to contact me 
by telephone at 085-8336094 or 01-8092526, or by e-mail to ailishmcdermott@rcsi.ie. 
 
Alternatively, please complete the response slip and send it to me in the stamped 
addressed envelope enclosed.  
 
I look forward to hearing from you. 
 
 
Yours sincerely, 
 
__________________________________  
Ailish McDermott BSc (Physio), MISCP 
Senior Physiotherapist, Neurosurgery 
HRB Clinical Research Fellow 
Beaumont Hospital 
Dublin 9. 
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Participant Information Leaflet  
Protocol Title: 
 
Principal Investigator’s Name: Ailish McDermott 
 
Principal Investigator’s Title: Senior Physiotherapist 
 
Telephone No. of Principal Investigator: 018092526 / 085 8336094 
 
You are being invited to take part in a clinical research study carried out at Beaumont 
Hospital and the Royal College of Surgeons in Ireland.  Before you decide whether or not 
you wish to take part, you should read the information provided below carefully and if you 
wish discuss it with your family, friends or GP.  Take time to ask questions – do not feel 
rushed or under any obligation to participate. You should clearly understand the risks and 
benefits of participating in this study so that you can make a decision that is right for you 
– this process is known as Informed Consent.  
 
You are not obliged to take part in this study and failure to participate will have no effect 
on your future care. You may change your mind at any time (before the start of the study 
or even after you have commenced the study) for whatever reason without having to 
justify your decision and without any negative impact on your care. 
 
WHY IS THIS STUDY BEING DONE?  
This study is being done because we know from experience and previous research that 
patients who suffer from compression of the spinal cord in their neck as a result of “wear 
and tear” (the condition called “cervical spondylotic myelopathy” in the title of the study) 
experience difficulties with walking. They may feel unsteady, the legs may feel stiff or 
weak, or they may not be able to walk as far or with the same ease as before. We hope 
that, by examining in more detail how patients with this condition walk, doctors and 
physiotherapists will better understand why these problems come about. We also hope it 
will help us to understand how walking patterns may change after having surgery. Finally, 
this study will help physiotherapists and doctors plan how best to treat patients with this 
condition after surgery. 
 
WHO IS ORGANISING AND FUNDING THIS STUDY? 
The Principal Investigator of this study is Ailish McDermott, Senior Physiotherapist. The 
Health Research Board has provided funding for the study to Ailish McDermott, who has 
registered for a PhD degree with the Royal College of Surgeons in Ireland. 
 
Gait Impairment in Cervical Spondylotic Myelopathy: Analysis, 
Impact on Function, and Effect of Surgical Intervention 
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HOW WILL IT BE CARRIED OUT? 
This research study commenced in October 2008. It will last for three years. Patients who 
have symptoms like unsteady walking or clumsy hands, and who have been told by their 
surgeon that they have spinal cord compression due to degenerative changes or “wear 
and tear” of the joints in the neck, will be asked to participate in the study. Participants will 
have an analysis of their walking conducted in the Human Movement Laboratory in the 
Physiotherapy Department of the Royal College of Surgeons in Ireland, 123 St. Stephen's 
Green, Dublin 2. 
 
WHAT WILL HAPPEN TO ME IF I AGREE TO TAKE PART? 
You will be given appointments to attend the Movement Laboratory in the Royal College 
of Surgeons in Ireland (RCSI), where an analysis of your walking will be carried out. If 
you are going to have surgery on your neck, the researcher will try to do two analyses of 
your walking about a month or less before you have your operation. The assessment in 
RCSI will take about two hours. Measurements will be taken of your height, weight, and 
the width of the joints in your leg. The range of movement and “stiffness” of the muscles 
and joints in your legs will be measured. You will have small electrodes (about 2cm 
square) attached to four muscles in your leg, and you will have markers placed on the 
joints of your leg. This is not painful, they are simply attached to your skin, though we will 
need to shave a small area of hair to allow the electrodes to stick properly. You will then 
be asked to walk along a 10 metre walkway a number of times while your walking pattern 
is recorded by the an infrared camera system (VICON). Next, you will be asked to walk a 
small flight of stairs if you are able to do this.  Finally, you will be given a questionnaire 
asking you about your health. This is called the “Short Form 36”. You may already have 
completed this questionnaire in the clinic in Beaumont within the past month. If so, we will 
use the results from the clinic and not ask you to complete it again.    
We may need you to come back to have a second, shorter assessment (about two 
hours), one week or less after the first assessment. This is required to ensure that the 
recordings from the infrared camera system are reliable, and are not greatly altered by 
slight variations that may occur between visits. It is important to ensure that the research 
is of high quality. 
We will then call you back for your third assessment about six months after you have had 
your operation, and for a fourth and final assessment about one year after your operation. 
These assessments will be exactly like the first one. 
                 
BENEFITS: 
Taking part in the study will allow the Principal Investigator to gather detailed information 
on your walking pattern. The results of the assessments will all be explained to you. If you 
wish, we can also share this information with your doctor, physiotherapist, or other 
healthcare professional, to improve their understanding of your condition, or to help them 
decide which treatment is of most benefit to you. If you would like your own copy of the 
results, we will give them to you on a CD. 
Your participation will benefit others in the future with the same condition as you, because 
health care professionals will improve their knowledge of cervical spondylotic myelopathy, 
and the treatment that might be needed for it. 
 
RISKS: 
There are three potential risks in the study:  
1. You may have a skin reaction to the sticky electrodes. The risk of this is low 
because the adhesive on the electrodes is hypoallergenic, however please inform 
the researcher if you have sensitive skin, or if you have had a reaction to 
something similar in the past. If this happens, the reaction is likely to be small, 
with some redness and itchiness of the skin where the electrode was placed. We 
will ask your doctor in Beaumont to take a look at the skin and give you some 
cream if needed. 
2. In order to gather sufficiently accurate information, we may require you to walk 
along the walking track as many as ten times, which will mean you will have 
walked about 100 metres. If your muscles are weak, you may become tired. If 
this happens, please tell the Principal Investigator who will ensure you are given 
enough rest between walks.  
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3. If your walking is unsteady, and you have had recent falls or need a walking aid 
or stick, there is a risk that you might fall during the test. This risk is no greater 
than your risk of falling while walking in your usual environment because the 
sensing equipment does not interfere with the way you walk. Please tell the 
Principal Investigator if you have had falls recently, if you need a walking aid or 
stick, or if you need someone to walk beside you. Remember, you can walk as 
slowly as you like during the test and take rest breaks between walks on the 10 
metre track. 
 
WILL THERE BE ANY ADDITIONAL COSTS INVOLVED? 
If you incur travel expenses to come to your appointment in the Royal College of 
Surgeons, please give your receipt to the Principal Investigator who will organise a 
refund. 
 
YOUR RESPONSIBILITIES AS A PARTICIPANT 
9. To attend for assessment of your walking pattern at the appointment times given, 
or to give the researcher adequate notice, i.e. more than 24 hours, if you need to 
change the appointment. 
10. To inform the researcher of any factors which may affect your ability to walk for 
the required length of time e.g. new medical conditions such as angina, a chest 
infection causing you to be breathless, or an injury to your leg. 
11. If you are a woman of child-bearing age, to inform the researcher if you are 
pregnant.  
12. To inform the researcher if you are currently on medication, or if you are currently 
having physiotherapy, or any other treatment for your condition. 
 
OUR RESPONSIBILITIES TO YOU AS INVESTIGATORS 
We will ensure that our assessment of your walking pattern is carried out safely, 
accurately, and following all protocols and procedures to minimise the risk to you, the 
participant, and to ensure that the quality of information we provide to you afterwards is of 
the highest possible quality. We will ensure that the results of your walking test are made 
available to you and any health care professionals involved in your care, if you wish. If 
you would like to know the results of the study when it is finished, we will organise a CD 
copy for you. 
 
CONFIDENTIALITY ISSUES 
When we take records of your assessment in the laboratory, we will not keep your name 
or any other details with this data. Instead, you will be given a “unique identifier” which 
will be coded on a secure hard drive and available only to the Principal Investigator. The 
document with this coded information will be destroyed as soon as the study is 
completed. The data from the laboratory, with details of your walking assessment, will be 
kept for a period of five years after the study is completed, because it may be included in 
future studies. If you wish to consent to this study only, and do not wish to consent to 
have your data included in possible future studies, please inform the researcher who will 
ensure your data are deleted after this study. 
We will contact your GP to advise them of your participation in this study with your 
consent. If you wish for us to provide a copy of the results of your walking test to your GP, 
we will provide these with your consent.   
We may also need to contact your physiotherapist to find out how many physiotherapy 
treatment sessions you have had, again with your consent. We will provide a copy of the 
results of your walking test to your physiotherapist if you would like us to do so. 
You may refuse, however, to have your GP or physiotherapist contacted, and this will not 
affect your participation in the study or your future care.  
The Principal Investigator may need to access your medical chart for details of your 
previous history and your treatment for your current condition.  
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IF YOU REQUIRE FURTHER INFORMATION 
If you have any further questions about the study, now or any future time, please contact 
the Principal Investigator:  
Ailish McDermott,  
Senior Physiotherapist,  
Beaumont Hospital,  
Dublin 9. 
Phone: 01-8092526 / 085-8336094. 
 
If you wish to withdraw from the study you may do so at any time without justifying 
your decision and your future treatment will not be affected.   
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CONSENT FORM 
Protocol Title: 
 
Please tick the appropriate answer. 
 
I confirm that I have read and understood the Patient Information Leaflet dated 
23/02/2010 attached, and that I have had ample opportunity to ask questions all of which 
have been satisfactorily answered.                                                             Yes   No 
 
I understand that my participation in this study is entirely voluntary and that I may 
withdraw at any time, without giving reason, and without this decision affecting my future 
treatment or medical care.                                                                          Yes   No 
 
I understand that my records may be viewed by individuals with delegated authority from 
Ailish McDermott, principal investigator.                                                    Yes    No 
 
I understand that my identity will remain confidential at all times.              Yes   No 
 
I am aware of the potential risks of this research study.                            Yes   No 
 
I have been given a copy of the Patient Information Leaflet and this Consent form for my 
records.                                                                                                      Yes    No 
 
I understand that the principal investigator, Ailish McDermott, may contact my General 
Practitioner to inform them of my participation in this study and my results. 
                                                                                                Yes     No 
 
I understand that the results of this study may be shared with my Chartered 
Physiotherapist to assist with my physiotherapy treatment.                      Yes     No 
 
I understand that the principal investigator, Ailish McDermott, may contact my Chartered 
Physiotherapist regarding my treatment to date.                                      Yes     No 
  
Gait Impairment in Cervical Spondylotic Myelopathy: Analysis, 
Impact on Function, and Effect of Surgical Intervention. 
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FUTURE USE OF ANONYMOUS DATA:   
I agree that I will not restrict the use to which the results of this study may be put. I give 
my approval that unidentifiable data concerning my person may be stored or 
electronically processed for the purpose of scientific research and may be used in related 
or other studies in the future. (This would be subject to approval by an independent body, 
which safeguards the welfare and rights of people in biomedical research studies - the 
Beaumont Hospital Ethics (Medical Research) Committee). 
                                                                                                  Yes      No 
 
Participant ________________           __________        ___________________ 
       Signature                          Date                 Name in block capitals 
 
Witness      ________________           _________         ___________________ 
       Signature                          Date                 Name in block capitals 
 
To be completed by the Principal Investigator or his nominee.  
 
I the undersigned, have taken the time to fully explained to the above participant the 
nature and purpose of this study in a manner that he/she could understand. I have 
explained the risks involved, the experimental nature of the treatment, as well as the 
possible benefits and have invited him/here to ask questions on any aspect of the study 
that concerned them. 
 
 
________________ _____________________     ___________     ________ 
Signature: Name in Block Capitals:     Qualification:   Date: 
 
3 copies to be made: 1 for patient, 1 for PI and 1 for hospital records. 
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Dr. ......... 
Address 
 
Re:  Participant’s Name and address 
 
Dear Dr.                   , 
 
I am conducting a study to identify the main problems with mobility and gait in cervical 
spondylotic myelopathy.  
 
(Participant’s name) has been recruited to the study.  The details are as follows: 
 
Title of the study:   
Gait Impairment in Cervical Spondylotic Myelopathy: Analysis, Impact on Function, 
and Effect of Surgical Intervention. 
 
Co-Investigators 
Prof. Ciaran Bolger, consultant neurosurgeon, Beaumont Hospital 
Ms. Dara Meldrum, lecturer in physiotherapy, Royal College of Surgeons in Ireland 
Ms. Louise Keating, lecturer in physiotherapy, Royal College of Surgeons in Ireland. 
 
This study involves (participant's name) undergoing gait analysis in the Human 
Movement Laboratory, RCSI School of Physiotherapy, prior to undergoing surgery for 
cervical spondylotic myelopathy. The analysis will be repeated at six months post-surgery 
to evaluate change. (Participant's name) will also be assessed on a simple physiotherapy 
score of mobility, the Modified Ashworth Scale for measurement of spasticity, and a 
quality of life questionnaire (Medical Outcomes Study Short Form 36). The results of the 
gait analysis will be collated with these measures to evaluate the effect of gait impairment 
on quality of life and functional mobility. 
 
 
Should you have any queries, I can be contacted at 01-8092526. 
 
 
Yours sincerely, 
 
________________________________ 
Ailish McDermott BSc, MISCP 
Senior Physiotherapist, Neurosurgery 
HRB Clinical Research Fellow 
Beaumont Hospital 
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Subject Unique Identifier 
 
 
 
Date of Assessment  
 
 
 
Assessment Number   
 
  
 
 
Section 1.  Background Data. 
 
1.1 Age at time of assessment  
 
 
1.2 Pre-op duration of symptoms  
 
 
1.3 Date of surgery    
 
 
1.4 Surgical Approach Anterior   Posterior  
 
1.5 Level of Surgery 
    
 
1.6 Details of Surgery 
 
 
 
 
  
 
   
1.7 Current Symptoms 
 
 
  
 
 
 
DATA  COLLECTION  SHEET 
Gait Impairment in Cervical Spondylotic Myelopathy: 
Analysis, Impact on Function, and Effect of Surgical 
Intervention 
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Section 2. Screening Questions. 
 
2.1 Past medical history  
 
 
 
 
 
 
2.2 Current Medications 
 
 
 
 
 
2.3 Level of mobility outdoors 
 
 
 
2.4 Number of falls in past six months:  Stumbles / near misses: 
 
     
2.5 Participant's own copy of gait results on CD?   
  
 
2.6 Previous skin reactions to electrodes or similar    
 adhesive material.   
 
   
    
 
2.7 Intensity of physiotherapy treatment post surgery 
 
INPATIENT number of sessions  Average time per session  
OUTPATIENT number of sessions  Average time per session  
TOTAL THERAPY TIME (hours)  
 
 
Additional Information 
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Section 3.  Severity of Myelopathy. 
 
3.1.  Nurick Score.   
 
Grade Description 
0 Signs or symptoms of root involvement, but without evidence of spinal cord 
disease. 
1 Signs of spinal cord disease but no difficulty in walking. 
2 Slight difficulty in walking, which did not prevent full-time employment. 
3 Difficulty in walking which prevented full time employment, or the ability to 
do all housework, but which was not so severe as to require someone's help 
to walk. 
4 Able to walk only with someone else's help or with the aid of a frame. 
5 Chairbound or bedridden. 
 
3.2. Modified Japanese Orthopaedic Association Score 
 
Subsection Description Score Score 
Given 
Motor dysfunction of the upper 
extremity. 
Unable to feed oneself. 
Unable to use knife and fork; able 
to eat with spoon. 
Able to use knife and fork with 
much difficulty. 
Able to use knife and fork with 
some difficulty. 
No dysfunction. 
0 
1 
 
2 
 
3 
 
4 
 
Motor dysfunction of the lower 
extremity. 
Unable to walk. 
Can walk on flat floor with walking 
aid. 
Can walk up and / or down stairs 
with handrail. 
Lack of stability and smooth gait. 
No dysfunction. 
0 
1 
 
2 
 
3 
4 
 
Sensory Deficit: 
   Upper Limb. 
Severe sensory loss or pain. 
Mild sensory loss. 
No dysfunction. 
0 
1 
2 
 
Sensory Deficit: 
   Lower Limb.                                                                            
 
Severe sensory loss or pain. 
Mild sensory loss. 
No dysfunction. 
0 
1 
2 
 
Sensory Deficit:  
    Trunk. 
Severe sensory loss or pain. 
Mild sensory loss. 
No dysfunction. 
0 
1 
2 
 
Sphincter dysfunction. Unable to void. 
Marked difficulty in micturition 
(retention). 
Difficulty in micturition (frequency, 
hesitation). 
No dysfunction. 
0 
1 
2 
 
3 
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Section 4.  Functional Mobility. 
 
4.1. Modified Rivermead Mobility Index (MRMI) 
 
Item Task Score 
R L 1 Turning Over. 
Please turn over from your back to your side.   
2 Lying to Sitting. 
Please sit up on the edge of the bed. 
  
3 Sitting Balance. 
Please sit on the edge of the bed (10 seconds). 
 
4 Sitting to Standing. 
Please stand up from your chair (<15 seconds). 
 
5 Standing. 
Please remain standing (10 seconds). 
 
R L 6 Transfers. 
Please go from the plinth to the chair and back again.   
7 Walking Indoors. 
Please walk 10 metres in your usual way. 
 
8 Stairs. 
Please climb up and down this flight of stairs in your 
usual way. 
 
R L  TOTAL 
  
 
SCORING SYSTEM 
0 Unable to perform 
1 Assistance of two people   
2 Assistance of one person  
3 Requires supervision or verbal instruction 
4 Requires an aid or an appliance 
5 Independent 
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Section 5.  Spasticity 
 
5.2 Ashworth Scale 
 
Muscle Group R L 
Rectus femoris   
Biceps femoris   
Adductor 
magnus / longus 
  
Tibialis anterior   
Gastroc / soleus   
SCORING SYSTEM 
0 = No increase in muscle tone. 
1 = Slight resistance, i.e. catch and release OR 
minimal resistance at end of ROM. 
1+ = Slight resistance, i.e. catch and release AND 
minimal resistance throughout remainder (less than 
half) of ROM. 
2 = More marked resistance throughout range, but 
affected part easily moved. 
3 = Considerable increase in tone, passive movement 
difficult  
4 = Affected part rigid in flexion or extension. 
 
Section 6. Quality of Life. 
 
6.1. Medical Outcomes Study Short Form 36 (SF-36) Score. 
 
Component  Score 
Physical functioning  
Role functioning- physical  
Bodily pain  
General health   
Vitality  
Social functioning  
Role functioning - emotional  
Mental health   
Health transition  
PHYSICAL COMPONENT SUMMARY  
MENTAL COMPONENT SUMMARY  
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Section 7. Anthropometric Data. 
 
!"#$%&'( )"*+,-"."'$( /*0,"(
6.1 Height (cm)  
6.2 Weight (kg)  
6.3 ASIS to ASIS (cm)  
  Left Right 
6.4 Leg length (cm)   
Trial 1   
Trial 2   
Trial 3   
6.5 Knee width (cm) 
AVERAGE   
Trial 1   
Trial 2   
Trial 3   
6.6 Ankle width (cm) 
AVERAGE   
Trial 1   
Trial 2   
Trial 3   
6.7 Tibial torsion (degrees) 
AVERAGE   
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Section 8.  Gait Analysis. 
 
8.1. Surface EMG Settings. 
 
Section Channel Gain (MVIC) Section Channel Gain (CGA) 
8.1 1  8.9 1  
8.2 2  8.10 2  
8.3 3  8.11 3  
8.4 4  8.12 4  
8.5 5  8.13 5  
8.6 6  8.14 6  
8.7 7  8.15 7  
8.8 8  8.16 8  
 
8.2. Trial Records. 
 
Trial Comment Force 
Plate 
(kN) 
Trial Comment Force 
Plate 
(kN) 
1   17   
2   18   
3   19   
4   20   
5   21   
6   22   
7   23   
8   24   
9   25   
10   26   
11   27   
12   28   
13   29   
14   30   
15   31   
16   32   
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function keygaitparams(p,k,type) 
% A function to run through a mat file AvgGaitData(p).(k).mat and 
extract key points for statistical analysis 
% Created by Ailish McDermott, 19-Jan-2011 
% Last modified 19-Jan-2011 
% p = patient number (healthy or CSM) 
% k = assessment number 
% type = whether patient is a healthy control or not (0 if no, 1 
if yes) 
% Change variables ROOT and FILEPATH if changing from MAC to 
Windows or vice versa 
% ------------------------- % 
 
root = '/Users/ailish/Documents/MATLAB/Polygon/'; 
if type == 1 
    filepath = [root,'HC/HC',int2str(p),'/Ax',int2str(k)];  % 
Filename depends on whether data is from a healthy control or CSM 
participant 
else filepath = [root,'CSM/',int2str(p),'/Ax',int2str(k)]; 
end 
 
inputfile = 
[filepath,'/AvgGaitData',int2str(p),'.',int2str(k),'.mat']; 
load(inputfile);                % Loads file of interest 
 
% Get kinematic variables % 
lpt_avg = mean(lpeltilt);       % Mean pelvic tilt during GC 
rpt_avg = mean(rpeltilt); 
lpo_rn = max(lpelobl) - min(lpelobl);   % Range pelvic obliquity 
rpo_rn = max(rpelobl) - min(rpelobl); 
lpr_rn = max(lpelrot) - min(lpelrot);   % Range pelvic rotation 
rpr_rn = max(rpelrot) - min(rpelrot); 
lhipic = lhipfe(1,1);           % Hip position at IC 
rhipic = rhipfe(1,1); 
lhipext = min(lhipfe);          % Peak hip extension 
rhipext = min(rhipfe);   
lhtspe = max(lhipfe) - min(lhipfe);     % Hip total sagittal plane 
excursion 
rhtspe = max(rhipfe) - min(rhipfe); 
lhaa_rn = max(lhipaa) - min(lhipaa);    % Range of hip motion in 
frontal plane 
rhaa_rn = max(rhipaa) - min(rhipaa); 
lhr_rn = max(lhiprot) - min(lhiprot);   % Range of hip motion in 
transverse plane 
rhr_rn = max(rhiprot) - min(rhiprot); 
lkneeic = lkneefe(1,1);         % Knee position at initial contact 
rkneeic = rkneefe(1,1); 
lkf_st = max(lkneefe(1:15));    % Peak knee flexion in stance 
rkf_st = max(rkneefe(1:15)); 
lkext = min(lkneefe);           % Peak knee extension 
rkext = min(rkneefe);    
lkfl_sw = max(lkneefe(30:51));  % Peak knee flexion in swing 
rkfl_sw = max(rkneefe(30:51));  
lktspe = max(lkneefe) - min(lkneefe);   % Knee total sagittal 
plane excursion 
rktspe = max(rkneefe) - min(rkneefe); 
lankic = lankdp(1,1);           % Ankle position at initial 
contact 
rankic = rankdp(1,1); 
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ladf_st = max(lankdp(1:30));    % Maximum ankle dorsiflexion in 
stance 
radf_st = max(rankdp(1:30)); 
lapf = min(lankdp);             % Peak ankle plantarflexion 
rapf = min(rankdp); 
ladf_sw = max(lankdp(30:51));   % Peak ankle dorsiflexion in swing 
radf_sw = max(rankdp(30:51));    
% Now get kinetic parameters % 
lgrfx_pk = min(lgrfx);          % Peak medio-lateral GRF (note: L 
is neg) 
rgrfx_pk = max(rgrfx); 
lgrfy1 = max(lgrfy);            % Peak braking antero-posterior 
GRF 
rgrfy1 = max(rgrfy); 
lgrfy2 = min(lgrfy);            % Peak propulsion AP GRF 
rgrfy2 = min(rgrfy);     
lgrfv1 = max(lgrfz);            % Peak vertical GRF 
rgrfv1 = max(rgrfz);             
lhmomf = min(lhipmomfe);        % Peak hip flexor moment 
rhmomf = min(rhipmomfe); 
lhmome = max(lhipmomfe);        % Peak hip extensor moment 
rhmome = max(rhipmomfe);         
lhmomab = max(lhipmomaa);       % Peak hip abductor moment 
rhmomab = max(rhipmomaa);    
lkmomf = min(lkneemom);         % Peak hip flexor moment 
rkmomf = min(rkneemom);          
lkmome = max(lkneemom);         % Peak knee extensor moment 
rkmome = max(rkneemom);          
lamomp = max(lankmom);          % Peak ankle plantarflexor moment 
ramomp = max(rankmom);   
lh1 = max(lhippower(6:20));     % H1 hip power 
rh1 = max(rhippower(6:20)); 
lh2 = min(lhippower(20:35));    % H2 hip power 
rh2 = min(rhippower(20:35)); 
lh3 = max(lhippower(25:51));    % H3 hip power 
rh3 = max(rhippower(25:51)); 
lk1 = min(lkneepower(2:10));    % K1 knee power 
rk1 = min(rkneepower(2:10)); 
lk2 = max(lkneepower(10:30));   % K2 knee power 
rk2 = max(rkneepower(10:30)); 
lk3 = min(lkneepower(30:40));   % K3 knee power 
rk3 = min(rkneepower(30:40)); 
lk4 = min(lkneepower(40:51));   % K4 knee power 
rk4 = min(rkneepower(40:51)); 
la1 = min(lankpower(5:25));     % A1 ankle power 
ra1 = min(rankpower(5:25)); 
la2 = max(lankpower);           % A2 ankle power 
ra2 = max(rankpower); 
% Save the output % 
outputfile = 
[filepath,'/KeyGaitParams',int2str(p),'.',int2str(k),'.mat']; 
eval(['save ', outputfile, ' lpt_avg rpt_avg lpo_rn rpo_rn lpr_rn 
rpr_rn lhipic rhipic lhipext rhipext lhtspe rhtspe lhaa_rn rhaa_rn 
lhr_rn rhr_rn lkneeic rkneeic lkf_st rkf_st lkext rkext lkfl_sw 
rkfl_sw lktspe rktspe lankic rankic ladf_st radf_st lapf rapf 
ladf_sw radf_sw lgrfx_pk rgrfx_pk lgrfy1 rgrfy1 lgrfy2 rgrfy2 
lgrfv1 rgrfv1 lhmomf rhmomf lhmome rhmome lhmomab rhmomab lkmomf 
rkmomf lkmome rkmome lamomp ramomp lh1 rh1 lh2 rh2 lh3 rh3 lk1 rk1 
lk2 rk2 lk3 rk3 lk4 rk4 la1 ra1 la2 ra2']); 
end 
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% getemg2 = A script file to extract 8 signals arrays from a 
defined gait cycle, using Workstation to provide gait cycle on and 
off times. 
% Written by Ailish McDermott; modified 19/08/10 
% For use with CSM or healthy control data 
% Input: filein = csv file to be read by MATLAB containing all the 
analog data from a single gait cycle; l1=frame of onset of left 
gait cycle; 
% l2=frame of offset of left gait cycle; r1=frame of onset of 
right gait cycle; r2=frame of offset of right gait cycle. Frames 
are based on Workstation time bar which captures at 50 Hz. 
% p = subject number 
% k = session code (1=preop1,2=preop2, 3=postop 6 months; 4= 
postop 1 year) 
% k for healthy controls: 1 = comfortable speed, 2 = matched speed 
% n = trial number (1-10) 
% Output: 8 EMG channels. 
%-------------------------------------------------- 
 
p = input('Please enter participant number '); 
k = input('Please enter assessment number '); 
n = input('Please enter trial number '); 
HC = input('Enter 1 if participant is a healthy control, 0 if not 
'); 
filein = input('Please enter filepath for reference csv file '); 
l1 = input('Enter frame for start of left gait cycle '); 
l2 = input('Enter frame for end of left gait cycle '); 
r1 = input('Enter frame for start of right gait cycle '); 
r2 = input('Enter frame for end of right gait cycle '); 
 
[numeric]=xlsread(filein);  % Specify filepath for .csv files 
containing gait cycle data 
time=numeric(:,1);    % Specify 1st column in numeric 
matrix to be time, in units of ms 
[x1]=find(time==(l1*20)); 
[x2]=find(time==(l2*20));  % Find matrix references for start 
and end points of left gait cycle where x=row. *20 translates 
Workstation frame to EMG units (50 to 1000 Hz). 
lrf=numeric(x1:x2,2);   % Define EMG for L rectus femoris as 
2nd column, rows defined by GC 
lbf=numeric(x1:x2,4);     % Define EMG for L biceps 
femoris as 4th column, rows x1-x2 
lta=numeric(x1:x2,6);     % Define EMG for L tibialis 
anterior as 6th column, rows as above 
lmg=numeric(x1:x2,8);     % Define EMG for L medial 
gastrocnemius, 8th column, rows as above 
[x3]=find(time==(r1*20)); 
[x4]=find(time==(r2*20));  % Find matrix references for start 
and end points of right GC 
rrf=numeric(x3:x4,3);     % Define EMG for R rectus 
femoris as 3rd column, rows defined by GC 
rbf=numeric(x3:x4,5);     % Define EMG for R biceps 
femoris as 5th column, rows as above 
rta=numeric(x3:x4,7);     % Define EMG for R tibialis 
anterior as 7th column, rows as above  
rmg=numeric(x3:x4,9);     % Define EMG for R medial 
gastrocnemius as 9th column, rows as above 
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if p < 10  
    if HC == 0 
    path = '08520'; 
    root = 'EMG0'; 
    else 
        path = 'HC0'; 
        root = 'HCEMG0'; 
    end 
else  
    if HC == 0 
        path = '0852'; 
        root = 'EMG'; 
    else 
        path = 'HC'; 
        root = 'HCEMG'; 
    end 
end 
if n < 10 
    stem = '.0'; 
else  
    stem = '.'; 
end 
 
savefile = ['C:\Documents and Settings\Vicon\My 
Documents\MATLAB\',path,int2str(p),'\',root,int2str(p),'.0',int2st
r(k),stem,int2str(n),'.mat']; 
save(savefile, 'rrf','lrf','rbf','lbf','rta','lta','rmg','lmg'); 
clear all 
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function ON = emgtiming3(signal) 
 
% A script file to determine muscle activation based on slope and 
amplitude of the EMG signal after it is modified by TKEO 
% Applies the TKEO function to an already filtered signal 
% Then smooths with a low-pass Butterworth 
% Created by Ailish McDermott, RCSI Movement Lab, 16-Nov-2010 
% Modified 18-Nov-2010  
% Inputs: signal  
% ----------------------- % 
 
sig = tkeo(signal);    % Apply TKEO to filtered gait data 
[B,A] = butter(2,0.05,'low'); % Get vectors for dual-pass filter 
for smoothing 
sig2 = filtfilt(B,A,sig); % Smooths the signal 
slope = gradient(sig2); % Gets the slope of the smoothed signal 
sig_on = abs(slope) > 1e-6; % Creates logical index where the 
absolute value of the slope is above a threshold 
th = (max(sig2))*0.03;  % Sets a threshold at 3% maximum value of 
signal 
sig_on2 = sig2 > th;    % Finds points where sig2 exceeds 
threshold value 
 
% Now put sig_on and sig_on2 side by side and sum the values 
% Create new logical matrix where both sig_on and sig_on2 declare 
1, i.e. both slope and amplitude exceed threshold 
 
isiton = [sig_on sig_on2]'; % Creates matrix of both "on" 
conditions in rows for summing columns 
both_on = sum(isiton);  % Sums the columns of the 2 row vectors 
timeon = both_on';  % Transposes the resulting vector back to a 
column instead of a row 
changetime = timeon == 2;   % Creates a new logical vector where 
both conditions are satisfied for slope and threshold 
 
% Now see if both conditions are satisfied for at least 24 of 25 
% consecutive samples 
 
TIME = [changetime(end-12:end); changetime; changetime(1:12)];    
% Appends the last 12 values to the beginning and first 12 values 
to end to create new vector TIME 
t = length(changetime);   % Gets the number of data points for new 
matrix containing 25 consecutive ON values 
R = zeros(t,1); % Initialises a matrix that will contain logical 
values of TIME 
 
for n = 1:t 
    R(n) = sum(TIME(n:n+24));   % Sums each consecutive set of 25 
data points 
end 
ON = R > 23;    % If 24 of 25 consecutive points are satisfying 
the on condition, then consider muscle to be on (allows for blips 
in middle of contraction) 
T = 1:t'; 
[AX,H1,H2] = plotyy(T,sig,T,ON);    % Plots signal and ON values 
on 2 y axes 
set(AX(2),'ylim',[0 1.5]);          % Sets limits of second y axis 
hold on     % Holds the graph 
plot(sig2,'r')   % Plots the smoothed signal for comparison (in 
red)  
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saveas(gcf,'muscleplot.fig'); 
hold off 
% Now find where the changes occur at the beginning and end of 
each "on" period 
% Sum each pair of consecutive values. If muscle is continuously 
OFF then sum = 0; if continuously ON then sum = 2; if changing 
then sum = 1 
R2 = [ON(end); ON; ON(1)];   % Creates R2 by appending start and 
end values of ON 
for n = 1:length(ON) 
    Alert(n) = sum(R2(n:n+1));   % Adds consecutive variables 
end 
CHANGE = Alert == 1; 
Idx = find(CHANGE == 1);    % Find indices where change is 
signalled 
percent = (Idx/length(ON))*100; % Gets percentage points in GC 
that changes occur 
save Idx ON percent 
end 
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%% DECLARATIONS AND INITIALIZATIONS 
  
% Calculates windowed (over- and non-overlapping) RMS of a signal 
using the specified windowlength y = rms(signal, windowlength, 
overlap, zeropad) 
% signal is a 1-D vector 
% windowlength is an integer length of the RMS window in samples 
% overlap is the number of samples to overlap adjacent windows 
(enter 0 to use non-overlapping windows) 
% zeropad is a flag for zero padding the end of your data...(0 for 
NO, 1 for YES) 
% ex. y=rms(mysignal, 30, 10, 1).  Calculate RMS with window of 
length 30 samples, overlapped by 10 samples each, and zeropad the 
last window if necessary 
% ex. y=rms(mysignal, 30, 0, 0).  Calculate RMS with window of 
length 30 samples, no overlapping samples, and do not zeropad the 
last window 
% 
% Author: A. Bolu Ajiboye 
  
function y = rms(signal, windowlength, overlap, zeropad) 
  
delta = windowlength - overlap; 
  
%% CALCULATE RMS 
  
indices = 1:delta:length(signal); 
% Zeropad signal 
if length(signal) - indices(end) + 1 < windowlength 
    if zeropad 
        signal(end+1:indices(end)+windowlength-1) = 0; 
    else 
        indices = indices(1:find(indices+windowlength-1 <= 
length(signal), 1, 'last')); 
    end 
end 
  
y = zeros(1, length(indices)); 
% Square the samples 
signal = signal.^2; 
  
index = 0; 
for i = indices 
    index = index+1; 
    % Average and take the square root of each window 
    y(index) = sqrt(mean(signal(i:i+windowlength-1))); 
end 
 
Ajiboye, A.B., 2006. "Signal RMS". 
http://www.mathworks.co.uk/matlabcentral/fileexchange/11871-signal-rms. 
 
328 
!""#$%&'(G*JJ,(:ZB/0&1$(01(./-.B-/0#(DB9.-#(-#$503#$&$5(F#-1.&0;(
/$%(-#$503#$&$5(F#-1.&0;(036#931-%(
The length of any given muscle, lm, at time t is expressed as: 
lm(t)/l0 = 1 + a!1(t) + b!12(t) + c!13(t) + d!2(t) + e!22(t) + f!23(t)  (Eq. 1) 
where lm is the length change (shortening) of the muscle (origin to insertion), l0 is the 
resting fibre length of the muscle when the body is in the anatomical position and all 
angles, !, = 0, !1 is the joint angle for a single joint muscle, in degrees, with flexor being 
positive, !2 is the joint angle for the adjacent joint for a biarticulate muscle with flexor also 
being positive, and a–f are coefficients determined by the curve fit calculated by Winter 
and Scott (1991) and provided in Table 1. 
When all joint angles ! = 0º, lm/l0 = 1 
If a parallel fibre muscle is being analysed, the velocity of the muscle fibres vf at a given 
time t in lo/s is the same as the velocity of the length of the muscle: 
 vf(t) = d/dt(lm(t)/l0)       (Eq. 2) 
where d/dt is the change in length of the muscle with respect to time, i.e. the first 
derivative 
For a pennate muscle, the angle of pennation will change with respect to time as a result 
of the length changes calculated in Eq. 1. The muscle volume remains constant, 
therefore the pennation angle "p will change with time as follows: 
 "p(t) = tan-1(sin"0/(cos"0 – (1 – lm(t)/l0)))     (Eq. 3) 
where "0 is the angle of pennation of the muscle at resting length, provided in Table 1. 
The active length of the muscle in l0 is lf(t): 
 lf(t)/l0 = sin"0/sin"p(t)       (Eq. 4) 
The velocity of the muscle fibres in l0/s is: 
 vf(t) = d/dt(lf(t)/l0)       (Eq. 5) 
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Muscle a b c d e f "0 
TA -6.07 x 10-3 5.86 x 10-5 4.5 x 10-7    8 
MG 1.22 x 10-2 -4.25 x 10-5 -6.12 x 10-7 -6.75 x 10-3 -9.16 x 10-6 -8.48 x 10-8 8 
RF 1.63 x 10-2 -1.75 x 10-5 -4.5 x 10-7 -1.16 x 10-2 -6.06 x 10-5 6.36 x 10-7 15 
BF 7.3 x 10-3 1.29 x 10-4 -8.52 x 10-7 -1.93 x 10-3 -9.26 x 10-6 1.15 x 10-7 0 
!0 = pennation angle at resting length, TA = tibialis anterior, MG = medial gastrocnemius, RF = 
rectus femoris, BF = biceps femoris, a, b, c = coefficients applied to the hip angle (BF and RF) and 
ankle angle (MG and TA), d, e, f = coefficients applied to knee angle (BF, RF, MG) 
Source 
Winter, D.A. & Scott, S.H., 1991. Technique for interpretation of electromyography for 
concentric and eccentric contractions in gait. Journal of Electromyography and 
Kinesiology, 1, 263-269. 
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function lengthening_velocity_locomotor_spasticity(p,k,n,hc,q) 
% A function to determine the lengthening velocities, lengthening 
velocity thresholds for EMG activation and slope of relationship 
between lengthening velocity and EMG for 8 lower limb muscles 
% Calculations from Winter, D.A. & Scott, S.H., 1991. Journal of Electromyography 
and Kinesiology, 1, 263-269. 
% Inputs: p = patient number, k = assessment number, n = trial 
number, hc = healthy control (1 = yes), q = reliability assessment 
not conducted (1 = true) 
% -------------------- % 
 
% DEFINE FILES TO BE LOADED  
if hc == 0 
    if q == 1 
        polygonfile = 
['/Users/ailish/Documents/MATLAB/Polygon/CSM/',int2str(p),'/Ax',in
t2str(k+1),'/Trial',int2str(n),'.mat']; 
    else polygonfile = 
['/Users/ailish/Documents/MATLAB/Polygon/CSM/',int2str(p),'/Ax',in
t2str(k),'/Trial',int2str(n),'.mat']; 
    end 
 
    rmsfile = 
['/Users/ailish/Documents/MATLAB/RMS/RMS_Normalised/EMG_RMS_Norm',
int2str(p),'.',int2str(k),'.',int2str(n),'.mat']; 
    timingfile1 = 
['/Users/ailish/Documents/MATLAB/TimingTests/LRF',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
    timingfile2 = 
['/Users/ailish/Documents/MATLAB/TimingTests/RRF',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
    timingfile3 = 
['/Users/ailish/Documents/MATLAB/TimingTests/LBF',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
    timingfile4 = 
['/Users/ailish/Documents/MATLAB/TimingTests/RBF',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
    timingfile5 = 
['/Users/ailish/Documents/MATLAB/TimingTests/LTA',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
    timingfile6 = 
['/Users/ailish/Documents/MATLAB/TimingTests/RTA',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
    timingfile7 = 
['/Users/ailish/Documents/MATLAB/TimingTests/LMG',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
    timingfile8 = 
['/Users/ailish/Documents/MATLAB/TimingTests/RMG',int2str(p),'.',i
nt2str(k),'.',int2str(n),'.mat']; 
 
else polygonfile = 
['/Users/ailish/Documents/MATLAB/Polygon/HC/HC',int2str(p),'/Ax',i
nt2str(k),'/Trial',int2str(n),'.mat']; 
    rmsfile = 
['/Users/ailish/Documents/MATLAB/RMS/RMS_Normalised/HCEMG_RMS_Norm
',int2str(p),'.',int2str(k),'.',int2str(n),'.mat']; 
    timingfile1 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCLRF',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
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    timingfile2 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCRRF',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
    timingfile3 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCLBF',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
    timingfile4 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCRBF',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
    timingfile5 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCLTA',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
    timingfile6 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCRTA',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
    timingfile7 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCLMG',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
    timingfile8 = 
['/Users/ailish/Documents/MATLAB/TimingTests/HCRMG',int2str(p),'.'
,int2str(k),'.',int2str(n),'.mat']; 
end 
 
load(polygonfile); 
rfo = round(RFO);  % RFO = right opposite foot off  
lfo = round(LFO);  % LFO = left opposite foot off 
load(rmsfile);  % rmsfile contains root mean square 
amplitude  
% 
% ------------------- % 
% INDIVIDUAL MUSCLE CALCULATIONS 
% Left rectus femoris 
% 
load(timingfile1); 
a = 1.63e-2;  % Constants from Winter & Scott (1991) 
b = -1.75e-5; 
c = -4.5e-7; 
d = -1.16e-2; 
e = -6.06e-5; 
f = 6.36e-7; 
pennation_angle = 15; 
t = linspace(0,LStrTime,51); 
time = t'; 
lrf_length = 1 + (a.*LHipFE) + (b.*(LHipFE.^2)) + (c.*(LHipFE.^3)) 
+ (d.*LKneeFE) + (e.*(LKneeFE.^2)) + (f.*(LKneeFE.^3)); 
pennation_angle_wrt_time = 
atand(sind(pennation_angle)./((cosd(pennation_angle)) - (1 - 
(lrf_length)))); 
lrf_active_length = 
sind(pennation_angle)./sind(pennation_angle_wrt_time); 
lrf_lengthening_velocity1 = diff(lrf_active_length)./diff(time); 
% Interpolate lrf_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(lrf_lengthening_velocity1)-1)/(101-
1):length(lrf_lengthening_velocity1); 
lrf_lengthening_velocity = 
interp1(1:length(lrf_lengthening_velocity1),lrf_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
lrf_slope_time = find(lrf_lengthening_velocity > 0); 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
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end 
percent_round = round(percent); 
try 
    lrf_threshold_options = find(percent_round >= 
min(lrf_slope_time)); 
    if mod(lrf_threshold_options(1),2) == 1     % Ensures that 
first indicator is an “on” value not an “off” value 
        lrf_critical_time = 
percent_round(min(lrf_threshold_options)); 
    else lrf_critical_time = 
percent_round(lrf_threshold_options(2)); 
    end 
    lrf_lengthening_velocity_threshold = 
lrf_lengthening_velocity(lrf_critical_time);   % Output variable 
catch 
    lrf_critical_time = NaN; 
    lrf_lengthening_velocity_threshold = NaN; 
end 
X = 
lrf_lengthening_velocity(min(lrf_slope_time):max(lrf_slope_time)); 
Y = lrf_rms_norm(min(lrf_slope_time):max(lrf_slope_time)); 
p_slope = polyfit(X,Y,1); 
lrf_response_slope = p_slope(1); 
% 
% ----------------------- % 
% Right rectus femoris 
% 
load(timingfile2); 
t = linspace(0,RStrTime,51); 
time = t'; 
rrf_length = 1 + (a.*RHipFE) + (b.*(RHipFE.^2)) + (c.*(RHipFE.^3)) 
+ (d.*RKneeFE) + (e.*(RKneeFE.^2)) + (f.*(RKneeFE.^3)); 
pennation_angle_wrt_time = 
atand(sind(pennation_angle)./((cosd(pennation_angle)) - (1 - 
(rrf_length)))); 
rrf_active_length = 
sind(pennation_angle)./sind(pennation_angle_wrt_time); 
rrf_lengthening_velocity1 = diff(rrf_active_length)./diff(time); 
% Interpolate rrf_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(rrf_lengthening_velocity1)-1)/(101-
1):length(rrf_lengthening_velocity1); 
rrf_lengthening_velocity = 
interp1(1:length(rrf_lengthening_velocity1),rrf_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
rrf_slope_time = find(rrf_lengthening_velocity > 0); 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
end 
percent_round = round(percent); 
try 
    rrf_threshold_options = find(percent_round >= 
min(rrf_slope_time)); 
    if mod(rrf_threshold_options(1),2) == 1     % Ensures that 
first indicator is an on value not an off value 
        rrf_critical_time = 
percent_round(min(rrf_threshold_options)); 
    else rrf_critical_time = 
percent_round(rrf_threshold_options(2)); 
    end 
    rrf_lengthening_velocity_threshold = 
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rrf_lengthening_velocity(rrf_critical_time);   % Output variable 
catch 
    rrf_critical_time = NaN; 
    rrf_lengthening_velocity_threshold = NaN; 
end 
X = 
rrf_lengthening_velocity(min(rrf_slope_time):max(rrf_slope_time)); 
Y = rrf_rms_norm(min(rrf_slope_time):max(rrf_slope_time)); 
p_slope = polyfit(X,Y,1); 
rrf_response_slope = p_slope(1); 
% 
% ----------------------- % 
% Left biceps femoris 
% 
load(timingfile3); 
a = 7.3e-3; 
b = 1.29e-4; 
c = -8.52e-7; 
d = -1.93e-3; 
e = -9.26e-6; 
f = 1.15e-7; 
t = linspace(0,LStrTime,51); 
time = t'; 
lbf_length = 1 + (a.*LHipFE) + (b.*(LHipFE.^2)) + (c.*(LHipFE.^3)) 
+ (d.*LKneeFE) + (e.*(LKneeFE.^2)) + (f.*(LKneeFE.^3)); 
lbf_active_length = lbf_length; 
lbf_lengthening_velocity1 = diff(lbf_length)./diff(time); 
% Interpolate lbf_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(lbf_lengthening_velocity1)-1)/(101-
1):length(lbf_lengthening_velocity1); 
lbf_lengthening_velocity = 
interp1(1:length(lbf_lengthening_velocity1),lbf_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
lbf_slope_time = find(lbf_lengthening_velocity > 0); 
for w = 1:length(lbf_slope_time) 
    if lbf_slope_time(w) < lfo 
        lbf_slope_time(w) = NaN; 
    else 
    end 
end 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
end 
percent_round = round(percent); 
try 
    lbf_threshold_options = find(percent_round >= 
min(lbf_slope_time)); 
    if mod(lbf_threshold_options(1),2) == 1     % Ensures that 
first indicator is an on value not an off value 
        lbf_critical_time = 
percent_round(min(lbf_threshold_options)); 
    else lbf_critical_time = 
percent_round(lbf_threshold_options(2)); 
    end 
    lbf_lengthening_velocity_threshold = 
lbf_lengthening_velocity(lbf_critical_time);   % Output variable 
catch 
    lbf_critical_time = NaN; 
    lbf_lengthening_velocity_threshold = NaN; 
end 
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X = 
lbf_lengthening_velocity(min(lbf_slope_time):max(lbf_slope_time)); 
Y = lbf_rms_norm(min(lbf_slope_time):max(lbf_slope_time)); 
p_slope = polyfit(X,Y,1); 
lbf_response_slope = p_slope(1); 
%  
% ------------------------ % 
% Right biceps femoris 
%  
load(timingfile4); 
t = linspace(0,RStrTime,51); 
time = t'; 
rbf_length = 1 + (a.*RHipFE) + (b.*(RHipFE.^2)) + (c.*(RHipFE.^3)) 
+ (d.*RKneeFE) + (e.*(RKneeFE.^2)) + (f.*(RKneeFE.^3)); 
rbf_active_length = rbf_length; 
rbf_lengthening_velocity1 = diff(rbf_length)./diff(time); 
% Interpolate rbf_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(rbf_lengthening_velocity1)-1)/(101-
1):length(rbf_lengthening_velocity1); 
rbf_lengthening_velocity = 
interp1(1:length(rbf_lengthening_velocity1),rbf_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
rbf_slope_time = find(rbf_lengthening_velocity > 0); 
for w = 1:length(rbf_slope_time) 
    if rbf_slope_time(w) < rfo 
        rbf_slope_time(w) = NaN; 
    else 
    end 
end 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
end 
percent_round = round(percent); 
try 
    rbf_threshold_options = find(percent_round >= 
min(rbf_slope_time)); 
    if mod(rbf_threshold_options(1),2) == 1     % Ensures that 
first indicator is an on value not an off value 
        rbf_critical_time = 
percent_round(min(rbf_threshold_options)); 
    else rbf_critical_time = 
percent_round(rbf_threshold_options(2)); 
    end 
    rbf_lengthening_velocity_threshold = 
rbf_lengthening_velocity(rbf_critical_time);   % Output variable 
catch 
    rbf_critical_time = NaN; 
    rbf_lengthening_velocity_threshold = NaN; 
end 
X = 
rbf_lengthening_velocity(min(rbf_slope_time):max(rbf_slope_time)); 
Y = rbf_rms_norm(min(rbf_slope_time):max(rbf_slope_time)); 
p_slope = polyfit(X,Y,1); 
rbf_response_slope = p_slope(1); 
% 
% ------------------------------- 
% Left tibialis anterior 
%  
load(timingfile5); 
a = -6.07e-3; 
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b = 5.86e-5; 
c = 4.5e-7; 
pennation_angle = 8; 
t = linspace(0,LStrTime,51); 
time = t'; 
lta_length = 1 + (a.*LAnkDP) + (b.*(LAnkDP.^2)) + 
(c.*(LAnkDP.^3)); 
pennation_angle_wrt_time = 
atand(sind(pennation_angle)./((cosd(pennation_angle)) - (1 - 
(lta_length)))); 
lta_active_length = 
sind(pennation_angle)./sind(pennation_angle_wrt_time); 
lta_lengthening_velocity1 = diff(lta_active_length)./diff(time); 
% Interpolate lta_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(lta_lengthening_velocity1)-1)/(101-
1):length(lta_lengthening_velocity1); 
lta_lengthening_velocity = 
interp1(1:length(lta_lengthening_velocity1),lta_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
lta_slope_time = find(lta_lengthening_velocity > 0); 
loppfo = round(LOppFO); 
for w = 1:length(lta_slope_time) 
    if lta_slope_time(w) < loppfo 
        lta_slope_time(w) = NaN; 
    else 
    end 
end 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
end 
percent_round = round(percent); 
try 
    lta_threshold_options = find(percent_round >= 
min(lta_slope_time)); 
    if mod(lta_threshold_options(1),2) == 1     % Ensures that 
first indicator is an on value not an off value 
        lta_critical_time = 
percent_round(min(lta_threshold_options)); 
    else lta_critical_time = 
percent_round(lta_threshold_options(2)); 
    end 
    lta_lengthening_velocity_threshold = 
lta_lengthening_velocity(lta_critical_time);   % Output variable 
catch 
    lta_critical_time = NaN; 
    lta_lengthening_velocity_threshold = NaN; 
end 
X = 
lta_lengthening_velocity(min(lta_slope_time):max(lta_slope_time)); 
Y = lta_rms_norm(min(lta_slope_time):max(lta_slope_time)); 
p_slope = polyfit(X,Y,1); 
lta_response_slope = p_slope(1); 
% 
% ----------------------- % 
% Right tibialis anterior 
% 
load(timingfile6); 
t = linspace(0,RStrTime,51); 
time = t'; 
rta_length = 1 + (a.*RAnkDP) + (b.*(RAnkDP.^2)) + 
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(c.*(RAnkDP.^3)); 
pennation_angle_wrt_time = 
atand(sind(pennation_angle)./((cosd(pennation_angle)) - (1 - 
(rta_length)))); 
rta_active_length = 
sind(pennation_angle)./sind(pennation_angle_wrt_time); 
rta_lengthening_velocity1 = diff(rta_active_length)./diff(time); 
% Interpolate rta_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(rta_lengthening_velocity1)-1)/(101-
1):length(rta_lengthening_velocity1); 
rta_lengthening_velocity = 
interp1(1:length(rta_lengthening_velocity1),rta_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
rta_slope_time = find(rta_lengthening_velocity > 0); 
roppfo = round(ROppFO); 
for w = 1:length(rta_slope_time) 
    if rta_slope_time(w) < roppfo 
        rta_slope_time(w) = NaN; 
    else 
    end 
end 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
end 
percent_round = round(percent); 
try 
    rta_threshold_options = find(percent_round >= 
min(rta_slope_time)); 
    if mod(rta_threshold_options(1),2) == 1     % Ensures that 
first indicator is an on value not an off value 
        rta_critical_time = 
percent_round(min(rta_threshold_options)); 
    else rta_critical_time = 
percent_round(rta_threshold_options(2)); 
    end 
    rta_lengthening_velocity_threshold = 
rta_lengthening_velocity(rta_critical_time);   % Output variable 
catch 
    rta_critical_time = NaN; 
    rta_lengthening_velocity_threshold = NaN; 
end 
X = 
rta_lengthening_velocity(min(rta_slope_time):max(rta_slope_time)); 
Y = rta_rms_norm(min(rta_slope_time):max(rta_slope_time)); 
p_slope = polyfit(X,Y,1); 
rta_response_slope = p_slope(1); 
% 
% ------------------- % 
% Left medial gastroc 
% 
load(timingfile7); 
pennation_angle = 8; 
a = 1.22e-2; 
b = -4.25e-5; 
c = -6.12e-7; 
d = -6.75e-3; 
e = -9.16e-6; 
f = -8.48e-8; 
t = linspace(0,LStrTime,51); 
time = t'; 
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lmg_length = 1 + (a.*LAnkDP) + (b.*(LAnkDP.^2)) + (c.*(LAnkDP.^3)) 
+ (d.*LKneeFE) + (e.*(LKneeFE.^2)) + (f.*(LKneeFE.^3)); 
pennation_angle_wrt_time = 
atand(sind(pennation_angle)./((cosd(pennation_angle)) - (1 - 
(lmg_length)))); 
lmg_active_length = 
sind(pennation_angle)./sind(pennation_angle_wrt_time); 
lmg_lengthening_velocity1 = diff(lmg_active_length)./diff(time); 
% Interpolate lmg_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(lmg_lengthening_velocity1)-1)/(101-
1):length(lmg_lengthening_velocity1); 
lmg_lengthening_velocity = 
interp1(1:length(lmg_lengthening_velocity1),lmg_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
lmg_slope_time = find(lmg_lengthening_velocity > 0); 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
end 
percent_round = round(percent); 
try 
    lmg_threshold_options = find(percent_round >= 
min(lmg_slope_time)); 
    if mod(lmg_threshold_options(1),2) == 1     % Ensures that 
first indicator is an on value not an off value 
        lmg_critical_time = 
percent_round(min(lmg_threshold_options)); 
    else lmg_critical_time = 
percent_round(lmg_threshold_options(2)); 
    end 
    lmg_lengthening_velocity_threshold = 
lmg_lengthening_velocity(lmg_critical_time);   % Output variable 
catch 
    lmg_critical_time = NaN; 
    lmg_lengthening_velocity_threshold = NaN; 
end 
X = 
lmg_lengthening_velocity(min(lmg_slope_time):max(lmg_slope_time)); 
Y = lmg_rms_norm(min(lmg_slope_time):max(lmg_slope_time)); 
p_slope = polyfit(X,Y,1); 
lmg_response_slope = p_slope(1); 
% 
% ---------------------- % 
% Right medial gastroc 
% 
load(timingfile8); 
t = linspace(0,RStrTime,51); 
time = t'; 
rmg_length = 1 + (a.*RAnkDP) + (b.*(RAnkDP.^2)) + (c.*(RAnkDP.^3)) 
+ (d.*RKneeFE) + (e.*(RKneeFE.^2)) + (f.*(RKneeFE.^3)); 
pennation_angle_wrt_time = 
atand(sind(pennation_angle)./((cosd(pennation_angle)) - (1 - 
(rmg_length)))); 
rmg_active_length = 
sind(pennation_angle)./sind(pennation_angle_wrt_time); 
rmg_lengthening_velocity1 = diff(rmg_active_length)./diff(time); 
% Interpolate rmg_lengthening_velocity to 101 data points for 
comparison 
% with EMG 
xi = 1:(length(rmg_lengthening_velocity1)-1)/(101-
1):length(rmg_lengthening_velocity1); 
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rmg_lengthening_velocity = 
interp1(1:length(rmg_lengthening_velocity1),rmg_lengthening_veloci
ty1,xi);   % OUTPUT VARIABLE 
rmg_slope_time = find(rmg_lengthening_velocity > 0); 
if ON(Idx(1)) == 0 
    percent = [0 percent 100]; 
else 
end 
percent_round = round(percent); 
try 
    rmg_threshold_options = find(percent_round >= 
min(rmg_slope_time)); 
    if mod(rmg_threshold_options(1),2) == 1     % Ensures that 
first indicator is an on value not an off value 
        rmg_critical_time = 
percent_round(min(rmg_threshold_options)); 
    else rmg_critical_time = 
percent_round(rmg_threshold_options(2)); 
    end 
    rmg_lengthening_velocity_threshold = 
rmg_lengthening_velocity(rmg_critical_time);   % Output variable 
catch 
    rmg_critical_time = NaN; 
    rmg_lengthening_velocity_threshold = NaN; 
end 
X = 
rmg_lengthening_velocity(min(rmg_slope_time):max(rmg_slope_time)); 
Y = rmg_rms_norm(min(rmg_slope_time):max(rmg_slope_time)); 
p_slope = polyfit(X,Y,1); 
rmg_response_slope = p_slope(1); 
%  
% Save output 
if hc == 0 
    outputfile = 
['/Users/ailish/Documents/MATLAB/RESULTS/Spasticity/Trials/Lengthe
ning_Scores',int2str(p),'.',int2str(k),'.',int2str(n),'.mat']; 
else outputfile = 
['/Users/ailish/Documents/MATLAB/RESULTS/Spasticity/Trials/Lengthe
ning_Scores_HC',int2str(p),'.',int2str(k),'.',int2str(n),'.mat']; 
end 
eval(['save ',outputfile,' lrf_critical_time 
lrf_lengthening_velocity_threshold lrf_response_slope 
lrf_lengthening_velocity lrf_active_length rrf_critical_time 
rrf_lengthening_velocity_threshold rrf_response_slope 
rrf_lengthening_velocity rrf_active_length lbf_critical_time 
lbf_lengthening_velocity_threshold lbf_response_slope 
lbf_lengthening_velocity lbf_active_length rbf_critical_time 
rbf_lengthening_velocity_threshold rbf_response_slope 
rbf_lengthening_velocity rbf_active_length lta_critical_time 
lta_lengthening_velocity_threshold lta_response_slope 
lta_lengthening_velocity lta_active_length rta_critical_time 
rta_lengthening_velocity_threshold rta_response_slope 
rta_lengthening_velocity rta_active_length lmg_critical_time 
lmg_lengthening_velocity_threshold lmg_response_slope 
lmg_lengthening_velocity lmg_active_length rmg_critical_time 
rmg_lengthening_velocity_threshold rmg_response_slope 
rmg_lengthening_velocity rmg_active_length']); 
clear all 
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Method of Streiner and Norman (2008) 
 
Calculation of the required sample size begins with an estimate of the likely intraclass 
correlation, R, and the desired confidence interval around R. The standard error, SE, is 
half the confidence interval. The number of observations for use in the study, k, must also 
be known. 
 
First compute: 
 R– = R – SE         (Eq. 1) 
 
Then calculate the z scores of R and R– as follows:  
 zR = !.ln((1 + (k – 1)R) / (1 – R)) 
and 
 zR– = !.ln((1 + (k – 1)R–) / (1 – R–))     (Eq. 2) 
 
SE of the z scores is then computed as follows: 
 SE = zR – zR–        (Eq. 3) 
 
From a previous equation derived by Streiner and Norman (2008): 
 SE(zR) = #(k / (2(k - 1)(n - 2)))      (Eq. 4) 
 
Therefore, squaring and cross multiplying, the sample size n can be calculated: 
 n = 2 + (k / (2(k – 1)( zR – zR–)2))      (Eq. 5) 
 
Source 
Streiner, D. & Norman, G., 2008. Reliability. Health measurement scales: a practical 
guide to their development and use. 4th ed. Oxford: Oxford University Press, 
167-210. 
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Controls Information Leaflet 
Protocol Title: 
Principal Investigator’s Name: Ailish McDermott 
Principal Investigator’s Title: Senior Physiotherapist 
Telephone No. of Principal Investigator: 018092526 / 085 8336094 
You are being invited to take part in a clinical research study carried out at Beaumont 
Hospital and the Royal College of Surgeons in Ireland.  Before you decide whether or not 
you wish to take part, you should read the information provided below carefully and if you 
wish discuss it with your family, friends or GP.  Take time to ask questions – do not feel 
rushed or under any obligation to participate. You should clearly understand the risks and 
benefits of participating in this study so that you can make a decision that is right for you 
– this process is known as Informed Consent.  
You are not obliged to take part in this study and failure to participate will have no effect 
on your future care. You may change your mind at any time (before the start of the study 
or even after you have commenced the study) for whatever reason without having to 
justify your decision and without any negative impact on your care. 
WHY IS THIS STUDY BEING DONE?  
This study is being done because we know from experience and previous research that 
patients who suffer from compression of the spinal cord in their neck as a result of “wear 
and tear” (the condition called “cervical spondylotic myelopathy” in the title of the study) 
experience difficulties with walking. They may feel unsteady, the legs may feel stiff or 
weak, or they may not be able to walk as far or with the same ease as before. We hope 
that, by examining in more detail how patients with this condition walk, doctors and 
physiotherapists will better understand why these problems come about. We are 
recruiting a population of healthy people to give us a “baseline” with which to compare the 
walking patterns of the people with the condition cervical spondylotic myelopathy. As a 
healthy control, your data will be compared to a patient of the same age and gender. 
WHO IS ORGANISING AND FUNDING THIS STUDY? 
The Principal Investigator of this study is Ailish McDermott, Senior Physiotherapist. The 
Health Research Board has provided funding for the study to Ailish McDermott, who has 
registered for a PhD degree with the Royal College of Surgeons in Ireland. 
Gait Impairment in Cervical Spondylotic Myelopathy: Analysis, 
Impact on Function, and Effect of Surgical Intervention 
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HOW WILL IT BE CARRIED OUT? 
This research study commenced in October 2008. It will last for three years. Patients who 
have symptoms like unsteady walking or clumsy hands, and who have been told by their 
surgeon that they have spinal cord compression due to degenerative changes or “wear 
and tear” of the joints in the neck, will be asked to participate in the study. Healthy 
controls, of the same age and gender, will then be recruited to provide an accurate 
reflection of a normal walking pattern. All participants will have an analysis of their 
walking conducted in the Human Movement Laboratory in the Physiotherapy Department 
of the Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2. 
WHAT WILL HAPPEN TO ME IF I AGREE TO TAKE PART? 
You will be given an appointment to attend the Movement Laboratory in the Royal 
College of Surgeons in Ireland (RCSI), where an analysis of your walking will be carried 
out. The assessment in RCSI will take between one and a half and two hours. 
Measurements will be taken of your height, weight, and the width of the joints in your leg. 
The range of movement and “stiffness” of the muscles and joints in your legs will be 
measured. You will have small electrodes (about 2cm square) attached to four muscles in 
your leg, and you will have markers placed on the joints of your leg. This is not painful, 
they are simply attached to your skin, though we will need to shave a small area of hair to 
allow the electrodes to stick properly. You will then be asked to walk along a 10 metre 
walkway a number of times while your walking pattern is recorded by the motion analysis 
system (VICON). Next, you will be asked to walk a small flight of stairs if you are able to 
do this.           
BENEFITS: 
Taking part in the study will allow the Principal Investigator to gather detailed information 
on your walking pattern. The results of the assessments will all be explained to you. If you 
would like your own copy of the results, we will give them to you on a CD. 
Your participation will benefit patients with cervical spondylotic myelopathy, as it will allow 
their walking patterns to be compared to healthy people of the same age and gender who 
do not have the condition. This will help healthcare professionals to understand this 
condition more fully, and to provide the treatments that are best supported by the 
evidence. 
RISKS: 
This research study evaluates your normal walking pattern, and for healthy people, this 
should not pose any difficulty. There is one small risk in relation to the equipment used, 
and that is the risk of a skin reaction to the sticky electrodes. The risk of this is low 
because the adhesive on the electrodes is hypoallergenic, however please inform the 
researcher if you have sensitive skin, or if you have had a reaction to something similar in 
the past. If this happens, the reaction is likely to be small, with some redness and 
itchiness of the skin where the electrode was placed. 
WILL THERE BE ANY ADDITIONAL COSTS INVOLVED? 
If you incur travel expenses to come to your appointment in the Royal College of 
Surgeons, please give your receipt to the Principal Investigator who will organise a 
refund. 
YOUR RESPONSIBILITIES AS A PARTICIPANT 
1. To attend for assessment of your walking pattern at the appointment time given, 
or to give the researcher adequate notice if you need to change the 
appointment. 
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2. To inform the researcher of any factors which may affect your ability to walk for 
the required length of time e.g. new medical conditions such as angina, a chest 
infection causing you to be breathless, or an injury to your leg. 
3. If you are a woman of child-bearing age, to inform the researcher if you are 
pregnant.  
4. To inform the researcher if you are currently on medication, or if you are currently 
having physiotherapy, or any other treatment for your condition. 
 
OUR RESPONSIBILITIES TO YOU AS INVESTIGATORS 
We will ensure that our assessment of your walking pattern is carried out safely, 
accurately, and following all protocols and procedures to minimise the risk to you, the 
participant, and to ensure that the quality of information we provide to you afterwards is of 
the highest possible quality. We will provide you with the results of your walking test, 
which is yours to keep. 
CONFIDENTIALITY ISSUES 
When we take records of your assessment in the laboratory, we will not keep your name 
or any other details with this data. Instead, you will be given a “unique identifier” which 
will be coded on a secure hard drive and available only to the Principal Investigator. The 
document with this coded information will be destroyed as soon as the study is 
completed. The data from the laboratory, with details of your walking assessment, will be 
kept for a period of five years after the study is completed, because it may be included in 
future studies. If you wish to consent to this study only, and do not wish to consent to 
have your data included in possible future studies, please inform the researcher who will 
ensure your data are deleted after this study. 
IF YOU REQUIRE FURTHER INFORMATION 
If you have any further questions about the study, now or any future time, please contact 
the Principal Investigator:  
Ailish McDermott,  
Senior Physiotherapist 
Beaumont Hospital,  
Dublin 9. 
Phone: 01-8092526 / 085-8336094. 
If you wish to withdraw from the study you may do so at any time without 
justifying your decision and your future treatment will not be affected.   
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CONSENT FORM – HEALTHY CONTROLS 
Protocol Title: 
 
Please tick the appropriate answer. 
I confirm that I have read and understood the Controls Information Leaflet dated 23/02/10 
attached, and that I have had ample opportunity to ask questions all of which have been 
satisfactorily answered.       Yes No 
I understand that my participation in this study is entirely voluntary and that I may 
withdraw at any time, without giving reason, and without this decision affecting my future 
treatment or medical care.      Yes No 
I understand that my identity will remain confidential at all times.   Yes No 
I am aware of the potential risks of this research study.   Yes No 
I have been given a copy of the Controls Information Leaflet, version 1, dated 23/02/10 
and this Consent form for my records.     Yes No 
FUTURE USE OF ANONYMOUS DATA:   
I agree that I will not restrict the use to which the results of this study may be put. I give 
my approval that unidentifiable data concerning my person may be stored or 
electronically processed for the purpose of scientific research and may be used in related 
or other studies in the future. (This would be subject to approval by an independent body, 
which safeguards the welfare and rights of people in biomedical research studies - the 
Beaumont Hospital Ethics (Medical Research) Committee.)  Yes No 
 
Participant ________________        ___________ ________________ 
       Signature                       Date              Name in block capitals 
 
Witness      ________________       __________ _______________  
     Signature                        Date Name in block capitals 
 
 
Gait Impairment in Cervical Spondylotic Myelopathy: Analysis, Impact on 
Function, and Effect of Surgical Intervention. 
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To be completed by the Principal Investigator or his nominee.  
 
I the undersigned, have taken the time to fully explained to the above participant the 
nature and purpose of this study in a manner that he/she could understand. I have 
explained the risks involved, the experimental nature of the treatment, as well as the 
possible benefits and have invited him/here to ask questions on any aspect of the study 
that concerned them. 
 
_______________    __________________        ____________     ______________  
Signature                   Name in block capitals       Qualification        Date         
 
 
 
 
 
 
 
 
